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Dedication
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Summ ary
Filarial nematode parasite infections are endemic in developing countries of the Tropics. 
Collectively known as filariasis, these helminth parasite infections can occasionally induce 
gross inflammatory pathology in the infected host, however, more commonly, the host 
exhibits a somewhat suppressed non-inflammatory immune response to the parasite, 
permitting longevity of infection. Improved sanitation, increased use of antibiotics and 
vaccination has all but eradicated parasite infection in developed. Western society. 
Coincident with this improvement in hygiene, however, inflammatory autoimmune (e.g. 
rheumatoid arthritis) and allergic disease (e.g. asthma) has become more prevalent in 
these countries; a trend not observed in parasite-endemic countries. The hygiene 
hypothesis controversially proposes that these trends are directly associated, by 
predicting that insufficient exposure to pathogens in childhood results in development of 
an aberrant immune system that responds inappropriately to non-pathogenic stimuli as is 
manifested by allergy and/or autoimmunity. Thus, conversely, it has been proposed that 
exposure to parasite infection may prevent development of autoimmune and/or allergic 
diseases.
Filarial nematodes secrete immunomodulatory excretory-secretory (ES) products into the 
host bloodstream, which act to modulate inflammatory host immune responses and thus, 
protect the parasite from elimination. ES-62, an immunomodulatory glycoprotein product 
of rodent filarial nematode, Acanthocheilonema viteae, has previously been shown to 
modulate the responses of several immune cell types to promote an anti-inflammatory 
immune response in vitro and in vivo. Thus, it was hypothesised that ES-62 may exhibit 
anti-inflammatory potential in models of inflammatory disease prevalent in the Western 
world. Indeed, in a collagen-induced model of rheumatoid arthritis (CIA) ES-62 treatment 
induced amelioration of inflammation. Furthermore, this effect was mediated when ES-62 
was administered before or after the onset of clinically detectable inflammation. In Chapter 
3 of this thesis, progress towards dissection of the mechanisms of action of ES-62 in the 
CIA model was made, by analysing the role of phosphorylchoiine (PC), a component of 
ES-62 and several other immunomodulatory pathogen-derived products. Indeed, the anti­
inflammatory action of ES-62 in the CIA model was found to be PC-dependent, evidenced 
by reproduction of the anti-inflammatory effect when PC conjugated to albumin protein, 
OVA (OVA-PC) was used as a substitute and loss of the effect when PC-deficient 
recombinant ES-62 (rES-62) was used. However, not all of the immunomodulatory effects 
of ES-62 in this model were deemed PC-dependent. For example, the previously 
determined inhibitory effect of ES-62 on antigen-specific lgG2a production in the CIA
m
model was found to be PC-independent and thus, not directly associated with the anti­
inflammatory action of ES-62. In addition, it was determined that ES-62 treatment in vivo 
or in vitro disrupted contact-dependent communication between T cells and macrophages, 
evidenced by inhibition of macrophage pro-inflammatory cytokine production. This method 
of cell-to-cell communication has been hypothesised as fundamental for progression and 
maintenance of synovial inflammation in RA, thus it was concluded that this may be a 
method by which ES-62 mediated therapeutic action in this model of autoimmune disease.
The anti-inflammatory action of ES-62 in vivo was not restricted to inhibition of TH1- 
mediated inflammation, such as that exhibited in CIA. Utilising a TH2-mediated ovalbumin 
(OVA)-induced model of allergic airway inflammation (such as that exhibited in asthma), it 
was determined that treatment with ES-62 during or after the onset of disease reduced 
peri-bronchial inflammation and airway eosinophilia (Chapter 4). This inhibitory action was 
associated with reduced production of antigen-specific TH2-type cytokines and antigen- 
specific IgE, a hallmark feature of allergic inflammation. Furthermore, examination of bone 
marrow dendritic cells (DC) derived from this model of airway inflammation revealed that 
ES-62 treatment resulted in differentiation of DC with a modulated phenotype, evidenced 
by enhanced expression of co-stimulatory molecules and production of TH1-promoting 
cytokine, IL-12, These findings suggested that such modulation of DC may be a 
mechanism of action by which ES-62 mediates anti-inflammatory action in this model.
In addition to the reduction of TH1-mediated inflammation and TH2-mediated 
inflammation in the CIA and OVA-induced airway inflammation models respectively, an 
anti-inflammatory effect of ES-62 was additionally demonstrated in the MRL//pr model of 
autoimmune systemic lupus erythematosus (SLE). In Chapter 5, prophylactic ES-62 
treatment of MRL/lpr mice was demonstrated to inhibit development of nephritis and 
articular inflammation, two pathologies commonly associated with SLE in humans. These 
actions of ES-62 were evidenced by a reduction of proteinuria levels and footpad swelling, 
respectively. The anti-inflammatory effects of ES-62 in this model were were not 
asso c ia te d  w ith  m o d u la tio n  o f lym phadenopathy, splenom egaly or 
hypergammaglobulinemia. However it was associated with a reduced inflammatory 
mediator response of lymph node cells and splenocytes to a mitogenic stimulus. 
Furthermore, DC derived from ES-62 treated MRL/lpr mice exhibited a reduced response 
to LPS stimulation, in terms of cytokine production, indicating that modulation of DC 
function may be a potential mechanism of action of ES-62 in this model of autoimmune 
inflammation.
IV
Consistent with a role for PC as an immunomodulatory component of parasite-derived 
molecules such as ES-62, it was previously demonstrated that PC-containing 
glycosphingolipid (GSL) derived from the filarial nematode, Ascaris suum, exhibits 
immunomodulatory properties when used to treat macrophages, B cells and peripheral 
blood monocytes. To extend this study, it was demonstrated in Chapter 6 that A. suum- 
derived GSL inhibited the response of DC to LPS, evidenced by a reduction in LPS- 
induced cytokine production and upregulation of cell surface co-stimulatory molecules. 
Previously, such immunomodulatory action of A. suum  GSL was demonstrated in 
macrophages to be PC-dependent. However the P[^dependency of GSL action was not 
apparent with DC. However, by examining synthetic mimetics of A. suum  GSL PC was 
confirmed as an immunomodulatory constituent of GSL, Nevertheless, the presence of PC 
was per se found to be insufficient for immunomodulatory action on cells of the innate 
immune response (e.g. macrophages and DC). Indeed, it was shown that carbohydrate 
components of glycolipids are also necessary for such modulation of an immune 
response. Nevertheless, the findings presented in this chapter indicated that small PC- 
containing molecules with immunomodulatory activity can be synthesised in the laboratory 
and therefore, represent potential candidates for design of immunomodulatory drugs.
DC are the principle antigen-presenting cell type responsible for activation of T cells and 
hence, the ensuing antigen-specific immune response in vivo. Throughout the studies 
comprising this project it was clear that DC are often targeted by immunomodulators such 
as PC-containing ES products to facilitate manipulation of the immune system. Thus, it 
was speculated that allergenic substances might also employ manipulation of DC function 
for induction of an allergic immune response. Indeed, in Chapter 7, it was demonstrated 
that 2S seed albumins, SFA 8 and Ber e 1, which exhibited distinct allergenic properties 
also mediated distinct effects on DC functions in vitro. Exposure to SFA 8 (of ambiguous 
allergenicity), but not Ber e 1 (allergenic), resulted in production of TH1-promoting 
cytokines (IL-12 and TNFa) and enhanced expression of co-stimulatory and antigen- 
presentation molecules by DC. Moreover, using a transgenic OVA -specific TCR system, 
it was observed that pre-treatment of DC with Ber e 1, but not SFA 8 induced production 
of TH2-promoting cytokines, IL-4 and IL-5 by co-cultured OVA -specific T cells. This was 
reflected in such T cells by an enhanced expression of GATA-3, a TH2-type transcription 
factor. Thus, it appeared that the allergenicity of Ber e 1, compared with SFA 8, was 
associated with its ability to stimulate TH2-promoting cytokine production by DC. 
Therefore, it was concluded that allergenic proteins can also mediate their effects via 
modulation of DC in susceptible individuals.
In summary, the novel findings presented in this thesis support the theory that parasite 
infection may be protective against development of autoimmune and allergic inflammatory 
diseases prevalent in developed society. Furthermore, this protective effect may be 
facilitated by the immunomodulatory actions of parasite-derived, PC-containing ES 
products. Thus, via modulation of the function of innate antigen-presenting cells, such as 
dendritic cells, immunomodulatory molecules are capable of manipulating the action of 
immune system as a whole. This discovery draws attention to a highly evolved anti­
inflammatory mechanism employed by parasites, which could potentially be exploited to 
design therapy for human inflammatory diseases of today.
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1 General Introduction
1.1 The immune system
Analogous to the defence of a country against its enemies, the human body must protect 
itself against invasion by pathogens, which is the role of the highly evolved human 
immune system. To carry out its function the Immune system forms two categories of 
defence. Firstly, forming the initial line of defence, the Innate immune response and 
secondly, eliciting a specifically tailored method of protection, the adaptive immune 
response.
1.1.1 The innate immune system: providing a physical barrier to infection
The innate immune system is less highly evolved than the adaptive immune system and 
comprises the entire immune system in invertebrates. Primarily, the role of the innate 
immune system is to prevent external pathogens entering the body tissues. This is 
achieved by a variety of physical mechanisms including shedding of epithelial skin layers, 
secreting mucus to line vulnerable epithelial areas of access to the body (such as the 
airways and intestine) and the epithelial cilia that sweep away this mucus layer. All of 
these methods help to refresh the surfaces of the body that come into contact with 
potentially pathogenic substances from the external environment.
Following breach of the external barriers (e.g. breaking the skin) the human body tissues 
are vulnerable to invasion by harmful pathogens, such as bacteria. At this point, the 
biologically active aspect of the innate immune system is triggered and is responsible for 
recognition and disposal of the invading pathogen. This aspect of innate immunity 
comprises soluble proteins and bioactive molecules that are either constitutively present 
in biological fluids (such as complement proteins), or are released from activated cells. 
These include cytokines that regulate the function of innate cells such as TNFa and 
IFNa/p, lipid mediators (e.g. leukotrienes and prostaglandins) of inflammation and 
bioactive enzymes (including plasmin) that contribute to inflammation. Innate immune 
system cells are normally phagocytes (e.g. macrophages, dendritic cells and neutrophils) 
or granulocytes (e.g. mast cells, eosinophils) adept at consuming particulate substances 
and secreting the soluble mediators of inflammation. To be effective, the immune system 
must accurately recognise pathogens and pathogenic substances (and distinguish them 
from self). In addition, it must destroy and dispose of such substances and finally, there 
must be appropriate communication of these actions between cells of the immune system. 
Thus, when activated, innate immune cells normally phagocytose pathogens and produce 
pro-inflammatory cytokines to activate other nearby innate immune cells.
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1.1.2 Recognition of pathogens by the innate immune system
Innate recognition of pathogens is achieved by activation of pattern recognition receptors 
(PRRs) expressed on the surface of innate immune cells, such as macrophages and 
dendritic cells (DC). These PRRs enable identification of pathogen-associated molecular 
patterns (PAMPs), exhibited by categories of common pathogens. Thus, ligation of PRRs 
activates mechanisms, which bring about destruction and disposal of the pathogen 
displaying the PAMP. Common examples of PAMPs include lipopolysaccharide (LPS), a 
component of Gram-negative bacterial cell wall, CpG DNA motifs (specific to bacteria), 
double stranded RNA (specific to viruses) and mannans, a component of fungi cell wall. 
To complement this range of PAMPs, there exists families of PRRs, for example. Toil-like 
receptors (TLRs), which are commonly expressed on the surface of several immune 
system cells. TLRs derive their name from their similarity to the protein Toll, involved in 
fungal defence by Drosophila [1]. These receptors are membrane bound and upon ligation 
by specific PAMP, they trigger an intracellular signaling pathway, which induces innate 
immune cell activation and responses. For example, TLR4, one of the first TLRs to be 
identified, is specific for LPS from Gram-negative bacteria [2].
1.1.3 Activation of the Adaptive Immune System
Of the cell types that comprise the innate immune response dendritic cells (DC) in 
particular have a wide-ranging, important role. As a professional antigen-presenting cell, 
one of the main functions of DC is to form a conduit between the innate and adaptive 
immune responses. Following exposure to ‘danger’ signals, such as pathogen products 
that signal via TLRs and pro-inflammatory cytokines, immature DC undergo a series of 
phenotypic changes. This results in the transition from a phenotype that is highly efficient 
at antigen-processing to a phenotype ideally suited for activating naïve CD4"" T cells. 
Thus, when a pathogen invades the body it is recognised by DC, which phagocytoses the 
pathogen and, following processing, presents antigen at the cell membrane, complexed 
with a class II major histocompatability complex (MHCII) protein. Once activated, the 
expression of co-stimulatory and adhesion molecules is upregulated on the surface of the 
DC in preparation for activation of a naïve CD4^ T cell (Figure 1.1) [3]. Naïve T cells 
express reciprocal surface proteins, which act as receptors for the co-stimulatory 
molecules expressed on the DC and help to ensure activation of the T cell in response to 
antigen recognition. Furthermore, the pattern of cytokines secreted by DC at the time of 
antigen-presentation helps to determine the phenotype of the adaptive immune response 
[4, 5].
1.1.4 Adaptive Immune System: initiation of the specific response
CD4' T cells are important for directing the nature of adaptive immune responses, which 
is achieved by secreting particular patterns of cytokines. This function normally
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determines whether an antigen-specific immune response is mediated by antibodies 
(humoral) or cells (e.g. CDS'" T cells). Thus, CD4* T helper cells generally direct (‘help’) 
the function of B cells, which are principally involved in secretion of antibodies. Antibodies 
act in an antigen-specific manner to promote pathogen elimination by targeting and 
activating the functions of cells of the innate immune system. In contrast, CDS'" T cells or 
cytotoxic T lymphocytes (CTLs), as their name implies, are primarily involved in effector 
cell-mediated responses, where upon recognition of their specific antigen they directly kill 
target cells.
Lymphocytes excel at recognition of antigens and like cells of the innate immune system, 
T and B cells also express recognition receptors on their surface, known as the T cell 
receptor (IC R) and the B cell receptor (BCR), respectively. The TOR and BCR are put 
together from a combination of several genes in such a way that each lymphocyte 
displays a different specificity and as a result recognizes unique antigen. Therefore, these 
receptors are much more selective than those expressed by cells of the innate immune 
response. Importantly, however, unlike the innate immune system this random generation 
of antigen receptors by the adaptive immune system means it cannot decipher the nature 
of the antigen, and therefore can result in the recognition of self-antigen, which can lead 
to autoimmune disease. Therefore, prior to export into the periphery, T and B cells 
undergo rigorous selection processes In the thymus and bone marrow, respectively, 
leading to the generation of a population of mature cells that are tolerant to self-antigen 
but specific for foreign antigen. Furthermore, in the periphery CD4* T cells will normally 
only be activated by antigen if the antigen for which they are specific is presented to them 
and, furthermore, only if it presented to them in the context of MHCll, with accompanying 
co-stimulation (e.g. via CD40-CD40L interaction). Considering only antigen-presenting 
cells express MHCll and co-stimulatory molecules, this system helps to ensure that only 
antigens that have first been recognized as pathogenic by cells of the innate immune 
response are able to activate T cells (Figure 1.2). Thus, upon presentation and 
recognition of specific antigen a lymphocyte will be activated to proliferate, generating 
several copies of itself, all with identical specificity, known as a clone. The majority of the 
members of this clone will then differentiate and carry out their effector function, while 
others remain, known as memory cells. Thus, any subsequent response to the same 
antigen will be faster and result in more efficient removal of the pathogen.
1.1.5 Different types of adaptive immune response
As mentioned above, the pattern of cytokines secreted by antigen-presenting cells at the 
time of T cell activation help to define the nature of the adaptive immune response. Two 
main types of antigen-specific adaptive immune response were originally identified and 
characterized as THI-type and TH2-type immune responses, based on the pattern of
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cytokines secreted by TH1 and TH2 CD4+ T helper (TH) cells respectively [6]. TH1 
immune responses are primarily cell-mediated involving the actions of CTLs and 
macrophages, whilst TH2 immune responses are generally antibody-mediated and 
involve the actions of mast cells and eosinophils (Figure 1.3). In terms of infection with 
pathogens, TH I-type immune responses are normally activated in response to 
intracellular (e.g. bacterial) infections and can be distinguished by production of IFN7 by 
TH1 cells, whilst TH2-type immune responses are activated by extracellular (e.g. helminth 
parasite) infection, characterised by production of TH2 cytokines, IL-4, IL-13 and IL-5 by 
CD4+ TH2 cells [7, 8].
Generally the aspects required to execute an adaptive immune response can be divided 
into two categories: initiation mechanisms and effector mechanisms (Figure 1.4). Initiation 
of the adaptive immune response involves recognition of the activating antigen (e.g. 
pathogen) and activation of CD4'‘ T cells, which then have the power to direct the cells of 
the adaptive immune response. Effector mechanisms of the immune response include the 
actions of the immune system following recognition of antigen, in an effort to destroy the 
antigen and rid the body of it. For example, B cell antibody production in conjunction with 
macrophage-mediated antigen phagocytosis or CTL-mediated cell destruction. Thus, 
initiation and effector mechanisms of the immune response generally involve cells of both 
the innate and adaptive immune responses.
1.2 Autoimmunity: the consequence of a dysfunctional immune 
system
The principle function of the immune system is to defend against infection by attacking 
and eliminating harmful pathogens, whilst not attacking the body’s own cells and tissues. 
A dysfunctional immune system can therefore initiate development of chronic, disabling 
autoimmune diseases. Indeed, more than 80 clinically distinct autoimmune diseases have 
been discovered and diagnosed to date [9]. Several of these diseases are well known, for 
example, rheumatoid arthritis (RA), multiple sclerosis (MS), type I diabetes and systemic 
lupus erythematosus (SLE); however most are relatively unheard of, such as pemphigus 
and autoimmune inner ear disease. Collectively, autoimmune diseases afflict 
approximately 5-8% of the US population. This prevalence is greater than that of cancer 
(approximately 3%) and in the same range as heart disease (8%)[9j. All autoimmune 
diseases are chronic, disabling disorders that have the ability to inflict a poor quality of life. 
Furthermore, these diseases can be organ-specific, such as diabetes; or can affect 
several body systems simultaneously, such as in SLE.
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1.2.1 T cells in autoimmunity
Prevention of the immune system targeting the body’s own cells or molecules (known as 
autoreactivity) is mediated by a series of processes known as immune tolerance ([10-12]) 
and is conducted in two main sites. Immature autoreactive B and T cells naturally arising 
in the bone marrow and thymus are prevented from maturing and entering the peripheral 
circulation, as part of a process known as central tolerance. However, this process is not 
perfect and a small percentage of auto reactive lymphocytes escape to the circulation. In 
normal non-autoimmune people, these autoreactive cells are prevented from attacking 
self by mechanisms of peripheral tolerance. Peripheral tolerance can be maintained in 
several ways ([13-15]). For example autoreactive lymphocytes require a secondary, co­
stimulatory signal to be present for adequate activation and initiation of an antigen-specific 
immune response. Thus, when an autoreactive cell recognises antigen in the absence of 
the secondary signal induced by inflammation they are eliminated from the circulation (by 
programmed cell death) or become functionally inactivated (anergic), preventing initiation 
of an inappropriate immune response. It has been suggested that this system is 
dysfunctional in autoimmune individuals, leading to activation of autoimmune responses. 
For example, it was demonstrated recently that development of inflammation in a model of 
MS was dependent upon expression of CD40, a co-stimulatory molecule that signals 
through CD40 ligand (GDI 54) on the surface of T cells [16]. Furthermore, it has been 
suggested that expression of co-stimulatory CD40 on DC acts to promote stimulation of 
an antigen-specific autoimmune response, whilst in the absence of GD40 tolerance to 
presented antigen is promoted [17]. Another mechanism of peripheral tolerance is through 
the action of a subset of T cells known as T regulatory cells (Tregs). By secreting anti­
inflammatory cytokines, such as IL-10, or via cell-cell contact, Tregs suppress the activation 
of autoreactive cells in the local environment. Evidence to support this theory was 
obtained when it was demonstrated that inflammatory bowel disease (IBD) -like 
inflammation spontaneously developed in IL-10 deficient mice [18, 19] and a model of MS 
spontaneously arises upon depletion of GD4^GD25^ T cells [20].
1.2.2 B cells in autoimmunity
As described above, the major role of B cells in the immune system is to produce 
antibodies that help target immune cells to the pathogen requiring destruction e.g. 
bacteria. In some autoimmune diseases, B cells mediate production of autoantibodies that 
are specific for self-antigen on cells or tissues within the body, hence targeting the 
immune system-mediated destruction of body tissues. In particular, it has been 
demonstrated that autoantibodies are a major mechanism of pathogenesis in systemic 
lupus erythematosus (SLE) [21-23].
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SLE is a prototypical inflammatory autoimmune disorder of heterogeneous pathology, 
affecting multiple organs and body systems, which can include lymph node enlargement, 
splenomegaly, vasculitis, glomerulonephritis and arthritis [21]. As a result of marked 
hypersecretion of autoantibodies and consequent inflammatory processes, tissue damage 
and end organ failure ensues in this chronic debilitating disease. The concentration of 
circulating anti-DNA autoantibodies Is significantly elevated in SLE patients and has been 
shown to correlate with disease severity; highlighting its function in mediation of disease 
pathogenesis [24].
Similarly, the identification of rheumatoid factor (antibody that binds to the Fc portion of 
immunoglobulins) [25] implicated B cell-secreted autoantibodies in mediation of RA 
pathogenesis [26]. Furthermore, the TH1 cells involved in MS pathogenesis provide help 
to B cells, which in turn secrete autoantibodies specific for myelin [27]. However, the 
importance of B cells and autoantibodies in MS pathogenesis has been a matter of 
debate, nevertheless it has been suggested that the level of circulating anti-MOG 
autoantibodies is predictive of eventual disease diagnosis [28], Likewise, autoantibodies 
specific for insulin and islet proteins can be detected in the bloodstream of eventual type 1 
diabetics as early as in utero, demonstrating the humoral component of pathogenesis in 
this disease [29, 30].
1.2.3 Genetics of autoimmunity
It has been identified that pre-disposition to autoimmune disease also has a genetic 
component. Thus, animal models of disease have highlighted different groups of genes 
that are associated with incidence of (or protection from) certain autoimmune disorders 
[31]. This is not to say that autoimmune diseases are inherited disorders, such as cystic 
fibrosis (which is the result of a single gene mutation) [32]. Rather, as a result of inheriting 
multiple alleles of genes involved in the function of the immune system, the combined 
effect induces susceptibility to the disease [33, 34]. These findings have been supported 
by several studies. For example, particular autoimmune diseases disproportionately affect 
certain genders, races and ethnic groups [35]. Moreover, information gained from studies 
of twins revealed that monozygotic twins are more likely to suffer the same autoimmune 
disorder than dizygotic twins [36]. For example, approximately 25% of monozygotic twins 
are concordant for SLE, supporting a genetic component in susceptibility to this disease 
[37]. Furthermore, relatives of individuals suffering from autoimmune disease are more 
likely to develop the same or another autoimmune disorder, than non-relatives. Genes 
implicated in susceptibility to autoimmunity include the MHC family of genes, which are 
involved in immune system regulation and recognition of antigen. These genes have been 
associated with disposition to MS, type I diabetes, RA, SLE and different types of irritable 
bowel disease [34, 38-41]. For example, specific human leukocyte antigen (HLA)-DR
18
genes, which also reside in the major histocompatibility complex (MHC) and participate in 
antigen presentation, have been consistently implicated [42, 43]. However, the risk of 
developing RA is at most 50% determined by genetic factors [44].
1.2.4 Environmental exposures influencing the development of 
autoimmunity
Concordance for autoimmune disease in monozygotic twins is never 100%, indicating that 
environmental exposure also has a significant role to play in onset of disease. Thus, 
infectious agents, chemicals and toxins have been implicated in induction of 
autoimmunity. In particular, bacterial and viral infections have been associated with 
triggering subsequent autoimmunity [45, 46]. The mechanism of this is unclear, although it 
has been postulated that molecular mimicry is a potential method, where infection- 
induced expansion of effector T cells that cross-react with self antigen persist in their 
attack after the infection has been cleared [47]. Alternatively, autoreactive T cells may be 
activated in a bystander mechanism by cells of the innate immune response releasing 
pro-inflammatory cytokines during an immune response to infectious pathogens [48]. 
Nevertheless, although several viral and bacterial infections have also been implicated in 
RA [44, 49], none have been conclusively supported.
The potential effects of occupational exposure to chemicals and toxins has not been 
thoroughly investigated however, exposure to mercury and silica has been demonstrated 
to cause autoimmunity in humans and animals [50, 51]. In addition, it has been 
demonstrated that reactive oxygen species may be involved in the pathogenesis of SLE 
[52].
Nutrition and smoking have been implicated as important lifestyle factors that influence 
onset and progression of autoimmunity. For example, it is known that smoking increases 
the risk of RA and reduces the risk of ulcerative colitis [53, 54] [53, 55], however studies 
investigating other disorders, such as SLE, have been inconclusive [56]. Based on studies 
in NOD mice (a murine model of type 1 diabetes; T1DM), it has been suggested that 
avoidance of dietary gluten can prevent development of T1DM [57], however this has 
been disputed by human studies [58]. By contrast, consumption of high levels of essential 
fatty acids (omega-3 and omega-6) has been shown to correlate negatively with 
susceptibility to RA [59], although these studies have received minimal support.
Finally, the disproportionate prevalence of autoimmunity in women of childbearing age 
has implicated sex hormones in the pathogenesis of these diseases. Women with MS 
outnumber men by as much as 2:1 and whilst SLE afflicts approximately 100 per 100,000 
[4], it is more common in women than men [60]. In an effort to explain this distribution, it is
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known that oestrogen stimulates B celt growth and production of antibodies and cytokines 
[61]. Likewise, other hormones present in enhanced levels in females, such as prolactin
and growth hormone, have been demonstrated to promote autoimmune disease [62, 63].
■This remains an active topic of research.
In summary, autoimmune diseases are characterised by the presence of clonally 
expanded populations of auto-reactive lymphocytes [11] that have escaped negative 
selection during development or have failed to become deleted following activation in the 
periphery. Mechanisms must be in place for successful pathogenesis of autoimmunity, 
involving persistent and accessible antigen, available and present co-stimulation and 
inadequate tolerance mechanisms (Figure 1.5). Therefore, full understanding of all these 
processes will aid the development of improved strategies for prevention of autoimmune 
disease. The common denominator in the majority of autoimmune diseases is that they 
are TH1-mediated, indicating that pro-inflammatory TH1 cell-mediated immune processes 
are generally responsible for initiation. In addition, humoral (antibody-mediated) immunity 
is a common feature in autoimmune disease, implicating B cells in disease pathogenesis. 
Animal models of autoimmune diseases have permitted extensive analysis of pathology in 
several conditions and continue to help identify putative therapeutic targets for human 
disease. The prevalence of several autoimmune diseases (e.g. T1DM) has been 
observed as currently increasing, indicating that lifestyle and environmental factors (that 
can ultimately be controlled) could be changed to slow or even reverse this progression. 
This may involve modulation of exposure to common bacterial or viral infections, or 
modification of our modern diet.
1.3 Allergy and Allergic Diseases
Allergies and allergic diseases can induce a vast spectrum of debilitation, which ranges 
from mild and easily controlled to chronically disabling and potentially fatal, depending on 
the allergy and the allergic individual. In a similar manner to autoimmune disease, 
allergies are usually mediated by inappropriate activation of an immune response. The 
terms allergy and atopy are generally used interchangeably to mean IgE-mediated 
hypersensitivity to non-pathogenic substances [64]. The prevalence of atopic disease 
varies in different parts of the world, and has been quoted between 17 and 25% [65]. 
Frequently, individuals exhibit more than one type of allergy or allergic manifestation (e.g. 
dermatitis and rhinitis). These allergic individuals are said to exhibit an atopic phenotype.
However, in immunological terms, allergy and autoimmunity are quite distinct. Thus, 
allergies are generally characterised by activation of TH2-mediated immune responses 
and are associated with elevated production of IgE antibody. Immediate-type 
hypersensitivity reactions are characteristic of allergies and are induced in response to
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IgE-mediated recognition of specific allergen. Allergic inflammation usually involves 
activation of innate immune cells such as mast cells [66], basophils and eosinophils by 
ligation of IgE expressed on their surface (Figure 1.6).
1.3.1 Allergens
When an allergic (or atopic) individual is exposed to normally harmless exogenous or 
foreign antigens (allergens), an allergic immune response is activated. Contact with 
allergen is via distinct routes, depending on the antigen. For example, contact with 
airborne allergens (e.g. house dust mite and pollen) occurs in the nasal and pulmonary 
mucosa, whilst contact with food allergens (e.g. nut or milk proteins) occurs via the mouth 
or gut mucosa. Inflammatory immune responses in allergic individuals are normally 
transient: i.e. they occur in response to allergen and can usually be prevented by avoiding 
contact with the allergen. For example, removal of food allergens from the diet or use of 
dust mite-impermeable mattress covers. However, avoidance is often not feasible to 
completely or satisfactorily avoid the allergen, e.g. tree and grass pollens [67].
The normal manifestation of allergy to inhaled allergens is allergic rhinitis, more commonly 
known as hayfever. Allergic rhinitis can be a seasonal or year-round affliction, depending 
on the allergen to which the allergic individual is sensitised. Similarly, food allergies are 
caused by an inappropriate inflammatory immune response to otherwise harmless food 
proteins, resulting in elevated production of allergen-specific IgE antibody. This must not 
be confused with non-immunological food intolerance. Foodstuffs commonly associated 
with allergy include cow’s milk, eggs, wheat, fish, nuts, soya bean and citrus fruit. The 
most common food allergen is cow’s milk protein [68]. Allergy to cow’s milk protein often 
presents in the first few months of life [69], diagnosed by erythema of the skin and 
possible dermatitis. Nut and fish allergies are commonly characterised by severe, life- 
threatening allergic responses such as urticaria, angioedema, pharyngeal and laryngeal 
oedema [66]. Furthermore an allergic reaction to these foodstuffs can be fatal through 
development of anaphylactic shock and asphyxia [70]. Severe allergy to fish or nut 
proteins are usually persistent life-long conditions, however, milder egg and cow’s milk 
allergies are normally transient afflictions that disappear after childhood [65]. It is common 
for atopic individuals sensitised to tree pollen to also be allergic to tree nuts, such as 
hazelnuts [71].
It has been suggested that allergies and allergic diseases are the result of a combination 
of multi-gene pre-disposition and environmental exposure to allergenic substances [72]. 
Exposure to food antigens in neonatal life has been implicated in establishment of allergic 
status in later life in susceptible individuals. However, support for this theory has been 
disputed. Whilst it has been demonstrated that exclusively breastfeeding an infant is
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protective from development of allergy to cow’s milk protein [73, 74], it has also been 
suggested that allergic sensitisation to other allergens may occur in utero or via the 
breastmilk. Therefore it has been advised that commonly allergenic substances should be 
omitted from the maternal diet during pregnancy and breastfeeding in suspected atopies 
[75]. Conflicting evidence concerning the prevention of allergy development in neonatal 
life continues to be published [76]. The best course of action for prevention of allergy in 
potentially atopic infants is currently unclear.
1.3.2 Treatment of allergies
Traditional pharmacological treatment of allergies (such as allergic rhinitis) has included 
oral anti-histamines and nasal corticosteroids. More recently, allergen immunotherapy has 
been investigated for use in the treatment of asthma and allergic rhinitis patients [77-80]. 
Allergen immunotherapy involves weekly subcutaneous administration of allergens at 
increasing doses until an optimal maintenance dose is attained. At this point, optimal 
doses are administered less frequently to maintain tolerance to the allergen. Beneficial 
effects of this type of therapy have been variable, however immunotherapy-induced 
reduction of symptoms have persisted after cessation of therapy in some patients. 
Nevertheless, the risk of systemic reactions during immunotherapy is substantial, as in a 
few rare cases, patients undergoing immunotherapy have died following onset of 
anaphylactic shock.
1.3.3 Allergic Diseases
Allergic diseases are inflammatory conditions associated with IgE-mediated inflammatory 
reactions and aberrant TH2-mediated immunity. In contrast to transiently manifested 
allergies, allergic diseases are chronic disabling afflictions that can be temporarily 
exacerbated by exposure to one or multiple allergens (e.g. asthma). Fatality as a result of 
allergic disease usually occurs during an episode of inflammatory exacerbation (e.g. an 
“asthma attack”). Asthma, allergic rhinitis (AR), and atopic dermatitis (AD) are considered 
the atopic triad [81].
1.3.3.1 Allergic Rhinitis
Allergic rhinitis (hay fever), affects approximately 10-20% of the population in developed 
countries [82] and is one of the most common chronic conditions for which medical care is 
sought. The variable inflammatory response exhibited in allergic rhinitis (including 
sneezing, watery rhinorrhea, nasal congestion, itchy palate and itchy, red, watery eyes) is 
initiated by ligation of allergen and IgE on the surface of mast cells in the airway [82, 83]. 
Sensitization to specific allergens can be identified by skin prick or in vitro tests for 
allergen-specific IgE antibody [67]. Inhaled allergens that normally cause allergic rhinitis 
include plant, animal, house dust mite and fungi-derived antigens, amongst others. Allergy
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to plant pollen is seasonal and therefore can be easily distinguished from perennial 
allergies, which are usually caused by house dust mite or animal dander. It has been 
suggested that development of allergic rhinitis can precede development of allergic 
asthma, therefore adequate treatment of allergic rhinitis might prevent development of 
asthma.
Immunologically, allergic rhinitis is characterised by eosinophilia of the airways and 
enhanced expression of epithelial and endothelial cell adhesion molecules [82]. The 
epithelial cell layer is an active centre of cell infiltration and inflammatory mediator release 
and the nasal mucosa is continually inflamed during the period of exposure to allergen. 
TH2-type cytokines (IL-4 and IL-5) and chemokines, released by T cells and mast cells, 
are present in elevated quantities and are a hallmark of AR inflammation. Likewise, 
histamine, released by mast cells, is a major mediator of AR.
1.3.3.2 Asthma
Asthma is a common allergic disease that has doubled in prevalence since 1980 [84] and 
affects approximately 3 million people in the UK [85]. As a chronic inflammatory 
pulmonary disorder, it is characterised by reversible airflow obstruction, airway 
hyperresponsiveness to allergenic and non-allergenic substances, wheeze, cough or 
shortness of breath [84]. Furthermore, asthma is categorised as an allergic disease thus, 
exposure to allergen induces exacerbation of airway inflammation in sensitised 
asthmatics. Indeed, exposure to allergens derived from house dust mite, cockroach and 
spores of the fungus, Alternaria, elicit the strongest reactions in asthmatics [86-88]. 
Kinetically and immunologically, asthmatics experience two types of inflammatory 
response to antigen (or allergen) challenge. Inhalation of aerosolised antigen causes 
immediate acute bronchospasm, known as the early response. The late phase response 
is exhibited 4-6 hours after exposure and is characterised by more severe airway 
obstruction.
1.3.3.3 The immediate asthmatic response
Epidemiological and clinical studies have demonstrated a correlation between IgE levels 
and asthma severity [89]. It is understood that the early asthmatic response to antigen is 
mediated by the action of allergy-associated IgE antibody. To initiate IgE synthesis, 
allergen must previously encounter and activate pulmonary DC. Activated DC 
subsequently migrate to the lymph nodes and present processed allergen to T and B 
cells. TH2 cytokines IL-4 or IL-13, in combination with T cell help, induce B cell secretion 
of IgE isotype antibody [90]. Within the lungs, allergen-specific IgE binds to high-affinity 
IgE receptors (FceR I) on the surface of mast cells or basophils and low-affinity FccRII on 
the surface of lymphocytes [91]. Thus, ligation of IgE with allergen induces the immediate
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response involving degranulation of mast cells and basophils resulting in release of 
inflammatory mediators including prostaglandins, leukotrienes, histamine and TH2 
cytokines, IL-4 and IL-5, which act to recruit more mast cells and eosinophils to the site of 
inflammation.
1.3.3.4 The late asthmatic response is mediated by TH2-type immune response
The late phase response is brought about as a result of infiltration of several different 
inflammatory cell types (including eosinophils, macrophages, neutrophils, TH2 cells, mast 
cells and basophils) to the lungs. As mentioned previously, the asthmatic airway is a TH2- 
polarised environment exhibiting enhanced levels of TH2 cytokines, IL-4, IL-5, IL-13 and 
IL-9 [92]. In response to recognition of antigen in the presence of TH2-promoting cytokine, 
IL-4, naïve T cells are activated and differentiate into TH2 cells, able to trigger a TH2- 
mediated specific immune response. Initiated 4-6 hours after the immediate inflammatory 
response, the late phase response is characterised by prolonged, more severe airway 
constriction and obstruction, compared with that exhibited in the early phase, and airway 
hyperresponsiveness.
In contrast to the majority of ‘simple’ allergies, asthma is a progressive disease, which can 
lead to permanent lung function impairment and irreversible airflow obstruction [93, 94]. 
The irreversible aspect of asthmatic inflammation is brought about slowly over time, by 
repeated activation of the early and late phase responses. Inflammatory mediators 
released during these processes result in pulmonary tissue damage and permanent 
structural remodelling of the airways (Chapter 4).
1.4 The Hygiene Hypothesis
The prevalence of allergies, allergic diseases and several autoimmune disorders has 
progressively increased in developed countries during the past 2-3 decades [95-101]. This 
has coincided with improved sanitation and healthcare and eradication of multiple life- 
threatening infectious diseases in these parts of the world. It has been suggested that the 
increased prevalence of allergy in developed countries is related to a lack of exposure to 
such infectious agents in childhood, while the immune system matures [102]. This theory 
has been dubbed ‘the hygiene hypothesis’ and has been a topic of much debate and 
controversy. In support of the hygiene hypothesis, the incidence of allergic disease and 
allergy is reduced in developing countries [103], where improvements in medical care and 
sanitation and changes in lifestyle during the past few decades have not been as 
pronounced as in developed countries.
Independent of socioeconomic status of country, a pattern of increased allergic disease in 
urban areas and decreased allergic disease in rural areas has also been observed [104,
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105]. The hygiene hypothesis proposes that these epidemiological observations are 
inextricably linked and advocates that exposure to bacterial or viral infections, in 
childhood, promotes development of a balanced immune system [106]. Without this 
neonatal ‘training’, the immune system behaves in an inappropriate manner in genetically 
pre-disposed individuals and the result is allergy [107]. A common outcome of changing 
lifestyles in developed countries is reduced family size. In a seminal study triggering 
formulation of the hygiene hypothesis [102], it was observed that the incidence of allergic 
rhinitis was inversely related to the number of children in the household. Furthermore, 
there was a higher incidence of allergic rhinitis and eczema in the oldest child of a family 
(who will have begun life with no siblings), than in younger children. It was proposed that 
increased numbers of siblings promotes increased exposure to infectious agents, e.g. 
rhinoviruses, (as a result of unhygienic contact with siblings) and protection from 
development of allergic disease. In developing countries lifestyle is more traditional and 
families are larger, supporting this relationship. However, the hygiene hypothesis, as 
described here, has been widely disputed [108,109].
1.4.1 Opposition to the Hygiene Hypothesis
It has been suggested that TH1 and TH2 immune responses are counter-balancing. 
Immunologically, the hygiene hypothesis proposes that stimulation of Thi-mediated 
immune responses (normally elicited in response to bacterial and viral infections) 
dampens the TH2 bias of the neonatal immune system and prevents development of 
inappropriate TH2-mediated allergy to irrelevant environmental antigens [107]. The 
process of polarising the immune response towards THI and away from TH2 responses 
has been termed immune deviation. The model of TH1-TH2 counterbalance, implicated in 
the hygiene hypothesis offers an explanation for increasing TH2-mediated allergy in the 
developed world. However this theory is contradicted by the observation that autoimmune 
diseases are simultaneously increasing in these countries. Autoimmune diseases are 
usually mediated by aberrant THI-type immune responses [109]; therefore increasing 
prevalence of THI-mediated autoimmunity in countries with improved sanitation and 
reduced exposure to THI-promoting infections is contradictory to the TH1-TH2 immune 
deviation mechanism of the hygiene hypothesis model.
Also in contradiction to the hygiene hypothesis, the majority of people in parasite endemic 
countries exhibit potent TH2-mediated immune responses to parasitic worms (helminths) 
[110]. This observation highlights the fact that children raised in these countries are not 
solely exposed to bacterial and viral Infections that induce THI-mediated immune 
responses. Despite displaying ‘TH2-skewed‘ immune systems (including high levels of 
serum IgE and TH2 cytokines), parasite-infected individuals do not develop associated 
allergy to environmental allergen. This is in direct contradiction to the hygiene hypothesis,
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which proposes that a TH2 biased immune system promotes development of allergy. In 
fact, schistosome-mfecieà Gabonese children exhibited a 63% reduced risk of allergy to 
house dust mite [111] and Nigerian children infected with Ascaris lumbricoides displayed 
relatively little evidence of allergic inflammation to environmental allergens [112]. These 
observations indicate that TH2 skewing of the immune system is not sufficient for 
development of allergic disease. Interestingly, the severity of parasite infection is inversely 
related to the incidence of allergy. Helminth-infected children exhibiting high levels of IgE 
specific for a selection of allergens, displayed reduced skin-prick reactivity to house dust 
mite and other allergens when compared with children that had a reduced parasite load 
[113]. Furthermore, a study in Brazil demonstrated that schistosome-infected subjects 
were 7 times less likely to be allergic to inhaled allergens than non-infected subjects [114]. 
These studies support a role for helminth-mediated suppression of allergy that is not 
mediated by reduction of TH2 immunity. When helminth infections were cleared by 
medication, skin-prick test reactivity to house dust mite increased, implicating parasite 
infection as inhibitory to development of allergy. This was further supported by a decrease 
in skin-prick reactivity as worm burden increased in parasite-infected subjects [115]. 
However, this pattern is not clear-cut: a few studies have found no association between 
allergy and helminth infection, and some studies have observed increased allergy in 
helminth-infected subjects [116]. The results of these studies might have been influenced 
by chronicity and severity of parasite infection, however it is important to take them into 
account when formulating hypotheses.
1.4.2 Reduced incidence of allergy in parasite-infected individual is due to 
an enhanced anti-inflammatory regulatory network
Replacing the theory of Th1-TH2 counterbalancing and immune deviation, it has been 
suggested that an enhanced anti-inflammatory network within the immune system is 
induced by exposure to parasite infection in childhood [117, 118]. Therefore, under this 
revised model, allergy is prevented by regulatory mechanisms that inhibit inflammatory 
immune effector mechanisms. The anti-inflammatory component of the immune system is 
facilitated by the action of anti-inflammatory cytokines IL-10 [117] and TGFp, secreted by 
a subset of CD4'' T cells known as regulatory T cells. IL-10 induced by allergen is 
inversely associated with the size of the allergic skin reaction to house dust mite [119] and 
both IL-10 and TGF|3 are capable of counter-regulating both THI and TH2 mediated 
inflammation [120-124], In accordance with the theory of enhanced regulatory 
mechanisms in parasite-infected individuals, robust anti-inflammatory networks are 
developed to restrict parasite-Ag-induced tissue damage. This anti-inflammatory network 
might underlie the reduced prevalence of allergy in helminth-infected people. Indeed, 
PBMC isolated from filariasis patients display elevated IL-10 production [123, 125, 126] 
and the reduced proliferative responses of lymphocytes and immunosuppressed
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phenotype exhibited in filariasis has been attributed to IL-10 and TGF|3[123]. Elimination 
of the parasite from the host often induces onset of parasite-induced inflammatory 
pathology, such as elephantiasis [127]. This observation provides further support for an 
enhanced anti-inflammatory network during active parasite infection. By direct inference, 
these findings suggest that atopic residents of developed countries have an 
underdeveloped anti-inflammatory aspect to their immune systems.
1.4.3 Reduced autoimmunity might also be explained by enhanced anti­
inflammatory network in parasitized individuals.
A robust anti-inflammatory network in parasitised individuals might also explain the 
reduced prevalence of inflammatory autoimmune disease in parasite-endemic areas. 
Regulatory signals act in a blanket manner to reduce inflammation, independent of 
immunological phenotype; therefore, in addition to reduction of TH2-mediated allergic 
inflammation, a robust anti-inflammatory network could inhibit TFH-mediated autoimmune 
inflammation. It has been suggested that the increasing prevalence of autoimmunity in 
industrialised areas, in parallel with improved sanitation and decreased exposure to 
infections, is contradictory to the hygiene hypothesis. Paradoxically, in a few studies, the 
prevalence of asthma and allergic disease (i.e. allergic rhinitis) have been positively 
correlated with the prevalence of autoimmune disease, for example, type 1 diabetes, 
rheumatoid arthritis and celiac disease [128-130]. This correlation indicates that Th1- 
mediated autoimmune responses and TH2-mediated allergic responses are not mutually 
exclusive and that there may be an underlying thread connecting these two types of 
aberrant immune activation. Potentially, the hygiene hypothesis could be extended to 
include autoimmunity. However, direct evidence linking lack of infections in childhood and 
development of autoimmune disease has not been obtained. This might be explained by 
the relatively low prevalence of autoimmune diseases (compared with allergy and allergic 
diseases), making it difficult to conduct epidemiological studies with adequate numbers of 
subjects.
1.4.4 By what mechanisms do parasites reduce inflammatory signals?
It has been established that parasite infections promote anti-inflammatory immune signals 
capable of inhibiting allergic responses. How is this facilitated? It is known that polyclonal 
IgE (specific for many different antigens) is elevated in parasite infection. Elevated levels 
of serum IgE are also indicative of atopy. In an effort to explain this apparent paradox, it 
was suggested that in parasite infection, non-allergen specific IgE and allergen-specific 
IgE bind to FceRI receptors on mast cells in a competitive manner. The excess of 
parasite-induced non-allergen specific IgE ensures that mast cell IgE receptors are 
occupied by many non-allergen specific IgE molecules and few allergen-specific IgE 
molecules. Mast cell degranulation requires binding of two allergen-specific IgE-FceRI to
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one antigen, therefore, the presence of many irrelevant IgE specificities will inhibit the j
allergic response to house dust mite [115, 131]. Whilst this hypothesis sounds plausible, it i
has not been universally supported.
An alternative explanation of the IgE paradox has been proposed. As mentioned above, 
TH2-type lgG4 antibody is also secreted in elevated quantities in parasite-infected people. i 
lgG4 inhibits mast cell degranulation induced by IgE [132]. As mentioned previously, mast 
cell degranulation initiates release of inflammatory mediators and cytokines. Therefore, 
this action of lgG4 could block the immediate allergic response to allergen. In support of 
this IgE-blocking theory, It has been identified that successful immunotherapy of allergy in 
humans is associated with induction of allergen-specific lgG4 antibody, despite persistent i
presence of allergen-specific IgE [133]. Supporting a role for lgG4 in down-modulation of 
allergic responses, prolonged exposure to cat allergens induced elevated serum lgG4 and ; i 
reduced atopy [134]. In summary, lgG4 has been considered an alternative TH2 antibody 
[134], inducing an augmented TH2 immune response that is not associated with allergic t
inflammation. Furthermore, it has been suggested that inflammation associated with t
autoimmunity could also be subverted by action of an augmented TH2 immune response 
such as that induced by lgG4 [135]. i
Clearly parasites can modulate the immune system in an intelligent way, so that the host 
maintains an appropriate degree of protection from the parasite, but the immune response 
is less inflammatory than that exhibited in response to other infectious agents. A mutual 
relationship ensues; the host does not eliminate the parasite and simultaneously, the 
parasite infection does not induce severe host tissue damage. With this knowledge, is it 
possible to exploit the anti-inflammatory effect of parasite infection for treatment of 
inflammatory diseases of the Western world? Recently, in a controversial study, Joel 
Weinstock treated volunteers with eggs of porcine whipworm Trichuris suis and 
discovered that active parasite infection induced amelioration of inflammatory bowel 
disease symptoms, normally mediated by a pro-inflammatory TH1 type immune response 
[136-138]. This was the first confirmatory study in humans of an effect frequently observed i
in murine models of autoimmune inflammation [32, 139, 140] and has been termed 'worm 
therapy’ [138]. Following the success of Weinstock’s study, treatment of MS (another a
TFH-mediated autoimmune disease) patients with T. suis eggs has been proposed [138]. i
This method of treating inflammatory conditions by direct administration of parasites, 
whilst clearly therapeutic, is relatively crude and not appealing for patients with atopic or 
autoimmune disease. To take this theme of research further, dissection of the mechanism 
of anti-inflammatory action by helminth parasites would provide a model for effective 
therapy of inflammation. Thus, pharmacologically mimicking the anti-inflammatory effect of
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helminths without the associated risk and disadvantages of chronic infection would be 
more appropriate for viable treatment of allergic and autoimmune disease.
1.5 Filarial Nematode Infections
1.2 billion people worldwide are at risk of infection with filarial nematodes (WHO 2005). 
Collectively known as filariasis, infection with filarial nematode parasites can be 
categorised into different forms (lymphatic filariasis or onchocerciasis), depending on the 
infective filarial nematode species. In humans, lymphatic filariasis is the result of 
mosquito-borne infection with one of three species of filarial nematode, Wuchereria 
bancrofti, Brugia malayi or Brugia timori. Due to its severe inflammatory pathologies (such 
as gross genital hydrocoele and morbidly swollen limbs (lymphoedema)) in a small 
percentage of infected individuals, lymphatic filariasis is commonly known as 
‘elephantiasis’. Onchocerciasis is caused by infection with Onchocerca volvulus, which is 
transmitted by the blackfly. Pathologies commonly associated with onchocerciasis include 
blindness (‘river-blindness’) and inflammatory skin lesions. Lymphatic filariasis has been 
identified as the second (second to mood (affective) disorders) leading cause of 
permanent and long-term disability world-wide [141-143].
1.5.1 Pathology associated with filarial nematode infection
By means of a mosquito bite, infective L3 larvae of the filarial nematode enter the host 
and migrate to a lymphatic vessel. Here, they grow and mature to adulthood by 
approximately 30 days post-infection {pi). The adult worms mate and the female produces 
millions of microfilariae (MF) by day 60 pi. The MF pass into the circulation, where 
mosquitoes take up a small number as part of a blood meal. Within the mosquito muscles 
the MF mature into L3 larvae, in preparation for infection of a new host to complete the life 
cycle [127](Figure 1.7).
It has been established that people living in filariasis endemic areas can be classified into 
one of three categories [127, 144]. ‘Asymptomatic microfilaraemia’ is the most common 
classification exhibited in populations of endemic countries. This category of people are 
MF'*’, but display no external symptoms or pathology to indicate the large numbers of 
microfilariae present in their circulation. Due to this apparent absence of immune 
response to MF, the infection can persist for decades within the host body. Individuals 
exhibiting chronic inflammatory pathology such as elephantiasis, lymphoedema and 
hydrocele comprise a second category. It is thought that eliminating the parasite infection 
from the host bloodstream induces chronic inflammation; therefore, these individuals are 
usually MF'. ‘Endemic normals’ comprise the remainder of the population, consisting of 
those who have been exposed to filarial nematodes, but exhibit no evidence of disease, 
despite the presence of anti-filarial antibodies circulating in their blood. The existence of
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‘endemic normal’ individuals is controversial and has been widely contested [127, 144]. 
Asymptomatic microfilaraemics can experience periods of acute inflammation, but how 
this change occurs is unclear. There is evidence to suggest that acute episodes of 
bacterial infection may be responsible for conversion from asymptomatic to chronic 
inflammation phenotype [145-147].
1.5.2 Immunology of filarial nematode infection
1.5.2.1 TH2-type immune response to parasites
Individuals harbouring MF exhibit markedly elevated levels of TH2-type lgG4 antibody and 
reduced levels other IgG subclasses (IgGI, lgG2 and lgG3) in their blood stream [148]. 
Furthermore, the levels of lgG4 have been shown to correlate with the severity of infection 
and MF counts [149, 150]. lgG4 does not fix complement unlike the other subclasses and 
binds weakly to Fc receptors, therefore it is thought that it binds filarial antigen without 
strong stimulation of effector cells.
IgE, a TH2-type immunoglobulin isotype often associated with inflammatory TH2- 
mediated allergic responses, is also induced in filaria-infected individuals. It has been 
suggested that IgE production may represent killing of worms in the host [151] and that 
IgE offers some protection from infection, because its levels are inversely associated with 
parasite load [152]. In support of this finding, IgE is exhibited at low concentrations in 
asymptomatic MF^ patients and in much higher concentrations in infected individuals with 
chronic inflammatory pathology (who have allegedly eliminated the MF)[153]. Although 
several immunological parameters have been measured in filariasis and onchocerciasis 
patients, the mechanism underlying the pathology of microfilaraemia has not been 
completely elucidated.
In filariasis patients, serum IFNy is reduced and IL-10 Is increased. IL-10 is a regulatory 
cytokine that can down-regulate IFNy, a key cytokine for promotion of THI-mediated 
immunity [154]. In summary, filarial nematode infected individuals exhibit a mild, mainly 
humoral, TH2-mediated immune response to infection. This type of immune response is 
much less inflammatory, and causes much less tissue damage than pro-inflammatory 
THI cell-mediated immune responses. Interestingly, the TH2-medlated immune response 
is mutually beneficial to the parasite and does not induce its elimination from the host.
1.5.2.2 Filarial nematode-infected individuals exhibit an immunosuppressed 
phenotype
In addition to exhibition of a TH2-mediated immune response, MF* patients appear 
somewhat immunosuppressed [155] hence, the normal immune response to inflammatory 
stimuli and subsequent (e.g. bacterial) infections is impaired in these individuals [156].
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The degree of immunosuppression appears to correlate with parasite load. In addition to 
increased production of IL-10 and high levels of lgG4, reduced T cell proliferation is a 
common symptom of MF* infected individuals [157, 158]. Parasite infection-induced 
immunosuppression is normally passed from mother to child in utero [159]. Babies born of 
filaria-infected mothers thus display reduced inflammatory responses to infection and 
generally also exhibit increased parasite loads also. The suppressed host immune system 
is beneficial to the filarial nematodes and ensures longevity of the parasite infection in the 
host, because once microfilariae have been released into the host bloodstream, an 
inflammatory immune response is damaging to both host and parasite. It has been 
suggested that immunosuppression may also render the individual susceptible to further 
infection with other parasites [160], however these areas of research are unclear. It is 
important to note that host immunity is not reduced to such a degree that a subsequent 
bacterial infection would be fatal; death of the host would not benefit the parasite either. 
More simply, the normal immune response is dampened, in order that inflammatory 
immune signals are not circulating in enhanced levels.
It has been suggested that anti-inflammatory T regulatory cells (Tregs) are responsible for 
reduced inflammatory responses in parasite Infected individuals [158]. Tregs are naturally 
occurring Ag-specific CD4* T cells that secrete IL-10 and TGFp, cytokines that can 
mediate anti-inflammatory effects. Tregs are induced by adult female worms that produce 
MF and by MF themselves. In support of this hypothesis, T cells that secrete IL-10 in 
response to filarial antigen have been isolated from PBMC of onchocerciasis patients with 
high MF loads [158].
1.5.3 ES products
Excretory-secretory (ES) substances produced by filarial nematodes have been 
postulated as mediators of the immunosuppressed phenotype exhibited in filariasis [161]. 
ES products include proteinases, protease inhibitors, cystatins, anti-oxidants and a 
homologue of macrophage inflammatory factor (MIF) [162, 163]. For example, parasite- 
derived antigens have been demonstrated to display collagenase activity [164]. 
Furthermore, cystatins (cysteine protease inhibitors) isolated from A. viteae, O. volvulus 
and B. maiayi have been studied in rodent models of infection. It has been demonstrated 
that after release from the nematodes, cystatins initiate down-regulatory mechanisms by 
inducing production of IL-10 [165] [166]. In support of this theory, immunosuppressed 
filariasis patients exhibit enhanced levels of circulating ES products, which correlate with 
parasite load [167]. Furthermore, the scale of immunosuppression exhibited in filariasis 
patients has been shown to correlate with the quantity of circulating parasite-derived 
antigen [168, 169].
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In a rodent model of infection with filarial nematodes, Acanthocheilonema viteae, 
enhanced secretion of ES products has been detected prior to onset of patency [170] and 
similar results have been obtained in a rodent model of infection with human parasite, B. 
malayi [171]. Satisfactory evidence confirming the immunomodulatory nature of parasite- 
derived ES products was obtained when ES product isolated from MF of W. bancrofti 
directly inhibited migration of leukocytes in patients with clinical filariasis [172]. In support 
of these findings, ES products derived from adult worms and MF of O. volvulus impaired 
proliferation of lymphocytes isolated from onchocerciasis patients [173].
1.5.4 ES-62
ES-62 is the 62kDa glycoprotein ES product of rodent fila ria l nematode 
Acanthocheilonema viteae [170]. Homologues of ES-62 are produced by human filarial 
nematode Brugia malayi and feline filarial nematode Brugia pahangi [174-176], ES-62 
comprises more than 90% of the total protein secretions produced by female adult (stage 
L4) A. viteae worms [170]. Work from this laboratory has focused on elucidating the 
structure, properties and functions of ES-62 in relation to the immune system, with the aim 
of elucidating the role and mechanism of action of ES products in human filarial nematode 
infections. In our laboratory, the immunological actions of ES-62 have been intensively 
investigated and ES-62 has been shown to exhibit a plethora of immunomodulatory 
actions on cells of the immune system in vitro and in vivo.
1.5.4.1 The structure of ES-62
Native ES-62 is tetrameric in structure and has been shown to contain three distinct types 
of N-glycan and the immunomodulatory post-translational modification, phosphorylcholine 
(PC) [177, 178]. N-glycans and PC are common components of molecules derived from 
filarial nematodes [179]. Analysis of the protein coding sequence revealed the presence of 
four potential N-linked glycosylation sites [180]. It is thought that PC is attached to the ES- 
62 molecule by binding directly to an N-acetyl glucosamine residue contained within the 
N-glycans. Several of the immunomodulatory actions of ES-62 have been attributed to the 
PC component of the native molecule, but it has not yet been defined whether the non-PC 
components of ES-62 exhibit any immunomodulatory functions. Analysis of the amino 
acid sequence of the non-PC components of ES-62 revealed 37-39% homology with a 
family of carboxy- and aminopeptidases, indicating that ES-62 might exhibit 
aminopeptidase activity [181]. Aminopeptidases are proteins necessary for protein 
degradation, cell cycle control and hormone level regulation, amongst other functions 
[182]. Indeed, a mild aminopeptidase action of ES-62 was confirmed by successful 
hydrolysis of aminopeptidase substrate, Leu-NHMec [180]. It was postulated that this PC- 
independent action of ES-62 might represent a parasite-specific function, for example, in 
digestion and uptake of proteins in the adult worm gut. Nevertheless, this proteolytic
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action of ES-62 was mild in comparison with its profound and widespread 
immunomodulatory activity.
1.5.4.2 The immunomodulatory effects of ES-62 in vitro
Treatment with relatively high concentrations of ES-62 (25-50^g/ml) induced low-level 
proliferation of murine splenic B cells in vitro [183]. However, this action was weak 
compared with the inhibitory effect of ES-62 (at low concentrations: 0.25-2p.g/ml) on B cell 
proliferation in response to ligation of the BCR [183]. This disruption of B cell activation 
was mediated by selective down-regulation of protein kinase C (PKC) isotypes and 
uncoupling of mitogenic signalling pathways, downstream of the BCR [184, 185]. 
Furthermore, this action of ES-62 was found to be PC-dependent as demonstrated by 
treatment with PC alone or PC-BSA in place of ES-62 [183] PC-dependent anti­
proliferative effects of ES-62 were also observed in cultured Jurkat T cells, rendering them 
anergic to TCR signalling [167], once again by interfering with the signalling cascades 
downstream of the Ag receptor [186]. These initial in vitro findings in lymphocytes 
provided the foundations for extensive work into the immunomodulatory and anti­
inflammatory properties of ES-62.
1.5.4.3 The immunomodulatory effects of ES-62 in vivo
ES-62 was initially described as a TH2-promoting molecule and this was supported by 
several findings. Injected into BALB/c mice, ES-62 induced an IgGI, but not an lgG2a 
antibody response directed against the non-PC components of its structure [167]. The 
IgGI antibody isotype promotes a TH2-mediated immune response and TH2 cytokine, IL- 
4, promotes antibody class switiching to IgGI [154]. The ES-62 specific IgGI antibody 
response was dependent on IL-4, demonstrated by absence of this antibody response in 
IL-4K0 mice [187]. IL-4 is fundamental to initiation of a TH2-mediated immune response 
and inhibits onset of a Th1 mediated immune response, by disruption of the IL-12 receptor 
(3 chain [188]. However, IL-4 deficient mice did not default to lgG2a antibody production in 
response to ES-62, indicating that suppression of the Th i mediated immune response to 
ES-62 was IL-4 independent. It was uncovered that the PC component of ES-62 was 
responsible for preventing development of a Thi-type antibody response, and this was 
induced in an IL-10 dependent manner [187].
1.5.4.4 Dissection of the effects of ES-62
Further support for ES-62 as a TH2-promoting molecule was obtained in dendritic cells. 
Treatment of bone marrow-derived dendritic cells conferred a TH2-inducing property on 
the cells and enabled them to prime naïve T cells into TH2 cells, secreting high levels of 
IL-4 and low levels of THI cytokine, IFNy [189]. This was corroborated by studies in 
peritoneal macrophages, where ES-62 inhibited pro-inflammatory cytokine production. In
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more detail, treatment of peritoneal macrophages with ES-62 alone induced low-level 
activation of the cells and production of Th1-promoting cytokine production, whilst 
rendering them hyporesponsive to subsequent stimulation with LPS and IFNy [190]. 
Moreover, the immunomodulatory effects of ES-62 on DC and macrophage function were 
largely mimicked by PC (conjugated to irrelevant protein, OVA or BSA) [191]. It was 
suggested that ES-62 diverted immune responses away from a pro-inflammatory TH I- 
mediated immune response in favour of a less inflammatory TH2-mediated immune 
response.
1.5.4.5 ES-62 IS anti-inflammatory In action
Recently it was proposed that rather than promoting a TH2 immune response, ES-62 
appeared to act in a more general anti-inflammatory manner. ES-62 treatment of mice in 
vivo (facilitated by subcutaneously implanted osmotic pumps continuously releasing ES- 
62 at concentrations similar to that secreted in filarial nematode infection) resulted in 
differentiation of bone marrow derived DC and macrophages that had an anti­
inflammatory phenotype [191]. More direct evidence of the anti-inflammatory action of ES- 
62 was obtained using a murine model of THI-mediated autoimmune inflammation, 
rheumatoid arthritis. ES-62 treatment of such collagen-induced arthritis delayed onset and 
severity of footpad inflammation and inhibited erosion of joints [192].
As mentioned previously, the immunomodulatory effects of filarial nematode infections 
has often been attributed to ES products generated by the parasites and secreted into the 
host bloodstream [161]. It has been suggested that ES products facilitate relay of 
inflammation-reducing signals from parasite to host immune system. Thus, it was 
proposed to exploit the facilitating action of a filarial nematode ES product to inhibit 
inflammation in allergic and autoimmune disease and ultimately, dissect the mechanisms 
of filarial nematode-mediated immunomodulation.
1.6 Aims of the thesis
The in vitro and in vivo immunomodulatory effects of ES-62, an ES product secreted by 
rodent filarial nematode A. viteae, have thoroughly and comprehensively been determined 
as a result of investigations conducted in this laboratory [193]. Therefore, the core aim of 
this project was to extend the previous research of this laboratory and determine the 
potential for exploitation of parasite product-induced immunomodulation in inflammatory 
disease by defining the anti-inflammatory properties of ES-62 in models of inflammatory 
diseases commonly exhibited in Western society. The specific aims of this thesis are 
described in more detail below.
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It has previously been determined that ES-62 delays onset and inhibits severity of 
inflammation in a murine model of rheumatoid arthritis [192]. However the mechanisms of 
action of ES-62 in this model have yet to be determined. Thus, a primary aim of this 
investigation was to confirm such action of ES-62 and extend this study to dissect the 
immunological mechanisms of anti-inflammatory action of ES-62 in a model of T h l-  
mediated autoimmune disease.
Previously, it has been identified that PC, a common component of pathogen-derived 
substances is largely responsible for several of the Immunomodulatory effects of ES-62. 
Thus, it was also aimed to determine the PC-dependency of the anti-inflammatory action 
of ES-62 in the arthritis model and furthermore, to examine the immunomodulatory 
properties of alternative structural components (e.g. carbohydrate) of parasite-derived 
substances on cells of the immune system.
It has been suggested that infection with helminth parasites inhibits murine models of 
allergy and TH2-mediated inflammation [110]. Following determination of ES-62-mediated 
inhibition of THI-mediated inflammation in a model of arthritis [192], the second aim of 
this project was to determine and dissect the action of ES-62 treatment in a model of TH2- 
mediated allergic disease, asthma.
As mentioned previously, SLE is an inflammatory autoimmune disease of heterogeneous 
pathology and ambiguous immunology. By utilising the MRL/lpr mouse model, 
inflammation commonly exhibited in human SLE can be examined in the laboratory. Thus, 
in addition, it was aimed to determine the effect of ES-62 treatment of the MRL/lpr model
of SLE. Furthermore, upon confirmation of any modulatory effect, it was aimed to dissect 
the mechanism of action of ES-62 in this model of inflammation.
Figure 1.1 Activation of dendritic cells and T cell priming
Immature dendritic cells (DC) normally reside in the peripheral tissues, where they 
perform a surveillance function. This function is mediated by uptake and processing of 
antigen which they encounter. In this maturation state DC exhibit low antigen-presentation 
capacity (low expression of MHCll) and express low levels of co-stimulatory molecules 
(such as CD40, CD80 and CD86). Following uptake and recognition of a pathogen- 
associated molecular pattern (PAMP; for example, lipopolysaccharide (LPS), a 
component Gram-negative bacterial cell wall), immature DC become activated or mature, 
signified by a morphological change (formation of dendrites). At this point, antigen uptake 
and processing functions are reduced and antigen presentation becomes the major 
function of the DC. Co-stimulatory molecules are up regulated on the surface of the DC 
and pro-inflammatory cytokines (such as TNFa and IL-12) are secreted. Following 
maturation, the antigen-presenting DC migrates to the secondary lymphoid organs in 
search of a naïve T cell, specific for the activating antigen. Priming of the naive T cell 
results in initiation of an antigen-specific immune response, the nature of which can be 
influenced by the pattern of cytokines secreted by the DC.
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Figure 1.2 Induction of immunity or tolerance to antigens
(A) Normally, presentation of self-antigen by DC to naïve autoreactive T cells results in 
apoptosis or anergy of the T cell. Thus, autoreactive I  cells are removed from the T cell 
repertoire and tolerance to the self-antigen is achieved.
(B) Conversely, when pathogenic antigens are presented by DC to naïve antigen-specific 
T cells, co-stimulatory molecules expressed on the surface of the DC are upregulated. 
Therefore, antigen-presentation in combination with a second co-stimulatory signal 
induces activation of the antigen-specific T cell, leading to proliferation and initiation of an 
immune response targeted at destruction and disposal of the pathogen.
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Figure 1.3 Effector functions of TH1 and TH2 CD4+ T cells
(A) The production of IFN-^ by TH1 cells is important for inducing the class switching of B 
cells to lgG2a production. These antibodies are highly efficient at fixing complement and 
can bind to high affinity FcyR expressed by macrophages. This is important for the 
opsonisation of particulate microbes, which promotes their phagocytosis by macrophages. 
IFN-y induces priming of macrophages, resulting in production of pro-inflammatory 
cytokines and synthesis of toxic oxygen radicals, hydrogen peroxide and nitric oxide. 
Finally, IFN-y and IL-2 are important for activating CDS"' CTLs to Increase their cytotoxic 
potential by inducing the production of perforin and granzyme. Following pathogen 
destruction, cellular debris is cleared by macrophage-mediated phagocytosis.
(B) The production of IL-4 by TH2 cells induces class switching of B cells to produce non­
complement fixing lgG1 antibodies. lgG1 acts to neutralise antigens and can promote 
their uptake without promoting inflammation. In addition, IL-4 induces the class switching 
of B cells to produce IgE antibody. IgE binds to FceRI expressed on mast cells, which 
together with IL-3 and IL-9 secreted by TH2 cells, primes mast cells for degranulation and 
release of inflammatory mediators following recognition of specific antigen. TH2 cytokine, 
IL-5 is an essential activator of and growth factor for eosinophils, which leads to the 
production of GM-CSF, IL-4, IL-5 and IL-13, which can lead to inflammation and augment 
TH2 development and responses.
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Figure 1.4 Immune response Initiation and effector mechanisms
An antigen-specific immune response is normally facilitated by initiation and effector 
mechanisms. Initiation of an antigen-specific immune response can be achieved by 
pathogen-induced DC activation and migration to the T cell area, followed by CD4* T cell 
priming. Following activation of antigen-specific CD4+ T cells, effector mechanisms are 
induced, which include CD8+ T cell mediated cytotoxicity, B cell mediated antigen-specific 
antibody production and macrophage activation. After destruction of pathogen (by 
cytotoxic T lymphocytes) and opsonisation of pathogen cells by pathogen-specific 
antibodies, the products of pathogen destruction are normally disposed of by 
phagocytosis.
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Figure 1.5 Development of an autoimmune response
An inflammatory autoimmune response can be initiated by activation of autoreactive T 
cells in response to recognition of self-antigen. However, the conditions required for 
activation of such T cells are unclear. Self-antigen might be presented by aberrant 
antigen-presenting cells (e.g. DC), promoted by the presence of danger signals, such as 
pathogen-derived antigens (e.g. LPS), products of inflammation, or pro-inflammatory 
cytokines. Inadequate peripheral tolerance mechanisms will ensure that activation of 
autoreactive T cells results in initiation of an inflammatory immune response, specific for 
the activating self-antigen. The inflammatory autoimmune response is mediated by the 
activation of normal immune effector cells (e.g. B cells and macrophages), leading to 
destruction of cells and tissues that express the self-antigen. Damage to tissue can lead 
to release of further self-antigen. Thus, in the presence of inflammatory mediators 
(released during mediation of the original autoimmune response), new autoreactive T 
cells can be activated and a positive feedback cycle of inflammation and tissue 
destruction may be set up.
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Figure 1.6 Development of an allergie immune response
Inhalation or Ingestion of allergen (non-self, non-pathogenic antigen) is recognised 
immediately by allergen-specific IgE, present in the allergenic individual. Ligation of 
allergen and IgE bound to FceRI on the surface of mast cells induces degranulation and 
release of inflammatory mediators, which recruit immune effector cells and TH2 cells to 
the site of allergen recognition. TH2 cells produce IL-4, which induces class switching of B 
cells to IgE production and mast cell activation, and IL-5, which induces differentiation and 
activation of eosinophils. Thus, a positive feedback cycle Is set up, generating 
inflammation in response to recognition of allergen. Usually, this cycle can be broken by 
prevention of allergen intake.
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Figure 1.7 Typical lifecycle of Wuchereria bancrofti and Brugia ma/ay/filarial 
nematode parasites
Adult worms live in the lymphatics of the human host where they reproduce sexually, 
releasing thousands of microflliariae into the bloodstream. These L1 larvae are ingested 
by mosquitoes when they take a bloodmeal. They shed their acellular sheath, penetrate 
the midgut and migrate into the flight muscles where they develop into L2 larvae. About 
two weeks later, L3 larvae migrate through the salivary glands to the proboscis. At this 
stage they can infect humans by injection into the skin when the mosquito feeds. They 
migrate into the lymphatics where they moult and mature into L4 larvae, before further 
maturing and differentiating to form adult worms. The development from microfilariae to 
adult worms can take several months and adult worms can live for many years.
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Appendix Figure 1 Predicted structure of ES-62 derived from A. viteae
ES-62 is known to be a PC-contalning N-linked glycoprotein. The structure of ES-62 is yet 
to be conclusively determined, but predictions have been made regarding the individual 
components of the complete glycoprotein. These have been detailed in this figure.
A, The location of key residues within the ES-62 sequence, including N-glycosylation 
sites, a possible site for interaction with PC donors, leucine-rich regions (likely to be 
involved in protein-protein interaction), and regions containing subcelluiar targeting 
motifs.
B, Prediction of a tertiary structure for the ES-62 monomer, indicating a helices and |3 
strands, as well as glycosylation sites, leucine-rich regions and residues involved in metal 
ion co-ordination (ES-62 shows homology with aminopeptidases that contain a divalent 
cation in their active site),
C, Proposed structure of the PC containing A/-glycans of ES-62. There is at least one and 
at most three N-linked glycans within the structure of ES-62. PC is linked to the glycans by 
phosphodiester linkage, with at least one (and at most 4) PC residues per glycan.
A, and B reproduced with kind permission from Goodridge et al, 2005
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2 Materials and Methods 
2.1 Animals
BALB/c, DBA/1, C57BL/6, ST2K0 (on a BALB/c background), DO. 11.10 (on a BALB/c 
background) and MRL//pr mice were used in undertaking this study. BALB/c, DBA/1 and 
C57BL/6 mice were purchased from Harlan Olac (Bicester, U.K.). ST2KO mice were 
maintained at the University of Glasgow and were a generous gift from Prof. S. Akira, 
University of Osaka, Osaka, Japan. DO. 11.10 mice were used to generate naïve CD4^T 
cells for T cell-DC co-culture experiments. These mice are homozygous for the transgenic 
TOR, which is specific for cOVA peptide323-3S9 in the context of l-A*^ . The T cells bearing 
the transgenic TOR were detected by flow cytometry using monoclonal antibody KJ1.26. 
All animals were specified pathogen-free and were housed under standard animal house 
conditions with free access to water and standard rodent pellets at the University of 
Glasgow Central Research Facilities or Joint Animal Facilities (Glasgow, U.K.) in 
accordance with local Home Office regulations.
2.2 Preparation of parasite products
2.2.1 ES-62
ES-62 is a secreted product of the adult filarial nematode, Acanthocheilonema viteae, 
which infects rodents. Its structure is tetrameric; a glycoprotein composed of four 62kDa, 
PC-contalning, monomers covalently attached to N-type glycans [194] ES-62 was 
prepared by Dr KM Houston and Ms C Egan at the Department of immunology. Institute 
for Biomedical Sciences, University of Strathclyde, as described previously [183]. In detail, 
ES-62 was purified from 500 ml of spent culture medium (endotoxin-free RPMI 1640 
(Invitrogen Life Technologies) with added endotoxin-free glutamine (2 mM), endotoxin-free 
penicillin (100 U/ml), and endotoxin-free streptomycin (100 pg/ml)) of adult A. viteae. To 
remove larval forms (microfilariae) released by the adult female worms, the medium was 
passed through a 0.22-pm pore size filter (Sigma-Aldrich). It was then transferred to a 
stirred cell ultrafiltration unit containing a YM10 membrane (Amicon). After reducing the 
volume of the sample to 5-10 ml and transferring the holding medium to endotoxin-free 
PBS, pH 7.2 (Cambrex Bioscience), it was further concentrated to 200-500 pi using 
Centricon microconcentrators with a 30-kDa cutoff membrane (Amicon). The sample was 
then applied to a 30 x 1 cm Superose 6 column (HR 10/30; BD Biosciences), fitted to an 
isocratic FPLC system (BD Biosciences), previously equilibrated with endotoxin-free PBS, 
pH 7.2, at room temperature. The column was eluted at a flow rate of 0.5 ml/min and 
monitored for absorbance at 280 nm. More than 95% of the protein eluted as a single 
peak, and this was purified ES-62. The purity and identity of each batch were confirmed 
by a combination of SDS-PAGE and Western blotting, the latter using a rabbit antiserum 
specific for ES-62. Endotoxin content of the ES-62 was determined using an Endosafe kit
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(Charles River Laboratories, Kent, UK). The purified ES-62 product contained <0.003 
endotoxin units/ml. In experiments where ES-62 was used in vitro, it was added to the 
culture media at 2 pg/mi.
2.2.2 GSL
Native A. suum glycosphingolipid was kindly prepared by Dr G Lochnit in the laboratory of 
Dr R Geyer, Institute of Biochemistry. University of Giessen, Giessen, Germany as 
described previously [195]. In detail. Ascaris suum worms (800g wet weight) were 
pulverized at 20°C in a pre-cooled Waring blender and lyophilized. Glycoiipids were 
extracted with chloroform, methanol, water 10:10:1 (v/v/v), chloroform, methanol, 0.8 M 
aqueous sodium acetate 30:60:8 (v/v/v), and 2-propanol, n-hexane, water 55:20:25 (v/v/v) 
and evaporated to dryness. To remove most of the contaminating triglycerides, the residue 
was treated with acetone at 4 ”0  for 2 h. Neutral and acidic glycosphingolipids were 
separated by DEAE-Sephadex A-25 column chromatography (Pharmacia). The column 
was equilibrated with and the sample taken up in chloroform/methanol/water 30:60:8 
(v/v/v). Neutral glycosphingolipids were obtained in the flow-through, and the acidic 
glycosphingolipids were eluted with chloroform, methanol, aqueous 0.8 M sodium acetate 
30:60:8 (v/v/v). Zwitterionic glycolipid fractions were further fractionated on a silica geleo 
column (Merck). Zwitterionic components were obtained by isocratic elution with 
chloroform/methanol/water 10:10:2.5 (v/v/v) from a silica geleo column (1-50 cm, 70-250 
mesh; Merck). After lyophilization, the glycosphingolipids were resuspended at 1 mg/ml in 
sterile PBS, sonicated, and stored at -20 °C until further use.
2.2.3 PC-free GSL
Removal of PC from the glycosphingolipid was also performed by Dr G Lochnit (Institute 
of Biochemistry, University of Giessen, Giessen, Germany). Briefly, native 
glycosphingolipid was dried in a stream of nitrogen and incubated for 24 h at 4 X  with 50- 
200 pi of hydrogen fluoride (HF, 48%; Fluka, Neu-Ulm, Germany). Excess was removed in 
a stream of nitrogen at room temperature.
2.3 Preparation of synthetic GSLs
The structures of three synthetic mimetics of incomplete native A. suum GSL are depicted 
in Figure 6.1. Mimetics of A. suum GSL were prepared as previously described [196-198]. 
Compound 1 resembles native glycosphingolipid but has the ceramide moiety replaced 
with an octyl group and lacks the two terminal sugars (galactose and N- 
acetylgalactosamine). Compound 2 differs in containing ceramide but lacks PC as well as 
the two terminal sugars [197, 198]. Compound 3 has features of a related PC-glycolipid 
from Pheretima species and consists of two galactose residues with PC attached to one 
and an octyl group to the other [196].
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2.4 Preparation of recombinant ES-62
Recombinant ES-62 was prepared from P. pastoris by Ms C Egan (Department of 
Immunology, University of Strathclyde, Glasgow.) as described previously [199]. ES-62 
w as a m p l i f i e d  by PGR us ing the p r im e r s :  MJA121 5 ’ -
AAGGGGTATGTCTGGAGAAAAGAGAGGCAGGTGTCCTTGCGGACAAAACTGTGGGT 
and MJA122 5’-ATGGGAATTGTTATAGGTTTTTGGATGAGA TTTGTGAGTAGT at 35 
cycles of 94°G for 30 secs, 54°G for 30 secs, 72°G for 90 secs, using Amplitaq (2U/100^ x1; 
Applied Biosystems, UK) according to the manufacturers instructions. pPlG9-derived 
plasmids containing ES-62 encoding sequences were linearised at the Sal I site for 4h at 
37°C. The linearised plasmids were then transformed into P.pastoris GS115 
(5[xg/transformation) and the transformed strains were selected on MD plates following 
electroporation according to the manufacturer’s instructions (Invitrogen). Selected clones 
were grown at high density (O D e o o n m  3-6) in 5 x 4 L flasks containing BMG (2L) at 30°G. 
The culture was then centrifuged (6000 x g for 15 min), and the pellet re-suspended in 
BMM (10 L) and incubated with agitation (200 rpm) at 30°G for 48-72h with addition of 
methanol (0.5% v/v) every 12h. After induction, the supernatant was separated from cells 
by centrifugation (6000 x g for 15 min) and filtered through a 0.45 pm membrane. 
Following HPLG purification more than 95% of the protein elutes as a single peak that 
represents ES-62. Purity and identity of each batch was confirmed by a combination of 
SDS-PAGE and Western blotting, the latter employing a rabbit antiserum specific for ES- 
62. Finally, the level of endotoxin in the recombinant ES-62 sample was confirmed using 
an Endosafe kit (Gharles River).
2.5 Preparation of nut derivatives
Nut derivatives were prepared by Dr MJG Alcocer (School of Life and Environmental 
Sciences, University of Nottingham, Nottingham, U.K.) as previously described [200]. 
Briefly, amplified genes for sunflower albumin 8 (SFA 8) and brazil nut albumin (Ber e 1) 
were ligated into pPlG9 (Invitrogen) plasmids and transformed into Pichia pastoris GS115 
(Invitrogen). Recombinant Ber e 1 and SFA 8 proteins were secreted by the yeast and 
purified by FPLG using a heparin-sepharose column. Both reverse phase purified 
recombinant proteins were shown to be absent of endotoxin as determined by an 
Endosafe Kit (Gharles River Laboratories, Ramsgate, UK).
2.6 Preparation of PC-OVA
OVA-PG was prepared by prepared by Ms G Egan (Department of Immunology, 
University of Strathclyde, Glasgow.) by combining diazoniumphenyl-PG and ovalbumin.
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Diazoniumphenyl-PC was prepared by dissolving 1 mmol of aminophenyl-PC (Toronto 
Research Chemicals) in 3 ml of 1 N HOI and adding 1 mmol of sodium nitrite. 
Diazoniumphenyl-PC (125 pmol) was coupled to 1.5 pmol of OVA by incubation in 5 ml of 
0.1 M borate buffer with 0.15 M sodium chloride, pH 9.0, for 12 h at 4°C, followed by 
dialysis against 10 mM phosphate buffer, pH 7.2. The absence of endotoxin from PC-OVA 
and OVA samples was confirmed using an Endosafe kit (Charles River Laboratories).
2.7 Murine Models of inflammation
2.7.1 Collagen-induced arthritis
CIA was induced and assessed by Drs A Boitelle and JA Gracie at the Centre for 
Rheumatic Diseases, University of Glasgow (Glasgow, U.K.) as previously described 
[192]. Male DBA/1 mice received 200 pg of bovine type II collagen (CM; Sigma-Aldrich) in 
CFA (Difco, Detroit, Ml) by intradermal injection (day 0). Collagen (200 pg in PBS) was 
given again on day 21 by i.p. injection. Control mice received PBS alone at the same time 
points. Mice were monitored daily for signs of arthritis for which severity scores were 
derived as follows: 0, normal; 1, erythema; 2, erythema plus swelling; 3, extension/loss 
function, and total score, sum of four limbs.
For the prophylactic treatment model (Figure 2.1a), mice were treated with 2 pg ES-62 s.c. 
on day -2, day 0 (day of immunization with Oil in CFA), and day 21 (i.p. collagen 
challenge). For the therapeutic studies (Figure 2.1b), mice were treated daily with 2 pg 
ES-62 s.c. for a total of 14 days commencing 1 day after CIA was clinically detectable. 
Control mice received PBS alone at the same time points.
2.7.2 Ovalbumin-induced asthma
The ovalbumin-induced asthma model was induced and maintained by Dr C McSharry, 
Department of Immunology, University of Glasgow. Following a similar previously 
published protocol ([201]; demonstrated in Figure 2.2), pulmonary inflammation was 
induced. Briefly, 6-8 week old female BALB/c mice were sensitised to whole ovalbumin 
(OVA) by intraperitoneal injection of 100 pg OVA in 1% alum (Alhydrogel; Brenntag 
Biosector, Fredriksund, Denmark) on days 0 and 14. On day 14 mice were additionally 
challenged intranasally with 50 pg aerosolised OVA in phosphate buffered saline (PBS) 
(after anaesthesia was induced with avertin (1,1,1-tribromoethanol) dissolved in amyl 
alcohol and diluted 1/40). On days 25, 26 and 27 mice were anaesthetised and re­
challenged with 50 pg aerosolised OVA in PBS, administered Intranasally. Control mice 
received PBS in place of OVA. Mice were euthanased on day 28 by lethal intraperitoneal 
injection of anaesthetic. For the prophylactic treatment model (Figure 2.2a), mice were 
treated with 2 pg ES-62 s.c. two days before and on the day of OVA administration. For
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the therapeutic studies (Figure 2.2b), mice were treated daily with 2 pg ES-62 s.c. for 
three days prior to sacrifice. Lungs were carefully dissected, fixed in Formalin and stored 
for sectioning. Dissection and processing continued as described in section 2.8 below.
2.7.3 Ovalbumin-induced chronic airway Inflammation
This chronic airway inflammation model (Figure 2.3) was designed as a preliminary model 
to extend the ovalbumin-induced asthma model (described above). The chronic airway 
inflammation model was induced and maintained by Dr C McSharry, University of 
Glasgow, Glasgow. 6 to 8 week-old female wild-type (BALB/c) and ST2K0 mice were 
treated as described for the asthma model (Section 2.7.2) until day 14. After this time, 
mice continued to receive once-weekly challenges with aerosolised ova until day 56. ES- 
62 treatment of this model was prophylactic. ES-62 (2 pg) in PBS was administered 
subcutaneously 2 days before and on the day of ovalbumin administration. Control mice 
received PBS. Mice were euthanased on day 57 by lethal intraperitoneal injection of 
anaesthetic.
2.7.4 Systemic Lupus Erythematosus (SLE) Model
Several different inbred murine models have been investigated for different aspects of 
autoimmune systemic lupus erythematosus pathogenesis and pathology [202]. The 
MRL/Mp-/pr//pr (MRL//pr) mouse substrain is genetically predisposed to the development 
of SLE-like syndrome, including pathologies such as lupus nephritis and spontaneous 
lupus-like skin lesions Thus, this model has been classified as clinically similar to the 
human disease. It has been determined that this mouse strain carries a mutation in the 
fas gene. The fas defect is believed to accelerate the autoimmunity of MRL//pr mice, 
which begins at the age of 3 months. The SLE model was maintained and continuously 
assessed by Drs A Boitelle, JA Grade and Prof IB Mclnnes at the Centre for Rheumatic 
Diseases, University of Glasgow (Glasgow, U.K.). Male MRL//pr mice were purchased at 
5-7 weeks old. Micturation was induced twice weekly and urine monitored for proteinuria 
and haematuria using a commercially available kit (Multistix; Bayer, Cambridge, U.K.). 
Mice were also assessed for arthritis using the score system adopted in the CIA model 
(Section 2.7.1). ES-62 (2 pg) diluted in PBS was administered subcutaneously twice per 
week. Control mice received PBS in place of ES-62. Autoimmunity was allowed to 
develop for 11 weeks before mice were euthanased by cervical dislocation. Kidneys were 
carefully dissected, snap frozen in OCT embedding medium and stored in liquid nitrogen 
for sectioning. Post-mortem  dissection and processing continued as described below 
(Section 2.8).
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2.8 Disease model post-mortem procedures
2.8.1 Broncho-alveolar lavage and analysis
Broncho-alveolar lavage was performed in mice from the asthma model (Section 2.7.2) as 
previously described [201]. Briefly, after lethal injection and careful dissection of the 
thorax, a 23G needle sheathed by plastic tubing was inserted, via a small incision in the 
trachea, and the airways flushed with 1ml PBS. BAL was centrifuged at 400 g for 5 
minutes and BAL fluid (supernatant) separated from BAL cells. BAL fluid was stored at 
-80°C until further analysis and BAL cells were resuspended in 1ml FAGSflow. Cytospin 
preparations of 10000-100000 cells were made, fixed with methanol, dried and stained 
using Rapi-Diff II (rapid Romanowsky stain). Subsequently, differential cell counts were 
made from these cytospins by counting at least 400 cells in random high-power 
microscope fields. Different cell types were determined by Identifying different staining 
and morphology. BAL fluid was analysed by ELISA or Luminex® for cytokine content.
2.8.2 Immunohistology of lung tissue
After BAL sampling, the lungs were removed and inflated with 1ml of 10% neutral- 
buffered formalin and then fixed in 10% neutral-buffered formalin for 72 h. The left lung 
was then dissected free and embedded in paraffin. Sections (6 pm) were stained with 
H&E and examined under xIO magnification, and peri-bronchial and peri-vascular 
inflammation assessed.
2.8.3 Serum preparation and analysis
Blood (1 ml) was obtained from each mouse, by cardiac puncture. This was centrifuged 
for 10 minutes to separate serum and blood cells. The serum was transferred to a 
separate tube and stored at -20°G until further analysis.
2.8.4 In vitro preparation of lymph node cells and splenooytes
Lymph nodes and spleen were carefully dissected from disease model mice. In the 
asthma and chronic airway inflammation models, lung-draining (thoracic, cervical and 
pulmonary) lymph nodes were kept separate from other (peripheral) lymph nodes and 
labelled as draining lymph nodes (DLN) and peripheral lymph nodes (PLN) respectively.
2.8.5 In vitro bone marrow cultures
Intact femurs were dissected from the mice and stored in RPMI on ice until further 
processing. Bone marrow was flushed from the bones using a 23G needle and syringe 
filled with RPMI 1640 (supplemented with 100 U/ml penicillin and 100 |xg/ml 
streptomycin). Bone marrow cells in suspension were underlaid with 1 ml FGS and 
incubated on ice to separate non-cell debris. After 5 min incubation time, the top layer was
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removed to another tube and underlaid with 1 ml PCS. Following centrifugation 400 x g, 5 
min, 4 X ), the resulting cell pellet was re-suspended in appropriate culture media.
2.8.6 Myography of airway smooth muscle
Myography is a method commonly used to study the contraction of smooth muscle in the 
walls of physiological vessels. Intact vessel rings are mounted on parallel pins within the 
myograph apparatus (Figure 2.4) and held under transverse tension. Contraction and 
relaxation of the smooth muscle in the vessel wall (to decrease or enlarge the vessel 
lumen) is detected and, via an isometric force transducer, can be measured. Mice from 
the asthma model were killed by an overdose of sodium pentobarbitone (0.01 ml/g) and 
the heart and lungs removed and placed in cold Krebs solution (composition (mM): NaCI 
118.4, NaHCOs 25, KCI 4.7, KH2PO4 1.2, MgSÛ4 0.6 , CaClg 2.5 and glucose 11.0; pH 
7.4). The trachea was dissected out and cleaned of the surrounding connective tissue. 
The trachea from each mouse were mounted on a Multi Myograph (Model 610, ‘myopin’ 
arrangement; Danish Myotechnology, Aarhus, Denmark) in Krebs solution at 37“C and 
bubbled with 16% O2, 5% CO2, 79% N2 throughout the entire experiment to simulate in 
vivo conditions. No attempt was made to remove the endothelial cell layer.
Preliminary experiments, using untreated BALB/c mice, were performed to assess the 
optimum tension at which the vessels should be held in the myograph apparatus. These 
experiments were conducted by increasing the tension across the vessels in a step-wise 
manner and measuring the maximum response to KCI (50 mM). The optimum tension was 
considered to be that when the maximum contractile response to KCI was greatest. These 
preliminary experiments indicated that 3.5 mN was the optimum tension at which the 
tracheal rings should be held for conducting the experimental protocols.
After experimental vessels were mounted on the myograph, they were left to equilibrate 
for at least 30 minutes or until they had attained a stable baseline. Tension was applied at 
this point and the vessels were allowed to equilibrate once more until a stable baseline 
had been achieved. Experiments involved: completing a maximal response to KCI (50 
mM) protocol, washout and restablisation of baseline, followed by completion of a MCh 
cumulative concentration-response protocol (CCRP). The MCh concentration was 
increased in half-log increments from 1x10"® to 3x1 O '^ M (Figure 2.5). Myodaq and 
Myodata software (Danish Myotech, Aarhus, Denmark) were used for data acquisition and 
data analysis respectively. Contractile responses are represented as a percentage of the 
vessels maximum response to KCI.
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2.9 Cell culture
2.9.1 Bone marrow-derived DC
Bone marrow dendritic cells were cultured as described previously [189]. Briefly, bone 
marrow progenitor cells were washed with sterile culture media and cultured for 6 days in 
large (175 cm^) flasks at 4x10® cells/ml in DC media (RPMI 1640 with 10% fetal bovine 
serum, penicillin (100 U/ml), streptomycin (100 fxg/ml), L-glutamine (2 mM), 2- 
mercaptoethanol (50 jxM) (all Gibco, Paisley, U.K.) and 10% culture supernatant of a GM- 
CSF-transfected X63 myeloma cell line at 37°C/5%C02/95% O2. Cells were fed with fresh 
medium on day 4 of culture.
2.9.2 Bone marrow-derived macrophages
Bone marrow-derived macrophages were cultured as described previously [191]. Briefly, 
bone marrow progenitor cells were cultured in macrophage media, which consists of 
DMEM (Life Technologies, Paisley, UK) containing 10% FCS (Life Technologies), 20% 
L929 cell culture supernatant (containing CSF-1), 2 mM L-glutamine, 50 U/ml penicillin, 50 
M.g/ml streptomycin and 5% horse serum. The macrophages were cultured at 
37°C/5%C02 for at least 6 days before beginning experiments. The media was replaced 
on day 4 of culture.
2.9.3 Generation of T cell blasts for cell contact assay with macrophages
On day 3 before set-up of the T cell-macrophage cell contact assay, spleens and lymph 
nodes were dissected from BALB/c mice and a single cell suspension was obtained by 
pushing them through Nitex mesh. This cell suspension was cultured at 1x10® cells/ml for 
3 days in lymphocyte media (RPMI 1640 with 10% FCS, 2 mM L-glutamine, 50 U/ml 
penicillin, 50 pig/ml streptomycin, 0.01% non-essential amino acids and 0.001% sodium 
pyruvate) containing PMA (10 ng/ml) and Con A (5 pg/ml) to generate T cell blasts 
(activated and proliferating T cells).
2.9.4 Purification of naïve CD4^CD62U' '^ ’^^ T cells for co-culture with DC
On the day of co-culture set-up, lymph nodes and spleens were dissected from untreated 
DO. 11.10 mice and a single cell suspension prepared by pressing through Nitex mesh. 
These cells were washed in RPMI 1640 and resuspended (10® cells/ml) in magnetic 
activated cell sorter (MACS) buffer (0.5% bovine serum albumin in PBS) and incubated 
with anti-CD4-MACS beads (Miltenyi Biotec), for purification using a MACS (LS) magnetic 
column. These purified CD4* T cells were further separated to isolate (naïve) 
CD62LXD4'^T cells using anti-CD62L-MACS beads and a magnetic (LS) column by 
following the manufacturers instructions (Miltenyi Biotec).
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2.9.5 THP-1 cells
THP-1 ceils are a human mononuclear cell line. These cells were cultured in RPMI (with 
10% FCS, 50 U/ml penicillin, and 50 pg/mi streptomycin) at 37°C until required.
2.9.6 Human peripheral blood T cells
Samples were derived with approval from Glasgow Royal Infirmary Ethical Committee, 
Glasgow UK. Peripheral blood (PB) T cells were prepared as described previously [203]. 
Briefly, normal donor derived PB T cells were stimulated for 72 h with PHA (5 pg/ml) / 
PMA (10 nM) in RPMI, with 2 mM L-glutamine, 100 lU/ml penicillin, 100 pg/ml 
streptomycin and 10% FCS, then fixed in 4% paraformaldehyde. Control non-activated PB 
T cells were also fixed for comparative purposes. Fixed PB T cells were then co-cultured 
with myelomonocytic THP-1 cells that were pre-treated with ES-62 (2 pg/ml) for 18 h.
2.10 In vitro assays
2.10.1 Culture of Dendritic Cells and Macrophages with LPS
On day 6 of bone marrow cell culture, DC or macrophages were gently removed from 
culture flasks. DC were plated out at 2x10® cells/well in a 6-well plate in a total volume of 
3ml DC culture media, whilst macrophages were plated out at 2x10® cells/well in triplicate 
in 96-well plates in a total volume of 250pl macrophage culture media. Cells were cultured 
unstimulated (media alone) or stimulated for 24 hours. For this stimulation DC were 
treated with 1 pg/ml lipopolysaccharide (LPS, from Salmonella Minnesota), whilst 
macrophages were treated with 100 ng/ml LPS plus 10  ^ U/ml murine IFNy (kindly donated 
by Prof. FY Liew, University of Glasgow). After this culture period, supernatants from both 
cell types were collected and stored at -20°C until analysis for cytokine content (section 
2.11.5). DC were gently removed from the culture well and separated from the culture 
supernatant by centrifugation, in preparation for analysis by flow cytometry (section 
2.11.3) or for co-culture experiments (section 2.10.2).
2.10.2 DC - DO.11.10 I  cell co-culture
After culturing bone marrow DC for 6 days, cells were gently removed from the culture 
flask. DC were plated out at 1 x 10® cells/ml in 6-well plates and grown in DC culture 
medium in the presence or absence of relevant stimulus for a further 24 h at 37°C. At the 
end of the DC 24h culture period, DC were washed three times with PBS before co- 
culturing with purified DO. 11.10 T cells (Figure 2,6). Briefly, CD4XD62L"'T cells were co­
cultured (2.5 X 10® cells/ml) with DC (2.5 x lO'’ cells/ml) in a total volume of 1 ml in 24-well 
tissue culture plates (for cytokine analysis) or in a total volume of 200 pi in 96-well tissue 
culture plates, (for proliferation analysis)(Nunc, Naperville, IL). Cells were cultured with or 
without cOVA peptide323-339 at various concentrations (0.03, 0.3, 3.0 and 30 nM) at 37°C. 
After 72h of culture, proliferation assay wells were pulsed with [®H] thymidine (1 pCi/well;
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Amersham, Buckinghamshire, U.K.) and cytokine assay wells were stimulated with PMA 
(50 ng/ml; Sigma) and ionomycin (500 ng/ml; Sigma). After a further 24h of culture (total 
co-culture time was 96h), cytokine assay culture supernantants were collected and stored 
at -20°C  and cells were harvested using a Betaplate 96-well automated harvester 
(Amersham Pharmacia Biotech) onto glass fibre filter mats (Wallac, Warrington, U.K.). 
Incorporated thymidine was assessed by liquid scintillation counting and results are 
expressed as counts per minute incorporated label ± S.E.M. (of triplicate culture wells).
2.10.3 T cell - Macrophage contact assay
The T cell - macrophage contact assay was designed to investigate only contact- 
dependent communication between T lymphocytes and macrophages. Macrophages were 
cultured from bone marrow progenitor cells as described above (section 2,9.2). After 7 
days of culture, macrophages were removed from their culture wells and washed three 
times with RPMI 1640. On the same day, T cell blasts (as described in section 2.9.3) were 
removed from their culture flask and fixed by incubating with 4% formaldehyde for 30 
mins, followed by washing three times with RPMI 1640. Macrophages and fixed T 
lymphocytes were plated out in triplicate in 96-well plates. Each well contained 2x10® 
macrophages and increasing numbers of lymphocytes (from 2x10®/well up to 1.6x10®/weII) 
in a total volume of 200|xl macrophage medium. After co-culturing at 3 7 X  for 48h, culture 
supernatants were collected and stored at -20°C.
2.10.4 In vitro cultures of LN cells and splenocytes from disease models
Single-cell suspensions of lymphocytes were obtained by pressing lymph nodes and 
spleens through Nytex mesh (Cadisch Precision Meshes Ltd, London, U.K.) to obtain a 
single cell suspension. Splenic red blood cells were removed by hypotonic lysis. Cells 
were cultured in RPMI 1640 medium at 1x10® cells/ml with 10% fetal bovine serum, 
penicillin (100 U/ml), streptomycin (100 pg/ml), L-glutamine (2 mM), 2-mercaptoethanol 
(50 pM), 1% non-essential amino acids and sodium pyruvate (1 mM) (all from Gibco Life 
Technologies, Paisley, U.K.). Cells were cultured, unstimulated (media alone) or in media 
containing antigen (whole OVA at 500 pg/ml (asthma model) or type II collagen at 50 
pg/ml (CIA model)) or mitogen (Con A at 5 pg/ml) for a 72h culture period.
2.11 In vitro analysis
2.11.1 RNA Extraction
At the end of the in vitro culture period, culture supernatants were removed and cells 
washed twice with cold, sterile PBS (Gibco, Paisley, U.K.). RNA-Bee solution (1 ml; AMS 
Biotechniology, Oxon, U.K.) was added directly to the cells in the culture wells and 
incubated at room temperature for 1 minute, to allow time for the cells to lyse, after which 
the samples were stored at -20°C until further use. The RNA-Bee samples containing the
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iysed ceils were then transferred to 1.5 ml microcentrifuge tubes, in preparation for the 
RNA extraction procedure. Chloroform (200 pi) was added to the tubes and samples were 
incubated for 10 minutes on ice. Following centrifugation at 13,000 x g (15 min, 4“C), the 
upper phase was removed and an equal volume of isopropanol was added. RNA was 
precipitated by incubation on ice for 30 min and separated by centrifugation at 13,000 x g 
(20 min). The remaining RNA pellet was washed with ethanol twice and dried before 
dissolving in diethyl pyrocarbonate (DEPC)-treated water. The RNA sample was heated to 
Q8°C for 2 min before further processing.
2.11.2 Taqman and RT-PGR
Taqman real-time PCR was conducted according to the manufacturer’s instructions (PE 
Biosystems, Foster City, USA) and as described by [204]. RNA was reverse transcribed 
using 100 U Superscript II RT (Life Technologies, Gaithersberg, USA) at 42°C for 50 min 
in the presence of 50 nM Tris-Hcl (pH8.3), 75 mM KCI, 3 mM MgCb, 5 mM DTT, 0.5 mM 
dNTPs and 5 pM oHgo(dT)i6 (Gibco BRL, Paisley, UK). Primers and fluorogenic probes 
(Table 2.1) were designed using the Primer Express™ vl.O program and purchased from 
Applied Biosystems. The probes used contained a reporter dye 5’-6-carboxy-fluorescein 
(FAM) and a quencher dye 3’-6-carboxy-tetramethyl rhodamine (TAMRA) and were HPLC 
purified. Extension from the 3’ end was blocked by attachment of a 3’ phosphate group.
PCR reactions were performed in the ABI-prism 7700 Sequence Detector, which contains 
a Gene-Amp PCR system 9600 (PE Biosystems). PCR amplifications were performed in 
triplicate in a total volume of 25 ml 10 mM Tris-HCI buffer (pH 8.3) containing 0.5 pi cDNA 
sample, 75 mM KCI, 10 mM EDTA, 200 pM dATP, dCTP, dGTP and 400 pM dUTP, 5 mM 
MgCb, 300 nM each primer, 200 nM probe, 0.625 U AmpliTaqGold™ and 0.25 U 
AmpErase UracilN-Glycolase (PE Biosystems). The PCR temperature protocol was as 
follows: 2 mins at 50 °C, 10 mins at 94°C, followed by 45 two-temperature cycles (15 
seconds at 94°C and 1 minute at 60°C). Data analysis was completed using Sequence 
Detection Software (PE Biosystems) and samples were normalised by the reference 
reporter hypoxanthine-guanine phosphoribosyltransferase (HPRT).
2.11.3 Analysis of DC surface expression
Bone marrow-derived DC were cultured and isolated from culture medium as described 
previously (sections 2.9.1 and 2.10.1) and surface expression was analysed by flow 
cytometry to determine the effect of experimental treatments on cell phenotype. DC were 
washed twice in 5 ml tubes (Becton Dickinson, UK) with 200 pi cold FACS buffer (PBS, 
1% BSA, 0.1% sodium azide) at 400 x g for 5 mins, 4°C.. An aliquot of DC from each 
experimental group was left unstained (no stain control). Whilst the remaining DC from 
each treatment group were separated into 5 aliquots and stained with PE-conjugated anti-
53
CD11c (to determine the CD11c'" dendritic cell population) and one of the following FITC- 
conjugated antibodies: anti-MHC class II, anti-CD40, anti-CDSO and anti-CD86, or anti- 
CD54-biotin followed by Streptavidin-FITC (all from BD Pharmingen) for 30 mins at 4°C. 
The optimum incubation concentration of these antibodies was previously determined by 
titration. Details of the antibodies used are presented in Table 2.2a. DC were washed with 
200 pi FACS buffer and re-suspended in 300 pi. Immediately prior to data acquisition, 50 
pg/ml propidium iodide (PI; Calbiochem) was added to each sample to enable 
identification of live cells during data analysis (live cells do not incorporate PI). Cellular 
fluorescence was aquired using a FACSCalibur™ Immunocytometry system (Becton 
Dickinson, Oxford, Oxon, UK) and CellQuest software. Data was compiled and analysed 
using FloJo software (Tree Star Inc., Oregon, USA) (Figure 2.7).
2.11.4 Serum antibody analysis
To detect Ig levels in serum samples from the disease model mice, Maxisorp (Nalge Nunc 
International, Denmark) ELISA plates were coated with 20 pg/ml OVA protein or type II 
collagen or 2 pg/ml purified capture antibody in PBS and incubated at 4°C overnight 
(details of antibodies used in this protocol are listed in Table 2.2b). Plates were washed at 
least 3 times with 0.05% Tween-20 in PBS before being blocked with 10% FCS for 1 hour 
at 37°C. Plates were washed and serum samples (diluted in 10% FCS in PBS) were 
titrated, added to the plate and incubated overnight at 4‘’C. Plates were washed again 
with 0.05% Tween-20 and biotin-conjugated anti-mouse detection antibody (2 pg/ml; BD 
Pharmingen) was added to the plate. The plate was incubated at room temperature for 1 
hour and washed. The plate was finally incubated with Streptavidin-HRP (1/1000 dilution 
in 0,05% Tween-20; BD Pharmingen) for 1h at room temperature. Plates were washed 
again and developed with tetramethylbenzidine (TMB) substrate (Insight Biotechnology 
Limited, Middlesex, U.K.). Absorbance at 630 nm was determined using an ELISA plate 
reader.
2.11.5 Cytokine analysis by sandwich ELISA
Cytokine ELISA was performed according to the antibody m anufacturer’s 
recommendations. IL-4, IL-5, IL-10, IFN-y and TNF-a were analysed using OPTEIA 
Mouse ELISA kits (BD Pharmingen) and IL-12p40 was analysed using antibody pairs (BD 
Pharmingen) Briefly, Maxisorp (Nunc, Roskilde, Denmark) ELISA plates were coated with 
anti-mouse capture antibody, diluted in sodium bicarbonate buffer (0.1 M, pH 7.4), or 
sodium phosphate buffer (0.2 M, pH 6.5) for IL-10 ELISA, overnight at 4‘^ C. Plates were 
washed with PBS-Tween (PBS containing 0.05% Tween 20) and blocked with 10% FBS 
in PBS for 1 hour at room temperature. All subsequent steps were performed at room 
temperature. After washing, samples and titrated standards were added to the plate and
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incubated for 2 hours. Plates were washed again and biotinylated anti-mouse detection 
antibody (BD Pharmingen), diluted in 10% FCS in PBS, was added to the plate. After a 
one-hour incubation, plates were incubated with streptavidin-HRP (BD Pharmingen) for 
approximately 1 hour, washed and developed using tetramethylbenzidine (TMB) substrate 
(Insight Biotechnology Limited, Middlesex, U.K.) and absorbance at 650 nm was 
determined using an ELISA plate reader (Dynex Technologies, Worthington, U.K.). 
Cytokine concentration was determined using the absorbance values obtained for the 
standards. The limit of detection was consistently 20 pg/ml.
2.11.6 Cytokine analysis by Luminex
In some experiments, the Luminex system was used to determine the concentration of 
several inflammatory cytokines simultaneously in culture supernatants. This was 
performed according to the manufacturers instructions using a Multiplex antibody bead kit 
(Biosource Inc., Worcester, U.S.A.) for Luminex. The Luminex method for cytokine 
quantitation employs spectrally encoded microbeads conjugated to antibodies specific for 
the range of cytokines to be measured. Each antibody is conjugated to individual beads 
that can be distinguished from beads conjugated to other antibodies by their individual 
fluorescence wavelength and size properties. Beads specific for particular cytokines can 
be gated to a particular region by the Luminex 100™ scanner (Bio-Rad Laboratories, 
Hercules, U.S.A.). Cytokine capture microbeads are incubated with samples and titrated 
standards at room temperature for 2 hours in a filter-bottom microplate, followed by 
washing and incubation with biotinylated detection antibody. This is followed by incubation 
with Streptavidin - R. Phycoerythrin (RPE) and a final wash step. Sample cytokine 
concentration is determined by comparing the fluorescence intensity of the microbeads in 
the sample wells with their counterparts in the known-concentration standards.
2.11.7 Tissue sectioning, staining and imaging
Intact lymph nodes, frozen in liquid nitrogen in OCT embedding medium (Miles, Elkart, 
USA) in cryomoulds (Miles), were cut into 6 pm thick sections using a cryostat 
(ThermoShandon, Cheshire, U.K.) and mounted on SuperFrost slides (ThermoShandon). 
Slides were fixed in formaldehyde and stored at -20°C until stained. Lymph node sections 
were stained using a protocol similar to that described previously [205]. Briefly, tissue 
sections were brought to room temperature in acetone for 10 min, air dried and 
rehydrated with PBS before being incubated in 0.1% azide/3% H2O2 for 45 min, to block 
endogenous peroxidase. Avid in solution (Vector Laboratories Ltd., Peterborough, UK) 
was added for 15 min to block unmasked endogenous biotin, then biotin solution (Vector 
Laboratories) was added to block excess avidin. Sections were washed in PBS after each 
treatment.
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Prepared sections were stained for expression of IgE as follows. Sections were incubated 
with permeabilization buffer (2% PCS, 2 nnM EDTA, pH 8.0, 0.5% saponin (Sigma- 
Aldrich)) for 30 min. After washing with PBS, sections were blocked with 1% blocking 
reagent (PerkinElmer) for 15 min. IgE was detected by incubating sections with 
biotinylated anti-lgE or rat anti-lgGI isotype control (diluted in 1% blocking reagent/G.1% 
saponin) for 40 mins. Sections were washed with TNT wash buffer (10% Tris (pH 7.5), 
10% NaCI and 0.05% Tween-20 (all Sigma) in distilled water) between incubations with 
Streptavidin-HRP (diluted 1/100 with 1% blocking reagent/0.1 % saponin; Perkin Elmer) for 
30 min and biotinylated tyramide (diluted 1/50 with amplification diluent; Perkin Elmer) for 
10 min. Fluorescence was attached to the IgE signal by incubating the sections with 
Streptavidin -  Alexa Fluor 647 (diluted 1/500 in TNB (10% Tris (pH 7.5), 10% NaCI and 
0.5% blocking reagent); Molecular Probes Inc., Eugene, U.S.A.) for 30 mins. At this stage, 
sections were also stained with FITG-anti-B220 (diluted 1/100 in TNB; BD Pharmlngen) to 
detect B cell follicles. Sections were washed with TNT and slides were mounted using 
Vectashield mounting medium (Vector). Photographs of sections were taken at x20 
magnification using a Hammamatsu camera and analysed using Openlab imaging 
software (Improvision, Coventry, U.K.). IgE positive cells were depicted in red.
2.12 Statistics
Where presented, statistical significance was determined by student’s t-test or AN OVA 
followed by Tukey’s multiple comparison, as appropriate. Statistical significance was 
assumed when p<0.05.
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Table 2.1 Primers and probes for Taqman Real-Time PCR
All probes and primers were purchased from Applied Biosystems
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Table 2.2 Antibodies used for flow cytometry and serum immunoglobulin
Table 2.2a Antibodies used for flow cytometry
All antibodies were purchased from BD Pharmlngen except KJ1.26, which was prepared 
in house from the B cell KJ1.26 hybridoma.
Table 2.2b Antibodies used for serum immunoglobulin analysis
All antibodies were purchased from BD Pharmlngen. OVA and Type II Collagen were 
purchased from Sigma.
58
crO" § O) cnCOcr CO COCO CO r " ro
roN)tocr
CO CO CO CO c_
ro(jO rocn"OŒQ .
CO CO COQ.Q .
toCO CO CO CO
00 00
CO
to
ZT T1 T|T1
c.Q . Q . tno>•a Q . CL
CO CO CO CO COQ.
Q .
O.
CO CO CO CO COcr
Q ,a.
& o.
o
CO CO CO CO
to toCO CO
CO COQ. o. Ol Q. Q .Q. O. CL CL O-CL CL CL tocrro ro
C O C O C Q C O C O C O C O C O C Q C O C O C O C O C O
ro00 ro 00 ro
Figure 2.1 Collagen-induced arthritis induction protocol
Male DBA/1 mice received 200 pg of bovine type II collagen in Complete Freund’s 
Adjuvant (CFA) by intradermal (/.cf.) injection (day 0). Collagen (200 pg in PBS) was given 
again on day 21 by i.p. injection.
Prophylactic treatment protocol: Mice were treated with 2 pg ES-62 (s.c.) on day -2, day 0, 
and day 21.
Therapeutic treatment protocol: Mice were treated daily with 2 pg ES-62 (s.c.) fora total of 
14 days commenced 1 day after CIA was clinically detectable.
Control mice received PBS in place of ES-62 at the same time points.
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Figure 2.2 Ovalbumin-induced airway inflammation protocol: prophylactic 
treatment with ES-62
BALB/c mice were sensitised with an ovalbumin (100 pg)/aluminium hydroxide (2 mg) 
emulsion intraperitoneally (OVA/ALUM i.p,) on days 0 and 14 and challenged with OVA 
(diluted in PBS) intranasally (OVA i.n.) on days 14 (50 pg), 25 (2 pg), 26 (2 pg) and 27 (2 
pg) to stimulate onset of airway inflammation. There were four experimental groups 
denoted: control, ES-62, asthma and asthma+ES-62. The term ‘Asthma’ was used 
because the allergic pulmonary inflammation exhibited in these mice was similar to that 
observed in asthma.
Prophylactic treatment protocol: ES-62 treatment (2 pg) was administered subcutaneously 
two days before and on the day of OVA administration, i.e. on days -2 , 0, 12, 14, 25 and 
27.
Therapeutic treatment protocol: ES-62 treatment (0.4 pg, 2 pg or 10 pg) was administered 
subcutaneously on days 25, 26 and 27.
Mice in control treatment groups were administered with PBS in place of OVA/ALUM, 
OVA or ES-62. On day 28 of the protocol mice were sacrificed by lethal injection of 
anaesthetic.
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Figure 2.3 Ovalbumin-induced chronic airway inflammation protocol: 
prophylactic treatment with ES-62
BALB/c mice were sensitised with an ovalbumin (100 ^ig)/aluminium hydroxide (2 mg) 
emulsion intraperitoneally (OVA/ALUM i.p.) on days 0 and 14 and challenged with OVA 
(diluted in PBS) intranasally (OVA i.n.) on day 14 (50 (ig) and once every seven days until 
day 56 (2 ^g), to induce chronic airway inflammation and airway remodelling. ES-62 
treatment (2 pig) was administered subcutaneously two days before and on the day of 
OVA administration, i.e., on days -2 , 0, 12, 14, 19, 21, 26, 28, 33, 35, 49, 42, 47, 49, 54 
and 56. Mice in the control treatment groups were administered with PBS in place of 
OVA/ALUM, OVA or ES-62. On day 57 of the protocol mice were sacrificed by lethal 
injection of anaesthetic.
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Figure 2.4 Myograph apparatus
Myography is an experimental method used to determine the contractile properties of 
small vessels (of internal diameter 100 p.m-3 mm) in terms of responsiveness to 
hormones, agonists or contractile agents. Using the Multi Myograph apparatus (Danish 
Myotechnology) in the 'myopin' arrangement, four individual vessels can be analysed in 
identical in vitro conditions. The (5 ml) organ baths are continually perfused with Krebs 
solution (bubbled with 16% O2, 5% CO2, 79% N2) and maintained at a concentration of at 
37°C throughout the entire experiment, to simulate in vivo conditions. Micro-dissected 
tracheal rings are fed onto the myopins taking care not to damage the tissue and the pre­
determined optimum tension is applied using the micrometer screw gauge. Treatments 
are applied directly to the organ bath therefore the treatment concentrations are 
calculated based on a final volume of 5 ml. The distal myopin (A) is fixed, whilst the 
proximal myopin (B) moves in response to contraction of the tissue or alteration of the 
micrometer screw gauge. Changes in tension of the tissue are detected by the transducer, 
which is electronically linked to the Myodaq (Danish Myotechnology) acquisition software.
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Figure 2.5 A typical cumulative concentration réponse protocol using the 
myography technique
This figure represents a typical tension plot obtained during induction of a cumulative 
concentration-response protocol, using the Multi Myograph apparatus (Figure 2.4) and 
Myodaq acquisition software (Danish Myotechnology). After the vessel is mounted on the 
myograph apparatus, it is left to equilibrate for at least 30 minutes or until it attains a 
stable baseline. The pre-determined optimum tension (3.5 mN) is then applied and the 
vessel Is allowed to equilibrate once more until a stable baseline tension had been 
achieved. At this point KCI is added to the organ bath (at a final concentration of 50 mM). 
Once the contractile response to KCI has plateaued (KCImax) the organ bath solution is 
washed and the vessel is allowed to attain a stable baseline once more. The cumulative 
concentration -  response protocol (CCRP) to a contractile agent (e.g. methacholine) is 
started by adding the lowest concentration (e.g. 1x10'^ M) of the agent to the organ bath 
and allowing the tension response of the vessel to plateau. Without washing, the 
concentration of the agent in the bath is increased to the next determined concentration 
and this pattern is repeated in (half log) increments until the vessel has been exposed to 
the highest concentration of the agent (e.g. 3x10''* M) and the tension response allowed to 
plateau. At this point the bathing solution in the organ bath is refreshed several times to 
wash the vessel. The maximum tension response of the vessel at each concentration of 
contractile agent can then be expressed as a percentage of KCImax-
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Figure 2.6 Determination of the percentage of CD4* transgenic OVA-specific 
TCR T cells In lymph node cell and splenocyte cultures from DO.11.10 
BALB/c mice
A Dot plot of forward scatter versus side scatter, showing the population of cells deemed 
healthy by their position on this plot. Forward scatter gives a measure of the size of cells, 
whilst side scatter gives a measure of their granularity. The gate indicates cells of the 
correct size and granularity associated with lymphocytes.
B-D Dot plot showing unstained lymphocytes (B). Dot plot of lymphocytes single stained 
with anti-CD4-PerCP, thus allowing identification of CD4'" I  lymphocytes (C) Dot plot of 
lymphocytes single stained with the anti-clonotypic KJ1.26-biotin-streptavidin-PerCP. This 
antibody binds the TCR expressed by CD4^ T cells from DO. 11.10 BALB/c mice, which is 
specific for the chicken ovalbumin peptide 323-339 bound to 1-Ad MHO class II (D).
E Dot plot showing the population of transgenic CD4"^KJ1.26^ T cells from a naïve mouse 
with gate for double positive CD4^KJ1.26"" T cells.
F Dot plot showing the population of transgenic CD4"^KJ1.26^ T cells from an immunised 
mouse. From this plot the population of GD4'^KJ1.26'*' T cells can be clearly identified and 
gated, thus allowing the percentage of CD4"^KJ1.26^ T cells from the total lymphocyte 
population to be calculated.
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Figure 2.7 FACS analysis of costimulatory molecule expression by dendritic
cells
A Dot plot of forward scatter versus side scatter, showing the population of cells deemed 
healthy by their position on this plot. Forward scatter gives a measure of the size of cells, 
whilst side scatter gives a measure of their granularity. The gate indicates cells of the 
correct size and granularity associated with dendritic cells
B Dot plot of forward scatter versus propidium iodide (PI) staining, showing the population 
of dendritic cells deemed viable by their lack of PI fluorescence. PI is excluded from viable 
cells, but can enter cells with porous membranes, such as dead cells, whereupon it binds 
the cellular DNA in a stoichiometric manner.
C Dot plot of cells from a murine bone marrow-derived dendritic cell culture (bmDC). Dead 
cells were excluded from analysis by adding propidium iodide (50 pg/ml) immediately prior 
to data collection, as healthy cells should not accumulate PI. Positive and negative PE 
and FITC quadrants were then established using unstained dendritic cells to take into 
account the auto-fluorescent nature of dendritic cells. Alternatively, positive and negative 
quadrants were similarly established using dendritic cells stained with the relevant isotype 
control antibodies for the costimulatory molecule being analysed.
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3 Investigation of the mechanisms of ES-62 mediated anti­
inflammatory action in Collagen-Induced Arthritis
3.1 introduction
Rheumatoid arthritis (RA) is a TH1-mediated autoimmune disease characterised by 
chronic articular inflammation, particularly of the small joints of the hands and feet. With a 
prevalence of 0.8%, RA is the most common and the most disabling chronic inflammatory 
joint disease in the UK [206]. In extreme cases the inflammation can also affect the major 
organs of the body. Progression of the disease leads to erosion of cartilage and, 
eventually, periarticular bone, which has crippling effects for the patient [207]. The 
aetiology of RA is currently unclear and it has recently been concluded that RA 
susceptibility and outcome are influenced by a combination of several genetic and 
environmental factors [208]. Evidence indicates that many RA patients have similar 
genetic backgrounds. A significant number of patients (more than 80%) express similar 
mutations in the HLA-DR locus [209], which encodes proteins that form part of the major 
histocompatibility complex (MHC) class II binding site. MHC expressed on the cell surface 
facilitates antigen presentation, thus, auto-antigen presentation has been suggested in 
theories of RA pathogenesis [210]. However, it must be noted that RA is not classified as 
a genetically-linked disease because not all RA patients exhibit HLA-DR anomalies and 
not all individuals exhibiting this genetic abnormality develop RA. As observed in several 
autoimmune disorders, the majority of RA sufferers are female, implicating gender and, 
therefore, sex hormones in susceptibility to RA.
3.1.1 Animal models of rheumatoid arthritis
Several laboratory models of RA have been developed to help dissect the mechanisms of
pathogenesis and chronic pathology exhibited in the human disease. Adjuvant arthritis
was the first described model of induced RA and is brought about by administration of
Complete Freunds Adjuvant (CFA) [211]. However, it remains unclear how (CFA) Is able
to induce joint-specific arthritis-like inflammation. Due to a lack of correlation of
effectiveness of treatment in this model and human RA, models of antigen-induced
arthritis (Agi A) superceded adjuvant arthritis [212]. Agi A can be induced by immunization,
involving administration of irrelevant antigen (usually BSA) in CFA, followed by challenge
(administration of antigen without CFA) [213]. This administration of antigen is usually
directly to the site of inflammation, i.e. the joint, and induces inflammation similar to that
observed in human RA joints. Progress in the design of arthritis models and increasing
knowledge about RA pathology led to development of the first collagen-induced arthritis
model in rats [214]. This model of arthritis reflects several features of human RA, including
histopathological features, such as joint erosion and several immunological aspects, such
as the inflammatory cell infiltrate and cytokines involved. When compared with previous
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models, it is believed that the CIA model exhibits the greatest similarity to the human 
disease [215, 216]. Unresponsive to NSAIDs or methotrexate (early RA treatments), CIA 
has been viewed as an ideal model for investigation of new RA therapies designed to 
treat patients not responding to conventional RA treatment [217, 218]. In laboratory 
research, CIA remains a versatile and economically viable method of investigating arthritis 
pathology and therapy. The most renowned and widely used CIA model is set up in mice 
by immunising (intradermally) with type II collagen and CFA and challenging 
(intraperitoneally) with type II collagen to create the pathology of arthritis in the joints of 
the feet [214, 219]. Thus, CIA has provided the field of arthritis research with insight into 
the immunopathology of human RA, highlighted several potential molecular targets for 
immunotherapy of RA patients and provided a system with which these targets can be 
investigated [220].
3.1.2 The immunopathology of rheumatoid arthritis
Samples obtained from animal models and patient biopsies have enabled the immunology 
of RA to be analysed and the cell types involved to be uncovered. In inflamed RA synovial 
joints there is mass infiltration of blood-derived cells. Synovial fluid is enriched with 
neutrophils, whilst T cells, macrophages and DC are also detected [207], suggesting that 
these cell types play an important role in the pathogenesis of RA. The synovial membrane 
encasing the joint becomes infiltrated by macrophages and T cells and, as a result, is 
increased in diameter. All the cell types present in this tissue are in an activated state, 
expressing surface molecules necessary for antigen-presentation and secreting pro- 
inflammatory mediators, which sustain the chronicity of the inflammatory environment.
Dendritic cells (DC) facilitate communication between cells of the innate and adaptive 
immune responses. They are also pivotal in initiation and direction of adaptive immune 
responses. Following activation in the periphery and migration to the secondary lymphoid 
organs, DC communication with T cells, via antigen-presentation, co-stimulation and 
cytokine secretion, helps to stimulate and co-ordinate inflammatory immune responses 
throughout the body tissues [3]. Mature antigen-presenting DC have been identified in RA 
synovial fluid and are thought to play an important role in amplification of the inflammation 
exhibited in RA [26, 221-224]. It has been identified that activated myeloid DC present 
within synovial fluid and synovial tissue may promote the inflammatory environment of the 
RA synovial joint [225, 226]. Hence, it has been suggested that DC may be an important 
therapeutic target for treatment of RA [227]. Interestingly, it has been shown that anti-TNF 
therapy (Infliximab) strongly inhibited the maturation and activation of circulating DC, 
demonstrated by reduced expression of the DC activation marker, CD83 in RA patients 
[228] and indicated that activation of DC is induced by TNFa.
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Activation of T cells marks the beginning of the antigen-specific phase of an immune 
response. It has been suggested that RA is a T cell-driven disease and that T cells direct 
the destructive action of the other cell types involved [229]. Moreover, it has been 
suggested that antigen-induced pathogenesis of RA could be brought about by 
autoreactive T cells. Indeed, T cells continuously infiltrate the RA synovium and comprise 
20-30% of the mononuclear cells present [207]. In support of the proposed TH1- 
phenotype of RA inflammation, the majority of T cells present are TH1-type, identified by 
their secretion of IFNy and many arthritis models rely on T cells to bring about the full 
extent of the pathology. For example, a direct role for antigen-specific T cells has been 
identified in the collagen-induced arthritis model [230]. Further support for T cell-mediated 
inflammation in CIA has been provided by blockade of CIA with cyclosporin, an antagonist 
of T cell signalling [231]. Moreover it is widely established that T cells have a role in 
helping B cell antibody secretion [232] and activation of other immune cell types present 
in the inflamed joint [233, 234]. Whether this is representative of the immunology in RA 
patients is yet to be determined.
Whilst it has yet to be confirmed, it has been recognised that B lymphocytes, by secretion 
of antibodies, play a significant role in the pathogenesis of many autoimmune diseases 
[235]. It has thus been postulated that RA is, at least in part, mediated by auto-antibody 
production. Auto-reactive B cells, present in the synovium, may be responsible for the 
autoimmune response observed in RA, via production of jo in t protein-specific 
immunoglobulin. Indeed, B cell depletion therapy is currently under trial as a new method 
of treating RA inflammation [236-238] as collagen specific antibodies are detected in 
circulation of RA patients. Consistent with this, mice deficient in B cells are resistant to 
CIA [239], however, in contrast, it has been demonstrated that injection of Rag-/- mice 
(that do not contain T cells or B cells) with type II collagen (without adjuvant) induced 
onset of arthritis. This indicated that collagen was capable of inducing chronic 
inflammation without activating cells of the adaptive immune response [240]. Therefore 
the relative importance of T and B cells in CIA inflammation and joint erosion remains 
unclear.
Monocytes infiltrate the RA synovial membrane and differentiate into mature 
macrophages [241], hence, the synovial lining in RA patients comprises activated 
macrophages alongside fibroblast-like synoviocytes [242]. Macrophages also become 
enriched in the invading pannus, the area where the synovial lining layer meets cartilage 
and tissue damage begins. It has been demonstrated that the number of macrophages 
present in the joint correlates with the severity of damage exhibited in RA patients [243]. 
Therefore, it is believed that macrophages play an important role in chronicity of RA. By 
secreting pro-inflammatory cytokines, such as TNFa and IL-1, and possibly participating in
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auto-antigen presentation, macrophages could recruit and activate other leukocytes and 
induce maintenance of the inflammatory environment in RA synovium. Nevertheless, it 
has been demonstrated that macrophages are not contributory to initiation of RA 
pathogenesis [244], suggesting that their primary function is facilitation of inflammatory 
effector mechanisms. However, the therapeutic action of traditional RA treatment, 
methotrexate, in some patients has been attributed to the anti-inflammatory effects of this 
anti-metabolite drug on effector synovial macrophages [244].
Clearly the inflamed synovium contains several inflammatory cell types, all with potentially 
complex roles in RA pathogenesis and maintenance of ongoing pathology. It has been 
suggested that arthritis pathology and pathogenesis is the result of interactions between 
these cell types. Dissection of these interdependent relationships may provide further 
insight into pathology and potential targets for therapy. For example, macrophages 
differentiate from myeloid precursor cells and have important functions in antigen 
presentation and maintenance of the inflammatory environment via cytokine production 
and cell surface co-stimulatory molecule expression. Within the synovial joint, 
macrophages, T cells and fibroblast-like synoviocytes (FLS) lie in close proximity [245]. 
Evidence has suggested that the pathogenesis of RA is facilitated by communication 
between such cells in the synovium, particularly in a cell-contact dependent manner. 
Mclnnes et al [245] formulated a hypothesis dissecting the communication between these 
three cell types into cell-contact-dependent and cytokine-secretion-dependent categories, 
which work together to bring about the production of matrix metalloproteinases and 
prostaglandins that facilitate the inflammation and erosion pathology of RA (Figure 3.1; 
[245]). In this model, T cells reciprocally activate macrophages and FLS. Facilitated by 
cell-cell contact, via membrane-bound cytokines and/or co-stimulatory molecules, T cells 
stimulate macrophages to produce RA-promoting, pro-inflammatory cytokines, such as 
TNFa, IL-1, IL-15 and IL-18. In turn, these cytokines re-stimulate the T cell to further 
activate the macrophage by cell contact, or perhaps via the production of IFNy, a T cell- 
specific, pro-inflammatory cytokine. In this manner a positive feedback communication 
system is set up. Synovial T cells interact in a similar manner with FLS and an 
inflammatory environment is created, initiating the production of matrix metalloproteinases 
and prostaglandins, which help to facilitate the cartilage destruction and inflammation 
exhibited in this disease respectively
3.1.3 Immunology of rheumatoid arthritis
RA has generally been associated with an imbalance of cytokines and the repertoire of 
cytokines in the inflamed synovium has been intensely investigated. Despite the majority 
of T cells found in the RA synovium being of the TH1 phenotype [246], the presence of T 
cell-produced cytokines, such as IL-2 and IFNy, is relatively low. In fact, cells of the innate
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immune system produce most of the synovial cytokines detected. TH1-promoting, pro- 
inflammatory cytokines, TNFa, IL-1, IL-6, IL-15, IL-18 and GM-CSF are most prevalent 
[203, 247] and likely secreted by infiltrating macrophages (and T cells) and resident 
synovial fibroblasts. TNFa, a pro-inflammatory cytokine predominantly secreted by 
macrophages and DC, is thought to have a paramount role in RA pathogenesis and IL-1, 
a cytokine whose production is induced by TNFa [248], are both chronically elevated in 
synovial fluid and serum of RA patients. Furthermore, a transgenic mouse that 
overexpresses TNFa exhibited spontaneous onset of arthritis [249]. Based on these 
combined findings it was concluded that TNFa was seminal in pathogenesis of arthritis 
and therefore an appropriate target for reduction of arthritic inflammation. It is believed 
that the major role of TNFa is in initiation and maintenance of the inflammatory 
environment in the synovium, whilst IL-1 appears to have a predominant role in joint 
destruction [250].
Identification of the complex role of cytokine networks within RA has led to development 
of anti-cytokine therapies for the disease [251]. The CIA model has been used extensively 
in pre-clinical trials for development of drugs now regularly used to treat RA patients [220, 
252], including inhibitors of TNFa [253] and IL-1 [254]. Anti-TNFa therapy has been most 
widely used [255], in combination with methotrexate, an anti-metabolite drug. As 
mentioned above, TNFa is upstream of IL-1 therefore, blockade of TNFa inhibits IL-1 
production. Furthermore, it was identified that TNFa antagonists induced inhibition of 
other pro-inflammatory cytokines found in RA synovium, promoting the theory that 
complex cytokine networks are involved [207]. Blockade of TNFa is mediated in RA 
patients by treatment with recombinant TNF receptor, or anti-TNF antibody, prescribed as 
Etanercept and Infliximab, respectively. Treatment with these drugs is successful in many 
patients, underlining the integral role of TNFa in inflammation progression. However, 30 to 
40% of RA patients do not experience anti-inflammatory effects from this type of therapy 
[256], highlighting the heterogeneous nature of this disease in different cases. Anti-IL-1 
treatment has been therapeutic in some patients but clearly, anti-cytokine therapy is not 
universally effective and new methods of therapy are currently being investigated. For 
example, blockade of B-cell activity with anti-CD20 monoclonal antibody (RItuximab) and 
the inhibition of T-cell activation with fusion protein CTLA4lg are currently undergoing 
trials as new treatments for RA [257].
3.1.4 Aims
As previously discussed in Chapter 1, in countries endemic for parasite infections, 
autoimmune disease is relatively rare [258], suggesting parasite infection may protect us 
from development of autoimmunity . In support of this theory, it has previously been
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demonstrated that infection with the parasite Schistosoma mansoni prevents induction of 
a model of autoimmune diabetes [140]. Could this inhibition of autoimmunity by parasite 
infection be mirrored in a model of RA? It has been suggested that parasite excretory- 
secretory (ES) products possess immunomodulatory properties and that diversion of 
inflammatory immune responses in parasitized individuals, to favour the survival of the 
parasite, is due to the action of these substances [161]. ES-62 is a 62kDa 
phosphorylcholine (PC)-containing glycoprotein that is secreted by the rodent filarial 
nematode, Acanthocheilonema viteae [170]. Research conducted previously in this 
laboratory [184-187, 189-191] has demonstrated that ES-62 has immunomodulatory 
actions on cells of the immune response. Indeed, it has been determined that the 
immunomodulatory effects of ES-62 extend to anti-inflammatory action in the murine CIA 
model. More specifically, prophylactic administration of ES-62 delayed the onset and 
reduced the severity of inflammation exhibited in CIA. In addition, in established disease, 
ES-62 suppressed mean articular index and articular swelling, two measures of the 
severity of the arthritis. These actions of ES-62 were manifested by a reduction in antigen- 
specific TH1-type cytokine production and serum T H I-type  antigen-specific 
immunoglobulin levels. Interestingly, no compensatory increase in collagen-specific TH2- 
type immunoglobulin was induced by ES-62, indicating that ES-62 did not induce these 
changes by counter-regulatory mechanisms. In summary, the in vivo mechanisms 
underlying the anti-inflammatory actions of ES-62 in CIA are yet to be established. The 
therapeutic potential of ES-62 in arthritic inflammation has also been determined using 
human RA samples. Co-culture of peripheral blood T cells from RA patients with 
macrophages in vitro induced contact-dependent TH1 cytokine production by the 
macrophages. This cytokine production was inhibited by pre-treatment of the 
macrophages with ES-62. These results indicated that ES-62-mediated down-modulation 
of the inflammatory immune response exhibited in RA might be advantageous, as a 
method of treatment.
Following demonstration of the ES-62 mediated inhibition of inflammation exhibited in 
murine CIA [192], the core aim of this investigation was to extend analysis of this model 
and to more thoroughly characterise the anti-inflammatory effects of ES-62. In addition, it 
was proposed to identify the structural components of ES-62 involved, the cell types 
employed to facilitate ES-62 action and the key signalling mechanisms used. The specific 
aims are outlined below:
1. It has previously been identified, in vitro, that several of the immunomodulatory 
effects of ES-62 on single cell types were facilitated by parasite-specific 
phosphorylcholine (PC). PC is a post-translational modification of the ES-62 
structure. Therefore, a primary aim of this investigation was to dissect the role of 
PC in the observed anti-inflammatory effects of ES-62 in the CIA model.
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2. The varied roles of different immune cell types involved in pathogenesis and 
chronic pathology of RA have previously been mentioned. It was a necessary aim 
of this investigation to identify the immune cell types that facilitated the actions of 
ES-62 in the CIA model of RA.
3. The marked immunomodulatory actions of ES-62 treatment on DC and 
macrophages have previously been characterised in vivo and in vitro. These two 
cell types are also known to have important roles in the CIA inflammatory 
processes. Therefore, specific dissection of the action of ES-62 on DC and 
macrophages in this model of arthritis was an integral aim of this investigation.
4. Modulation of the macrophage-T ceil interaction hypothesised to be integral to 
arthritis pathogenesis [245] may be a viable method for inhibition of disease onset 
and/or progression. It was also planned therefore to develop an in vitro system 
with which to determine whether this was a method by which ES-62 might inhibit 
onset and progression of CIA mediated inflammation.
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3.2 Results
3.2.1 ES-62 inhibits onset of inflammation and reduces established
inflammatory pathology in the collagen-induced arthritis model.
It has previously been demonstrated in this laboratory that ES-62, both prophylactically 
and therapeutically, mediates inhibition of inflammation In the CIA model of arthritis [192] 
by inhibiting antigen-specific THI-type inflammation in this TH1-mediated autoimmune 
disease model. To review, and as confirmation of these studies, when ES-62 is 
administered in a prophylactic manner, it significantly reduces arthritic swelling and delays 
the onset of arthritis induced by the collagen administration protocol. This is demonstrated 
by inhibition of arthritic score (a measure of severity of inflammation) and reduction in the 
incidence of footpad inflammation (Figure 3.2). As shown previously [192], ES-62- 
mediated inhibition of such inflammation in this arthritis model is associated with 
significantly reduced collagen-specific proliferation and TH1-promoting cytokine 
production by draining lymph node cells (Figure 3.2). Furthermore, ES-62-mediated 
inhibition of TH1-promoting cytokine production does not stimulate a compensatory 
increase in TH2 (IL-4 and IL-5) cytokine production (results not shown), but enhances 
production of antigen-specific regulatory cytokine, lL-10. Additionally, ES-62 treatment of 
CIA significantly diminishes the collagen-specific serum lgG2a levels (Figure 3.3) in this 
model. Furthermore, inhibition of antigen-specific serum lgG2a by ES-62 is not associated 
with any compensatory modulation of collagen-specific IgGI, lgG3 or IgM (Figure 3.3).
When ES-62 is administered therapeutically (after the onset of inflammation), it 
significantly inhibits progression of inflammation and joint erosion (Figure 3.4). The 
inhibitory action of ES-62 in this therapeutic treatment model is also facilitated by 
modulation of antigen-specific responses in draining lymph node cells. More specifically, 
therapeutic ES-62 treatment reduces collagen-induced lymph node cell proliferation and 
abrogates IFNy, TNFa and IL-6 (Figure 3.5), but not IL-10 (results not shown) release ex 
vivo. Although serum levels of collagen-specific !gG2a and IgGI were also previously 
reported to be slightly inhibited by ES-62 in this therapeutic treatment model [192], no 
statistical reduction could be detected in these studies (Figure 3.6). In summary, ES-62 
treatment prevents both onset of inflammation and reduction of existing inflammation 
exhibited in the collagen-induced arthritis model.
3.2.2 The effects of treating CIA model inflammation with a PC-free 
recombinant homologue of parasite-derived ES-62
Phosphoryichoiine (PC) has been characterised as an immunomodulatory moiety utilised 
by several pathogens and it has been identified as a component of ES-62 [177], with PC 
being covalently attached to the glycoprotein backbone of ES-62. Interestingly, in vitro
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treatment of immune system cells with PC conjugated to an irrelevant protein, BSA 
(bovine serum albumin), mimicked many of the effects of ES-62 [167], demonstrating that 
PC may be the active component of ES-62. To test this theory a PC-free recombinant 
homologue of ES-62 (rES-62) has been synthesised utilising the protein synthesis 
machinery of the yeast P. pastoris. As the yeast expression system does not possess the 
necessary machinery to attach PC to the glycoprotein backbone, rES-62 does not contain 
PC. Despite exhibiting increased mannose content, and differences in secondary and 
tertiary structure compared with parasite-derived ES-62 [199], rES-62 has been 
recognised by rabbit antisera against native ES-62 and therefore represents a potential 
PC-free version of the A. v/Yeae-derived ES product. Therefore, to address whether PC 
was necessary for ES-62-mediated inhibition of CIA model inflammation, rES-62 was 
used to treat CIA model mice in place of native ES-62 in the prophylactic and therapeutic 
treatment models.
In contrast to the action of native ES-62, prophylactic treatment of the CIA model with 
rES-62 did not significantly inhibit the severity of CIA (Figure 3.7). In more detail, the 
arthritic score of mice treated with rES-62 was not significantly different to those treated 
with PBS from day 23 onwards. However, interestingly, rES-62 treated CIA model mice 
exhibited earlier onset of prominent arthritic inflammation (days 16-17) when compared 
with PBS treated mice (days 19-20). Perhaps surprisingly, given the observed differences 
in pathology, the average levels of collagen-specific serum immunoglobulin (Ig) were 
similar in ES-62 and rES-62 treated mice. Thus, as with the serum from ES-62 treated 
mice, serum obtained at the end of the protocol from rES-62 treated mice exhibited 
significantly reduced levels of collagen-specific lgG2a, when compared with serum from 
PBS treated mice (Figure 3.7). Similarly, a compensatory modulation of collagen-specific 
IgGI, lgG3 or IgM by rES-62 was not observed.
Having determined that rES-62 treatment did not inihibit onset of CIA inflammation in the 
prophylactic treatment model, we continued our analysis of rES-62 action in the 
therapeutic treatment model. Treatment of CIA model mice with rES-62 after the onset of 
inflammation did not significantly modulate the incidence or severity of arthritis exhibited. 
On average, the mean arthritic score of CIA model mice treated therapeutically with rES- 
62 was maintained at a high level, not significantly different to PBS treated mice, until 
sacrifice (Figure 3.8). Furthermore, the average arthritic score of mice treated with rES-62 
was significantly greater than that of mice treated with native ES-62 in this treatment 
protocol. It appeared that. In a similar manner to the results of prophylactic rES-62 
treatment, therapeutic treatment with rES-62 did not exhibit a significant inhibitory effect 
on collagen-induced inflammation. Consistent with this, serum samples obtained from 
rES-62, ES-62 and PBS treated mice, at the end of the therapeutic treatment protocol, did
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not reveal significantly different profiles of collagen-specific IgG I, lgG2a, lgG3 or IgM 
(Figure 3.8).
In summary, the results were consistent with previously determined findings of this 
laboratory, which concluded that PC may be required for the anti-inflammatory actions of 
ES-62 in vitro [167]. Following this investigation it was concluded that the PC component 
of ES-62 might be necessary for adequate inhibition of inflammation in the CIA model. 
This was illustrated by the inability of PC-deficient rES-62 to inhibit CIA-mediated 
inflammation. This finding was consistent and independent of the pattern of rES-62 
administration. In other words, rES-62 did not inhibit CIA mediated inflammation when 
administered during initiation of inflammation or after the onset of clinically detectable 
inflammation. However, it was of interest that prophylactic rES-62 treatment appeared to 
promote premature inflammation during days 16-21 of the collagen administration 
protocol. This indicated that this recombinant glycoprotein may have immunostimulatory 
potential. Due to lack of immune-dampening PC [177] or increased immunostimulatory 
mannose content [199] within the structure of rES-62, compared with parasite-derived ES- 
62. The similarity of the collagen-specific Ig profile of serum from rES-62 treated mice and 
serum from ES-62 treated mice (in the prophylactic treatment model) indicated that ES-62 
mediated inhibition of lgG2a is PC-independent. Furthermore, it therefore appeared that 
ES-62-mediated modulation of serum lgG2a was not directly related to modulation of 
pathology.
3.2.3 The effects of treating CIA model inflammation with 
phosphoryichoiine
It is clear from the results described in section 3.2.2 that PC may be a required 
component of ES-62, in mediation of the anti-inflammatory effects observed in the CIA 
model. However, as mentioned previously, rES-62 is not simply a PC-free copy of native 
ES-62; it also contains high levels of mannose. An experiment was therefore designed to 
determine whether PC, independently of the rest of the ES-62 structure, was capable of 
inducing inhibition of the TH1-type inflammation exhibited in this model. To facilitate this 
investigation CIA model mice were treated (in place of ES-62) with PC conjugated to an 
irrelevant protein, ovalbumin (OVA-PC). It has been suggested that PC conjugated to a 
protein (instead of PC alone) is more likely to resemble ES-62 with respect to circulation in 
the bloodstream [199]. Furthermore, it has previously been shown that PC conjugated to 
BSA or OVA can mimic several of the immunomodulatory effects of ES-62, in vitro and in 
vivo [167, 183, 185, 191]. As a negative control for OVA-PC treatment, a group of CIA 
model mice were additionally treated with sham-conjugated ovalbumin (OVA). 
Prophylactic treatment of mice with OVA-PC significantly reduced the onset and severity 
of CIA inflammation, when compared with the OVA treatment group (Figure 3.9). This
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result provided support for the findings described above, that the PC component of ES-62 
may be responsible for ES-62-mediated inhibition of CIA model inflammation. In addition, 
these findings suggested that PC was independently capable of anti-inflammatory action 
in this arthritis model and that the ES-62 glycoprotein structure is dispensable. However, 
serum samples from OVA and OVA-PC-treated CIA model mice exhibited very similar 
average levels of collagen-specific IgGI, lgG2a and lgG3, indicating that, unlike ES-62, 
PC did not specifically modulate antigen-specific IgG production or isotype (Figure 3.9). 
Interestingly, collagen-specific serum IgM levels were reduced in OVA-PC treated mice 
compared to OVA treated mice. The reduction of antigen-specific IgM by PC was similar 
to the previously observed (non-significant) action of ES-62. Nevertheless, at this stage, it 
was only possible to conclude that prophylactic treatment with OVA-PC mediated 
inhibition of coiiagen-induced inflammation, but not modulation of serum antigen-specific 
IgG.
Treatment of CIA model mice with OVA-PC after the onset of clinically detectable arthritis 
also prevented progression of the inflammation severity (Figure 3.10). Thus, whilst OVA- 
treated mice exhibited an increase in this measure of inflammation severity, the arthritic 
score of OVA-PC treated mice did not progress throughout the treatment period, although 
the incidence of arthritis was not modulated in either treatment group. These combined 
observations suggested that treatment with OVA-PC offered some protection from 
progression of arthritic inflammation in this model. In particular, PC was responsible for 
this action because inhibition of disease progression was not observed in OVA-treated 
mice. As with the prophylactic model, analysis of serum immunoglobulin revealed no 
significant differences in the average levels of collagen-specific IgGI, lgG2a, lgG3 and 
IgM subclasses between OVA and OVA-PC treated mice (Figure 3.10). This indicated that 
PC, administered therapeutically, did not modulate antigen-specific antibody production in 
this model.
3.2.4 Analysis of the serum cytokine profile of CIA model mice in the 
prophylactic treatment model
It has been well documented that serum levels of certain circulating cytokines and 
chemokines represent the severity of inflammatory pathology exhibited In RA [259, 260]. 
For example, serum samples from RA patients exhibit high concentrations of pro- 
infiammatory cytokines, TNFa and IL-1 and these cytokines have been identified as 
integral to arthritis pathogenesis [207]. It was therefore proposed that examination of the 
cytokine and chemokine content of serum samples from mice in the CIA model would 
provide useful information about the inflammatory and immunological phenotype of mice 
in each treatment group and how the structural components of ES-62 were acting.
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Serum samples were obtained from CIA model mice in each treatment group and tested 
for several cytokines commonly identified in inflammation. Samples from the PBS 
treatment group were found to contain measurable quantities of pro-inflammatory 
cytokines, IL~1a, IL-12, and IL-2 (Figure 3.11). lL-1a has been implicated in arthritis 
pathogenesis [207], IL-12 is required for induction of THI-type inflammation [261] and IL-2 
is a potent activator and mitogenic stimulator of T cells [262]. Therefore, the presence of 
these cytokines implied that inflammatory processes were ongoing in the CIA model mice. 
TH2-type cytokine, IL-5 [263] and anti-inflammatory cytokine, IL-10 [264], were also 
identified in these serum samples (Figure 3.11), however they were detected in relatively 
low concentrations, which indicated that TH2 or anti-infiammatory signals were minimal in 
this model. Other pro-inflammatory cytokines (IL-1 [3, IL-6, IL-17, IFNy and TNFa) and TH2 
cytokines (IL-4 and IL-13) analysed were not detected in the serum samples from PBS 
treated CIA model mice. In summary, the overall cytokine profile of serum samples from 
PBS-treated CIA model mice confirmed a predominantly inflammatory TH1 phenotype of 
the inflammation exhibited in this disease model. However, the pro-inflammatory cytokine, 
TNFa, was not detected in any of the serum samples analysed. This was surprising, 
considering TNFa has been identified as integral to RA pathogenesis [265].
Treatment of CIA model mice with ES-62, in a prophylactic manner, did not significantly 
modulate the mean concentrations of the serum cytokines detected compared with those 
of the PBS treated mice (Figure 3.11). It was observed however, that the range of 
concentrations of some serum cytokines displayed by mice in the PBS treatment group 
had been modulated by ES-62 treatment. More specifically, serum samples from 4 out of
9 mice in the ES-62 treatment group exhibited increased serum IL-1 a concentration 
relative to the top concentration detected In the PBS treatment group. This was surprising, 
given the observed reduction in inflammatory pathology observed in the ES-62 treatment 
group mice. Furthermore, it appeared that serum IL-1a concentration exhibited by 
individual mice might be inversely related to inflammation status, because the mice in the 
ES-62 treatment group that exhibited the highest IL-1 a concentrations also displayed 
minimal arthritic scores.
The mean serum concentration of anti-inflammatory/TH2 cytokine, IL-10, was subtly 
elevated in serum samples from ES-62-treated mice (as a result of an outlier), compared 
with the mean level detected in the PBS treatment group. This difference was not 
significant and no correlation was observed between inflammation scores and serum IL-
10 levels, however, the promotion of IL-10 by ES-62 treatment suggested potential 
enhancement of anti-inflammatory signals by ES-62.
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Serum samples from the rES-62 treatment group mice also contained detectable levels of 
all the cytokines observed in serum from PBS and ES-62 treatment group mice (described 
above) (Figure 3.11). As described in section 3.2.2, prophylactic treatment of CIA model 
mice with rES-62 did not prevent onset of inflammation, unlike prophylactic treatment with 
native ES-62, suggesting that PC was the major component of ES-62 responsible for 
inhibition of CIA-mediated inflammation. It was therefore of interest to examine the j 
cytokine profile of serum samples from rES-62 treatment group mice to enable direct I 
comparison with the ES-62 treatment group mice. Interestingly, serum samples from rES- 
62 treated mice contained significantly higher levels of IL-12 than serum from PBS and 
ES-62 treatment groups. Therefore, rES-62 administration appeared to induce IL-12 
secretion, in vivo, by CIA model mice. It has previously been demonstrated that 
administration of IL-12, in combination with type II collagen, induced severe arthritis in 
DBA/1 mice [266]. Therefore, the increased production of IL-12 induced by rES-62 may 
underlie the enhanced inflammation observed in rES-62-treated mice compared with 
PBS-treated mice. Also of interest, although not significantly different, the mean serum t
concentration of IL-1 a in rES-62 treated mice was reduced compared to the mean level 
detected in the ES-62 treatment group and similar to the level detected in the PBS 
treatment group. Furthermore, the inverse correlation between serum IL-1 a concentration ,i
in individual mice and arthritic score observed In the ES-62 treatment group was no longer . t  
apparent in the rES-62 treatment group. Based on these comparisons, it appeared that 
whilst, IL-1 a concentration might be related to the in vivo effects of ES-62, it was not 
directly related to inflammatory pathology in this model. Anti-IL-1 treatment has been 
shown to ameliorate murine CIA [267] therefore, the inverse relationship observed in this 
model was surprising. Interestingly, the mean concentration of IL-10 detected in serum 
samples from rES-62 treated mice was less than detected in serum samples from native 
ES-62 treated mice, however, this difference was not significant and most likely due to the 
outlier from the ES-62 treatment group. In summary, a modest enhancement of the serum 
TH1 cytokine balance of CIA model mice was induced by rES-62 treatment and this 
change appeared to be due to lack of PC and/or presence of additional immunogenic 
components within the structure of rES-62. i
As previously described (section 3.2.3), treatment of CIA model mice with OVA-PC 
inhibited onset of inflammation In a similar manner to that induced by native ES-62 
treatment, implicating PC in mediation of ES-62-induced anti-inflammatory effects. It was 
proposed that comparison of serum cytokine changes in ES-62- and OVA-PC-treated CIA 
model mice (in terms of their control treatments, PBS and OVA, respectively) would help 
to clarify the relationship between serum profile and inflammatory pathology. Serum 
samples obtained from OVA and OVA-PC treated mice contained measurable levels of ail 
the cytokines detected in serum from PBS and ES-62 treated CIA model mice (described
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above) (Figure 3.11). Careful scrutiny of the pattern in cytokine levels between serum 
from PBS and ES-62 treated mice and serum from OVA and OVA-PC treated mice, 
respectively, revealed similarities between ES-62 and OVA-PC. Thus, the mean value of 
serum IL-1 a concentration was significantly elevated in OVA-PC treated mice compared 
with OVA treated mice. Although not significant, increased serum IL-1 a concentration had 
also been detected in response to ES-62 treatment, compared with PBS. As mentioned 
above, promotion of IL-1 a was not induced by rES-62. Therefore, serum IL-1 a 
concentration appeared to be Inversely related to Inflammation severity in these PC- 
treated models. It was interesting to observe that serum IL-10 levels were particularly low 
in OVA and OVA-PC treated mice compared with PBS and ES-62 treated mice. This 
appears to negate any proposal that promotion of serum IL-10 (observed in ES-62 treated 
mice) was PC-induced.
3.2.5 Analysis of the serum chemokines and growth factors in CIA model 
mice in the prophylactic treatment model
Chemokines and growth factors secreted by several different ceil types in chronic 
Inflammation are Important mediators of the inflammatory immune response, which act to 
recruit ceils and, in conjunction with cytokines, promote maintenance of the inflammatory 
environment. KC (keratin ocyte-derived chemokine) and M IP-1a (macrophage 
inflammatory protein-1 a), powerful chemokines that function in recruitment of neutrophils 
[268, 269], were detected in serum samples from PBS treated CIA model mice (Figure 
3.12). KC is induced by TNFa [270], which indicates that TNFa must have been 
produced, perhaps at an earlier time-point, in this model. Also detected in PBS-treated 
mice were interferon inducible protein-10 (IP-10) and MIG (monokine induced by gamma 
interferon), which are important markers of IBN^-mediated inflammation [271, 272], and 
fibroblast growth factor-basic (FGF-2), a potent stimulator of cellular proliferation and 
angiogenesis [273]. These findings indicated that, in addition to TNFa, IFNy is likely to 
also have been involved in development of the inflammation exhibited in these mice. FGF 
is an important growth factor implicated in stimulation of several cell types and promotes 
development of new blood vessels, necessary for chronicity of inflammation. To obtain a 
comprehensive overview of the chemokines and growth factors produced in the CIA 
model mice, serum samples were also analysed for, but found not to contain, detectable 
levels of GM-CSF, MCP-1 and VEGF. In summary, several inflammatory chemokines, 
important for promotion of inflammation, were detected in PBS-treated CIA model mice 
and this corresponded with the predominantly pro-inflammatory repertoire of serum 
cytokines also present (section 3.2.4).
Treatment of CIA model mice with ES-62, in a prophylactic manner, induced some 
changes to the repertoire of serum chemokines exhibited in CIA model mice (Figure 3.12).
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It was observed that the inflammatory neutrophilic chemokine, KC, was only detected in 2 
out of 9 mice in the ES-62 treatment group (compared with 4 out of 9 in the PBS 
treatment group), which distinctly, but not significantly, reduced the mean serum 
concentration of KC in response to ES-62 treatment. However, no correlation was 
observed between the concentration of serum KC and arthritic score in individual mice in 
these treatment groups. As mentioned previously, it has been shown that KC is induced 
by TNFa and, hence, may represent TNFa levels in this model [270]. Furthermore KC has 
been found in the blood and joints of arthritic rats in an adjuvant-induced arthritis model
[274] and has been shown to correlate with the development of arthritis in Lyme disease
[275]. Therefore, whilst it is not clear why TNFa was not detected in the serum of CIA 
model mice, it appeared that reduced levels of serum KC, in the ES-62 treated mice, were 
consistent with the observed reduction in inflammatory pathology in this treatment group.
Serum samples from the rES-62 treatment group CIA model mice contained measurable 
levels of all the chemokines detected In PBS and ES-62 treatment group mice, except KC 
(Figure 3.12). The absence of KC was surprising, as this chemokine had been observed 
in serum samples from PBS and ES-62 treatment groups. It was therefore proposed that 
the reduction in KC levels observed In the ES-62 treatment group may have been induced 
by the non-PC components of ES-62 and hence, was more potently observed in CIA 
model mice treated with PC-deficient rES-62. However, this theory contradicted the 
previous proposal that serum KC levels reflected the severity CIA pathology.
In an effort to further clarify the role of PC in the observed actions of ES-62 on serum 
chemokines. Serum samples obtained from OVA and OVA-PC treated, CIA model mice 
were analysed and found to contain measurable levels of all the chemokines detected in 
serum from PBS and ES-62 treated CIA model mice (described above) (Figure 3.12). A 
pattern was observed in the subtle changes to mean serum levels of MiG, MIP-1a and KC 
induced by ES-62 and OVA-PC treatment. More specifically, a modest promotion of MIG 
and MIP-1a was observed upon treatment with ES-62 and treatment with OVA-PC 
relative to PBS and OVA treatment, respectively. Furthermore, non-significant reduction in 
the mean serum KC levels observed in ES-62 treated mice (compared with PBS treated 
mice) was also observed in OVA-PC treated mice (compared with the OVA treatment 
group). It was interesting that the pattern of serum MIG and MIP-1a levels inversely 
reflected the severity of inflammatory pathology in the PBS, ES-62, OVA and OVA-PC 
treatment groups. The reduction in serum KC induced by OVA-PC questioned the theory 
put forward above, that KC was inhibited by a non-PC component of ES-62. Furthermore, 
the suggested pattern of reduced serum KC concentration In ES-62 and OVA-PC treated 
mice directly reflected the pattern of inflammatory pathology in these treatment groups, 
implying that, in this model, KC might be an indicator of inflammation severity. In
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conclusion, the simiiaritles In the action of ES-62 and OVA-PC on inflammatory serum 
chemokines suggested that PC was responsible for these changes, however, it must be 
remembered that the changes in serum chemokines were non-significant, therefore, 
conclusive statements cannot be made at this time.
3.2.6 Analysis of the serum cytokine profile of CIA model mice in the 
therapeutic treatment model
After observation of minimally modulated patterns in serum cytokine profiles of CIA model 
mice treated prophylactically with ES-62 (and derivatives), analysis of serum from 
therapeutic model mice was conducted to determine whether treatment of CIA after the 
onset of inflammation led to more obvious modulation of serum factors. However, few of 
the serum cytokines detected at the end of the prophylactic protocol could be detected in 
the serum of CIA model mice culled from the therapeutic treatment protocol (Figure 3.13). 
More specifically, IL-2 and IL-12, pro-inflammatory cytokines identified in the prophylactic 
treatment model mice, were identified in serum samples from PBS-treated CIA mice, 
however, IL-1 a, IL-10 and IL-5, were not. As conducted in the prophylactic treatment 
model, serum samples from therapeutically treated CIA mice were also analysed for IL- 
1(3, IL-4, IL-6, IL-13, IL-17, IFNy and TNFa content, but these cytokines were also not 
detected.
Although there was a spread of concentrations within the PBS and ES-62 treatment 
groups, treatment of CIA model mice with ES-62 after the onset of inflammation did not 
significantly modulate the mean serum levels of IL-2 or IL-12 (Figure 3.13). Therefore, 
unlike the findings from the serum analysis in the prophylactic treatment model, there 
were no indications of ES-62-mediated immunomodulation, at least in terms of serum 
cytokine levels. Nevertheless, there did appear to be positive correlation between serum 
IL-12 concentration and inflammation score in individual PBS- and ES-62-treated mice, 
because mice exhibiting the highest concentrations of serum IL-12 also exhibited the 
highest inflammation scores. However, this pattern was not reflected in serum IL-2 
concentrations.
Serum samples obtained from rES-62 treated mice also contained IL-2 and IL-12, as had 
been identified in PBS and ES-62 treated mice (Figure 3.13). In a similar manner to ES- 
62, therapeutic treatment with rES-62 did not significantly modulate the mean levels of the 
serum cytokines detected. Therefore, it appeared that therapeutic treatment of CIA mice 
with ES-62, independent of the PC-content, did not modulate the concentration or type of 
serum cytokines.
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Interestingly, IL-2 was detected in serum samples from OVA-, but not OVA-PC-treated 
CIA model mice (Figure 3.13). As mentioned above, the inhibitory effect of OVA-PC on IL- 
2 was not observed in ES-62 treated mice, however it must be noted that relatively low 
concentrations of IL-2 were detected overall. The analogous patterns between serum 
cytokine profiles in OVA/OVA-PC and PBS/ES-62 treated mice described in the 
prophylactic treatment model clearly was not observed upon analysis of serum samples 
from these treatment groups in the therapeutic treatment model. Furthermore, although 
not significant, the mean serum concentration of pro-inflammatory cytokine, IL-12, was 
also reduced in OVA-PC treated mice, when compared with OVA-treated mice in this 
model. This reduction had not been observed in mice treated therapeutically with ES-62. 
Furthermore, the positive relationship between serum IL-12 and arthritic score displayed 
by PBS- and ES-62-treated mice was not observed in the OVA or OVA-PC treatment 
groups. Reduction of serum IL-2 and IL-12 might suggest a reduced pro-inflammatory 
phenotype in keeping with the observed reduction of inflammation In the OVA-PC 
treatment group. However, based on the results of the cytokine analysis, it was unclear 
why therapeutic treatment with OVA-PC, but not ES-62, had modulated the levels of 
serum pro-inflammatory cytokines.
3.2.7 Analysis of the serum chemokines from CIA model mice in the 
therapeutic treatment model
Many of the inflammatory chemokines that were detected in serum samples from the 
prophylactic treatment model, were also detected in serum samples from therapeutically 
treated CIA model mice (Figure 3.14). More specifically IP-10, MIG and MIP-1a, but not 
KC, were detected in serum from PBS-treated mice in this model, indicating that an 
inflammatory immune response was ongoing in these mice. Treatment of CIA model mice 
with ES-62 after the onset of inflammation did not significantly modulate the average 
levels of the three serum chemokines detected, however, some non-significant trends 
were observed (Figure 3.14). The range of serum concentration of inflammatory 
chemokine, MIP-1a was noticeably reduced in the serum of ES-62 treated mice. This drop 
was consistent with the observed reduction in inflammation in the ES-62 treatment group. 
Furthermore, MIP-1a is a neutrophilic chemokine induced by inflammation-promoting 
TNFa [276] and therefore may represent a measure of inflammation severity within these 
mice.
To determine whether MIP-1a reduction was a PC-dependent effect of ES-62 treatment, 
serum samples from rES-62 treated mice were also analysed for chemokine content. 
Similarly to PBS and ES-62 treated mice, IP-10, MIP-1a and MIG were detected in serum 
samples from rES-62-treated mice (Figure 3.14). Although not significant, rES-62 
treatment induced mild enhancement of the mean serum concentrations of IP-10 and MIG
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compared with PBS and ES-62 treatment. Furthermore, it appeared that the serum 
concentrations of MIG (but not IP-10) in individual PBS- and ES-62-treated mice 
correlated positively with inflammation status, determined by arthritic score, because mice 
that exhibited the highest MiG concentrations in the treatment groups also exhibited the 
highest arthritic scores. As previously mentioned, IP-10 and MIG are inflammatory 
chemokines and their secretion is induced by the TH1 cytokine, IFNy. The promotion of 
IP-10 and MIG by rES-62 was, therefore, consistent with enhanced TH1-mediated 
inflammation in this treatment group. Interestingly, rES-62 treatment appeared to maintain 
the mean concentration of serum MIP-1a, which had been inhibited in ES-62 treated 
mice. More specifically, treatment with rES-62 resulted in mean MIP-1a levels similar to 
that exhibited in the PBS treated mice, potentially supporting a role for PC in inhibition of 
this chemokine.
It was more difficult to elucidate the profile of the pro-inflammatory chemokines, M!P-1a, 
IP-10 and MIG, in serum samples from OVA-PC treated mice (Figure 3.14) due to outlier 
responses. Indeed, the mean serum concentrations of MIP-1a, IP-10 and MIG appeared 
to be elevated in response to OVA-PC, compared with samples from OVA, PBS and ES- 
62 treated mice. This was surprising as an increased serum concentration of pro- 
infiammatory chemokines was not consistent with OVA-PC mediated inhibition of 
inflammatory pathology in this model, however, modest promotion of MIG and MIP-1a in 
response to OVA-PC treatment had been observed in the prophylactic treatment model 
(Figure 3.12). However, these changes to mean chemokine levels were non-significant 
and probably due to outlying readings, therefore, most likely they do not represent 
modulation of the overall inflammatory status of these mice. Furthermore, the correlation 
between arthritic score and MIG concentration observed in individual mice in the PBS, 
ES-62 and rES-62 treatment groups was not displayed by the OVA or OVA-PC treatment 
groups.
3.2.8 Analysis of the serum growth factors in CIA model mice in the 
therapeutic treatment model
The growth factor, FGF-2, that had been detected in serum samples from CIA mice in the 
prophylactic treatment model, was also found to be circulating In the serum of mice from 
the therapeutic treatment CIA model (Figure 3.15). In addition, VEGF, an important 
inducer of angiogenesis and a common feature of chronic inflammatory pathology [277], 
was also detected in serum from these mice. Identification of two important mediators of 
cellular growth, proliferation and angiogenesis Indicated that inflammatory mechanisms 
associated with induction of chronicity and tissue remodelling had been activated in these 
mice.
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Serum FGF concentration in CIA modei mice was not significantly modulated by 
therapeutic ES-62 treatment (Figure 3.15). However, surprisingly, the mean serum 
concentration of VEGF was elevated in ES-62 treated mice, compared with PBS treated 
mice, indicating that ES-62 treatment might induce promotion of VEGF secretion. This 
was unexpected, because circulating levels of VEGF have previously been associated 
with inflammation severity in RA [278]. As it had previously been identified that therapeutic 
ES-62 treatment inhibited arthritic inflammation in the CIA modei, promotion of VEGF by 
ES-62 appeared counter-intuitive. Nevertheless, the overall detected concentrations of 
VEGF in PBS and ES-62 treated mice were very low.
Therapeutic treatment of CIA with rES-62 significantly increased the mean serum FGF 
concentration and markedly increased the mean serum VEGF concentration exhibited, 
compared with the PBS treatment group (Figure 3.15). Although not significantly different 
to the concentrations exhibited by ES-62 treated mice, the enhancement of VEGF and 
FGF concentration was consistent with the increased severity of inflammation exhibited in 
the rES-62 treated mice. The concentration of serum VEGF was promoted to a greater 
degree by rES-62 treatment of CIA modei mice than that exhibited in response to ES-62 
treatment (described above), hence this comparison indicated that, given the range of 
concentrations across which VEGF might act, the magnitude of the modulation induced by 
ES-62 may not be important.
Interestingly, the mean serum VEGF concentration was abrogated in OVA-PC treated CIA 
model mice when compared with OVA treated mice (Figure 3.15). Considering the 
previously determined anti-infiammatory action of OVA-PC in CIA, reduction of VEGF was 
consistent with a role for VEGF in mediation of inflammation in this model. Furthermore, it 
was observed that the mean VEGF levels were higher in OVA treated mice than PBS 
treated mice, however this difference was not significant. It was interesting to observe that 
despite the previously described analogous effects of ES-62 and OVA-PC treatment on 
serum chemokine levels, OVA-PC mediated inhibition of VEGF was not mirrored by ES- 
62. This apparently inconsistent pattern had previously been observed during analysis of 
serum cytokines in this CIA model (described above, Figure 3.13).
In summary, whilst a predominantly THI-like phenotype cytokine and chemokine profile 
was observed in both treatment models, a reduced number of cytokines were detected in 
serum samples from therapeutically treated, compared with prophylactically treated CIA 
model mice. The reduction in cytokine content in the latter model might be explained by 
the fact that serum samples obtained from mice in the prophylactic and therapeutic 
treatment models were taken at different time-points (day 33 and days 29-35, 
respectively). Apparent inconsistencies in the effects of ES-62 and OVA-PC treatments on
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serum cytokine and growth factor content were aiso observed in the therapeutic, but not 
the prophylactic treatment modei. These apparently contradictory effects may represent 
differences In the immunomodulatory potencies of ES-62 and OVA-PC, however, as 
mentioned earlier, it must be considered that serum cytokine analysis reflects a ‘snapshot’ 
of cytokines circulating at the time of sacrifice (which was different for each treatment 
modei) and may not directly represent the overall immunology of the modei.
Clearly PC is an important component of the ES-62 molecule, capable of independent 
anti-inflammatory action, which mimics the inhibitory actions of ES-62 observed in TH I- 
type CIA model inflammation. Furthermore, the PC-dependent anti-infiammatory actions 
of ES-62 were apparent when CIA model mice were treated before or after the onset of 
inflammation. More specifically, prophylactic treatment of CIA modei mice with ES-62 
partially prevented the development of a potent inflammatory TH1-type immune response, 
which was facilitated by antigen-specific lgG2a and TH1 cytokine production In control 
(PBS-treated) mice. Alternatively, therapeutic treatment of CIA model mice with ES-62 
reduced the inflammatory pathology exhibited in the jo int and therefore prevented 
exacerbation of disease, but did not modulate the established antigen-specific antibody 
response mediated by collagen-specific IgG production. Thus, it appeared that the anti- 
infiammatory effects of ES-62 in each type of treatment model might be the result of ES- 
62 action on different cell types. For example, in the prophylactic treatment model, ES-62 
action may be most prevalent on cells involved in the development of the TH1-type 
immune response. Alternatively, in the therapeutic treatment model, ES-62 may mediate 
its anti-inflammatory action via modulation of the function of immune effector cells, 
responsible for maintenance and progression of the immune response.
3.2.9 Investigating the effect of ES-62 on the in vitro function of bone 
marrow DC derived from naïve mice
Dendritic cells (DC) comprise an integral cellular component of immune response 
development and it is well-established that the precise DC phenotype directs the resultant 
immune response. Therefore, dissection of ES-62 action in the CIA model began by 
investigating the effect of in vivo exposure to ES-62 on DC phenotype and function. The 
first step was to confirm the in vitro actions of ES-62 on DC phenotype and function 
described by this lab previously. Thus, DC were cultured from bone marrow of BALB/c 
mice, pre-treated with ES-62 for 24h and then stimulated with media or LPS for a further 
24h. Treatment with ES-62 alone induced low-ievel IL-12p40 and TNFa production by DC 
(Figure 3.16), suggesting that the ceils were modestly activated by ES-62. However, the 
ES-62-induced DC cytokine production was significantly less than that induced by LPS 
treatment. Furthermore, pre-treatment of DC with ES-62 before subsequent stimulation 
with LPS resulted in significant inhibition of LPS-induced IL-12 and TNFa production.
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Thus, in terms of DC cytokine production, ES-62 exhibited dual activatory and inhibitory 
actions on DC in vitro.
To determine whether the dual actions of ES-62 were also exhibited in terms of cell 
surface marker expression. DC from each in vitro treatment group were stained and 
analysed by flow cytometry for expression of co-stimulatory (CD40, CD80, CD86) and 
adhesion (CD54) molecules required for DC-mediated activation of T cells and the 
adaptive immune response. Interestingly, iow-ievel activation action of ES-62 treatment 
alone, observed in the cytokine secretion patterns, was not mirrored in terms of ceil 
surface expression levels (Figure 3.17). Occasionaiiy CD40 expression was upregulated 
in response to ES-62, but usually, ES-62-treated DC appeared immature in phenotype. 
LPS treatment of DC induced marked upreguiation of all cell surface molecules analysed. 
However, in contrast to the cytokine analysis results, ES-62 pre-treatment of DC did not 
notably modulate subsequent LPS-mediated upreguiation of ceil surface expression. In 
summary, the in vitro actions of ES-62 on DC appeared to target cytokine secretion, but 
not expression of surface markers.
3.2.10 Bone marrow DC derived from CIA model mice exhibit a modulated 
phenotype
Taking together how ES-62 can modulate bone marrow-derived DC immunology in vitro 
with previous work suggesting that similar effects could be obtained following in vivo 
exposure [191], it was decided to investigate whether ES-62 treatment induced 
modulation of bone marrow-derived DC phenotype in CIA model mice. Thus, femurs were 
dissected from CIA model mice at the end of the prophylactic treatment protocol and bone 
marrow from each treatment group was pooled. DC were derived from such pooled bone 
marrow and cultured in vitro for 7 days before being stimulated for a further 24h with 
media or LPS before phenotype analysis.
Firstly, it was investigated whether bone marrow-derived DC from CIA model mice 
exhibited a different cell surface phenotype to naïve (non-diseased) MHC-matched 
(DBA/1) mice. In addition, it was also planned to investigate whether exposure to ES-62 in 
vivo modulated the phenotype of bone marrow-derived DC obtained from the CIA model 
mice.
When compared with DC cultured from bone marrow of naïve DBA/1 non-model mice, DC 
derived from CIA model mice exhibited upregulated expression levels of antigen- 
presentation, co-stimuiatory and adhesion molecules MHC II, CD40, CD80, CD86 and 
CD54 (Figure 3.18). This indicated that bone marrow-derived DC from CIA model mice 
exhibit a more activated or mature phenotype, compared with DC cultured from naïve 
syngeneic mice.
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LPS treatment of naïve and CIA model DC in vitro uniformly upregulated the expression 
levels of the cell surface markers analysed on DC from non-model and CIA model mice. 
As a result, under LPS conditions, differences in surface expression of DC from the model 
and naïve mice were not as obvious. Culture supernatants of the CIA model and non­
model DC were also analysed for cytokine content, firstly under control conditions and 
then following LPS treatment. Detectable concentrations of IL-10, IL-12 and TNFa (Figure
3.19) were spontaneously secreted by DC from CIA model and naïve mice. Consistent 
with their mature surface expression profiie, DC cultured from CIA model mice secreted 
enhanced levels of TH1-type/pro-inflammatory cytokines, TNFa and IL-12, but not 
regulatory cytokine, IL-10, when compared with DC cultured from naïve mice. This 
difference supported the previous conclusion, that DC cultured from CIA model mice 
exhibited a matured, somewhat activated phenotype compared with DC from naïve mice. 
LPS treatment in vitro markedly enhanced the overall levels of IL-12, TNFa and IL-10 
cytokine production by both naïve and CIA model DC. Interestingly, the TNFa response to 
LPS was less and the IL-10 response to LPS was greater in DC from CIA model mice 
compared with DC from non-diseased mice. However, despite statistical significance 
these differences in cytokine production levels were relatively small and did not appear to 
represent any real trend of distinction between the two types of DC. In summary, LPS 
treatment of CIA model and naïve derived DC revealed that cells from both backgrounds 
exhibited normal upregulatory and cytokine production responses to inflammatory stimuli. 
Nonetheless, the inflammatory response to LPS masked real differences in DC phenotype 
that were induced by in vivo treatments).
3.2.11 The effect of ES-62 treatment in vivo on the phenotype of bone 
marrow DC derived from CIA model mice
To determine whether ES-62 treatment of CIA model mice in vivo induced yet further 
modulation of bone marrow-derived DC phenotype, DC were cultured from pooled bone 
marrow samples of ES-62-treated CIA model mice. Following analysis of these DC for 
surface marker expression it was concluded that prior ES-62 treatment in vivo did not 
induce discernible modulation of the surface expression profile of DC derived from CIA 
model mice. In more detail, ES-62 treatment of CIA model mice resulted in differentiation 
of DC that exhibited similar expression profiles of MHC li, CD80, CD86 and CD54 to DC 
from CIA model mice (Figure 3.18). Occasionally, modest increases in CD40 expression 
by DC from ES-62-treated CIA model mice were observed. To summarise, the activated, 
matured phenotype of DC derived from CIA model mice was maintained despite ES-62 
treatment in vivo. Interestingly, DC from ES-62 treated CIA model mice exhibited a 
somewhat reduced CD40, CD54 and CD86 upreguiation response to LPS, compared with 
DC from control (PBS-treated) CIA model mice. These subtle differences in the
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upreguiation response to LPS suggested that DC from ES-62 treated CIA model mice 
might exhibit a restricted response to inflammatory stimuli in vivo.
However, ES-62 treatment of CIA model mice resulted in differentiation of DC that 
secreted significantly increased levels of IL-12, but not TNFa or IL-10, when compared 
with DC from control CIA model mice (Figure 3.19). The enhanced IL-12 production was, 
therefore also significantly increased from the levels secreted by DC from naïve mice, 
which indicated that, in terms of IL-12 production, the activated phenotype of DC from CIA 
model mice was maintained despite in vivo ES-62 treatment. Interestingly, the IL-12 and 
TNFa response to LPS was significantly greater by DC from ES-62 treated CIA mice 
compared with DC from control CIA mice. In summary, analysis of DC from CIA model 
mice revealed an activated matured cell phenotype, compared with DC derived from 
naïve mice and this was not prevented by ES-62 treatment of CIA model mice in vivo. 
Nevertheless, some differences in expression of ceil surface markers and production of 
cytokines were apparent between DC from ES-62 treated and control CIA model mice.
3.2.12 Investigation of the role of PC in ES-62-mediated action on bone 
marrow DC derived from CIA model mice
It was decided to investigate the nature of the subtle effects of ES-62 treatment of the CIA 
model mice on subsequently differentiated bone marrow DC. To determine whether the 
PC component of ES-62 was involved in these effects, DC from CIA model mice that had 
been treated with rES-62 or OVA-PC were cultured and compared with DC cultured from 
CIA model mice that had been treated with PBS, ES-62 or OVA respectively.
3.2.12.1 The effect of PC on DC surface expression profile
DC cultured from native ES-62 and rES-62 treated CIA model mice exhibited similar 
expression profiles of MHCII antigen-presenting molecules and co-stimulatory molecules, 
CD40, CD80 and CD86. Interestingly, CD54 expression was marginally increased on DC 
from rES-62 treated mice, compared with DC from ES-62 treated mice (Figure 3.18). 
Nevertheless, the overall surface expression phenotype of DC cultured from CIA model 
mice treated with rES-62 or native ES-62 was largely similar. In response to LPS 
stimulation in vitro, DC cultured from rES-62 treated mice exhibited somewhat enhanced 
LPS-induced upreguiation of MHC ii and CD86, compared with DC from ES-62 treated 
mice. This difference suggested that DC from rES-62 treated CIA model mice exhibited an 
augmented response to LPS treatment. Nevertheless, this effect was modest.
As previously observed between DC from ES-62 and rES-62 treated mice, expression of 
the surface markers analysed was highly similar on DC cultured from OVA and OVA-PC 
treated mice (Figure 3.21). LPS treatment in vitro induced marked uniform upreguiation of
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MHCII, CD40, CD54, CD80 and CD86 expression on DC from OVA and OVA-PC 
treatment groups. However, although DC from both OVA-PC and OVA treated mice 
expressed high levels of MHCII in response to LPS treatment, DC from the latter mice 
expressed the greatest levels of MHCII. The pattern of inhibited LPS-induced upreguiation 
of MHCII expression had previously been exhibited by DC from ES-62, but not rES-62 
treated mice. Thus, it was suggested that in vivo treatment of CIA model mice with PC- 
containing compounds might result in development of DC that exhibit an inhibited 
response to LPS, in terms of MHCII expression. However, on the whole, the surface 
expression profiles of DC cultured from bone marrow samples of CIA model mice were 
not extensively modified by prior in vivo treatment with ES-62, rES-62 or OVA-PC.
3.2.12.2 The effect of PC on DC cytokine production
To complete the analysis of the role of PC in ES-62-mediated actions on DC derived from 
CIA modei mice, cytokine production by DC from rES-62 and OVA-PC-treated CIA model 
mice was compared with DC from ES-62 and OVA-treated CIA model mice respectively. 
DC from rES-62-treated mice spontaneously secreted less IL-12, but not TNFa or IL-10 
than DC from ES-62 treated mice. Nevertheless, the difference was minimal and was 
maintained at a significantly higher level than was secreted by DC from CIA model mice 
(Figure 3.20). Although DC cytokine production levels were uniformly elevated by LPS 
stimulation in vitro, LPS-induced TNFa and IL-10 production by DC cultured from the rES- 
62 treated mice was less than that secreted by DC from ES-62 treated mice under the 
same conditions. However, similar to the responses of DC from ES-62 treated mice, the 
level of LPS-induced IL-12 and TNFa production by DC from rES-62 treated mice 
remained greater than that produced by DC from PBS-treated CIA mice. This indicated 
that DC from rES-62 treated mice generally exhibited similar cytokine production profile to 
DC from ES-62 treated mice, under control and LPS conditions.
DC cultured from bone marrow of OVA and OVA-PC treated CIA model mice also 
consistently secreted increased levels of IL-12 and TNFa when compared with DC 
cultured from naïve mice. Interestingly, DC cultured from bone marrow samples of OVA- 
PC treated mice spontaneously secreted significantly less TNFa, but not IL-12 or IL-10, 
than DC cultured from OVA treated mice (Figure 3.22). This trend of reduced TNFa 
production had previously been exhibited by DC cultured from ES-62 treated mice (Figure
3.19), but the difference was not significant.
Treatment of these DC in vitro with LPS induced marked increases in the production of IL- 
12, IL-10 and TNFa by DC from OVA and OVA-PC treated CIA model mice. However, 
LPS-induced IL-12 and TNFa production by CIA model-derived DC in vitro was enhanced 
by prior in vivo treatment of CIA model mice with OVA-PC compared with OVA. This
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enhanced LPS response by DC from OVA-PC treated CIA mice mirrored the response of 
DC from ES-62 treated CIA mice, as described above, indicating that this action may be 
PC-induced.
In summary, DC cultured from CIA mice treated with OVA-PC exhibited similar surface 
expression and cytokine production profiles to DC cultured from CIA mice treated with ES- 
62. This correlation indicated that the changes to DC phenotype induced by prior in vivo 
exposure to ES-62 were PC-dependent. However, in comparison to the previously 
published effects of ES-62 treatment in vivo [191], the differences in phenotype of bone 
marrow-derived DC from the CIA modei as a result of ES-62 treatment in vivo were 
minimal. Therefore, the major alterations in DC phenotype were reflected by comparison 
of DC from naïve and CIA model mice, with only minor changes to DC phenotype induced 
by further in vivo treatment of CIA model mice with ES-62, rES-62 or OVA-PC. Thus, 
despite treatment of CIA model mice with PC (in the form of ES-62 or OVA-PC) promoting 
differentiation of DC that secrete reduced levels of arthritis-promoting TNFa, an effect 
which might be anti-inflammatory in this model, it was concluded that the majority of 
changes to bone marrow-derived DC phenotype by ES-62 treatment of CIA were most 
likely not associated with inhibition of inflammation. Nevertheless, it was interesting to 
observe that many of the weak modulatory effects of ES-62 observed were PC- 
dependent,
3.2.13 The effect of therapeutic ES-62 treatment on the phenotype and 
function of DC derived from CIA model mice
In addition to their functions in initiation of immune response development, DC also form 
an important part of the effector immune response. Through communication with other 
innate immune cells, DC mediate maintenance and progression of inflammation at the 
inflammatory site [225, 279]. As previously described, ES-62 treatment of CIA model mice 
after the onset of ciinicaliy detectable arthritis inhibited progression of inflammation and 
joint erosion ([192] and section 3.2). Following confirmation that the in vivo collagen 
administration protocol responsible for inducing CIA inflammation brings about 
differentiation of bone marrow-derived DC with an activated, matured phenotype, it was 
decided to determine whether the therapeutic ES-62 treatment protocol was associated 
with modulation of bone marrow-derived DC phenotype. Therefore, DC were cultured from 
bone marrow of CIA model mice in the therapeutic treatment model and surface 
expression levels of MHCII, CD40, CD54, CD80 and CD86 were analysed ex vivo.
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3.2.13.1 The effect of therapeutic ES-62 exposure on CIA model-derived DC surface 
expression
DC cultured from mice treated therapeutically with ES-62 exhibited reduced expression of 
antigen-presentation molecule, MHCII and co-stimulatory molecule, CD86 when 
compared with DC cultured from control (PBS-treated) CIA mice (Figure 3.23). This 
suggested that exposure of bone marrow cells to ES-62 in vivo resulted in differentiation 
of DC with a reduced antigen-presentation and co-stimuiatory capacity, in other words, a 
less mature phenotype. Interestingly, moderately reduced expression levels of MHCII had 
previously been exhibited by DC cultured from ES-62 treated mice in the prophylactic 
treatment model. This consistency indicated that inhibiting the expression of this antigen- 
presentation molecule was an effect induced irrespective of the pattern of ES-62 
administration in vivo.
LPS stimulation of DC cultured from CIA model mice in vitro induced upregulated 
expression of the co-stimuiatory molecules CD40, CD80 and CD86 and the adhesion 
molecule CD54. Interestingly DC cultured from ES-62 treated CIA mice displayed 
somewhat inhibited LPS-induced upreguiation of CD54 and CD80. Similarly, the reduced 
level of expression of MHCII on DC cultured from ES-62 treated CIA mice was maintained 
following LPS stimulation. Therefore, therapeutic ES-62 treatment of CIA model mice in 
vivo (after the onset of inflammation) resulted in consequent differentiation of DC that 
displayed an inhibited response to LPS stimulation in vitro. Slight hints of this effect of ES- 
62 treatment had previously been observed during analysis of DC cultured from CIA 
model mice treated prophylactically with ES-62, however the effect appeared more 
obvious in DC from CIA mice that had undergone therapeutic treatment with ES-62. The 
enhanced effect of ES-62 treatment in the therapeutic treatment protocol, suggested that 
the term and pattern of ES-62 treatment in vivo influenced the effect of ES-62 on resultant 
bone marrow derived DC phenotype.
3.2.13.2 The effect of therapeutic ES-62 on CIA model-derived DC cytokine 
production
Consistent with the response observed in DC from the prophylactic treatment modei, the 
level of spontaneous IL-12 production by DC cultured from therapeutically ES-62 treated 
CIA modei mice was greater than that produced by DC from PBS treated mice, although 
this difference was not significant (Figure 3.24). In contrast, when compared with DC 
cultured from bone marrow of control CIA model mice, DC cultured from ES-62 treated 
CIA model mice secreted significantly reduced levels of TNFa. It was of particular interest 
that ES-62 treatment of CIA model mice in vivo reduced TNFa secretion by DC derived 
from these mice in vitro, because this pro-infiammatory cytokine has been identified as 
important for pathogenesis of arthritis Inflammation. This trend of reduced TNFa, but not
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IL-12 production by bone marrow-derived DC was also exhibited by DC cultured from ES- 
62 treated CIA model mice in the prophylactic treatment model. Therefore, it appeared 
that this inhibitory action of ES-62 was specific for TNFa production by DC, which might 
suggest that modulation of TNFa, not IL-12, was most important for amelioration of 
inflammation in this model. Interestingly, DC cultured from CIA model mice that had been 
treated therapeutically, rather than prophylactically, with ES-62 exhibited the TNFa- 
reducing effect of ES-62 treatment in vivo much more prominently. Therefore, this action 
of ES-62 was consistent but influenced by the term and timing of ES-62 treatment in vivo. 
LPS stimulation in vitro of DC cultured from the CIA model mice induced increased 
production of cytokines overall, however DC cultured from CIA model mice treated 
therapeutically with PBS or ES-62 did not exhibit significantly different patterns of cytokine 
production in response to LPS (Figure 3.24).
In summary, the therapeutic ES-62 treatment protocol, administered to CIA model mice in 
vivo, appeared to induce a more pronounced modulation of the phenotype of DC 
subsequently cultured from the bone marrow of the ES-62 treated mice than that 
observed for DC derived from the prophylactic treatment model. The amplification effect 
(from prophylactic to therapeutic ES-62 treatment) probably reflected the influence of the 
term and timing of ES-62 treatment in vivo on bone marrow derived ceil phenotype.
3.2.14 Comparison of the effects of recombinant ES-62 and OVA-PC 
treatment on DC derived from CIA model mice
Unlike treatment of the CIA model mice with native ES-62, treatment with rES-62 after the 
onset of established inflammation did not inhibit progression of inflammation. However, 
therapeutic treatment with OVA-PC, in place of ES-62 did mimic the anti-inflammatory 
effects of the latter in this model of inflammation. It was therefore important to determine 
the phenotype of DC derived from bone marrow of rES-62 or OVA-PC treated mice in the 
therapeutic treatment modei. DC derived from CIA mice treated therapeutically with rES- 
62 or PBS were cultured in vitro and analysed by flow cytometry to determine the cell 
surface expression profiie of antigen-presentation, co-stimulatory and adhesion molecules 
(Figure 3.23). Interestingly, DC cultured from rES-62 treated CIA model mice exhibited 
elevated expression of MHCII, CD80 and CD86, when compared with DC cultured from 
PBS treated CIA model mice. As described above, DC cultured from ES-62 treated CIA 
mice displayed reduced MHCII and CD86 expression compared with DC from PBS 
treated CIA mice. Thus, the action of rES-62 treatment on the phenotype of subsequently 
cultured DC was opposite to the action of parasite-derived ES-62 treatment.
DC cultured from bone marrow of selected OVA and OVA-PC treated mice were similarly 
analysed by flow cytometry to determine their cell surface expression profiie (Figure 3.23).
92
DC cultured from OVA-PC treated mice exhibited reduced MHCII, CD40, CD80 and CD86 
expression and increased CD54 expression, when compared with DC from OVA treated 
mice. This observed reduction in the expression levels of MHCII and CD86 on the surface 
of DC had previously been exhibited by DC cultured from ES-62 treated mice, but not 
rES-62 treated mice, in this therapeutic treatment model. Thus, these combined findings 
supported a role for PC in this inhibitory action of ES-62. Furthermore, it appeared that the 
inhibitory effect of OVA-PC was more potent than that of ES-62, resulting in differentiation 
of DC with reduced expression of additional co-stimulatory molecules, CD40 and CD80. It 
was unusual, however, that CD54 expression was elevated on DC from OVA-PC treated 
CIA mice.
LPS stimulation in vitro of DC from CIA model mice treated with PBS, rES62, OVA or 
OVA-PC induced upreguiation of CD40 and CD86 expression. Additionally, LPS 
stimulation of DC from mice treated with OVA induced upreguiation of CD54, and CD80. 
The respective expression profiles of DC from rES-62 treated mice compared with that of 
DC from PBS treated mice were maintained under LPS conditions. That is, DC cultured 
from rES-62 treated CIA mice exhibited increased expression of MHCII and CD86 and 
similar expression of CD54, CD40 and CD80 when compared with DC from PBS treated 
mice, following LPS stimulation. As described above, native ES-62 treatment of CIA 
model mice resulted in development of DC with an inhibited upreguiation response to LPS 
in vitro. The absence of this modulated phenotype in DC from rES-62 treated mice, 
suggested that this action of native ES-62 might be due to PC.
Treatment with LPS induced upreguiation of CD40, CD54, CD80 and CD86 expression on 
DC cultured from OVA and OVA-PC treated CIA model mice. However, DC cultured from 
OVA-PC treated CIA mice displayed an inhibited CD80 upreguiation response to LPS, 
compared with DC cultured from OVA-treated CIA model mice. The inhibited upreguiation 
response to LPS observed in DC from OVA-PC treated mice had been a feature of ES-62, 
but not rES-62, action on DC cultured from CIA mice in this treatment model. Thus, this 
effect of ES-62 treatment was most likely PC-dependent.
3.2.15 Comparison of the effects of therapeutic OVA-PC or rES-62 treatment 
on CIA model-derived DC
DC cultured from CIA mice treated therapeutically with rES-62 did not produce 
significantly different levels of TNFa, IL-12 or IL-10, when compared with the cytokine 
production by DC from such PBS treated CIA mice (Figure 3.25). By contrast, it had 
previously been shown (Figure 3.24) that DC, cultured from therapeutically ES-62 treated 
mice, secreted significantly less TNFa than DC cultured from control CIA mode mice. 
Therefore this inhibitory action of prior ES-62 treatment on DC phenotype was lost when
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CIA model mice were treated with rES-62 in vivo. This difference indicated that PC might 
be responsible for the reduced spontaneous TNFa production observed in DC from mice 
treated therapeutically with native ES-62.
Likewise, there were no significant differences in IL-12 or IL-10 production by DC cultured 
from OVA treated or OVA-PC treated CIA model mice (Figure 3.26). However, 
surprisingly, DC cultured from OVA-PC treated CIA model mice spontaneously secreted 
increased levels of TNFa compared with DC cultured from OVA-treated CIA model mice. 
This was opposite to the effect induced on DC cytokine production by ES-62 treatment of 
CIA in this model (Figure 3.24). Therefore it was unclear what the role of PC was in ES-62 
mediated inhibition of TNFa production by DC cultured from CIA model mice.
LPS stimulation in vitro of DC cultured from CIA model mice that had been treated 
therapeutically with PBS, rES-62, OVA or OVA-PC induced elevated production of IL-12, 
IL-10 and TNFa by all types of DC. There were no significant differences in the LPS- 
induced cytokine production between DC from PBS treated mice and DC from rES-62 
treated mice. Interestingly, the IL-12 response to LPS was significantly inhibited in DC 
cultured from OVA-PC treated CIA mice compared with DC cultured from OVA-treated 
mice. This inhibited cytokine production response to LPS stimulation had not previously 
been displayed by DC cultured from CIA model mice in the ES-62 therapeutic treatment 
model, indicating that this was a novel effect of OVA-PC treatment in this model of 
inflammation.
In summary, the effects of ES-62 treatment of CIA model mice on the surface expression 
levels, but not cytokine production profiie, of DC subsequently derived from bone marrow 
of those mice appeared to be PC-dependent. In conclusion, it was identified that the 
patterns observed in the phenotype of DC cultured from the CIA model mice that had 
been treated prophylactically with ES-62 were observed more potently in phenotype of DC 
cultured from CIA model mice that had been treated therapeutically with ES-62.
3.2.16 The effects of in vitro treatment with ES-62 on bone marrow 
macrophages derived from naïve mice
During an established inflammatory immune response, macrophages play a key role in 
maintenance or progression of inflammation and recruitment of cells to the inflammatory 
site, via production of cytokines [280]. Thus, it was postulated that examination of 
macrophages was required as part of the process to dissect the mechanisms comprising 
the observed anti-inflammatory actions of ES-62 in CIA. Initially it was important to clarify 
the direct action of ES-62 treatment on macrophages in vitro.
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It has previously been identified that ES-62 treatment of bone marrow-derived 
macrophages in vitro induces modulation of macrophage cytokine production [190, 191]. 
To confirm, bone marrow-derived macrophages were pre-treated with ES-62 for 18h and 
then stimulated with media or LPS plus IFNy for a further 24h. After the culture period, 
supernatants were analysed for cytokine production. This combination stimulus is used as 
macrophages, unlike DC, need be to primed with IFNy prior to stimulation with LPS, to 
enable a complete response in vitro. Such IFN7 treatment simulates the inflammatory 
environment in which macrophages normally function, thus inducing preparation for an 
inflammatory immune response. Treatment of macrophages with ES-62 alone induces low 
level IL-12 and TNFa production (Figure 3.27). This cytokine production is at a much 
lower level than that induced by LPS/IFNy treatment. Moreover, pre-treatment of 
macrophages with ES-62 before subsequent stimulation with LPS/IFN7 results in 
significant reduction in LPS-induced IL-12 and TNFa production. This analysis clearly 
demonstrates that ES-62 can directly modulate macrophage cytokine production in 
response to an inflammatory stimulus.
3.2.17 Investigating inflammation induced by cell-cell contact in arthritis
It has been well documented that the arthritic inflammatory joint is enriched with antigen- 
presenting ceils and T lymphocytes [265]. The communication between these two cell 
types is central to progression and maintenance of the inflammatory environment and 
erosion of the joint. In particular, it has been suggested that ceil-ceil contact dependent 
communication between T cells and macrophages within the synovial joint is important for 
maintenance of inflammation in the progression of arthritis. This theory was proposed by 
Mclnnes’ et ai [245] as a potential target for therapy of arthritis. More specifically, contact 
with activated T ceils induces activation of macrophages and production of pro- 
infiammatory cytokines, such as TNFa and inflammatory mediators, such as matrix 
metaiioproteinases and prostaglandins. As previously discussed, the macrophage-derived 
cytokine, TNFa, has been identified as integral to the onset and progression of 
inflammatory arthritis. Furthermore, TNFa induces activation of macrophages. Thus, 
contact-dependent communication between T ceils and macrophages enables 
amplification of cytokine production, which is observed in the inflammatory RA joint. 
Based on the observed anti-infiammatory effects of ES-62 treatment in the CiA model of 
arthritis, it was proposed that ES-62 might disrupt this particular communication pathway 
between T cells and macrophages to facilitate (at least in part) inhibitory action, 
particularly in established CIA (therapeutic treatment model).
Support for Mclnnes’ theory [245] was provided by co-culturing paraformaldehyde-fixed, 
PHA-activated peripheral blood T cells from healthy humans with macrophage-like ceils 
from a human cell line (THP-1 cells; [192]). It was observed that the resulting T cell
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contact induced marked TNFa production by the THP-1 celis (Figure 3.28). Interestingly, 
pre-treatment of THP-1 celis with ES-62 in vitro significantly inhibited the observed 
contact-induced TNFa production. Thus, It was suggested that the inhibitory action of ES- 
62 demonstrated in vitro might be a method by which ES-62 mediates inhibition of 
inflammation in the CIA joint. However, it was decided that further investigation into this 
artificial human cell system would not be as profitable as developing an in vitro murine 
assay, which would be directly applicable to the murine CIA model system that had been 
investigated up to this point. Therefore it was proposed to develop an in vitro murine cell 
system for analysis of macrophage cytokine production in response to T cell contact.
3.2.18 Development of an murine cell system for investigation of contact- 
dependent communication between T cells and macrophages in vitro
The Mclnnes et al ([245]) theory of RA pathogenesis Indicated that antigen-independent, 
T ceii-contact dependent macrophage pro-inflammatory cytokine production is a core 
component in maintenance of autoimmune disease pathology. In an analogous manner to 
the human T cell-THP-1 cell system, cell contact assays were designed (using murine 
bone marrow-derived macrophages and PMA/Con A-activated lymph node T celis) to 
develop a working cellular model, which could be manipulated in the laboratory for 
investigation of the precise mechanisms underlying contact-induced cytokine production 
by macrophages. Pro-infiammatory TNFaand IL-12 production were measured as an 
indication of macrophage activation. Preliminary experiments established a positive 
relationship between T cell to macrophage ratio and macrophage cytokine production 
(Figure 3.29). In more detail, production of TNFa and IL-12 by macrophages was 
positively associated with the number of fixed T cells present in the co-culture, indicating 
that T cell contact induced macrophage cytokine production.
3.2.19 The effect of ES-62 exposure on contact-dependent communication 
between T cells and macrophages.
To determine the effect of direct ES-62 treatment on contact-dependent communication 
between T ceils and macrophages, bone marrow-derived macrophages, PMA/ConA- 
activated T ceils or both ceil types were pre-treated with ES-62 before co-culture. When 
untreated macrophages were co-cultured with T ceils that had been pre-treated with ES- 
62 prior to activation with PMA/ConA and fixation, T ceil contact induced macrophage 
TNFa production was slightly decreased relative to that observed with such macrophages 
alone (Figure 3.30). By contrast, pre-treatment of macrophages with ES-62 significantly 
reduced their production of IL-12, but not TNFa, in response to T cell contact. However, 
pre-treatment of both, macrophages and T ceils with ES-62 significantly inhibited T cell 
contact-induced TNFa and IL-12 production by macrophages. It was concluded that, in 
this system, ES-62 could act to inhibit T cell mediated induction of macrophage TNFa and
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IL-12 production. Furthermore, the observed TNFa-reducing effect of ES-62 treatment on 
T cells and macrophages may be of therapeutic value in vivo, given that TNFa has been 
shown to be integral to arthritis pathogenesis.
Thus, it was proposed that this inhibitory effect of ES-62 in vitro might be a method 
employed by ES-62 in vivo, for mediation of anti-inflammatory action in the CIA model. To 
determine whether the inhibitory action of ES-62 on T cell contact-mediated cytokine 
production by macrophages might be induced in vivo, a further investigation was 
designed. Mice were treated twice in vivo with ES-62 and following sacrifice, bone 
marrow-derived macrophages were cultured and T cells were obtained from lymph nodes. 
Bone marrow derived macrophages and T cells were also cultured and obtained from 
untreated mice for comparison. Firstly, T cells from ES-62 treated mice were co-cultured 
with bm-macrophages from untreated mice. Overall, IL-12 and TNFa production by bone 
marrow-derived macrophages from untreated mice was low in both the presence and 
absence of co-culture with activated T cells. fFigure 3.310 Nevertheless it appeared that 
there was some T cell contact-induced IL-12, but not TNFa production by macrophages, 
identified because IL-12 production was positively associated with increasing ratios of T 
cells to macrophages. This effect was maximal at the ratio 8:1; T cells to macrophages. 
The observed lack of T cell contact-induced macrophage TNFa production (when T cells 
are from mice treated with ES-62) indicated that T cell contact-induced TNFa and IL-12 
production by macrophages might be differentially regulated, that is, the in vivo effects of 
ES-62 treatment on T cells disrupts contact-dependent induction of TNFa, but not IL-12 in 
this system.
Secondly, bone marrow macrophages derived from mice that had received ES-62 
treatment in vivo were co-cultured with fixed, activated T cells from untreated mice (Figure 
3.32). Interestingly, although macrophages cultured alone spontaneously produced 
elevated levels of TNFa and IL-12, co-culture with increasing numbers of T cells did not 
significantly modulate macrophage cytokine production, indicating that T cell contact- 
dependent macrophage production of IL-12 and TNFa does not occur when macrophage 
pre-cursors have been pre-treated with ES-62 in vivo.
In summary, it appeared that treatment of mice in vivo with ES-62 disrupted T cell contact- 
induced cytokine production by macrophages. Furthermore, it was concluded that prior 
treatment of either cell type with ES-62 in vivo induced disruption of this method of 
macrophage activation and inflammatory cytokine production, indicating that this was a 
potential mechanism by which ES-62 might mediate anti-inflammatory action in vivo in the 
CIA model.
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3.3 Discussion
It has previously been established that ES-62 can induce inhibition of TH1-type immune 
responses in vitro [^89]. In this chapter, evidence has been provided to confirm, the 
previously identified, ES-62-mediated inhibition of TH1-type inflammation in vivo, in a 
model of inflammatory autoimmune rheumatoid arthritis [192]. Furthermore, progress has 
been made towards dissection of the mechanisms of ES-62 action in this model, by 
analysing the roles of sub-structural components of ES-62 and investigating the immune 
cells Involved in mediation of ES-62 action.
3.3.1 The role of PC in the anti-inflammatory action of ES-62 on CIA model 
inflammation
As stated above, ES-62 significantly inhibited the severity of joint-specific inflammation in 
a laboratory model of arthritis. Moreover, inhibition of CIA inflammation was observed 
when ES-62 was administered either prophylactically (during set-up of the inflammatory 
condition) or therapeutically (after the onset of inflammation). The inflammation exhibited 
in the collagen-induced model of rheumatoid arthritis was confirmed as THI-type, 
demonstrated by antigen-specific lymphocyte production of TH1-promoting cytokines 
(IFN7 and TNFa), detection of an antigen-specific THI-type antibody response (lgG2a) 
and a pro-inflammatory cytokine milieu in the serum. Prophylactic ES-62 treatment of the 
CIA model mice reduced the development of such hallmark features of TH I-type 
inflammation in this model. Following confirmation of the previously published [192] anti­
inflammatory actions of ES-62 in this model, the investigation progressed to analyse the 
role of PC in the effects of ES-62. The anti-inflammatory action of ES-62 was found to be 
lost when a PC-deficient recombinant homologue of ES-62 (rES-62) was employed. This 
highlighted the potentially important role of PC in ES-62 mediated inhibition of CIA 
inflammation. Furthermore, PC conjugated to albumin protein (OVA-PC), was capable of 
mimicking the anti-inflammatory action of ES-62 treatment in the CIA model. PC is a 
common component of pathogen-derived substances, with important dual functions in 
immune system activation and immune response evasion [177]. Previously, it has been 
demonstrated that PC, alone or conjugated to an irrelevant albumin protein, can largely 
mimic the in vivo and in vitro immunomodulatory actions of ES-62 on individual cell types 
[167, 185, 190, 191, 281]. Furthermore, it has also been previously identified that 
continuous exposure of mice to PC in vivo (via the use of osmotic pumps) induced 
modulation of peritoneal macrophage cytokine production ex vivo and development of 
bone marrow-derived DC with a modulated phenotype [191]. This was concluded to be 
similar to the effects of ES-62 exposure on these cell types. The results presented in this 
chapter represent new information demonstrating that PC (conjugated to OVA) can largely 
mimic the anti-inflammatory actions of ES-62 in a model of autoimmunity.
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Given that substances such as ES-62 are secreted continually into the host bloodstream 
during infection with filarial nematodes it might be proposed that parasite infection may 
prevent development of inflammatory autoimmune disease, such as arthritis, in the host. 
Indeed, it has been demonstrated that infection with protozoan parasite. Trypanosoma 
brucei brucei (Tbb) ameliorates CIA inflammation in Dark Agouti (DA) rats [282]. In more 
detail, DA rats were infected with Tbb prior to collagen immunisation, employing a similar 
collagen administration protocol to that used in the murine CIA model. Similar to the 
effects of prophylactic ES-62 treatment in murine CIA, Tbb infection inhibited development 
of collagen-specific IgG and decreased expression of TH1 cytokine, IFNy in draining 
lymph nodes of the CIA model rats. This provides evidence to support the statement 
made above, that active parasite infection might prevent the development of inflammatory 
autoimmune disease in vivo. Interestingly, Tbb-mediated amelioration of CIA 
inflammation in the DA rat was also associated with and induction of anti-inflammatory 
cytokine. TGFp. Thus, it would be interesting to determine if TGFp was also induced by 
ES-62 in the murine CIA model. Furthermore, in the rat CIA model, it was observed that 
the anti-inflammatory action of Tbb was only mediated by infection with live and not 
inoculation with dead parasites, suggesting that the anti-inflammatory effects were due to 
a product of Tbb and not the parasite itself. Thus, it would also be prudent to determine 
whether the anti-inflammatory effects of Tbb infection in the DA rat model of CIA are due 
to the immunomodulatory actions of a parasite-derived product, analogous to ES-62.
3.3.2 ES-62-mediated inhibition of antigen-specific lgG2a Is PC- 
independent and not anti-inflammatory
Ultimately, inflammation and pathology in CIA occurs as a result of developing a chronic 
collagen-specific TFH-type immune response. Analysis of serum antibody levels is a 
method often used to determine the nature of the immune response underlying 
inflammatory pathology. Previously, it was demonstrated that ES-62-mediated inhibition of 
inflammation in the CIA model was associated with reduced antigen-specific igG2a, a 
TH1-promoting antibody subclass. Furthermore, such action was observed when CIA 
model mice were treated with ES-62 prophylactically or therapeutically. Serum samples 
from CIA model mice in both treatment models were also analysed for lgG1, lgG3 and 
IgM and revealed no modulation, indicating that ES-62 action on the antibody response 
was specific for TFI1-promoting IgG subclass, 2a.
Interestingly, the anti-inflammatory action of OVA-PC on CIA model mice was not 
associated with significant modulation of the level or nature of the serum antibody 
response, indicating that the inhibitory action of ES-62 on antigen-specific lgG2a was PC- 
independent. Furthermore, despite lacking anti-inflammatory action in the CIA model, 
treatment of CIA model mice with PC-deficient rES-62 induced inhibition of antigen-
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specific lgG2a production, similar to that Induced by treatment with parasite-derived ES- 
62. Thus, inhibition of collagen-specific lgG2a by native and rES-62 indicates that this 
effect was mediated by component(s) common to both substances. The apparent 
inconsistency in anti-inflammatory action and lgG2a inhibition confirmed that the lgG2a- 
reducing action of ES-62 in the prophylactic treatment model was PC-independent, 
furthermore, it indicated that serum antibody profile did not reflect the inflammatory status, 
in terms of cytokine production and arthritic score, of the mice in the CIA model.
These findings are particularly interesting as it was previously shown that PC (as a 
component of ES-62) prevents development of an lgG2a antibody response specific for 
non-PC epitopes of ES-62 [187], whilst not modulating the IgGI antibody response. 
However it must be highlighted that such lgG2a-inhibiting action of PC was targeted to the 
antibody response to ES-62. In the CIA model the antibody response measured was 
collagen specific, thus it appears that PC functions to prevent development of a TH1- 
mediated antibody response to non-PC parts of ES-62 (or possibly other substances to 
which it is conjugated), but not other distinct antigens (such as collagen). Indeed, this 
action of PC may have a role in maintaining the circulatory concentration of ES-62 during 
infection with A. viteae, as antibody ligation would result in opsonisation of ES-62, 
preventing its action.
Nevertheless, the action of OVA-PC in CIA was anti-inflammatory, therefore it appears 
that modulation of the collagen-specific lgG2a antibody response is not necessary for 
inhibition of inflammation in this model. The anti-inflammatory action of OVA-PC in the 
CIA model, without corresponding modulation of serum lgG2a may appear inconsistent as 
lgG2a levels are generally considered to correspond with inflammation severity in CIA. 
However, previous studies have argued against a correlation in lgG2a levels and CIA 
incidence in mice and demonstrated maintenance of a T h i immune response despite 
absence of an lgG2a antibody response [283, 284]. It was particularly interesting that 
treatment with OVA-PC slightly reduced collagen-specific IgM levels, an effect not 
observed in ES-62-treated mice. Therefore, this might be considered an action of PC that 
is masked when PC is incorporated within the structure of parasite-derived ES-62.
In this series of investigations, prophylactic but not therapeutic treatment of CIA model 
mice with ES-62 inhibited antigen-specific lgG2a levels, however, inhibition of collagen- 
specific lgG2a had previously been documented as an effect of both prophylactic and 
therapeutic ES-62 treatment in this model [192]. Coinciding with this slight change in the 
actions of ES-62, a shift in the severity of induced inflammation in the CIA model has 
been observed. Indeed, several models of CIA have been investigated in this laboratory 
since publication of the initial data. During this time, the supply of mice and collagen has
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changed and challenges concerning induction of inflammation have been encountered 
and resolved. As a result, recent models of CIA have exhibited lower levels of overall 
induced inflammation, compared with the preliminary models used to determine the anti­
inflammatory action of ES-62 in CIA. Thus, whilst the anti-inflammatory action of ES-62 
remains, loss of the lgG2a-reducing capacity of ES-62 in the recent therapeutic treatment 
models may be a consequence of lower overall inflammation. Indeed, inhibition of 
antigen-specific lgG2a was also not observed when CIA was treated therapeutically with 
rES-62, therefore, like ES-62, the inhibitory action of rES-62 induced when administered 
prophylactically was also lost, when this treatment was administered after the onset of 
Inflammation. In summary, it can be concluded that ES-62 (and rES-62) treatment of the 
recent models of CIA (presented in this thesis) prevents development of the collagen- 
specific igG2a response, but does not induce reduction of existing antigen-specific lgG2a 
levels.
3.3.3 The serum profiles of cytokines, chemokines and growth factors in 
CIA model mice
Serum samples from the CIA model mice exhibited expression of a range of cytokines, 
chemokines and growth factors. However, the range of factors detected in serum from 
CIA mice in the therapeutic model compared with the prophylactic model was reduced. As 
these mice have received identical collagen treatment in vivo, this difference must be due 
to the timing of sacrifice and serum collection in each model. In more detail, CIA model 
mice in the prophylactic treatment model were sacrificed on day 33 and serum obtained, 
whilst CIA model mice in the therapeutic treatment model were sacrificed between days 
29 and 35 of the experiment (depending on the time of inflammation onset and hence, the 
end of the treatment period, 14 days later). Thus, it is clear that the levels of serum 
cytokines, chemokines and growth factors exhibited by the CIA model mice change over a 
period of days. Nevertheless, certain cytokines (IL-2, IL-12), chemokines (IP-10, MIG, 
MIP-1 a) and growth factors (FGF) were consistently detected, indicating that these 
soluble mediators might play important roles in the pathogenesis of this model. Cytokines 
help to form and define the nature of the developing immune response in arthritis, whilst 
the directed movement of immune cells during an immune response is highly dependent 
on the chemokine network [207, 285]. More specifically, chemokines orchestrate the 
trafficking of dendritic cells, T cells and B cells needed to generate an immune response. 
IL-12 is an important cytokine necessary for development of a THI-mediated immune 
response [261], whilst IL-2 is important for T cell survival and function [262]. Furthermore,
IL-10, a cytokine often identified in serum samples of CIA model mice in this investigation, 
has been identified as upreguiated in peripheral blood of RA patients [286] and has been 
demonstrated as acting in an anti-inflammatory, regulatory manner on synovial cells [207]. 
Furthermore, IL-10 has been identified as regulatory to TNFa in RA [287].
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It has been well established that the chemokines MIG, MlP-1a and lP-10 are released by 
innate immune cells, such as macrophages, in response to activation by inflammatory 
mediators such as IFNy. Upon recognition of such chemokines, immature dendritic cells 
are recruited to the site of inflammation [285]. At the site of inflammation, immature DC 
are activated by the inflammatory milieu and are enabled to present antigen to and 
activate naïve T cells. Chemokines are also involved in recruiting lymphocytes from the 
blood across the endothelium of venules and to the inflammatory site. As ligands for CXC- 
chemokine receptor-3 (CXCR3) receptors on activated T cells, IP-10 and MIG are 
believed to be important for development of immune responses mediated by TFI1 cells 
[285]. MIG and IP-10 also bind to and activate CXCR3 expressed on NK cells and is 
important for the recruitment of these cells Into tissues. All of these cellular recruitment 
factors are required and appropriate for development of inflammation such as that 
exhibited in CIA.
Along with PDGF and TGFp, fibroblast growth factor (FGF) is a major contributor to 
synovial cell hyperplasia in RA [207]. Furthermore, VEGF, which was detected in serum 
samples from the therapeutic treatment model, is important for neovascularisation in RA
[288]. Thus, the serum factors detected have appropriate inflammation-promoting roles in 
CIA.
3.3.4 The effect of ES-62 treatment of CIA on the serum cytokine, 
chemokine and growth factor profile
Prophylactic ES-62 treatment of the CIA model induced modestly increased serum levels 
of pro-inflammatory cytokine, IL-1a, in some mice. Indeed, this IWenhancing effect 
was potently mimicked by treatment with OVA-PC, but was not induced by treatment with 
rES-62, indicating that this was likely to be a PC-dependent action of ES-62, IL-1 has 
been identified as contributory in the pathogenesis of RA [207, 267], thus the increased 
serum IL-1 a concentration would appear inconsistent with the anti-inflammatory effects of 
treatment with ES-62 or OVA-PC in these mice. Flowever, it has recently been 
demonstrated that whilst over-expression of IL-1 a in a transgenic mouse led to 
development of severe arthritis, the severity of arthritis was related to activity of 
membrane associated IL-1 a and not to serum concentration or activity of soluble IL-1 a
[289]. This may offer some explanation for the apparent discrepancy between the serum 
IL-1 a levels and inflammation exhibited in this model. Furthermore, in accordance with the 
findings of the aforementioned study, it might be proposed that ES-62 acts to reduce 
membrane-bound IL-1 a, as a potential mechanism of anti-inflammatory action in CIA 
model mice. Interestingly, serum IL-1 a concentration appeared to correlate inversely with 
the inflammatory score of the mice in the ES-62 treatment group, suggesting that an
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increase in IL-1 a was somehow related to the anti-inflammatory effect of ES-62 in these 
mice. However, this pattern was not maintained throughout the treatment groups, 
indicating that this association may not be real.
In addition to IL-1, TNFa has also been identified as integral to development of arthritis 
inflammation, indeed blockade of TNFa is routinely used to reduce RA inflammation in 
humans [255]. Thus, it was surprising to note that TNFa was not present in serum 
samples from the CIA model mice. It has been suggested that TNFa is expressed in 
synovial membrane at onset of arthritis in the CIA model, [207], whilst IL-1 is detected 
later (1-2 days after the development of clinical inflammation). Therefore, it is possible that 
TNFa would be detected in serum samples obtained from CIA model mice at an earlier 
time-point (e.g. day 18-20). Nevertheless, KC and MIP-1a (that are induced by TNFa) 
were consistently detected in serum samples from the prophylactic treatment model, 
implicating upstream TNFa action. Interestingly, the expression of GRO-2 (the human 
counterpart of murine KC) and M lP -la  have been shown to be upreguiated in synovial 
fibroblasts in RA patients [290]. GRO-2 functions chiefly in recruitment of neutrophils to 
the inflammatory site whilst MIP-1a recruits mainly monocytes and T cells, cell types 
known to be involved in synovial inflammation in RA.
Thus, although TNFa was not detected in serum samples from CIA model mice, it is 
possible that TNFa was still acting locally, at the inflammatory site for example, inducing 
production of KC and MiP-1a at this location, but not circulating in the bloodstream. 
Furthermore, serum KC concentration was modestly reduced by treatment with ES-62 and 
OVA-PC, indicating that earlier production of TNFa may have been reduced by both of 
these treatments. Interestingly, serum IL-10 levels were not modulated by ES-62 
treatment indicating that promotion of this anti-inflammatory cytokine [291] was not a 
method employed by ES-62 for inhibition of inflammation, at least at this stage of the 
protocol.
Clearly, analysis of serum cytokines, chemokines and growth factors provided informative 
data about the soluble mediators circulating at the time of sacrifice, however it was not 
clear whether the factors detected were representative of the overall immune status of the 
CIA model mice (such as the serum antibody profile) or whether the slight changes 
induced by ES-62 reflected the anti-inflammatory effects of this glycoprotein in the joints. 
Consistent with this, it has been suggested that synoviocyte cytokine production may give 
a more accurate indication of arthritis severity in human RA and murine models [207]. 
Thus, examination of cytokine profiles in synovial samples from these mice might provide 
more conclusive information.
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3.3.5 The immunostîmulatory action of rES-62 in CIA model mice
Treatment of CIA model mice with rES-62 did not inhibit CIA inflammation and this was 
attributed to a lack of PC within the structure of rES-62. However, in addition, prophylactic 
treatment of CIA model mice with rES-62 appeared to promote prematurely enhanced 
collagen-induced inflammation and onset of arthritis. This observation indicated that rES- 
62 exhibits pro-inflammatory properties, consistent with the elevated serum IL-12 
concentration observed in these mice. Indeed, it has been shown that mice treated with 
IL-12 developed significantly higher incidence and more severe collagen-induced arthritis 
[292]. Furthermore, it has been demonstrated that serum IL-12 levels reflect disease 
activity in humans and that IL-12 is involved in the production of pro-inflammatory 
cytokines in RA [293]. In addition, blockade of IL-12 has been shown to reduce the 
severity, but not the incidence, of CIA [294]. Interestingly, another study demonstrated 
that IL-12 has a stimulatory role in early arthritis expression, (accelerated onset and 
enhanced severity of CIA were provoked when IL-12 was administered around the time of 
arthritis onset), whereas it has a suppressive role in the established phase of collagen 
arthritis [295]. Thus, rES-62-induced promotion of CIA inflammation may be attributed to 
its IL-12-înducing action. However, it is not yet known how it induces IL-12.
Recombinant ES-62 was generated using the protein synthesis machinery of the yeast P. 
pastoris. Thus, several candidates may be responsible for the immunostimulatory action 
of rES-62 exhibited in the CIA model. Firstly, it might be considered that if PC is 
responsible for dampening inflammatory immune responses to native ES-62, the absence 
of PC may confer immunostimulatory properties on the rES-62 molecule. Indeed it has 
been identified that removal of PC from parasite-derived ES-62 (by treating with 1-deoxy- 
mannojirimycin (dMM) or hemicholinium-3 (HC-3)) prevented PC-dependent blockade of 
lgG2a antibody production against non-PC epitopes of ES-62 [187]. Thus, it is possible 
that lack of PC prevents masking of ES-62 antigenicity, resulting in an immunostimulatory 
substance that appears pathogenic and therefore stimulates an inflammatory immune 
response (and IL-12 production) in the CIA model.
Secondly, it has been recently identified that yeast-derived rES-62 exhibits increased 
mannose content compared to parasite-derived ES-62 [199]. Mannose is a common 
pathogen-associated carbohydrate and, therefore, activates immune responses in vivo. 
Mannose receptors are commonly expressed by cells of the innate immune response 
(such as macrophages and dendritic cells) as part of their repertoire of pattern-recognition 
receptors and upon ligation of these receptors the cells become activated. For example, 
the mannose receptor has been shown to recognise and bind components of mannose- 
containing 7. spiralis muscle larvae [296], leading to cytokine production by macrophages. 
Therefore, the enhanced mannose content of rES-62 may induce an additional immune
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response in CIA model mice, leading to activation of innate immune cells, increased IL-12 
production and enhanced severity of CIA.
Finally, another factor to consider is that yeast-derived rES-62 also exhibits altered 
secondary and tertiary structures to parasite-derived ES-62 [199]. Using biophysical 
analysis methods it was recently determined that the secondary structure of rES-62 
exhibits a reduced proportion of a-helices and increased proportions of ^-sheets and p- 
turns compared with native, parasite-derived ES-62 [181, 199], indicating that rES-62 
does not completely mimic the conformation of ES-62. Furthermore, using small angle X- 
ray scattering, it was demonstrated that the shape of rES-62 was most likely elongated 
[199], which was in contrast to the previously determined globular tertiary structure of 
parasite-derived ES-62 [181]. Thus, the refolded secondary and altered tertiary structures 
of rES-62 (compared with parasite derived ES-62) may influence the way in which the 
epitopes of rES-62 are presented to cells of the immune response in CIA model mice. For 
example, rES-62 may be recognized as pathogenic and, hence, activate additional 
immune responses. Ultimately the enhanced severity of CIA in rES-62 treated mice may 
be a result of a combination of any of the three factors mentioned above. The mechanism 
underlying this immunostimulatory action of rES-62 will only be conclusively identified 
upon further investigation.
3.3.6 Dendritic cells from CIA model mice exhibit a mature phenotype
Dendritic cells are integral and fundamental for organisation and initiation of immune 
responses in vivo [3]. Therefore, disruption of DC signalling and onward communication 
would be an efficient method by which immune responses could be modulated. Compared 
with DC cultured from bone marrow of naïve mice, DC cultured from CIA model mice 
exhibited a matured phenotype, demonstrated by enhanced expression levels of cell 
surface markers required for activation of T cells and increased spontaneous cytokine 
production levels. Therefore, cells which differentiated from bone marrow progenitors in 
the CIA model mice were pre-activated as a result of the collagen immunisation protocol 
(depicted in Figure 3.33). The activated THI-promoting status of cells such as DC would 
help to accelerate the development of the THI-type immune response required for 
establishing inflammation in this model.
3.3.7 The effects of treatment of CIA model mice with ES-62 on DC 
phenotype: prophylactic vs therapeutic treatment
As described above, ES-62 treatment of CIA model mice significantly inhibited articular 
inflammation. In addition, it has previously been demonstrated that a modulated DC 
phenotype results following in vivo exposure of bone marrow (in otherwise untreated 
mice) to ES-62 [191]. Thus it has been suggested that ES-62 is able to modulate
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development of an immune response in vivo via rewiring of bone marrow DC progenitors. 
To determine whether ES-62 employed this mechanism to ameliorate disease in the CIA 
system, the phenotypes of DC cultured from PBS- and ES-62-treated CIA model mice 
were compared.
Prophylactic treatment of CIA model mice with ES-62 induced differentiation of bone 
marrow-derived DC that exhibited a subtly modulated phenotype compared with DC 
derived from control CIA model mice. In more detail, ES-62 treatment in vivo induced 
differentiation of DC that exhibited enhanced IL-12 production. Considering IL-12 is a 
THI-promoting cytokine, this action of ES-62 might appear counterintuitive to the anti­
inflammatory action of ES-62 in this model of THI-mediated inflammation, however, as 
mentioned above it has been demonstrated that the action of IL-12 can change during the 
course of CIA inflammation development. For example, IL-12 has been identified as 
immunosuppressive after the onset of inflammation in CIA [295], thus, enhanced 
production of IL-12 by DC at this stage in the model could represent an anti-inflammatory 
effect of ES-62. It must also be considered that in this investigation production of only the 
p40 subunit of IL-12 has been measured. Bioactive IL-12 exists as a heterodimer 
composed of p40 and p35 subunits. Furthermore, it is known that IL-12 can also exist as a 
homodimer of two identical p40 subunits (IL-12p40/p40). This p40 homodimer has very 
different immunological activity to the heterodimer IL-12p40/p35 [297, 298]. Indeed, it has 
been demonstrated that treatment with IL-12p40 homodimer (in low concentrations) 
inhibits inflammation exhibited in a model of colitis by blocking the IL-12 receptor and 
antagonising the action of heterodimeric IL-12 [299]. Thus, it might be proposed that, via 
this mechanism, the enhanced IL-12p40 secreted by DC derived from ES-62-treated mice 
could act in an anti-inflammatory manner in vivo in the CIA model. Conclusive elucidation 
of this theory might be permitted following further investigation.
Nevertheless, the modulation of phenotype induced by ES-62 was minimal relative to that 
induced by the collagen administration protocol. Interestingly, the modulatory action of 
ES-62 on DC phenotype was more obvious when ES-62 was administered in the 
therapeutic treatment model. Such difference in the potency of ES-62 action indicated that 
the timing and quantity of ES-62 treatment in vivo influenced its action on resultant DC 
phenotype.
To explain, during the prophylactic treatment model, ES-62 was administered only three 
times, on days -2 , 0 and 21, therefore the last exposure to ES-62 was administered 12 
days before sacrifice. In contrast, in the therapeutic treatment model, ES-62 was 
administered to CIA model mice daily for 14 days immediately prior to sacrifice of the mice 
and subsequent culture of bone marrow-derived DC. Thus bone marrow cells of CIA
106
model mice in the therapeutic treatment model were exposed to a greater number of ES- 
62 applications, which were administered immediately prior to the start of the DC culture 
period. Therefore, the potency of the modulatory effect of ES-62 on DC derived from CIA 
model mice was most likely directly related to the duration and quantity of ES-62 exposure 
in vivo. Indeed, significant modulatory effects of ES-62 on DC phenotype ex vivo have 
been demonstrated when bone marrow cells are exposed in vivo to ES-62 continually, via 
the use of osmotic pumps, which continuously release ES-62 at a concentration similar to 
that produced during active infection with filarial nematodes [191]. In more detail, DC 
derived from such ‘ES-62 pump’ mice exhibited an immature phenotype and an inhibited 
response to LPS stimulation in vitro. By comparison, the modulation of bone marrow- 
derived cell phenotype induced by this type of continuous ES-62 exposure was more 
pronounced that that observed in response to daily boluses of therapeutic ES-62 
treatment in the CIA model. This difference helps to confirm that the nature and duration 
of ES-62 treatment in vivo may be directly related to the extent of modulation of DC 
phenotype that results.
Nevertheless, it must be considered that the modulation of DC phenotype by ES-62 
treatment of CIA model mice in vivo was modest, even in DC cultured from the therapeutic 
treatment model. Moreover, the subtle effects of ES-62 on DC phenotype were largely 
overshadowed by the powerful modulatory effect of the collagen administration protocol 
on this cell type. Therefore, in future investigations of this model, it would be interesting to 
examine the phenotype of DC cultured from bone marrow taken at different time-points 
throughout development of the CIA model and determine any change over time. Similarly, 
it may be informative to extract mature peripheral tissue DC from CIA model mice and 
compare phenotype with DC cultured from bone marrow taken at the same time-point. 
The results of such investigations may help to clarify the in vivo effects of ES-62 on DC in 
developing and established CIA.
3.3.8 PC-dependent modulation of DC phenotype
It appears likely that the small additional changes to DC phenotype induced by ES-62 
treatment in vivo may not reflect the marked reduction in inflammation exhibited by the 
ES-62 treated CIA model mice. Nevertheless, in an attempt to determine the PC- 
dependency of ES-62-mediated modulation of DC phenotype in this model, DC derived 
from ES-62- rES-62- and OVA-PC treated CIA model mice were compared. Despite 
concluding that the changes to DC phenotype induced by prophylactic ES-62 treatment of 
CIA model mice were modest, a few effects were particularly interesting. Firstly, DC from 
ES-62 treated mice exhibited a trend of reduced TNFa production, which was more 
significantly exhibited by DC from OVA-PC treated mice, but not observed in DC from 
rES-62 treated mice. Therefore DC with reduced TNFa production were promoted only by
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the treatments that contained PC, suggesting that this was a PC-dependent effect. TNFa 
blockade has been used as an effective treatment for arthritis [255] therefore, if this 
TNFa-reducing effect was more potent, it might have an anti-inflammatory effect in this 
model. Indeed, an effect such as this may be more apparent in vivo, and may be lost in 
vitro due to the required culture time for differentiation of DC.
Secondly, ES-62 treatment of CIA model mice in vivo promoted the DC inflammatory 
cytokine response to LPS in vitro. This was unexpected because it was the reverse effect 
to that induced by ES-62 when administered directly to DC in vitro or when administered 
to bone marrow progenitors in vivo via osmotic pumps [191]. Nevertheless, this effect was 
additionally observed in DC from OVA-PC treated mice, but not DC from rES-62 treated 
mice, suggesting that this was also a PC-dependent effect. It is unclear how this PC- 
dependent action of ES-62 and OVA-PC on DC cytokine production would be related to 
ES-62 or OVA-PC induced anti-inflammatory action in this model, however it must be 
reiterated that these modulatory effects of ES-62 and OVA-PC, whilst significant, were 
relatively small.
In summary, it was concluded that whilst ES-62 clearly was capable of modulation of DC 
phenotype, its action was mild in this disease model. Nevertheless, ES-62 treatment after 
the onset of established inflammation did inhibit inflammation, therefore ES-62 must be 
targeting other cell types to induce this significant anti-inflammatory action, in established 
disease.
3.3.9 Cell-cell communication in the inflammatory site
Of the several cell types commonly found in close proximity in the arthritic synovium, 
macrophages and T cells are major players [300]. Furthermore, communication between 
macrophages and T cells is thought to be of central importance in propagation of 
inflammation in the joint. For example TNFa production in RA synovium is T-cell 
dependent, as removal of CD3-positive T cells from RA synovial mononuclear cells 
resulted in significant reduced macrophage-derived TNFa production [301].
It was suggested by Mclnnes et al [245] that contact-dependent communication between 
activated T cells and adjacent macrophages in the arthritic synovium is fundamental for 
development and amplification of inflammation in arthritis. More specifically, T cells 
activated by pro-inflammatory cytokines or components of the extracellular matrix, but not 
via ligation of the antigen receptor (i.e. bystander activation), promote pro-inflammatory 
cytokine (e.g. TNFa) and inflammatory mediator (e.g. matrix metalloproteinases and 
prostaglandins) production by macrophages [302]. Since cytokines generated by this 
method could in turn activate T cells, positive feedback and amplification of inflammation
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may be initiated (Figure 3.1). Therefore, disruption of this method of cell-cell 
communication would represent an efficient mechanism by which inflammation in arthritis 
could be reduced locally.
Indeed, support for this theory was provided by co-culture of fixed, activated human 
peripheral blood T cells (from healthy or RA donors) and human macrophage-like THP-1 
cells, which induced TNFaproduction by the THP-1 cells (Figure 3.28). Furthermore, 
TNFa production by the THP-1 cells in response to contact with the T cells was inhibited 
when the THP-1 cells were pre-treated with ES-62. Confirming that, via modulation of 
macrophage function, T cell contact-induced cytokine production was a viable target for 
ES-62 in mediation of anti-inflammatory effects.
Macrophages are innate cells possessing important roles in maintenance and progression 
of inflammation at the inflammatory site. As mentioned previously, by secreting 
chemotactic factors and cytokines, macrophages function to recruit other immune cells to 
the inflammatory site and promote their survival and activation [285]. Furthermore, it has 
been clearly established that macrophages are important cells for maintenance of 
inflammation in the arthritic joint. For example, this cell type represents a primary source 
of TNFa, a cytokine known to be integral to arthritis pathogenesis [207]. It has previously 
been demonstrated that ES-62 treatment of macrophages, in vivo or in vitro inhibits the 
normal inflammatory cytokine secretion response of this cell type [190, 191]. Furthermore, 
this action has subsequently been found to be PC-dependent. Recently, another study 
has demonstrated sim ilar macrophage inhibiting properties of a PC-containing 
phospholipid, which inhibited TNFa production by macrophages and endothelial cells 
[303], indicating that this action of ES-62 might also be employed by other PC-containing 
parasite derived substances. Considering that macrophages confer a significant 
contribution to local inflammation in arthritis and that ES-62 is capable of inhibiting 
macrophage inflammatory responses, macrophages represented a promising target for 
ES-62 mediated anti-inflammatory action in the CIA model, especially in the therapeutic 
treatment protocol.
3.3.10 ES-62 disrupts I  cell contact induced macrophage activation
In accordance with the Mclnnes theory of RA pathogenesis [245], it was proposed that the 
anti-inflammatory action of ES-62 treatment in the CIA model might be mediated by 
disruption of contact-dependent T cell-macrophage communication. Therefore, analysis of 
T cell contact-induced macrophage cytokine production was conducted. Using a specially 
designed in vitro system that employed murine cells it was possible to demonstrate T cell 
contact-induced macrophage cytokine production (Figure 3.29). Furthermore it was clear 
that prior ES-62 treatment of T cells or macrophages in vitro, or both cell types in vivo,
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acted to disrupt this method of communication, demonstrated by inhibition of macrophage 
cytokine production. Therefore it was concluded that this represented a potential method 
by which ES-62 might inhibit established inflammation in the CIA model (illustrated in 
Figure 3.34). In future experiments it would be interesting to investigate the PC- 
dependency of this action of ES-62, however, due to time constraints this was not 
possible during this study.
A particularly interesting observation concerning regulation of IL-12 and TNFa production 
was made during analysis of this in vitro system. Following in vivo treatment of T cells with 
ES-62, it was demonstrated that macrophage TNFa, but not IL-12 production (in response 
to T cell contact) was inhibited. This difference indicated that T cell contact-induced 
production of IL-12 and TNFa by macrophages might be differentially regulated. 
Ultimately treatment of macrophages or T cells with ES-62 consistently targeted TNFa 
production. Considering TNFa is an integral cytokine for development of inflammation in 
CIA, this action of ES-62 in vivo would be selectively anti-inflammatory.
In summary, ES-62 treatment disrupts contact-dependent communication between T cells
and macrophages, evidenced by inhibition of macrophage cytokine production levels. It
has previously been identified that ES-62 modulates macrophage cytokine production in
response to LPS by suppressing the activation of mitogen-activated protein (MAP)
kinases, p38 and JNK [304], which are required for production of cytokines, such as IL-12
and TNFa. Furthermore, ES-62 promotes the activation of Erk MAP kinase [305], which
functions as a negative regulator of IL-12 in macrophages. Thus, it was planned to
investigate expression of MAP kinases In macrophage-like THP-1 cells, in response to
treatment with ES-62 alone. However, preliminary experiments examining expression and
activation of Erk, JNK, p38 and Akt MAP kinases in THP-1 cells following ES-62 treatment
did not provide conclusive data (results not shown). Furthermore, previous investigations
conducted in this laboratory have concluded that whilst the direct action of ES-62 on T cell
cytokine production is minimal, ES-62 treatment of T cells inhibits their proliferation in
response to ligation of the antigen receptor [186]. Such ES-62-mediated disruption of TCR
signalling (leading to abrogated proliferation) is associated with disruption of TCR
coupling to phospholipase D, protein kinase 0, phosphatidylinositol-3-kinase and Ras Erk
MAP kinases [304]. Furthermore, it has previously been demonstrated that ES-62
treatment alone induces Erk phosphorylation in T cells [186], before desensitizing these
cells to activation by anti-CD3. However, as yet it has not been determined whether ES-
62 can modulate T cell signalling when they are activated in a bystander mechanism,
such as that described in Mclnnes’ theory [245]. In accordance with the previously
documented effects of ES-62 treatment alone, the results of a preliminary experiment
conducted during study of ES-62 action in the CIA model indicated that ES-62 treatment
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of CIA model mice in vivo induced transient Erk phosphorylation ex wVo in lymph node T 
cells from CIA model mice. This was not observed in T cells from PBS-treated CIA model 
mice (results not shown). Therefore, via modulation of Erk MAP kinase activation in T 
cells, ES-62 treatment of CIA model mice might induce desensitisation of T cells to 
bystander activation, resulting in reduced expression of co-stimulatory (e.g. CD154 and 
CD28) and adhesion molecule (e.g. LFA-1 and ICAM-1) receptors on the surface. As 
these surface molecules are required for mediation of contact-dependent communication 
between T cells and macrophages [245], thus the action of ES-62 on T cell activation 
might disrupt T cell contact-mediated macrophage pro-inflammatory cytokine production 
and therefore progression of inflammation in the CIA model. However, as yet, the 
signalling mechanisms employed by ES-62 for mediation of inhibitory action on T cell 
contact-induced macrophage cytokine production are not known. Following further 
investigation, it will be possible to elucidate these mechanisms.
3.3.11 Conclusion
It has previously been demonstrated that ES-62 inhibits inflammation exhibited in murine 
collagen-induced arthritis, a well-established model of human RA [192]. Data presented in 
this chapter has provided evidence to extend this previous study and examine more 
closely the mechanisms of anti-inflammatory action induced by ES-62 in CIA.
First and foremost, the major finding described in this chapter has been that PC largely 
mimics the anti-inflammatory action of ES-62 in CIA. This finding can be added to the 
wealth of actions of ES-62 that have been found to be PC-dependent [167, 185, 190, 191, 
281]. However, not all of the effects of ES-62 on this model were PC-dependent. As 
previously published, ES-62-mediated inhibition of the inflammation exhibited in CIA was 
associated with reduction of both antigen-specific THI cytokine production and THI-type 
antibody (lgG2a) production. The results presented in this chapter have confirmed that 
although ES-62 does inhibit development of the collagen-specific lgG2a response in the 
CIA model, this particular action on antibody levels is not directly associated with or 
necessary for reduction of inflammation. Furthermore, this action of ES-62 appears to be 
PC-independent. Interestingly, the collagen immunisation protocol appeared to modulate 
bone marrow progenitor cells, in order that resultant bone marrow-derived DC (CIA DC) 
exhibited a matured phenotype. The effect of ES-62 exposure in vivo was modestly 
reflected in the phenotype of the CIA DC, however the phenotype was not significantly 
altered by ES-62 to such an extent that it appeared responsible for the anti-inflammatory 
action observed.
It is well-established that the communication between the cells present in the inflamed
synovium is integral to amplification and maintenance of articular inflammation in arthritis
[245, 306]. By employing an in vitro cell-contact system, it became clear that ES-62 is
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capable of significantly disrupting T cell contact induced macrophage cytokine production. 
Thus, it is postulated that ES-62 mediated anti-inflammatory action in this model of 
arthritis might be, at least partially, mediated by inhibition of contact-dependent 
macrophage activation and cytokine production. The potential anti-inflammatory action of 
ES-62 is illustrated in Figure 3.35.
As mentioned in Chapter 1, ES-62 has several homologues secreted during infection with 
human filarial parasites. Thus, it might be postulated that the reduced incidence of 
inflammatory autoimmune diseases, such as RA, in countries endemic for filariasis could 
be attributed to the anti-inflammatory action of filarial nematode ES product homologues 
of ES-62.
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Figure 3.1 Contact-dependent mechanisms by which T cells contribute to 
synovial inflammation
Through cell contact, using membrane-bound cytokines and/or co-stimulatory and 
adhesion molecules, T cells can stimulate macrophages to produce pro-inflammatory 
cytokines such as TNFa, IL-1, IL-15 and IL-18. In turn, these cytokines re-stimulate the T 
cell to further activate the macrophage, by cell contact or perhaps via the production of 
IFNy, another pro-inflammatory cytokine. In this way a positive feedback system is set up. 
The synovial T cell interacts in a similar manner with the fibroblast-like synoviocytes and 
an inflammatory environment is created. This interaction initiates the production of and 
activates matrix metalloproteinases (MMPs) and prostaglandins (PGs), which facilitate 
cartilage destruction and inflammation exhibited in RA respectively [245].
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Figure 3.2 ES-62 treatment delays onset and reduces severity of collagen-
induced arthritis
A and B, DBA/1 mice were Immunised on days 0 and 21 with collagen, and were treated 
with ES-62 on days -2 , 0 and 21 (n = 9) or PBS (n = 9). Clinical score and incidence of 
arthritis were monitored daily. Data are presented from day 16 to day 28, expressed as 
mean ± SEM and are representative of at least 10 independent experiments. For mean 
articular index (A), *, p <  0.05 (ES-62), compared to PBS (Student’s t-test). Although also 
reduced by prior exposure to ES-62, no statistical difference was observed for incidence 
of arthritis (B) between ES-62 treated and control mice.
C-F Pooled draining lymph node cells were collected from ES-62 treated or PBS control 
mice (n = 3) on day 28 and cultured in medium alone (open bars) or with 50 pig/ml 
collagen (filled bars). T cell proliferation (C) and cytokine production (D-F) are expressed 
as mean ± SEM and are representative of at least 10 independent experiments. *, p< 0.05 
compared with PBS control.
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Figure 3.3 ES 62 reduces serum antigen-specific lgG2a in coliagen-induced
arthritis
Serum samples were obtained from mice in each treatment group on day 28 and diluted 
accordingly with PCS. Collagen-specific lgG1, lgG2a, lgG3 and IgM levels in serum 
samples from PBS and ES-62 treated mice were measured by ELISA. Data are individual 
measurements (n = 9/group), expressed as mean concentration (pg/ml) ± SEM and are 
representative of at least 5 independent experiments. *, P < 0.05 versus ES-62 (Student’s 
t-test).
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Figure 3.4 ES-62 treatment inhibits the severity of coliagen-induced arthritis 
when administered therapeutically
DBA/1 mice were immunised on days 0 and 21 with collagen and arthritic animals were 
treated daily one day after detectable clinical CIA with ES-62 (n = 6) or PBS (n = 5).
A, Mean articular index (A) was monitored daily and data are presented from day 18 to 
day 28, expressed as mean ± SEM and are representative of at least 10 experiments. *, P 
< 0.05 (ES-62), compared to PBS (Student’s t-test).
B-F At sacriffce, arthritic paws from the therapeutic study were removed and sections 
stained with hematoxylin and eosin (B & C), or toluidine blue (D & E). B and D Profound 
infiltration, cartilage surface erosion and loss of proteoglycan was observed in PBS 
control as indicated by the arrows, whereas treatment with ES-62 exhibited significantly 
reduced histologic evidence of destruction (C & E). F, Histological appearances were 
scored for the presence of synovial bone erosion, hyperplasia, and cellular infiltration In 
ES-62 (open bars) or PBS (filled bars)-treated paws. *, P < 0.05 versus PBS control 
(Mann-Whitney U test). Data are mean ± SEM (n = 10 / group). Original magnification, (A 
& B), X 25 ; (C & D), X 50.
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Figure 3.5 Suppression of established disease by ES-62 is associated with 
reduction in pro-inflammatory cytokine production in vitro
Draining lymph node cells from arthritic mice (n = 3) treated with either ES-62 or PBS 
were cultured with medium (open bars) or collagen (filled bars) and T cell proliferation (A) 
and cytokine production (IFNy, (A), TNFa (B) and IL-6 (D)) were assessed as previously 
described. Data are expressed as means ± SEM and are representative of at least 5 
experiments P <  0.05 ES-62 versus PBS (Student's t test).
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Figure 3.6 ES-62 does not reduce serum antigen-specific lgG2a in
established coiiagen-induced arthritis
Serum samples were obtained from mice in each treatment group on day 28 and diluted 
accordingly with PCS. Collagen-specific lgG1, lgG2a, IgGS and IgM levels In serum 
samples from PBS and ES-62 treated mice were measured by ELISA. Data are individual 
measurements (n = 5 / group), expressed as mean absorbance (OD630nm) ± SEM and 
are representative of at least 3 experiments. *, P <  0.05 versus ES-62 (Student’s t-test).
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Figure 3.7 Prophylactic treatment with recombinant ES-62 does not inhibit 
onset or reduce severity of collagen-induced arthritis
A and B, DBA/1 mice were Immunised on days 0 and 21 with collagen, and were treated 
with ES-62 (n = 9), recombinant ES-62 (n=9) or PBS (n = 9) on days -2 , 0 and 21. Clinical 
score and incidence of arthritis were monitored daily. Data are presented from day 16 to 
day 28, expressed as mean ± SEM and are representative of at least 2 independent 
experiments. For mean articular index (A), ***, p < 0.001 rES-62 compared to PBS. For 
incidence of arthritis (B) **, P<0.01 rES-62 compared to ES-62 (Student’s t-test).
C-F Serum samples were obtained from mice in each treatment group on day 28 and 
diluted accordingly with FCS. Collagen-specific IgGI (C), lgG2a (D), IgGS (E) and IgM (F) 
levels in serum samples from PBS, ES-62 and rES-62-treated mice were measured by 
ELISA. Data are individual measurements (n = 9 / group), expressed as mean 
concentration (pg/ml) ± SEM and are representative of 2 experiments. *, p< 0.05 rES-62 
versus PBS (Student’s t-test).
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Figure 3.8 Recombinant ES-62 treatment does not inhibit the severity of
established collagen-induced arthritis
A, DBA/1 mice were immunised with collagen and arthritic animals were treated daily one 
day after detectable clinical CIA with rES-62 (n=5), ES-62 (n = 6) or PBS (n = 5). Mean 
articular index was monitored daily and data are presented from day 18 to day 28, 
expressed as mean ± SEM. Data are representative of 2 independent experiments. ***, p< 
0.001, rES-62 compared to ES-62 (Student’s t-test).
B-E Serum samples were obtained from mice in each treatment group on day 28 and 
diluted accordingly with FCS. Collagen-specific IgGI (B), lgG2a (C), IgGS (D) and IgM (E) 
levels in serum samples from PBS, ES-62 and rES-62 treated mice were measured by 
ELISA. Data are individual measurements (n = 5 / group), expressed as mean 
absorbance (OD630nm) ± SEM and are representative of 2 independent experiments. No 
significant differences in Ig levels were observed between serum samples from PBS, ES- 
62 or rES-62 treated mice (Student’s t-test).
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Figure 3.9 OVA-PC treatment delays onset and reduces severity of collagen-
induced arthritis
A, B DBA/1 mice were immunised on days 0 and 21 with collagen, and were treated with 
ES-62 (n = 9), PBS (n = 9), OVA-PC (n = 9) or OVA (n = 9) on days -2 , 0 and 21. Clinical 
score and incidence of arthritis were monitored daily. Data are presented from day 16 to 
day 28 (ES-62 and PBS) or 30 (OVA and OVA-PC), expressed as mean ± SEM and are 
representative of at least 2 independent experiments.. For mean articular index (A) and 
incidence of arthritis (B) **, P < 0.01 OVA compared to OVA-PC (Student’s t-test).
C-F Serum samples were obtained from mice in each treatment group at sacrifice and 
diluted accordingly with FCS. Collagen-specific IgGI (C), lgG2a (D), IgGS (E) and IgM (F) 
levels in serum samples from PBS, OVA and OVA-PC treated mice were measured by 
ELISA. Data are individual measurements (n = 9 / group) and expressed as mean 
concentration (pg/ml) ± SEM. Data are representative of 2 independent experiments. *, 
p<0.05 OVA vs OVA-PC treated mice (Student’s t-test).
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Figure 3.10 OVA-PC treatment inhibits the severity of established collagen-
induced arthritis
A, DBA/1 mice were immunised with collagen and arthritic animals were treated daily one 
day after detectable clinical CIA with OVA-PC (n=5) or OVA (n = 6). Mean articular index 
was monitored daily and data are presented from day 18 to day 28, expressed as mean ± 
SEM. Data are representative of 2 independent experiments. ***, P < 0.001 (OVA) 
compared to OVA-PC (Student’s t-test).
B-E Serum samples were obtained from mice in each treatment group at sacrifice and 
diluted accordingly with PBS. Collagen-specific IgGI (B), lgG2a (C), IgGS (D) and IgM (E) 
levels in serum samples from OVA and OVA-PC treated mice were measured by ELISA. 
Data are individual measurements (n = 5 / group) and expressed as mean absorbance 
(OD630nm) ± SEM. Data are representative of 2 independent experiments. No significant 
differences were observed between serum samples from OVA and OVA-PC treated mice 
(Student’s t-test).
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Figure 3.11 Comparison of serum cytokines in CIA model mice
Serum samples were obtained from mice in each treatment group at sacrifice and 
analysed, using the Lumlnex system, to detect IL-1a (A), IL-2 (B), IL-12 (C), IL-5 (D) and 
IL-10 (E). Data are plotted as the mean of duplicate serum samples from individual PBS, 
ES-62, rES-62, OVA and OVA-PC (n=9/group) treated mice; the bar represents the group 
mean value. Data are representative of 2 independent experiments. **, p<0.05 (rES-62 
versus ES-62 treatment group) and *, p<0.05 (OVA versus OVA-PC treatment group) 
(Students t-test)
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Figure 3.12 Comparison of serum chemokines and growth factors in CIA 
model mice
Serum samples were obtained from mice in each treatment group at sacrifice and 
anaiysed, using the Luminex system, to detect MIP-1a (A), KC (B), IP-10 (0), MIG (D) 
and FGF (E). Data are plotted as the mean of duplicate serum samples from individual 
PBS, ES-62, rES-62, OVA and OVA-PC (n=9/group) treated mice; the bar represents the 
group mean value. Data are representative of 2 Independent experiments. There were no 
significant differences between mean concentrations of serum chemokines detected in 
samples from any of the treatment groups (Students t-test).
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Figure 3.13 Comparison of serum cytokines in established CIA
Serum samples were obtained from mice in each treatment group at sacrifice and 
analysed, using the Luminex system, to detect IL-2 (A) and IL-12 (B). Data are plotted as 
the mean of duplicate serum samples from individual PBS (n=5), ES-62 (n=6), rES-62 
(n=5), OVA (n=5) and OVA-PC (n=3) treated mice; the bar represents the group mean 
value. Data are representative of 2 independent experiments. There were no significant 
differences between mean concentrations of serum cytokines detected in samples from 
any of the treatment groups (Students t-test).
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Figure 3.14 Comparison of serum chemokines in established CIA
Serum samples were obtained from mice in each treatment group at sacrifice and 
analysed, using the Luminex system, to detect IP-10 (A), MIG (B) and MIP-1a (0). Data 
are plotted as the mean of duplicate serum samples from individual PBS (n=5), ES-62 
(n=6), rES-62 (n=5), OVA (n=5) and OVA-PC (n=3) treated mice; the bar represents the 
group mean value. Data are representative of 2 independent experiments. There were no 
significant differences between mean concentrations of serum chemokines detected in 
samples from any of the treatment groups (Students t-test).
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Figure 3.15 Comparison of serum growth factors in established CIA
Serum samples were obtained from mice in each treatment group at sacrifice and 
analysed, using the Luminex system, to detect growth factors FGF (A) and VEGF (B). 
Data are plotted as the mean of duplicate serum samples from individual PBS (n=5), ES- 
62 (n=6), rES-62 (n=5) OVA (n=5) and OVA-PC (n=3) treated mice; the bar represents the 
group mean value. Data are representative of 2 independent experiments. *, p<0.05 PBS 
vs rES-62 treated mice (Students t-test).
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Figure 3.16 Effects of ES-62 pre-exposure on LPS-induced bone marrow- 
derived DC pro-inflammatory cytokine production
Bone marrow-derived dendritic cells were grown from BALB/c mice in vitro in the 
presence of GM-CSF for 6 days. These bmDC were then either stimulated with GM-CSF 
alone or with ES-62 (2 M.g/ml) for 24 hours on day 6 and subsequently in the absence or 
presence of LPS (1 jxg/ml) for an additional 24 hours on day 7. On day 8, IL-12p40 (A) 
and TNF-a (B) in culture supernatants were measured by ELISA. Data are presented as 
means ± SD and are representative of over 5 independent experiments. *** p<0.005 ES- 
62 compared to none, ES-62+LPS compared to LPS.
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Figure 3.17 Effects of ES-62 and/or LPS on the costimulatory molecule 
expression by murine bone marrow-derived dendritic cells
Bone marrow-derived dendritic cells were grown from BALB/c mice in vitro in the 
presence of GM-CSF for 6 days. These bmDC were then either stimulated with GM-CSF 
or ES-62 (2 [ig/ml) for 24 hours on day 6 and subsequently in the absence or presence of 
LPS (1 \ig/m\) for an additional 24 hours on day 7. On day 8, cells were harvested and cell 
surface expression of costimulatory molecule expression was analysed by flow cytometry 
as described in Materials and Methods. Data are presented as dotplots and the % of cells 
contained within each quadrant is located in the corners of the dotplots. Additionally, the 
mean fluorescent intensity (MFI) (in red) of the double positive population in shown in the 
upper right quadrant. The data presented are from a single experiment representative of 
at least 5 other independent experiments.
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Figure 3.18 Bone marrow-derived DC from CIA mice exhibit a modulated 
phenotype
DBA/1 CIA model mice were treated and sacrificed as described in the legend to Figure
3.2. Femoral bone marrow from CIA model mice and naïve mice was removed and pooled 
by treatment group. Bone marrow-derived DC were cultured in vitro for 7 days and 
stimulated with media (panel A) or LPS (Ijxg/ml; panel B) for 24h. Expression of MHCII, 
CD40, CD54, CD80 and CD86 on DC was analysed by flow cytometry. Data were gated 
on the C D IIc^ population and expressed as histograms depicting the expression level of 
the surface marker versus the number of cells, as a percentage of the maximum CDIIc*^ 
cell number. Results depicted are from one experiment representative of two independent 
experiments.
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Figure 3.19 ES-62 treatment of CIA model mice modulates cytokine 
production by bone marrow derived DC
DBA/1 CIA model mice were treated and sacrificed as described in the legend to Figure
3.2. Femoral bone marrow from CIA model mice and naïve DBA/1 mice was removed and 
pooled by treatment group. Bone marrow-derived DC were cultured in vitro for 7 days and 
stimulated with media (panel A) or LPS (1p,g/ml; panel B) for 24h. Culture supernatants 
were analysed for 11-12, TNFa, and IL-10 by ELISA. ELISA data are expressed as mean 
concentration (pg/ml) ± SD (n=3) and are representative of at least 2 independent 
experiments. ***, p<0.001; **, p<0.01 and *, p<0.05 vs DC from naïve mice; +, p<0.05, ++, 
p<0.01, +++, p<0.001 vs PBS DC by Student's t-test.
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Figure 3.20 Recombinant ES-62 treatment of CIA model mice modulates 
cytokine production by bone marrow derived DC
DBA/1 CIA model mice were treated and sacrificed as described in the legend to Figure
3.2. Femoral bone marrow from CIA model mice and naïve DBA/1 mice was removed and 
pooled by treatment group. Bone marrow-derived DC were cultured in vitro for 7 days and 
stimulated with media (panel A) or LPS (1 p-g/ml; panel B) for 24h. Culture supernatants 
were analysed for IL-12, TNFa, and IL-10 by ELISA. Naïve mouse, PBS and ES-62 
treatment group data from Figure 3.19 are re-plotted in this figure in addition to data from 
rES-62 treatment group and are expressed as mean ± SD (/?=3) and are representative of 
at least 2 independent experiments. *, p<0.05 versus ES-62 DC and +, p<0.05, ++. 
p<0.01, +++, p<0.001 versus PBS DC by student’s t-test.
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Figure 3.21 The effect of OVA-PC treatment of CIA model mice on bone 
marrow-derived DC phenotype
DBA/1 CIA model mice were treated and sacrificed as described in the legend to Figure
3.2. Femoral bone marrow from CIA model mice and naïve mice was removed and pooled 
by treatment group. Bone marrow-derived DC were cultured in vitro for 7 days and 
stimulated with media (panel A) or LPS (1 pg/ml; panel B) for 24h. Expression of MHCII, 
CD40, CD54, CD80 and CD86 on DC was analysed by flow cytometry. Data were gated 
on the CD11c^ population and expressed as histograms depicting the expression level of 
the surface marker versus the number of cells, as a percentage of the maximum C D IIc^ 
cell number. Results depicted are from one experiment representative of two independent 
experiments.
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Figure 3.22 OVA-PC treatment of CIA model mice modulates cytokine 
production by bone marrow derived DC
DBA/1 C IA  model mice w ere treated and sacrificed as described in the legend to Figure
3.2. Femoral bone marrow from C IA  model mice and naïve DBA/1 mice w as rem oved and 
pooled by treatm ent group. Bone marrow-derived DC w ere cultured in vitro for 7 days and 
stimulated with m edia (panel A) or LPS (1[xg/ml; panel B) for 24h. Culture supernatants  
w ere analysed for IL-12, T N F a , and IL -10 by ELISA. Data are expressed as m ean ±  SD  
(n=3) and are representative of at least 2 independent experim ents. ***, p<0.001 and **, 
p<0.01 versus O VA  DC by student's t-test.
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Figure 3.23 Analysis of the phenotype of bone marrow-DC derived from CIA 
model mice that have been treated therapeutically with ES-62, rES-62 or 
OVA-PC
DBA/1 CIA model mice were treated as described in the legend to Figure 3.4. Femoral 
bone marrow from CIA model mice was removed at sacrifice and pooled by treatment 
group. Bone marrow-derived DC were cultured in vitro for 7 days and stimulated with 
media (panels A, C & E) or LPS (Vg/m l; panels B, D & F) for 24h. Expression of MHCII, 
CD40, GD54, CD80 and CD86 on DC was analysed by flow cytometry. Data were gated 
on the C D I I ^  population and expressed as histograms depicting the expression level of 
the surface marker versus the number of cells, as a percentage of the maximum CD11c^ 
cell number. Results depicted are from one experiment representative of two independent 
experiments.
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Figure 3.24 Bone marrow-derived DC from CIA model mice that have been 
treated therapeutically with ES-62 exhibit modulated cytokine production
DBA/1 CIA model mice were treated as described in the legend to Figure 3.4 and femoral 
bone marrow was removed at sacrifice. Bone marrow-derived DC from each treatment 
group were cultured in vitro for 7 days and stimulated with media (panel A) or LPS 
(1 |Ag/ml; panel B ) for 24h. Culture supernatants were analysed for IL-12, 
TNFa, and IL-10 by ELISA. ELISA data are expressed as treatment group mean ± SD 
(n=3) and are representative of at least 2 independent experiments. ***, p<0.001 vs 
control by student’s t-test.
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Figure 3.25 Cytokine production by bone marrow-derived DC from CIA 
model mice that have been treated therapeutically with recombinant ES-62
DBA/1 CIA model mice were treated as described in the legend to Figure 3.4 and femoral 
bone marrow was removed at sacrifice. Bone marrow-derived DC from each treatment 
group were cultured in vitro for 7 days and stimulated with media (panel A) or LPS 
(1 ng/ml; panel B) for 24h. Culture supernatants were analysed for IL-12, 
TNFa, and IL-10 by ELISA. Data are expressed as treatment group mean ± SD (n=3) and 
are representative of at least 2 independent experiments. No statistical differences were 
observed in cytokine production levels between DC from control CIA model mice and DC 
from CIA model mice treated with recombinant ES-62.
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Figure 3.26 Bone marrow-derived DC from CIA mice that have been treated 
therapeutically with OVA-PC exhibit a modulated phenotype
DBA/1 CIA model mice were treated as described in the legend to Figure 3.4 and femoral 
bone marrow was removed at sacrifice. Bone marrow-derived DC from each treatment 
group were cultured in vitro for 7 days and stimulated with media (panel A) or LPS 
(1 |ig/m l; panel B ) for 24h. Culture supernatants were analysed for IL-12, 
TNFa, and IL-10 by ELISA. Data are expressed as treatment group mean ± SD and are 
representative of at least 2 independent experiments. ***, p<0.001; **, p<0.01 vs DC from 
OVA treated mice by student’s t-test.
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Figure 3.27 Effects of ES-62 pre-exposure on LPS-induced bone marrow- 
derived macrophage pro-inflammatory cytokine production
Bone marrow-derived macrophages were grown from BALB/c mice in vitro in the 
presence of CSF-1 for 6 days. These bm-macrophages were then either cultured with 
CSF-1 alone or with ES-62 (2 ^ig/ml) for 24 hours on day 6 and subsequently in the 
absence or presence of LPS (1 pig/ml) for an additional 24 hours on day 7. On day 8, IL- 
12p40 (A) and TNF-a (B) were measured in culture supernatants, by ELISA. Data are 
presented as mean ± SD and are representative of over 5 independent experiments. * 
p<0.05, **p<0.01.
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Figure 3.28 ES-62 inhibits TNFa production from human activated T cell- 
macrophage cell-contact cultures
Purified human peripheral blood T cells were cultured unstimulated (open bars), or 
activated by PHA and PMA (filled bars), then fixed in paraformaldehyde to preserve 
membrane structural integrity. THP-1 cells were pre-treated with media or ES-62 for 18h 
prior to co-culture with fixed T cells at a ratio of 1:8. Harvested culture supernatants were 
measured for TNFa release by ELISA. Results are depicted as mean ± SD (n=3) and are 
representative of at least 3 independent experiments. ***, p<0.01 vs untreated THP-1 
cells, determined by student's t-test.
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Figure 3.29 T cell contact promotes macrophage pro-inflammatory cytokine 
production
Bone marrow-derived macrophages were grown in vitro from bone marrow of BALB/c 
mice in the presence of CSF-1 for 7 days. On day 4 of macrophage culture, lymph node T 
cells from BALB/c mice were cultured in vitro and activated with PMA (10 ng/ml) and Con 
A (5 ;ig/ml) for 3 days. On day 7, T cells were fixed by incubating in formaldehyde, before 
co-culture in fresh media with the bm-macrophages for 24 hours. No cytokine release was 
detected following culture of fixed T cells alone. Culture supernatants were analysed for 
TNFa (A) and IL-12 p40 (B) by ELISA. Data are expressed as mean ± SD (n=3) and are 
representative of 3 independent experiments. *, p<0.05, **, p<0.01, ***, p<0.001 vs 
macrophages alone (ANOVA)
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Figure 3.30 ES-62 pre-treatment of T cells or macrophages disrupts T cell 
contact mediated macrophage pro-inflammatory cytokine production
Bone marrow-derived macrophages were grown in vitro from bone marrow of BALB/c 
mice in the presence of CSF-1 for 6 days. On day 4 of macrophage culture, lymph node T 
cells from BALB/c mice were cultured in vitro and activated with PMA (10 ng/ml) and Con 
A (5 fig/ml) for 2 days. On day 6, both cell types were re-plated and stimulated with media 
or ES-62 for 18h. On day 7, T cells were fixed by incubating in formaldehyde, before co­
culture in fresh media with the bm-macrophages, in the ratio 15:1, for 24 hours. Culture 
supernatants were analysed for TNFa (A) and IL-12 p40 (B) by ELISA. Data are 
expressed as mean ± SD (n=3) and are the results of one experiment *, p<0.05 and 
**, p<0.01 vs control (ANOVA).
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Figure 3.31 ES-62 treatment of BALB/c mice disrupts T cell contact mediated 
macrophage pro-inflammatory cytokine production
Bone marrow-derived macrophages were grown in vitro from bone marrow of BALB/c 
mice in the presence of CSF-1 for 6 days. On day 4 of macrophage culture, lymph node T 
cells from BALB/c mice that had previously been treated with ES-62 (2 fxg) in vivo were 
cultured in vitro and activated with PMA (10 ng/ml) and Con A (5 fxg/ml) for 3 days. On 
day 7, T cells were fixed by incubating in formaldehyde, before co-culture in fresh media 
with the bm-macrophages, in different ratios, for 24 hours. Culture supernatants were 
analysed for TNPa (A) and IL-12 p40 (B) by ELISA. Data are expressed as mean ± SD 
(n=3) and are the results of one experiment. **, p<0.01 and ***, p<0.001 vs macrophages 
alone (ANOVA).
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Figure 3.32 ES-62 treatment of BALB/c mice disrupts macrophage pro- 
inflammatory cytokine production In response to T cell contact
BALB/c mice were administered subcutaneously with ES-62 (2 jxg). After 9 days bone 
marrow-derived macrophages from the ES-62 treated mice were grown in vitro in the 
presence of CSF-1 for 6 days. On day 4 of macrophage culture, lymph node T cells from 
untreated BALB/c mice were cultured in vitro and activated with PMA (10 ng/ml) and Con 
A (5 ng/ml) for 3 days. On day 7, T cells were fixed by incubating in formaldehyde, before 
co-culture in fresh media with the bm-macrophages, in different ratios, for 24 hours. 
Culture supernatants were analysed for TNFa (A) and IL-12 p40 (B) by ELISA. Data are 
expressed as mean ± SD (r?=3) and are the results of one experiment. No significant 
differences between co-cultures and macrophages cultured alone were detected.
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Figure 3.33 The collagen administration protocol Induces differentiation of 
bone marrow derived DC with a mature phenotype
In naïve DBA/1 mice, in vitro culture of bm progenitor cells in the presence of GM-CSF 
induces differentiation of immature DC exhibiting low levels of e.g. antigen-presentation 
molecule, MHCII, co-stimulatory molecules, CD40, CD80 and CD86 and adhesion 
molecule CD54. Stimulation of these immature DC with LPS in vitro induces activation of 
the DC, evidenced by increased expression of antigen presentation, co-stimulation and 
adhesion molecules and release of pro-inflammatory cytokines, IL-12 and TNFa. In 
addition, maturation of DC involves a morphological change, with mature DC exhibiting 
dendrites ideally suited for activation of naïve I  cells. In contrast, in vitro culture of bone 
marrow progenitor cells from CIA model mice, in the presence of GM-CSF, results in 
differentiation of DC that are ‘pre-matured’, evidenced by their spontaneous secretion of 
pro-inflammatory cytokines and expression of high levels of co-stimulatory, adhesion and 
antigen-presentation molecules.
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Figure 3.34 ES-62 mediated inhibition of synovial inflammation via 
disruption of T cell- macrophage communication
(Figure adapted from [245])
Activated TH1 cells present in the synovial tissues of CIA model mice act to prime 
macrophages in a contact independent manner, by producing TH1 cytokine, IFNy. In 
addition, contact-dependent macrophage cytokine production is permitted by T cell and 
macrophage expression of membrane bound cytokines, co-stimulatory molecules and 
adhesion molecules. In response to contact-dependent or independent activation by T 
cells, macrophages release pro-inflammatory cytokines, such as TNFa and IL-12. 
Furthermore, activation of macrophages in this way may lead to production of matrix 
metalloproteinases (MMPs) and prostaglandins (PGs), which help to mediate the 
inflammation, tissue destruction and hence, the pathology exhibited in CIA.
The results of this investigation, and previous investigations by this laboratory, have 
demonstrated that ES-62 acts to inhibit pro-inflammatory cytokine production by 
macrophages in response to contact-dependent and contact-independent stimulation. It is 
not currently known what mechanism is employed by ES-62 for disruption of T cell 
contact-mediated macrophage cytokine production, however it is possible that it may act 
via modulation of the expression of cytokines, co-stimulatory molecules and adhesion 
molecules on T cells, macrophages, both. Ultimately, disruption of T cell-induced 
macrophage activation may also lead to inhibited production of tissue-damaging MMPs 
and PGs.
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Figure 3.35 A model of ES-62 mediated inhibition of inflammation in
collagen-induced arthritis
in CIA model mice pre-matured DC, expressing collagen antigens and secreting pro- 
inflammatory cytokines (IL-12 and TNFa), induce priming of naïve CD4^ T cells into 
collagen-specific TH1 effector cells in the lymph nodes. Such TH1 effector cells migrate to 
the inflammatory site (the synovium) and, in turn, release IFNy in response to antigen 
(collagen) stimulation. In response to IFNy stimulation, macrophages in the inflammatory 
site are activated to release pro-inflammatory cytokines (e.g. IL-12 and TNFa) and 
inflammatory chemokines (e.g. M lP-la , MIG and IP-10). These inflammatory chemokines 
induce recruitment of immature DC and naïve CD4'" T cells from the periphery to the 
inflammatory site. Once recruited, immature DC become activated by the inflammatory 
milieu and antigens present and help to activate recruited naïve CD4^ T cells. In addition, 
T cell contact-induced macrophage activation contributes further pro-inflammatory 
cytokines and mediators of tissue destruction (e.g. matrix metalloproteinases and 
prostaglandins) to the existing inflammatory milieu. Production of TH1-promoting 
cytokines promotes survival and activation of the cell types present and chemokines 
recruit further cells. Thus, a positive feedback cycle of inflammation is set up.
ES-62 has previously been demonstrated to Inhibit antigen-specific production of IFNy by 
TH1 cells in CIA and pro-inflammatory cytokine production by macrophages and DC in 
response to inflammatory stimuli. In addition, it has been demonstrated in this chapter that 
ES-62 disrupts T cell contact-induced macrophage activation, evidenced by pro- 
inflammatory cytokine production. Therefore via these mechanisms at least, ES-62 could 
mediate anti-inflammatory action in this system.
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4 ES-62 inhibits TH2-iike infiammation in an ovaibumin-induced
mode: of asthma
-a4.1 Introduction
%Asthma is a disease of developed, westernised countries. At this time, Scotland is home |
to more childhood asthma sufferers than any other country in the world and is the country 
with the third highest prevalence for adult asthma patients [307]. Asthma in humans is a 
chronic pulmonary disease characterised by persistent airway inflammation, periods of 
acute airway obstruction and bronchial hyperresponsiveness [308]. Whilst it is known that 
the inflammation exhibited in asthma occurs as a consequence of a dysregulated TH2- 
mediated immune response, current understanding of the precise aetiology of asthma is 
unclear [103]. It has been suggested that genetic pre-disposition to development of TH2- 
type inflammation [309] in combination with environmental exposures; for example with 
allergenic substances, during infancy has significant roles to play [310]. Indeed, in a
' I
Greek study it was demonstrated that the prevalence of asthma varies with the level of 
exposure to house dust mite, a common allergen to which asthmatics can become 
sensitised [311]. However, the role of exposure to allergens from pets in asthma 
development has fuelled conflicting arguments [312, 313]. Furthermore, the roles of home 
central heating methods and exposure to cigarette smoke or gas cooking fumes have also
been investigated [314-319]. It has even been suggested that the frequency of moving %home contributes to asthma development [320]. As yet, the key conditions necessary for 
development of asthma have not been conclusively defined and, therefore, it is most likely 
that asthma is result of a number of inter-related factors.
4.1.1 Animal models of asthma
To dissect the immunological mechanisms by which asthma is initiated in humans, 
researchers have employed a number of murine models. In antigen-induced asthma 
models, inflammation is generated by sensitising TH2-prone mice with antigen (co­
administered intraperitoneally with a TH2-skewing adjuvant e.g. aluminium hydroxide), to 
induce development of an antigen-specific memory immune response, and then 
subsequently challenging with aerosolised antigen intranasally, to induce an TH2-
mediated inflammatory immune response in the lungs [321, 322]. One of the most
common antigen-induced models of asthma is the ovalbumin (OVA)-induced airway
inflammation model generated in BALB/c mice (Figure 2.2), where inflammation
generated in response to the OVA administration protocol is induced over a relatively
short period of 28 days. This short-term model of airway inflammation induces TH2-
mediated airway inflammation and bronchial hyper-reactivity, similar to that observed in
human asthma and has been widely used to study the pathogenesis and investigate
potential therapies for this inflammatory condition. [321, 323]. However, it is well-
established that the short-term ovalbumin-induced asthma model does not precisely
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mimic all of the pathology exhibited in human asthma and hence, is normally used to 
examine only the acute inflammatory component of asthmatic disease. In human 
asthmatics, it has been identified that exposure to chronic long-term reversible pulmonary 
inflammation, leads to irreversible tissue damage within the lungs and eventually, airway 
remodelling [84]. Airway remodelling normally involves hyperplasia and hypertrophy of 
airway smooth muscle and deposition of collagen. These changes modulate airway 
integrity and elasticity, thus inhibiting efficient gas exchange, which contributes to the 
pathology exhibited in asthma. Therefore, to determine the secondary effects of exposure 
to long-term asthmatic inflammation, a model of chronic airway inflammation and 
pulmonary remodelling can be generated. This model [324] is simply an extension of the 
ova-induced asthma model (Figure 2.3) and enables investigation of the physiological and 
immunological effects associated with long-term pulmonary disease in humans. Using this 
model it was previously demonstrated that longer-term pulmonary inflammation induced 
irreversible structural changes to the airways, such as smooth muscle and goblet cell 
hyperplasia and deposition of collagen. Thus, it was possible that this model exhibits a 
more accurate representation of the effects of chronic inflammation in human asthma, 
nevertheless, the majority of studies investigating the immunological basis of the 
pathogenesis of asthma have been conducted in the shorter-term model.
4.1.2 The immunopathology of asthma
As mentioned previously, it has been well documented that the inflammation exhibited in 
asthma is associated with action of a TH2-mediated immune response. Using procedures 
such as broncho-alveolar lavage (BAL), the major inflammatory cell infiltrates of the 
airways have been identified and shown to include allergy-associated leukocytes such as 
eosinophils, macrophages, mast cells and TH2 lymphocytes. Moreover, it has been 
demonstrated that all these cells have a role to play in the pathogenesis of asthma. In 
particular, TH2 lymphocytes, mast cells and eosinophils secrete TH2 cytokines, such as 
lL-5, IL-4 and IL-13, which recruit further infiltration of inflammatory cells and maintain or 
amplify the TH2 inflammatory immune response [91].
Of the many different classifications of asthmatic disease exhibited by patients, possibly 
the best known is allergic asthma, triggered by exposure to environmental allergen [325]. 
In allergic asthma, allergen inhalation and recognition by cells resident in the airways 
activates onset of an asthma ‘attack’. Not all allergic asthmatics are atopic (a genetic 
predisposition to allergy) but, like atopic individuals, asthma patients exhibit increased 
levels of serum IgE, the signature antibody isotype in allergy. IgE is centrally involved in 
the pathogenesis of asthma and the onset of an acute attack of inflammation [326, 327]. 
Although IgE can exist as a soluble molecule in the airway, it is usually found bound to the 
high affinity IgE receptor, FceRI on the surface of mast cells (or the low affinity IgE
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receptor, FceRI 1/CD23 on other leukocytes). When allergen Is inhaled, it is recognised 
specifically by IgE and the resulting antlgen-lgE complex cross-links the FceRi-lgE 
receptor complexes on the mast cells [328] and degranulation ensues [329]. The 
degranulation process results In release of inflammatory mediators such as leukotrienes 
and TFI2 cytokines such as IL-4 and IL-5. It is understood that inflammatory mediators 
and granule proteins liberated from mast cells facilitate the inflammatory and degradative 
changes observed in the asthmatic epithelium [91]. TH2 cytokines (IL-4, IL-5 and IL-13), 
produced by mast cells and other TH2 effector cells, activate a cascade of inflammation- 
generating activity [330]. IL-4 is a key promoter of the TH2-mediated immune response 
and can induce differentiation of eosinophils from bone marrow progenitor cells, which 
expand to form an IL-4 producing innate cell population, thus amplifying the TH2 cytokine 
environment and hence the TH2 immune response in vivo [331]. IL-4 also promotes B cell 
antibody isotype switching, to increase IgE production [332]. Facilitated by the action of 
IL-5 and chemokines like eotaxin, eosinophils are recruited to the airways and activated 
[91]. Furthermore, IL-13 can also ligate the IL-4 receptor and has been shown to be 
required for allergen-induced airway hyper-responsiveness in mouse models of allergic 
airway inflammation [333]. In particular, IL-4 and IL-13 have been demonstrated to play 
prominent roles in the initiation and effector mechanisms of asthmatic inflammation, 
respectively [84].
Current treatm ent strategies for asthma involve long-term adm inistration of 
corticosteroids, to reduce general inflammation and therapeutic use of broncho-dilator 
agents (beta(2)-adrenoceptor agonists) [334, 335]. Interestingly, blockade of TH2 
cytokines (IL-4 or IL-5), as a treatment strategy for asthma (in a parallel manner to antl- 
TH1 cytokine treatment in RA) has generally proved unsuccessful in amelioration of all 
asthma-associated pathologies, probably because the development of inflammation in 
asthma is a result of the action of complex cytokine networks and pathways. Thus, 
disruption of mechanisms that initiate the TH2-type inflammation (i.e. upstream of TH2 
cytokine production) would most likely be a more successful method of therapy. As 
mentioned previously, IgE levels are consistently elevated in atopic and non-atopic 
asthma patients and have integral roles to play in asthma pathogenesis, therefore, anti- 
IgE therapy has recently been proposed for treatment of asthmatic inflammation [336]. 
This type of treatment prevents IgE binding to FceRI receptors on mast cells and FceRI! 
on other leukocytes, therefore disrupting the inflammatory cascade initiated by IgE ligation 
and mast cell degranulation. It has yet to be determined whether this type of treatment will 
help to reduce inflammation associated with asthma long-term.
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4.1.3 ST2
The ST2 gene (also known as T1, Fit-1, or DER4) encodes a protein (ST2L) selectively 
expressed on the surface of CD4'' TH2, but not TH1 cells, whose expression is regulated 
by TH2 transcription factor, GATA-3 [337-339]. In addition to membrane-bound ST2L, the 
ST2 gene also encodes a shorter soluble protein, ST2. ST2L has been identified as 
helping to initiate the TH2 immune response [340] therefore it has been suggested that 
ST2 expression/signalling is important for the function of TH2 cells, however evidence to 
support or disprove this has been contradictory. For example, in a TH1-mediated CIA 
model, blockade of ST2 exacerbated the severity of the disease whilst TH1-mediated 
resistance to Leishmania major infection was promoted [337], indicating that blockade of 
ST2 protein inhibited development of a functional TH2 immune response. Furthermore, 
knock-out of the ST2 gene inhibited infiltration of eosinophils and production of TH2 
cytokines in a TH2-mediated pulmonary granuloma model [341]. Soluble ST2 has been 
shown to inhibit the inflammatory cytokine response to LPS and down-regulate TLR4 
expression on the surface of macrophages, thereby reducing TH1-mediated LPS-shock in 
mice. [342]. Flowever, in contrast, Hoshino et al [343] have demonstrated that ST2- 
deficient mice maintain their capacity for development of normal TH2 cell responses in 
TH2-mediated helminth parasite infection and a model of allergic airway inflammation. 
Likewise, it has been observed that T1 (ST2)-deficient and ST2 receptor transgenic mice 
develop normal TH2 responses to parasite infection [344]. Thus, conclusive 
demonstration of the role ST2 is yet to be established. If achieved, this knowledge may 
provide further understanding of pathogenesis, and represent a potential therapeutic 
target, in TH2-mediated inflammatory conditions such as asthma.
4.1.4 Is infection with parasites protective against development of 
asthma?
As mentioned in Chapter 1, the hygiene hypothesis aims to explain the increased 
prevalence of allergy and allergic disease in developed countries (and increasing 
incidence in developing countries as they become more affluent) as a result of increased 
sanitation and reduced exposure to pathogens in early childhood [102]. In particular, 
exposure to helminth parasite infections in developing countries is common. Indeed, it has 
been suggested that helminth infection protects individuals from atopic asthma, prevalent 
in developed countries. [110, 131, 345]. Moreover, it has been suggested that 
immunomodulatory excretory-secretory (ES) products, generated by parasites, modulate 
the host immune response, to favour survival of the parasite and longevity of infection. 
Immunomodulatory ES products are continuously released into the host blood stream 
[161] during infection with filarial nematodes. Therefore it has been postulated that they 
might facilitate inhibition of asthma and other inflammatory atopic diseases in parasite- 
infected individuals.
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4.1.5 Aims
It has previously been established that ES-62, an immunomodulatory ES product of 
rodent filarial nematode, A. viteae, inhibits TH1-mediated inflammation exhibited in a 
murine model of arthritis (Chapter 3 and [192]). This inhibitory action was associated with 
reduction of antigen-specific TH1 cytokine production and possible modulation of contact- 
dependent communication between activated T cells and macrophages. Indeed, 
amelioration of TH1-type inflammation by ES-62 treatment was in accordance with the 
previously demonstrated actions of ES-62 in vitro. In more detail, via modulatory action on 
dendritic cells, ES-62 has been demonstrated to reduce a TH1-promoting immune 
response, whilst simultaneously promoting a TH2-type immune response [189]. Thus, it 
might be predicted that ES-62 treatment of TH2-type inflammation, in a murine model of 
asthma, would induce exacerbation of disease. However, as part of extensive in vitro 
investigations, it has been concluded that ES-62 induces anti-inflam matory  action in 
several cell types in vitro [193]. Therefore, the core aim of this chapter was to determine 
whether ES-62 treatment mediates anti-inflammatory action in a model of acute TH2- 
mediated allergic inflammation such as OVA-induced asthma.
As mentioned above, changes to airway physiology are often exhibited in patients with 
long-term pulmonary inflammation. For example, narrowing of airways and loss of 
elasticity can occur as a result of airway smooth muscle proliferation. Changes In smooth 
muscle contractility in murine models can be measured in vitro using a well-established 
laboratory technique, myography. It has not previously been determined whether the 
short-term model of OVA-induced airway inflammation exhibits associated airway smooth 
muscle changes or indeed, whether treatment of the model with ES-62 affects airway 
smooth muscle physiology. Thus, it was planned to investigate the contractility of airway 
smooth muscle obtained from the OVA-induced asthma model mice. As mentioned 
previously, the short-term OVA-induced asthma model can be adapted to develop a 
model of chronic airway inflammation and remodelling, which exhibits physiological 
features similar to those displayed by chronic asthmatics, for example, fibrosis, in 
particular, it was of interest to determine whether the immunology underlying the 
physiological changes to airway integrity induced by chronic airway inflammation were 
different from those responsible for acute airway inflammation, such as in the short-term 
model of OVA-induced asthma. Thus, it was planned to investigate the immunology of the 
longer-term model of airway inflammation, to compare and contrast with the immunology 
of the shorter-term model. In addition, the effect of ES-62 treatment on a model of long­
term airway inflammation had not previously been determined. Thus, it was additionally 
planned to determine the immunological effects of treatment of the longer-term airway 
inflammation model with ES-62,
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It is well established that asthma-like pulmonary inflammation is mediated by a TH2-type 
immune response. TH2-associated factor, ST2, has previously been analysed in a murine 
model of acute airway inflammation [343], but not in a longer-term airway-remodelling 
model. Therefore, the immunological role of ST2 in initiation of long-term pulmonary 
inflammation is currently unknown. Thus, it was additionally proposed to determine 
whether the model of longer-term airway inflammation can be induced in ST2-deficient 
mice and to investigate the role of ST2 in the immunology underlying inflammation in this 
model. Furthermore, it has previously been demonstrated that administration of soluble 
ST2 ameliorates Inflammation in CIA [346]. Similarly, ES-62 treatment has also been 
shown to mediate anti-inflammatory action In the CIA model (Chapter 3 and [192]). 
However, it is not currently known whether the ST2 protein or ST2 downstream signalling 
bears any correlation or relationship to the in vivo actions of ES-62. Thus, assuming it was 
possible to induce the long-term pulmonary inflammation model in ST2-deficient mice, it 
was planned to determine the role of ST2 in the action of ES-62 treatment of the long­
term pulmonary inflammation model.
In summary, the Individual aims of this investigation were:
1. To determine and characterise the effect of ES-62 treatment (prophylactically and 
therapeutically) on the inflammation exhibited in the short-term ova-induced 
asthma model.
2. To determine whether the ova-induced asthma model exhibits accompanying 
changes in airway smooth muscle physiology similar to that exhibited in human 
asthma patients by analysing the contractility of airway smooth muscle and, 
furthermore, to determine any action of ES-62 on airway smooth muscle 
contractility.
3. To extend immunological analysis of ES-62 action on pulmonary inflammation, by 
examining a model of longer-term pulmonary inflammation and airway remodelling.
4. To determine the immunological role of TH2 marker gene ST2 in a model of 
longer- term pulmonary inflammation.
5. To determine any relationship or correlation between ST2 and the effects of ES-62 
treatment in the long-term pulmonary inflammation model.
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4.2 Results
4.2.1 OVA-induced airway inflammation model
The OVA-induced airway inflammation model was set up as described previously and in 
(figure 2.2). On day 28 of the OVA administration protocol, mice were sacrificed, broncho- 
alveolar lavage (BAL) was performed and the cytokine and cell profile of the lavage fluid 
was analysed. Macrophages were the predominant cell type detected in the lavage from 
all treatment groups (Figure 4.1). Flowever, significantly enhanced levels of eosinophils 
were identified in the BAL fluid of Asthma group mice, when compared with control mice 
(Figure 4.1). In support of these findings, histological analysis of lung tissue from Asthma 
group mice revealed profuse peribronchial inflammation, mucosal hyperplasia and 
eosinophil infiltration (Figure 4.1), compared with lung tissue from control mice (Figure
4.1).
Consistent with inflammation of a TFI2 phenotype, the BAL fluid from asthma group mice 
contained enhanced levels of TH2 cytokines, IL-4 and IL-5 and reduced levels of TH1 
cytokine, IFNy fig u re  4.2). Satisfied that the ovalbumin administration protocol induced 
hallmark features associated with asthma in humans, this model was considered 
appropriate for determination of the effects of ES-62 on TFi2-mediated inflammation.
4.2.2 Decreased OVA-induced airway eoslnophilia and IL-4 in mice treated 
with ES-62.
Ovalbumin sensitised and challenged mice, which had been treated prophylactically with 
ES-62 displayed significantly reduced levels of airway eosinophils compared to mice that 
had not received ES-62 treatment. In contrast, there were no significant effects on the 
proportion of airway macrophages, epithelial cells, lymphocytes or neutrophils (Figure
4.1), indicating that this action of ES-62 was eosinophil-specific. Furthermore, 
development of peribronchial inflammation as displayed by Asthma group mice was 
reduced by treatment with ES-62 (Figure 4.1). As mentioned above, the TF12 nature of 
the airway inflammation was demonstrated by elevated IL-4 and IL-5 levels in the BAL 
fluid of mice from the Asthma  group (Figure 4.2), the former of which was significantly 
reduced by ES-62. The very low levels of BAL IFN-y production (Figure 4.2) were not 
significantly modulated by ES-62 treatment. In summary, the action of ES-62 on airway 
cytokine profile was targeted specifically for reduction of TFI2 cytokine production.
4.2.3 Effect of ES-62 treatment on antigen-specific responses by draining 
lymph node cells
It has been demonstrated that the pulmonary inflammation exhibited in asthma is the 
result of an activated antigen-specific immune response, under the direction of TH2 cells. 
During asthma pathogenesis TFI2 cells become activated in lung-draining lymph nodes
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before migration to the site of inflammation. To begin dissection of the underlying 
mechanisms of pulmonary inflammation in this model, thoracic, cervical and pulmonary 
draining lymph nodes (DLN) were obtained. DLN cells from each treatment group were 
pooled and cultured in vitro, stimulated with antigen (OVA) or mitogen (Con A). Ex vivo 
DLN cells from mice that had received the airway inflammation protocol {Asthma and 
Asthma + ES-62 groups) displayed elevated spontaneous proliferation compared to those 
from contro l or ES-62 groups (Figure 4.3a). Re-stimulation with OVA in vitro, induced 
antigen-specific proliferation in Asthma group DLN cells, which was not modulated by 
prior treatment with ES-62 in vivo. This result indicated that targeting proliferation of lymph 
node cells was not a method employed by ES-62 for mediation of anti-inflammatory 
effects in vivo. However, ES-62 significantly inhibited antigen-specific IL-4, IL-5 and IL-10 
production by such DLN cells in vitro (Figure 4.3b-d). By contrast, Ag-specific production 
of TH1/pro-inflammatory cytokines such as IFNy and TNFa were not reduced by prior 
exposure to ES-62 in vivo (indeed the latter was elevated) (Figure 4.3e,f). These effects of 
ES-62 were antigen-specific because mitogen (ConA)-induced proliferation and cytokine 
responses were unaffected by ES-62 treatment (Figure 4.4). Therefore, it appeared that 
ES-62 inhibited antigen-specific TH2 cytokine production as a method of preventing 
development of asthma-like airway inflammation in this model.
4.2.4 The effects of ES-62 treatment on antigen-specific responses by 
splenocytes.
To determine any difference between local and systemic lymphocyte responses, 
splenocytes from each treatment group were cultured and stimulated in a similar manner 
to DLN cells from this model. Consistent with the findings obtained in DLN cells, 
splenocytes from the Asthma group showed antigen-specific enhancement of proliferation 
when re-stimulated with OVA in vitro (Figure 4.5a), which was not modulated by prior 
exposure to ES-62 {Asthma + ES-62) in vivo. Likewise, ES-62 treatment in vivo inhibited 
antigen-specific IL-4 production by splenocytes following ex vivo re-stimulation with OVA 
(Figure 4.5b), however antigen-specific IL-5 and IL-10 levels were unaffected (Figure 
4.6c-d). Furthermore, whilst the level of antigen-specific IFNy was unaffected by ES-62 
(as also witnessed with DLN cells), TNFa release was enhanced by prior exposure to ES- 
62 in vivo (Figure 4.5f). As with DLN, the ex wVo proliferative and cytokine responses of 
splenocytes to mitogenic Con A were unaffected by ES-62 treatment (Figure 4.6). 
Collectively, the decrease in TH2 responses and maintenance or increase of Thi/pro- 
inflammatory responses observed in DLN cells and splenocytes derived from the Asthma 
+ ES-62, relative to the Asthma, groups of mice suggests that ES-62 mediates its anti­
inflammatory action on airways by diverting the immune response away from the 
pathological TH2 bias.
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4.2.5 The effect of ES-62 on asthma model lymph node cells is dependent 
upon anatomical site.
With the aim of obtaining a full body profile of lymphocyte responses, ex wVo analysis of 
lymph node cells was extended to additional anatomical sites. Thus, peripheral lymph 
nodes (PLN), obtained from anatomical areas distal to the lungs, were pooled in treatment 
groups. PLN cells were Isolated, cultured and stimulated in vitro, using the same methods 
as have been described for DLN cells. It was observed that the effects of prior in vivo 
exposure to ES-62 were quite different in cells derived from peripheral lymph nodes (PLN) 
compared to draining lymphoid organs. PLN cells from mice that had been treated with 
ES-62 {ES-62 and Asthma + ES-62 groups) showed increased levels of spontaneous 
proliferation ex vivo, relative to those from con tro l or Asthma groups (Figure 4.7a). 
However, stimulation of PLN cells with OVA in vitro did not significantly modulate the rates 
of proliferation in cells from any of the treatment groups, indicating that the recall antigen 
specific responses displayed by splenocytes and DLN cells were absent in the PLN cell 
population. Cytokine analysis indicated the overall in vitro cytokine production by PLN 
cells, where detectable, was very low. Whilst the control and Asthma groups did not 
produce any increase in IL-4, IL-5 or IL-10 following stimulation with OVA ex vivo, cells 
from those groups, which had been exposed to ES-62 in vivo, showed low but increased 
levels of lL-5 and IL-10 when challenged with Ag (Figure 4.7b-d). In contrast, prior 
exposure to ES-62 had negligible effects on the very low production of IFNy or 
TNFa (Figure 4.7e,f). The lack of responses to OVA in the control and Asthma groups are 
therefore perhaps consistent with the secondary immune response to aerosolised Ag 
being generally restricted to the appropriate DLN and spleen whereas, because of the 
subcutaneous delivery of ES-62, some weak, yet significant responses can be detected in 
cells derived from ES-62-treated groups. Moreover, the overall polarisation of such 
responses towards a TH2/anti-inflammatory phenotype reflects our previous in vivo 
studies on the immune response to ES-62 itself [193, 347].
4.2.6 ES-62 treatment of Ova-induced airway inflammation inhibits Ova-
specific IgE production
Inflammatory signals are communicated around the body using various methods. One 
method of communication between different immune action sites is through the use of 
immunoglobulin (Ig) isotypes. IgE is the signature TH2 antibody isotype and is an 
important mediator in the pathogenesis of allergic inflammation in asthma. Therefore it 
was necessary to determine whether the anti-inflammatory action of ES-62 on TH2 
cytokine production in this model was reflected by a change in the pattern of IgE antibody 
secretion in vivo. Serum from all groups of mice was thus analysed in vitro for total IgE 
and OVA-specific IgE content. Analysis of IgE levels in the serum showed that whilst 
OVA-specific and total IgE levels were elevated in the Asthma relative to the controi and
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ES-62 groups (Figure 4.8a,b;), this elevation of antibody production was significantly 
inhibited by prophylactic treatment {Asthma + ES-62 group) with ES-62.
Serum samples were also analysed for OVA-specific IgG of TH1 AND TH2 subclasses, 
lgG2a and lgG1 respectively. Both OVA- specific lgG2a and lgG1 were detected in the 
serum from mice which had received the ova administration protocol, however 
prophylactic treatment of these mice with ES-62 did not significantly alter the production of 
either Ig isotype (Figure 4.8c,d), indicating that modulation of antigen-specific IgG 
subclasses was not a method employed by ES-62 for preventing development of 
inflammation in this model.
4.2.7 In situ IgE expression in airway inflammation model lymph nodes
It is well documented that B cells found in the lymph nodes are the primary generators of 
Ig. Following stimulation with TH2 cytokine, IL-4, B cell antibody production is switched to 
TH2-type isotype, IgE. Sections of LN were therefore analysed for IgE and B220 (a 
marker of B cells) expression. Following examination of Figure 4.8, it can be concluded 
that LN from mice that had undergone the OVA-induced asthma protocol expressed 
increased levels of IgE, due to more brightly stained areas of the lymph node sections, 
than LN from control mice. Furthermore, it was obvious, from examination of the section 
pictures, that IgE staining was present in areas that appeared follicle-shaped within the 
lymph node section, suggesting that IgE was predominantly restricted to the B cell 
follicular areas in the LN.
4.2.8 ES-62 mediates anti-inflammatory action in established airway
inflammation
The results described above indicate that ES-62 can inhibit the pulmonary inflammation 
that develops in a model of asthma, when administered prophylactically, before onset of 
inflammation. In addition, it was necessary to determine whether ES-62 could mediate 
anti-inflammatory action in this model, when administered therapeutically (i.e. after the 
onset of pulmonary inflammation). Therefore, a second model of OVA-induced pulmonary 
inflammation was set up, identical to that previously described and ES-62 was 
administered only on days 25 and 27 of the OVA administration protocol (Figure 2.3). 
Administered therapeutically, ES-62 maintained its inhibition of OVA-induced pulmonary 
inflammation, as demonstrated by reduction of eosinophil numbers in the BAL fluid 
(Figure 4.9). Furthermore, this eosinophilia-reducing action of ES-62 was found to be 
dose-dependent.
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4.2.9 The effects of ES-62 treatment on antigen-specific DLN cell 
responses in established airway inflammation
Following confirmation of the therapeutic effects of ES-62 in the OVA-induced asthma 
model, it was logical to determine whether the anti-inflammatory action of ES-62 was 
associated with modulation of DLN cell antigen-specific responses. Using the method 
adopted for analysis of the prophylactic treatment model, DLN cells, obtained from mice in 
the therapeutic treatment model, were cultured ex vivo and re-stimulated with OVA. 
Although not significant, it was identified that therapeutic treatment with ES-62 appeared 
to inhibit antigen-specific IL-4 and IL-5 cytokine secretion in response to re-stimulation 
with OVA in vitro. Furthermore, the modest inhibitory effect of ES-62 appeared to be dose- 
dependent (Figure 4.9). These findings indicated that ES-62-mediated inhibition of 
inflammation in the therapeutic model might be, at least partially, facilitated by inhibition of 
antigen-specific TH2 cytokine production. This effect was similar to, but less potent than 
the observed action of ES-62 in this model when administered prophylactically.
4.2.10 ES-62 treatment of established airway inflammation does not 
modulate serum immunoglobulin.
To determine whether therapeutic ES-62 treatment modulated serum antibody levels in 
this model, analysis of serum samples was conducted. Interestingly, it was observed that 
therapeutic treatment with ES-62 did not significantly modulate total or OVA-specific IgE 
levels detected in the serum (Figure 4.10). These findings indicated that ES-62 was 
capable of preventing development of enhanced serum IgE, as had been determined in 
the prophylactic treatment model, but not reduction of existing IgE levels after 
establishment of disease. To obtain a more complete picture of the phonotype of serum Ig 
in this model. OVA- specific IgGI and !gG2a were also analysed in the serum from the 
therapeutic treatment model mice. Consistent with the findings in the prophylactic 
treatment model, therapeutic treatment with ES-62 did not significantly modulate the 
production of either IgG subclass (Figure 4.10c, d).
4.2.11 The OVA-induced airway inflammation model does not display 
augmented airway smooth muscle contractility
It is well established that an irreversible remodelling of airway structure accompanies the 
reversible inflammation exhibited in asthma [84]. This remodelling includes fibrosis and 
narrowing of the airways, reduced elasticity and increased contractility (or tightening) of 
the pulmonary smooth muscle. An experiment was designed to determine whether there 
was any difference in airway smooth muscle contractility in the model of airway 
inflammation and if so, could ES-62's inhibitory capacity extend to inhibition of these 
structural changes.
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In a preliminary experiment a four-group ova-induced pulmonary inflammation model was 
set up as before, with a prophylactic ES-62 treatment protocol and the tracheal smooth 
muscle was analysed. Using a large vessel myograph, the force of contraction of tracheal 
rings from mice in both treatment groups in response to methacholine (MCh) was 
measured. Comparison of the cumulative concentration-response curves, plotted as a 
percentage of the maximum response to potassium chloride (Figure 4.11), indicated 
negligible difference between the smooth muscle from each model treatment group. 
These findings were consistent with those of previous investigators, using a porcine 
model of airway hyper-responsiveness [348],
4.2.12 An OVA-induced model of chronic airway inflammation.
The results of the myograph experiments highlighted the short-term nature of the 
pulmonary inflammation set up in the ova-induced inflammation model. As an extension of 
the airway inflammation study, analysis of the immunological parameters in a model of 
irreversible pulmonary inflammation was proposed. To accomplish this the previously 
used airway inflammation model was adapted by maintaining the ovalbumin 
administration protocol and extending the time of inflammation to ensure the model 
acquired adequate features of longer-term pulmonary disease (Figure 2.3). It has 
previously been identified that this prolonged OVA-administration protocol induces fibrosis 
of the airways, e.g. deposition of collagen [324], therefore groups administered with long­
term ovalbumin were termed, "Fibrosis". There were three treatment groups in this model; 
Control, Fibrosis and Fibrosis + ES-62. ES-62 was administered in a prophylactic manner 
to the latter treatment group.
Due to the physiological severity of this extended inflammation induction protocol, 4 out of 
the 6 mice in the wild-type fibrosis treatment group did not survive until the end of the 
experimental protocol (day 56) and therefore, this model was not further pursued. 
Interestingly, all mice in the Fibrosis + ES-62 and control treatment groups did survive, 
which immediately indicated that ES-62 treatment might be, in some way, counteracting 
the severity of the extended ovalbumin administration protocol. Nevertheless, as a result 
of this unexpected loss samples from the Fibrosis group mice were limited, therefore the 
in vitro analysis was adapted to make best use of the samples available. For example, 
due to limited resources, insufficient lymph node cells were available for culture, however, 
sufficient quantities of splenocytes (which responded in a similar manner to DLN cells in 
the short term model) from all three experimental groups were obtained to allow 
comparison of treatment groups ex vivo.
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4.2.13 Splenocyte cytokine production in the chronic airway inflammation 
model
To determine the antigen-specific responses of lymphocytes ex wVo splenocytes from this 
model were cultured in vitro and their responses to antigen and mitogen analysed. 
Splenocytes isolated from fibrosis model mice were cultured in vitro and stimulated with 
antigen (OVA) or mitogen (Con A). After 72h the culture supernatants were analysed for 
TH2 cytokines; IL-4, IL-5 and IL-10 and THI-promoting cytokines; IL-12 and TNFa. 
Splenocytes from mice in each treatment group displayed spontaneous IL-12 secretion ex 
wVo (Figure 4.12e). Consistent with a TH2 phenotype, splenocytes from fibrosis mice 
produced less THI-promoting IL-12 than control cells (from mice that had not received 
OVA in vivo). Prophylactic ES-62 treatment of fibrosis mice appeared to promote the level 
spontaneous IL-12 production by splenocytes (Figure 4.12e). This pattern of ex vivo IL-12 
production between splenocytes from the different treatment groups was repeated 
following stimulation with OVA or Con A in vitro, indicating that splenocyte IL-12 
production in this model was constitutive, not antigen-specific and independent of culture 
conditions. However, antigen-specific production of TH2 cytokines was displayed by this 
cell type, in response to re-stimulation with OVA in vitro. TH2 cytokines, IL-5, IL-4 and IL- 
10 (Figure 4.12a-c) were produced only by splenocytes from mice that had undergone the 
ova-administration protocol in vivo (i.e. fibrosis and fibrosis+ES-62 mice). Findings 
consistent with this inflammation model exhibiting a TH2 phenotype. Interestingly, in 
response to OVA treatment, low levels of the pro-inflammatory cytokine, TNFa, were also 
produced by splenocytes from the three in vivo treatment groups (Figure 4.12d). 
Considering that low levels of TNFa were secreted by splenocytes from control mice, it 
was concluded that this cytokine secretion was not antigen-specific. Thus, similar to the 
findings In the previous model, antigen-specific cytokine production by splenocytes from 
this chronic airway inflammation model was predominantly TH2 in phenotype.
Surprisingly, prophylactic ES-62 treatment of fibrosis group mice in vivo increased 
antigen-specific IL-5, IL-4 and IL-10, but not TNFa production by splenocytes in vitro. This 
TH2-promoting action of ES-62 was opposite to that observed in splenocytes in the short­
term asthma model described above and is interesting in view of the survival-promoting 
effects of ES-62 in this model. However, in addition to its TH2-promoting functions, IL-10 
also functions as an anti-inflammatory cytokine, thus, it is possible that ES-62-mediated 
promotion of IL-10 production is anti-inflammatory in effect. As a polyclonal stimulation for 
comparison, splenocytes were additionally cultured with mitogenic Con A, but the 
response was modest. More specifically, Con A treatment in vitro induced low levels of IL- 
5, IL-4 and IL-10 by splenocytes (Figure 4.12a-c) from all treatment groups. In addition, as 
mentioned above, spontaneous ex wVo IL-12 production levels were not significantly 
modulated further (figure 4.18e). However, splenocytes from control mice appeared to
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produce elevated quantities of TNFa in response to Con A, indicating that the TNF a -  
producing cell population had been targeted by this mitogen in this group (Figure 4.12d).
4.2.14 ES-62 treatment of chronic airway inflammation inhibits production 
of antigen-specific immunoglobulin isotypes associated with a TH2 
phenotype.
It has been well documented that IgE is an immunoglobulin isotype that promotes TH2- 
driven inflammatory conditions. As described above, prophylactic ES-62 treatment inhibits 
antigen-specific and total IgE levels in the serum of asthma model mice. Therefore, in this 
model of TH2-driven inflammation, serum levels of IgE and IgG were analysed. 
Concurrent with the findings of the asthma model, the chronic airway inflammation 
induction protocol induced markedly elevated antigen-specific IgGI, lgG2a and IgE in the 
serum of fibrosis group mice (Figure 4.13a-c). Total serum IgE was also measured and 
found to be markedly elevated in fibrosis compared to control mice (Figure 4.13d). 
Interestingly, prophylactic ES-62 treatment of fibrosis significantly reduced ova-specific 
IgGI, lgG2a and IgE, but not total IgE. ES-62-mediated reduction of ova-specific IgE had 
previously been observed in the asthma model with prophylactic ES-62 treatment, 
however, reduction of antigen-specific IgGI and lgG2a are novel actions of ES-62 in this 
fibrosis model. This result suggested that in the longer-term inflammation model, ES-62 
was permitted to modulate a wider range of immunoglobulin isotypes. It is noteworthy that 
the Ig isotype most inhibited by ES-62 treatment (IgG I) is of the TH2 (inflammation- 
promoting) phenotype. This observation indicated that ES-62 inhibited the inflammation 
exhibited in the fibrosis model by, at least, modulating the antigen-specific response of the 
antibody production machinery.
4.2.15 OVA-induced chronic airway inflammation in ST2-deficient mice.
ST2, a protein with homology to the IL-1 receptor family, has been found to be stably and 
selectively expressed on the surface of CD4+ TH2 cells and not on Th i cells. Thus, it has 
been suggested that ST2 expression/signalling is important for the function of TH2 cells. It 
is well documented that chronic airway inflammation is facilitated by a TH2 immune 
response. Therefore, if ST2 is a marker of TH2 cells and is required for normal TH2 cell 
function, perhaps long-term TH2 airway inflammation cannot be induced in a system that 
lacks ST2. To test this theory, the chronic airway inflammation protocol (figure 2.4) was 
administered in ST2 ‘knock out’ (ST2K0) mice, which were deficient in ST2. ST2 research 
is currently very controversial and there is a large body of conflicting evidence as to the 
importance, function and action of ST2. Following one line of evidence, soluble ST2 
protein has been shown to have similar effects to ES-62 on innate immune cells, by 
inhibiting macrophage pro-inflammatory cytokine production in response to LPS [342]. To 
determine any association between the effects of ES-62 and ST2, the chronic airway
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inflammation model in ST2K0 mice was treated prophyiactioaily with ES-62 (in a similar 
manner to that used in wild-type mice).
4.2.16 Comparison of the splenocyte response in wild-type and ST2- 
deficient models of chronic airway inflammation
To establish the role, if any, of ST2 in the development of the chronic airway inflammation 
model, the OVA-induced chronic airway inflammation induction protocol was administered 
in ST2KO mice. Comparison of splenocyte responses in the wild-type and ST2KO models 
revealed an interesting difference. Whilst treated identically ex vivo, the cytokine 
responses of splenocytes from ST2K0 model mice were consistently greater than those 
of splenocytes from wild-type mice. However, the pattern  of cytokine production by 
splenocytes from both models was maintained. As observed in the wild-type model, 
constitutive ex wVo IL-12 production was displayed by splenocytes from the ST2K0 model 
(Figure 4.12). Similarly, antigen-specific IL-4, IL-5 and IL-10 were produced by 
splenocytes from both models (Figure 4.12a-c and f-h) in response to re-stimulation with 
OVA in vitro. Collectively, these findings indicated that knock-out of ST2 did not prevent 
development of antigen-specific TH2 cells in this extended model of airway inflammation. 
Although ST2 deficiency appeared to induce more potent splenocyte cytokine responses, 
the overall antigen-specific response pattern exhibited by this cell type had not been 
altered.
Furthermore, ES-62-mediated enhancement of splenocyte cytokine production, exhibited 
in the wild-type model, was maintained in the ST2K0 model, indicating that this action of 
ES-62 was ST2-independent. More specifically, ES-62 continued to elevate splenocyte 
antigen-specific IL-5, IL-4 and IL-10 and spontaneous IL-12 production, whilst not 
modulating TNFa secretion, in the ST2K0 model (Figure 4.12). In summary, knocking out 
ST2 appeared to induce a more strongly polarised antigen-specific TH2 response by 
splenocytes, but did not modulate ES-62 action on this particular cell type.
4.2.17 Lymph node cell responses in chronic airway inflammation: the role 
ofST2.
Unlike the effects of the chronic airway inflammation model in wild-type mice, the 
extended ovalbumin administration protocol did not prove fatal in 8T2KO mice. This 
difference in the survival of the mice might indicate that inflammation and pathology was 
less severe in ST2K0 mice, however this proposal is somewhat at odds with the 
aforementioned splenocyte responses. Nevertheless, survival of sufficient numbers of 
ST2K0 model mice in both treatment groups permitted analysis of lymph node cell 
responses in this model. Consistent with the splenocyte responses in the wild-type model, 
there was spontaneous ex vivo IL-12 production in ST2KO DLN (Figure 4.14d), PLN
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(Figure 4.14h) and spleen cells (Figure 4.12e). Moreover, in response to re-stimulation 
with OVA in vitro, antigen-specific IL-4, IL-5, IL-10 and TNFa production was exhibited by 
ST2KO DLN cells (Figure 4.14a-c and e) and splenocytes (Figure 4.12a-d). However, 
TH1-promoting TNFa production was low, suggesting that in the ST2K0 mice the 
cytokine response was still of a TH2 phenotype. PLN cells from the ST2KO model mice 
secreted only modest levels of IL-5 and IL-10 in response to OVA re-stimulation in vitro, 
indicating that few antigen-specific cells were present in the lymph nodes distal to the 
anatomical site of induced inflammation and that the antigen-specific response was 
predominantly conducted by local lymph node cells and splenocytes. Such an 
absent/reduced antigen-specific response of PLN cells had previously been observed in 
the asthma model.
4.2.18 The effects of ES-62 treatment on antigen-specific lymph node cell 
responses in the OVA-induced chronic airway inflammation model in 
ST2-deficient mice.
Prophylactic treatment of ST2K0 chronic airway inflammation model mice with ES-62 
further increased antigen-specific IL-4 (Figure 4.14a), yet decreased antigen-specific IL-5 
(Figure 4.14b) and did not significantly modulate antigen-specific IL-10 (Figure 4.14c) 
production by DLN cells. Furthermore, OVA-specific DLN cell TNFa production, whilst 
relatively low in value, was reduced by prior treatment with ES-62 in vivo (Figure 4.14e). 
This pattern of ES-62 action on the antigen-specific response of DLN cells was different 
from the pattern displayed by splenocytes from this model. Although the action of ES-62 
on antigen-specific IL-4 was maintained, the effects of ES-62 on antigen-specific IL-10 
and IL-5 were absent and reversed respectively. Nevertheless, promotion of DLN cell 
antigen-specific IL-4 production was the most potent of ES-62 mediated effects in this 
model, suggesting that enhancement of TH2 cytokine production remained the primary 
function of ES-62 in these cells.
As mentioned above, antigen-specific PLN cell production of IL-5 and IL-10 (Figure 
4.14f,g) was apparent but in very low concentrations (less than 30pg/ml) around the limit 
of detection. Interestingly, prior ES-62 treatment in vivo abrogated antigen-specific IL-5 
production by PLN cells from the ST2K0 fibrosis model. Although not significant, ES-62 
also reduced the mean concentration of IL-10 produced by PLN cells in response to OVA. 
It was interesting that, as with the short-term asthma model, the effects of ES-62 were 
opposite in DLN and PLN cells from this model, i.e. promotion and reduction of antigen- 
specific TH2 cytokine production respectively.
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Consistent with observations in the wild-type model splenocytes, the response of LN cells 
from the ST2K0 mice to Con A treatment in vitro predominantly reflected production of 
TH1 cytokines, IL-12 and TNFa.
4.2.19 Comparison of wild-type and ST2-deficient chronic airway 
inflammation models: immunoglobulin production
Comparison of serum Ig profiles between wild-type and ST2K0 models revealed 
interesting differences in the levels of antigen-specific IgE and IgG generated (Figure 
4.13). Despite the relatively lower levels of antigen-specific TH2-iike cytokine (IL-4 and IL- 
5) production ex vivo, serum OVA-specific IgE was greater in wild-type fibrosis mice, 
when compared with serum from ST2K0 fibrosis mice, indicating that ST2K0 mice were 
less able to induce an antigen-specific antibody response of TH2 signature isotype, IgE. 
Interestingly, serum levels of total IgE were similar in wild-type and ST2K0 fibrosis mice, 
thus, ST2 must be necessary for induction of antigen-specific IgE, but not total IgE levels 
in this model. Furthermore, In the wild-type fibrosis mice, serum OVA-specific lgG2a 
levels were significantly less than that detected in serum from ST2KO fibrosis mice 
(Figure 4.13b). Given that lgG2a is a THI-type IgG subclass, this finding indicated that a 
more potent TH1-mediated immune response had been activated in ST2K0 mice. Thus, 
ST2 must also be necessary for reducing production of TH1-promoting serum lgG2a in 
this model. Serum levels of OVA-specific IgGI were similar in wild-type and ST2K0 
fibrosis model mice, indicating that the production of this TH2-type subclass of antigen- 
specific IgG in this model was not dependent upon ST2 expression (Figure 4.13a).
4.2.20 ES-62 treatment of chronic airway inflammation in ST2-deficient mice 
does not modulate antigen-specific immunoglobulin production
To clarify the action of ES-62 in the ST2K0 fibrosis model, serum levels of antigen- 
specific IgE and IgG and total IgE from ST2-deficient mice in each treatment group were 
examined (Figure 4.13). The results for analysis of serum from control mice in the wild- 
type fibrosis model were added to the graphs for comparison.
It was clear from comparison with control wild-type samples that serum Ig was secreted in 
increased amounts in ST2K0 relative to wild-type mice that had undergone the extended 
OVA administration protocol (Figure 4.13). In contrast to the findings of serum analysis in 
the wild-type model, prophylactic treatment of fibrosis in ST2KO mice with ES-62 did not 
significantly modulate serum OVA-specific IgGI, lgG2a, IgE or total IgE (Figure 4.13a-d), 
suggesting that ST2 expression may be necessary for ES-62-mediated modulation of 
antibody production or Ig isotype.
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Analysis of the effects of ES-62 on serum Ig between wild-type and ST2K0 models also 
revealed interesting information about the roles of ES-62 and ST2 in this model. As 
mentioned previously, ES-62 inhibited production of OVA -specific IgE in the wild-type 
fibrosis mice, but not in the ST2KO fibrosis mice (Figure 4.13c). This difference could 
indicate that ST2 is required for ES-62 mediated inhibition of antigen-specific IgE in this 
model, however, as mentioned above. ST2K0 fibrosis mice were unable to induce a large 
antigen-specific IgE response. Thus it is also possible that ES-62's inhibitory action on 
antigen-specific IgE is simply not apparent in ST2K0 fibrosis mice because the levels are 
minimal anyway. It is not clear from this analysis which theory is correct. However, as the 
OVA-specific IgGI response in wild-type and ST2K0 mice were equivalent, it was 
apparent that ES-62 mediated inhibition of OVA-specific IgGI in wild-type fibrosis mice 
was prevented in ST2K0 mice (Figure 4.13a). This result was unambiguous, indicating 
that whilst ST2 was not necessary for development of the antigen-specific IgGI response 
in this model, it was required for the antigen-specific inhibitory effect of ES-62 on this TH2- 
type IgG subclass. Clearly, in this model ES-62 was unable to mediate its normal 
immunomodulatory action on serum antibody levels in mice that did not express ST2. As 
described above, the OVA-specific lgG2a response was enhanced in ST2-deficient 
fibrosis mice compared with their wild-type counterparts. Nevertheless, ES-62 treatment 
of wild-type or ST2-deficient fibrosis mice did not induce significant modulation of the level 
of OVA-specific lgG2a in serum from either type of mouse in this model. Thus, despite the 
enhancing effect of ST2-deficiency on the antigen-specific lgG2a response, it was clear 
that ES-62 did not target production of this THI-type IgG subclass in this model.
In summary, in this model ST2 was required for developing of an antigen-specific IgE 
response, preventing development of an antigen-specific lgG2a response and the 
inhibitory effect of ES-62 on antigen-specific Ig of TH2 phenotype. In terms of serum 
antibody profile, ST2KO mice appeared to develop a mixed lgG1/lgG2a (TH2/TH1) 
immune response to the OVA administration protocol, but appeared incapable of 
mounting an IgE response. Thus, as IgE is a TH2-type antibody isotype, it appeared that 
the antibody response in the ST2K0 mice was polarised away from TH2 phenotype.
4.2.21 ES-62 treatment of OVA-induced airway inflammation modulates co- 
stimulatory molecule expression and cytokine production of bone 
marrow-derived cells
Following investigation of varied models of TH2-mediated inflammation and the inhibitory 
effects of ES-62 on such inflammation, it was of interest to determine the mechanisms 
employed by ES-62 to communicate with the immune system and intervene with the 
inflammation development machinery. Previous work published by this laboratory has 
demonstrated that ES-62 mediates profound and significant effects on cells in the first line
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of defence or innate Immune system, for example, antigen processing cells (APC) such as 
macrophages and dendritic cells [189-191], Furthermore, evidence from this laboratory 
indicates that, via modulation of dendritic cell phenotype and cytokine production, ES-62 
is permitted to indirectly modulate TH cell phenotype and hence, the nature of the ensuing 
immune response [189].
To determine whether APC modulation was a viable method by which ES-62 induces its 
inhibitory action in the short-term airway inflammation model, bone marrow-derived 
dendritic cells were cultured from the bone marrow of the prophylactic treatment model 
mice. The phenotype of these DC was assessed in unstimulated and LPS-matured 
conditions by analysing cell surface marker expression and cytokine production. Bone 
marrow-derived DC cultured from control mice that had been treated with ES-62 in vivo 
displayed a moderately matured phenotype, when compared with DC from control mice 
that had not been treated with ES-62. More specifically, ES-62 treatment induced 
upregulated cell surface expression of antigen-presentatlon and co-stimulatory molecules, 
MHC II, CD40 and CD86 (and marginal upregulation of CD80 expression) on cells 
subsequently cultured from bone marrow progenitors. This maturation effect was 
independent of OVA treatment in vivo and therefore only observed in DC derived from 
mice that had been treated with ES-62. (Figure 4.15, panel A). Indeed, DC derived from 
the ‘Asthma’ (i.e. OVA alone) treatment group were essentially phenotypically identical to 
those derived from the control treatment group mice. Interestingly, this upregulatory effect 
of prior ES-62 treatment in vivo on resultant bone marrow-derived DC is the reverse 
action to that induced by continuous ES-62 exposure in vivo in naïve mice [191]. In more 
detail, ES-62 administered continuously in vivo for 14 days, via the use of osmotic pumps, 
conferred an immature phenotype on the bone marrow DC subsequently derived from 
such mice. Nevertheless, the cell surface molecules that were upregulated on DC from 
ES-62 treated asthma model mice are important for DC mediated T cell priming. In 
particular, CD86 is an important co-stimulatory signal, required for successful priming of 
naïve T cells by antigen-presenting DC, leading to differentiation of antigen-specific T 
helper (TH) cells [349, 350].
In vitro stimulation of asthma model bone marrow DC with LPS induced upregulation of all 
cell surface molecules analysed, on DC from all four in vivo treatment groups (Figure 
4.15, panel B). Nevertheless, a distinct ES-62-specific pattern was maintained following 
LPS treatment. Thus, DC from mice treated with ES-62 in vivo displayed a slightly 
inhibited LPS-induced upregulation of MHCII, CD40, CD54 and CD80. DC from the 
Asthma+ES-62 treatment group mice consistently expressed the lowest levels of all five 
surface markers in response to LPS treatment. These findings indicated that in ES-62- 
treated asthma model mice, the normal response of bone marrow derived DC to potent
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pro-inflammatory stimuli (such as LPS) was dampened. Furthermore, such an inhibited 
upregulation response to LPS treatment in vitro was characteristic of DC derived from 
mice that had previously been exposed to ES-62 (administered via osmotic pumps) in vivo 
[191].
To obtain a more complete picture of the phenotype of DC derived from asthma model 
mice, the culture supernatants of the bone marrow-derived DC described above were 
analysed for cytokine content. Bone marrow-derived DC from mice in each treatment 
group produced detectable levels of IL-12 and TNFa. The patterns of IL-12 and TNFa 
production reflected the maturation status, as indicated by cell surface expression of 
these bone marrow-derived DC. More specifically, DC cultured from asthma model mice 
that had been treated with ES-62 in vivo displayed enhanced production of IL-12, when 
compared with DC from mice that had not been treated with ES-62 (Figure 4.16, panel A). 
Low-level induction of IL-12, following ES-62 treatment of bone marrow-derived cells has 
previously been demonstrated in vitro, but not in vivo [190, 191]. Interestingly, the TNFa 
production by DC from each treatment group was very low overall (15-20 pg/ml) and did 
not vary between treatment groups. In summary, ES-62 treatment in vivo appeared to 
modulate bone marrow progenitor cells in order that they differentiate into DC with slightly 
enhanced TH1-promoting cytokine production and expression of surface markers.
Following analysis of spontaneous IL-12 and TNFa production patterns of DC derived 
from this model, the DC cytokine production profile in response to LPS was determined. 
LPS stimulation induced markedly increased production of IL-12 and TNFa by the DC 
derived from the asthma model mice. Interestingly, the pattern of spontaneous IL-12 
production by DC derived from the different in vivo treatment groups was maintained (at 
higher concentrations) in response to LPS (Figure 4.16, panel B). More specifically, DC 
from mice treated with ES-62 in vivo secreted more LPS-induced IL-12 than DC from 
Control and Asthma mice. Similarly, although the concentration of DC TNFa was 
increased by LPS stimulation, the level of production was not significantly different 
between DC from each of the in vivo treatment groups. Therefore, whilst the pattern of DC 
surface expression was altered by LPS treatment, the pattern of IL-12 secretion was not. 
Furthermore, the pattern of cytokine production by DC derived from ES-62 treated mice in 
this inflammation model was uncharacteristic of the previously determined effects of ES- 
62 treatment in vivo [191]. More specifically, prior treatment of naïve mice with ES-62 in 
vivo induces differentiation of bone marrow DC that display an inhibited TH1-promoting 
cytokine production response to LPS, similar to the effects of ES-62 pre-treatment on 
bone marrow-derived DC in vitro [191]. Nevertheless, in summary, ES-62 treatment of 
asthma model mice in vivo induced modulatory effects on the phenotype and function of 
DC derived from bone marrow of mice in this model of TH2-medlated inflammation.
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4.2.22 OVA-induced chronic airway inflammation promotes development of 
a modulated bone marrow-derived cell phenotype, which is prevented 
by ES-62 treatment
As described above, prophylactic treatment of the Ovalbumin-induced asthma model with 
ES-62 modulated (subsequently induced) DC function and phenotype. Following 
demonstration of ES-62-mediated modulation of antigen-specific responses and serum 
antibodies in the longer-term chronic airway inflammation model, analysis was extended 
to determine the effects of ES-62 treatment on bone marrow-derived DC from this fibrosis 
model. Thus, bone marrow-derived DC from each treatment group in the fibrosis model 
were cultured in vitro for 7 days from femoral bone marrow progenitor cells and stimulated 
with LPS. Following culture, DC were stained for expression of cell surface molecules 
normally upregulated by activated DC in vivo. The results of this analysis are presented In 
Figure 4.17. Close examination revealed that DC derived from fibrosis mice displayed 
reduced expression of cell surface antigen-presentation and co-stimulatory molecules, 
when compared with DC from the control treatment group (Figure 4.17, panel A). More 
specifically, in fibrosis DC, a population with low expression levels of MHCII, CD40, CD54, 
CD80 and CD86 was apparent, that was not observed in DC from the other treatment 
groups. When fibrosis was treated with ES-62 in vivo, the low-level expressing 
populations were lost and the histogram of expression (for each surface marker) shifted to 
the right. Thus, it appeared that ES-62 treatment restored the BMDC phenotype towards 
that observed in DC from the control treatment group mice. It was interesting to note that 
the ‘upregulatory’ action of ES-62 on DC from this model had also been (modestly) 
observed in DC from the shorter-term airway inflammation model (section 4.2.21).
The response to LPS, by DC from the fibrosis model was mediated by upregulation of 
expression of all five surface molecules analysed. This shift was exhibited in DC from all 
treatment groups (at least in terms of loss of the low-level expressing populations) in 
response to LPS (Figure 4.17 panel B). The pattern of expression profiles displayed 
between untreated DC from different treatment groups was maintained in response to 
LPS. More specifically, DC derived from mice in the fibrosis treatment group continued to 
express lower overall levels of MHCII, CD40, CD54, CD80 and CD86 than DC from those 
in the control treatment group. Similarly, DC derived from mice in the fibrosis + ES-62 
treatment group displayed slightly increased expression levels of the same cell surface 
markers, compared to those derived from the fibrosis treatment group. Therefore, 
although LPS induced upregulation of all the DC surface markers analysed in vitro, the 
patterns of surface expression induced by the fibrosis induction protocol and ES-62 
treatment in vivo were not modulated.
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In parallel with analysis of DC surface markers, the cytokine production profiles of DC 
derived from the fibrosis model were determined. DC derived from this model 
spontaneously produced detectable levels of the TH1-promoting cytokines, IL-12 and 
TNFa and anti-inflammatory cytokine, IL-10 (Figure 4.18, panel A). However, compared to 
IL-12 production, the TNFa production by the DC in this assay was modest. The OVA 
administration protocol induced increased constitutive production of IL-12 and slightly (but 
not significantly) elevated TNFa by DC. The elevated IL-12 production was prevented by 
ES-62 treatment in vivo, indicating that ES-62 treatment in vivo had rescued the 
modulatory effect of the fibrosis induction protocol on bone marrow-derived cell pro- 
inflammatory cytokine production. The restorative effect of ES-62 in this model had also 
previously been observed in terms of DC surface expression pattern. Interestingly, DC 
cultured from control mice spontaneously produced relatively high concentrations of IL-10 
(over 700pg/ml), this was inhibited in DC derived from fibrosis treatment group mice, 
irrespective of ES-62 treatment in vivo (Figure 4.18, panel A).
Production of IL-12 and TNFa by DC derived from all the treatment groups was markedly 
increased upon treatment with LPS (Figure 4.18, panel B). Furthermore, the pattern of 
production of IL-12 and TNFa in response to LPS was uniform between the DC from 
different in vivo treatment groups. In more detail, DC cultured from control mice in this 
model displayed marked production of IL-12 and TNFa in response to LPS. However, the 
TNFa and IL-12 responses to LPS were significantly less in DC derived from the fibrosis 
treatment group. Interestingly, ES-62 treatment of fibrosis in vivo appeared to Induce 
partial rescue of the inflammatory cytokine response to LPS, by permitting LPS-induced 
production of IL-12 and TNFa to a concentration not significantly different from that 
produced by DC derived from control mice. Therefore, similar to the pattern of IL-12 
production by these cells under control conditions, in vivo ES-62 treatment prior to the in 
vitro differentiation of bone marrow-derived DC appeared to rescue the modulatory effect 
of the fibrosis induction protocol on DC cytokine production. Additionally, LPS treatment 
induced production of IL-10 by DC from each treatment group, however, there were no 
significant differences in the levels of IL-10 produced by different treatment groups.
Collectively, the analysis of bone marrow-derived DC cultured from the chronic airway 
inflammation model indicated that both, the fibrosis induction protocol, and ES-62 
treatment, modulated the phenotype of bone marrow progenitor cells. This resulted in 
differentiation of DC with a modulated phenotype and function. Moreover, the modulation 
of DC phenotype or function induced by the fibrosis induction protocol was, at least 
partially, corrected by simultaneous ES-62 treatment. Furthermore, the combined fibrosis 
induction protocol and ES-62 treatment in vivo induced differentiation of bone marrow- 
derived DC that displayed a somewhat matured phenotype (evidenced by upregulation of
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cell surface markers) and that were potentially biased towards promoting a TH1 immune 
response (evidenced by enhanced production of TH1-promoting cytokine, IL-12).
4.2.23 ES-62 mediated restoration of bone marrow-derived cell phenotype 
in OVA-induced chronic airway inflammation is further promoted in 
ST2-deficient mice.
It had previously been determined that knock-out of ST2 prevented development of OVA- 
specific IgE antibody responses and mediation of some ES-62 actions. Therefore, it was 
important to determine the action of the OVA-immunisation protocol and the effect of ES- 
62 treatment on bone marrow-derived DC from the ST2-deficient fibrosis model. Bone 
marrow-derived DC from ST2KO fibrosis model mice were cultured as described above. 
DC phenotype and function was again assessed by analysing cell surface expression and 
cytokine production.
Analysis by flow cytometry uncovered interesting changes in the cell surface expression 
patterns of DC derived from the ST2K0 mice, however firstly, it must be clarified that the 
overall cell surface expression differences observed between DC derived from different in 
vivo treatment groups were modest. Firstly, a comparison of DC derived from wild-type 
and ST2KO mice in the fibrosis treatment groups was made. Close inspection of the 
respective cell surface expression profiles (Figure 4.19) revealed that the DC derived from 
ST2-deficient fibrosis model mice exhibited a somewhat matured phenotype compared 
with the DC derived from wild-type fibrosis model mice. In more detail, a population of DC 
expressing low levels of MHCII, CD40, CD54 and CD86 was apparent in DC cultures from 
wild-type fibrosis model mice. The number of cells in this low-expressing population was 
however less in DC derived from ST2-deficient fibrosis treatment group mice. Thus, it 
appeared that knock-out of ST2 prevented differentiation of DC with an immature 
phenotype in response to the OVA immunisation protocol, as had been induced in the 
wild-type model (described above).
Interestingly, ES-62 treatment of ST2-deficient fibrosis model mice in vivo appeared to 
‘correct’ this effect of ST2 knock-out. More specifically, the population of low-level 
expressing cells identified in DC cultures from wild-type fibrosis model mice was also 
apparent in DC cultures from ES-62-treated ST2K0 fibrosis model mice. (Figure 4.19, 
panel A). Thus, the DC surface expression profiles of MHCII, CD40, CD54, CD80 and 
CD86 on DC derived from ‘wildtype fibrosis’ and ‘ST2K0 fibrosis+ES-62’ mice were highly 
similar.
This down-regulatory effect of ES-62 on surface expression of DC from the ST2K0 
fibrosis model was particularly interesting because it was the reverse of its action on DC 
from the wild-type fibrosis model.
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The response of ST2KO fibrosis model DC to LPS stimulation in vitro was also analysed 
and compared with that of wild-type fibrosis model DC. In agreement with previous 
experiments, LPS treatment induced some upregulation CD40, CD54, CD80 and CD86 
analysed on DC from the three experimental groups in this model (Figure 4.19, panel B). 
Interestingly, the expression profiles of MHCII, CD40, CD54 and CD86 on DC derived 
from wild-type and ST2-deficient fibrosis model mice became more alike upon LPS 
treatment, mainly comprising loss of the low-level expressing population of cells in DC 
cultures from wild-type fibrosis mice, observed under control conditions. Similarly, surface 
expression levels of MHCII, CD40, CD80 and CD86 on DC derived from ‘ST2K0 fibrosis’ 
and ‘ST2K0 fibrosis+ES-62’ mice were highly similar. Thus, LPS treatment in vitro 
appeared to have a more pronounced upregulatory effect on DC derived from wild-type 
fibrosis mice and ST2-deficient fibrosis mice that had been exposed to ES-62, than on DC 
derived from ST2-deficint fibrosis mice that had not been treated with ES-62. However, it 
must be noted that the majority of responses to LPS were slight. These combined results 
highlighted two differences in this ST2K0 model. Absence of the ST2 gene appeared to 
prevent the normal action of the fibrosis induction protocol on resultant DC phenotype. 
However, interestingly, ES-62 treatment of ST2-deficient fibrosis model mice appeared to 
‘rescue’ the effect of ST2-deficiency, in terms of the modulation of DC phenotype. More 
specifically, in the fibrosis model in ST2K0 mice, DC derived from mice treated with ES- 
62 were less mature than DC from mice not treated with ES-62. This was in direct contrast 
to the findings of the wild-type experiment, where ES-62 treatment induced production of 
more mature DC. To investigate this more fully, the supernatants from these cultures were 
analysed for cytokine content.
Culture supernatants from DC derived from the ST2KO fibrosis model were analysed for 
IL-12, TNFa and IL-10 and the results compared with those from the wild-type fibrosis 
model mice (Figure 4.20). Similar to DC derived from the wild-type model, DC derived 
from ST2K0 mice in from both treatment groups spontaneously produced low 
concentrations of TNFa (approximately 80pg/ml), higher quantities of IL-12, and negligible 
IL-10 (Figure 4.20, panel A). Interestingly, spontaneous production of TNFa by DC 
derived from ST2K0 fibrosis model mice was significantly greater than that released by 
DC derived from wild-type fibrosis model mice. Furthermore, similar to its action in the 
wild-type fibrosis model, ES-62 treatment of the ST2K0 fibrosis model mice in vivo did not 
modulate this level of spontaneous TNFa production by resultant DC. In contrast, 
spontaneous IL-12 production levels by DC derived from ES-62-treated ST2K0 fibrosis 
model mice were significantly enhanced from the levels produced by DC derived from 
fibrosis model mice of either strain. Thus, consistent with the findings of the DC surface
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expression analysis in this model, the IL-12-induction effect of ES-62 was opposite to the 
observed inhibitory effect of ES-62 on IL-12 production by DC from the wild-type model.
LPS stimulation of DC in vitro induced marked increases in production of IL-12, TNFa and 
IL-10 by ST2KO fibrosis model DC, which were not significantly modulated by ES-62 
treatment in vivo (Figure 4.20, panel B). In the wild-type model, the modulatory action of 
ES-62 was still apparent in response to LPS. Therefore, this difference indicated that ST2 
might be required for ES-62-mediated enhancement of the TH1-promoting cytokine 
production response of DC to LPS.
In summary, modulatory action of prior ES-62 treatment on phenotype and function of DC 
subsequently derived from fibrosis model mice was apparent in the presence and 
absence of ST2 expression. However, the specific actions of ES-62 on DC derived from 
ST2K0 mice were altered, when compared with those displayed in DC from wild-type 
mice. That is, the effect of ES-62 on surface expression and spontaneous IL-12 
production was reversed in DC derived from ST2-deficient fibrosis model mice. This 
difference may form part of the explanation for redundancy of ES-62 action in the ST2KO 
fibrosis model.
4.2.24 Investigation of the phenotype of bone marrow macrophages derived 
from asthma model mice
Macrophages are important cells of the innate immune response involved in facilitation 
and maintenance of inflammation. Via recruitment and activation of inflammatory cells and 
destruction of pathogens or tissue debris at the site of inflammation, macrophages form 
an integral component of established TH1 and TH2 immune responses.
To investigate the effects of in vivo exposure on macrophages and their progenitors, 
macrophages derived from the bone marrow of asthma mice and asthma + ES-62 mice 
were cultured in vitro and their cytokine production was analysed. Interestingly, it was 
apparent that the bone marrow-derived macrophages from the different in vivo treatment 
groups spontaneously produced differential levels of cytokines. In more detail, 
macrophages from mice that had received the ova-induced inflammation protocol in vivo 
produced significantly enhanced levels pro-inflammatory cytokines, TNFa and IL-12, 
when compared with macrophages from control treatment group mice (Figure 4.21), 
indicating that macrophages cultured from bone marrow of ova-treated mice exhibited an 
activated phenotype. Low levels of IL-10 were also constitutively produced, with 
macrophages from the asthma group mice producing the greatest amount. Interestingly 
ES-62 treatment of asthma model mice in vivo inhibited the spontaneous production of all 
three cytokines by the bone marrow derived macrophages subsequently derived from this
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model. In summary, ES-62 mediated impedance of inflammation in this model was 
associated with inhibition of spontaneous cytokine production by bone marrow-derived 
macrophages.
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4.3 Discussion
The results presented in chapter 3 illustrated the substantial inhibitory effects of ES-62 on 
TH1-mediated inflammation in vivo, using a model of rheumatoid arthritis. In this chapter, 
evidence demonstrating a novel inhibitory action of ES-62 in inflammation generated by a 
TH2-type immune response has been put forward. Furthermore, the anti-inflammatory 
potential of ES-62 in this type of inflammation was made clinically relevant by 
demonstrating the persistence of the inhibitory action when administered after the onset of 
antigen-induced inflammation.
4.3.1 ES-62 inhibits TH2 mediated airway inflammation
To reiterate, ES-62 significantly inhibited OVA-induced eosinophilia and peribronchial 
inflammation in a short-term model of asthma-like pulmonary inflammation. Consistent 
with asthma in humans, the inflammation generated in this OVA-induced model was found 
to be of TH2 phenotype, identified by analysis of the airway cytokine profile. Furthermore, 
ES-62 appeared to specifically target the TH2-facilltated, allergen-induced inflammation, 
because the IL-4 concentration detected in the airways was inhibited by ES-62 treatment. 
Satisfied that ES-62 inhibited cardinal features of airway inflammation (eosinophilia and 
TH2 cytokines), investigation of this model proceeded to examine the immune response 
at various locations within the body.
The antigen-specific TH2 cytokine production observed by cells from draining lymph 
nodes and spleen was not apparent in peripheral LN cells, indicating the local nature of 
the immune response to the OVA sensitisation and challenge protocol. In contrast, the 
effects of ES-62 treatment were evident within and outwith the local inflammation- 
exhibiting areas. More specifically, ES-62 inhibited antigen-specific TH2 cytokine 
production by lymphocytes near the site of inflammation, whilst modestly elevating the 
proliferation of lymphocytes in peripheral lymph nodes, distant from the site of 
inflammation. The OVA administration protocol stimulated DLN cell and splenocyte 
proliferation and this effect was not further modulated by ES-62 treatment, indicating that 
the differences observed in ex vivo cytokine production by these cells could be considered 
a selective effect of ES-62 rather than non-specific suppression. Indeed, it appeared that 
ES-62 induced inhibition of inflammation in this model by modulating the antigen-specific 
response of splenocytes and DLN cells. Furthermore, the effects of ES-62 were 
dependent upon the location of the cells within the body and, moreover, their proximity to 
(and, hence, influence on) the site of inflammation.
With the aim of analysing the systemic effects of this model of TH2-mediated 
inflammation, serum samples and sections of lymph nodes were analysed for IgE content. 
Antigen-specific IgE has an important role in facilitating TH2-type allergic inflammation
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[351] and, via the bloodstream, the allergy-inducing action of IgE is communicated around 
the body. ES-62 significantly inhibited ova-specific IgE concentration in the serum and 
appeared to reduce the level of IgE expressed in the lymph node follicles. This indicated 
that secretion and expression of the signature TH2 Ig isotype, was targeted by ES-62 
action and may underlie some of the anti-inflammatory effects observed. Indeed, anti-lgE 
therapy has been proposed for treatment of allergic disease [336, 352], supported by the 
findings that reduction of IgE leads to decreased mast cell degranulation, inhibition of 
release of inflammatory mediators and abrogation of the inflammatory cascade [351, 353]. 
Relating to this, it was interesting to note that administration of ES-62 after the onset of 
inflammation did not modulate serum IgE. This indicated that ES-62 was able to inhibit the 
development of the IgE response (exhibited with prophylactic treatment), but not reduce 
established production levels of IgE. Moreover, this difference in the action of ES-62 
between treatment protocols, suggested that ES-62 might act differently when 
administered before and after the onset of inflammation in this model of TH2-like 
inflammation. Although serum antigen-specific IgGI and lgG2a responses were exhibited 
in the asthma model mice, ES-62 treatment did not significantly modulate the production 
of either. It is well known that IgGI and lgG2a promote TH2 and TH1 immune responses 
respectively. Therefore, it is clear that ES-62 does not exert its anti-inflammatory effects in 
this model via disruption of IgG production or polarisation of the IgG response.
To begin to dissect the mechanisms of anti-inflammatory action of ES-62 in this model, 
bone marrow-derived DC were analysed. DC have been shown to expand in the lung after 
antigen challenge in this type of inflammation model [354] and are paramount in initiation 
of adaptive immune responses due to their ability to efficiently process and present 
antigen to naïve T cells [355]. Indeed, it has been demonstrated that depletion of CD11^ 
DC from a model of airway inflammation prevented development of asthma-like pathology 
[356]. It is well established that DC facilitate their communication with T cells by altering 
cell surface expression (of e.g. co-stimulatory molecules) and secreting cytokines. Indeed, 
it was recently demonstrated that modulation of surface expression on CD IIc '" antigen- 
presenting cells induces inhibition of allergic airway inflammation in mice [357]. 
Furthermore, multiple previously published studies conducted in this laboratory have 
highlighted profound immunomodulatory action of ES-62 on cytokine production and cell 
surface expression by DC [189-191]. Thus, in line with previous research, it was 
hypothesised that ES-62 may be inducing anti-inflammatory action in this model via 
modulation of this cell type. Examination of DC cultured from the short-term airway 
inflammation model revealed significant effects of ES-62 on DC phenotype. More 
specifically, DC were observed to be somewhat activated by ES-62 to produce TH1 
cytokines (such as IL-12) and appeared more mature in phenotype, exhibiting increased 
expression of cell surface markers, such as CD40, required for priming T cells. It has been
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suggested that CD40 may have a protective function in asthma development, because 
CD40-deficient mice exhibited enhanced responses in a model of airway inflammation 
[358], therefore ES-62 mediated enhancement of CD40 expression on DC may contribute 
to the anti-inflammatory effects observed in this model.
It has also previously been demonstrated that ES-62 treatment of DC in vitro (in the 
absence of any other immunomodulatory influence) promotes development of a TH2-type 
immune response [189]. This was associated with an immature phenotype of the DC, 
evidenced by low-level expression of cell surface markers and low-level production of 
TH1-promoting cytokines. Thus, by contrast, it might be hypothesised that a mature 
phenotype and enhanced production of TH1-promoting cytokines, as displayed by the DC 
derived from ES-62 treated mice in the asthma model, could promote development of a 
TH1-mediated immune réponse and polarise responses away from a TH2-phenotype. 
Therefore it might be proposed that the difference in the action of ES-62 in the asthma 
model may have been in response to the ongoing OVA-specific TH2-mediated immune 
response in these mice. However, it must be remembered that ES-62 induced these 
effects in control treatment group mice also, suggesting that it was most likely not in 
response to the effects of the existing TH2-type immune response.
Evidently, ES-62 treatment of mice in this model significantly altered the phenotype of 
bone marrow progenitor cells in vivo, resulting in modulation of the function of the cells 
that differentiated from these precursors. It may be possible to postulate that the 
increased production of IL-12 by bone marrow DC, exposed to ES-62 in vivo, led to 
inhibition of pulmonary inflammation, based on previously published research. Thus, IL-12 
has been reported to suppress allergen-induced eosinophil infiltration of the lungs [359] 
and relieve airway constriction. Furthermore, DC production of IL-12, induced by bacteria, 
or by employing adenovirus to alter DC IL-12 expression [360], alleviates TH2-faci!itated 
eosinophilic inflammation and airway hyper-reactivity in murine models of asthma. Based 
on these studies, the DC-activating action of ES-62 observed in the current investigation 
would appear to be sufficient for inhibition of pulmonary inflammation. However, this 
postulation is contradicted by the findings of Kuipers et ai [361], who demonstrated that 
LPS-induced DC-facilitated inhibition of pulmonary inflammation was independent of IL-12 
production by the DC.
Whilst ES-62 treatment of mice resulted in production of activated DC that produce 
increased levels of IL-12, the cell surface expression upregulation response of these cells 
to potent immunogenic agent, LPS, was inhibited. Furthermore, this inhibitory action was 
most pronounced in DC derived from ES-62 treated mice that had received OVA 
immunisation and challenge. This indicates that these cells might exhibit an inhibited
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response to inflammatory stimuli, in vivo, for example at the site of inflammation. Indeed, it 
has been suggested that LPS is required for TH2 sensitisation in mouse models of 
asthma [362]. Furthermore, this inhibitory action of ES-62 on the response to LPS is 
characteristic of its previously determined actions on bone marrow-derived cells in vitro 
[190], however It must be noted that in these in vivo experiments, ES-62 was 
administered subcutaneously, therefore not directly to the cells, thus the last application 
was 7 days prior to the in vitro LPS stimulation. This provides more support for the theory 
that ES-62 modulates bone marrow progenitor cells in vivo and that this modulation is 
maintained as the cells differentiate.
Nevertheless, considering the previously demonstrated anti-inflammatory effects of ES-62 
on DC phenotype in vitro and in vivo [191] it was unexpected that ES-62 treatment of the 
asthma model would induce development of DC that exhibited an enhanced cytokine 
production response to LPS in vitro. However, it might be proposed that increased 
production of THI-promoting cytokine, IL-12 by DC in response to inflammatory stimuli is 
an effect that would help to induce a THI-mediated immune response, and hence, 
polarise the immune response away from a TH2-phenotype. Thus, on a background of 
TH2-mediated inflammation, this THI-promoting action of ES-62 might be anti­
inflammatory.
The therapeutic effect of ES-62 treatment, after the onset of inflammation indicated that 
the modulatory effects of this parasite product were most likely not confined to 
manipulation of initiation of the immune response. It was more probable that ES-62 action 
also inhibited ongoing and established inflammatory effector mechanisms. Therefore, 
bone-marrow derived macrophages, effector cells that are commonly located in 
inflammatory sites and are the predominant immune effector cell resident in the alveolar 
spaces [363], were also analysed.
Clearly, the OVA administration protocol applied in this model induced modulatory effects 
on bone marrow-derived macrophage function, demonstrated by heightened production of 
inflammatory cytokines. This pattern of increased cytokine production indicated that these 
macrophages were pre-activated. Furthermore, the inhibitory effect on cytokine production 
by macrophages derived from ES-62 treated mice was reflected in ES-62-mediated 
modulation of airway inflammation in this model. Indeed, TNFa production by 
macrophages has been attributed to promotion of inflammation exhibited in asthma. 
Asthma patients often exhibit increased levels of TNFa In broncho-alveolar lavage fluid 
[364] and furthermore, increased airway TNFa levels have been associated with 
increased airway hyper-reactivity in murine models of asthma [365]. It has been 
demonstrated that the association between TNFa levels and airway inflammation arise
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because TNFa induces production of chemokines and pro-inflammatory mediators, which 
induce upregulated expression of adhesion molecules (e.g. ICAM-1 and VCAM-1) on the 
surface of epithelial cells, that in turn, leads to recruitment of leukocytes to the airways 
[366]. Thus, the TNFa-reducing effect of ES-62 on macrophages may be anti­
inflammatory in this model of airway inflammation. However, the overall reduction of 
cytokine production by macrophages derived from ES-62 treated mice in this model 
indicates that these cells are most likely, less activated. Nevertheless, as macrophages 
form an important component of inflammation induction in this model, a reduced activation 
status might also induce anti-inflammatory effects.
It was interesting that this action of ES-62 on macrophage cytokine production was 
opposite to the observed effects on bone marrow derived DC, indicating that ES-62 action 
on bone marrow progenitor cells in this model does not necessarily induce identical 
effects on the cell types into which they differentiate. However, it is well established that 
as part of an immune response, DC and macrophages fulfil different roles. For example, 
DC are a fundamental cell type for initiation of an immune response, by priming antigen- 
specific T cells, whilst macrophages are well-established innate cell type, with important 
roles in mediation of inflammation at the inflammatory site. In other words, whilst the roles 
of DC and macrophages within the immune system can overlap, DC are generally 
considered to be involved in immune response initiation, whilst macrophages are 
considered effector cells. Thus, it is perhaps logical that ES-62 mediates different actions 
on these cells. Such different actions may represent the respective effects of ES-62 on 
the initiation and effector mechanisms of this model, which have been depicted in Figure
4.22 and Figure 4.23.
4.3.2 The airway inflammation model does not exhibit structural changes 
associated with human asthma
It is well documented that the reversible inflammation exhibited in human asthma Is 
accompanied by irreversible and progressive pathological changes in the lungs such as 
airway fibrosis, hyperplasia of smooth muscle and goblet cells and narrowing of the 
airways. However, it remains a matter of debate whether the irreversible changes in the 
airways induce the periods of reversible acute airway hyper-reactivity and inflammation or 
vice versa [367]. Nevertheless, it is generally accepted that the structural changes 
exhibited do exacerbate the effects of an acute attack of inflammation in asthma.
Using myography, tracheal smooth muscle contractility in the asthma model was 
compared with that of control mice. It was found that the short-term model of airway 
inflammation did not exhibit obvious associated changes in such smooth muscle
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contractility. It has, however, recently been identified, using a murine model, that hyper­
responsiveness of airway smooth muscle in asthma is exhibited by bronchial, but not 
tracheal smooth muscle [368]. Therefore, because tracheal smooth muscle was analysed 
in this model, this may have been the reason for this negative outcome. The myography 
apparatus used was not designed for analysis of airways smaller than murine trachea, 
however future investigations might prove more informative by examining smaller airways 
from the pulmonary tree in this model.
Nevertheless, this finding indicated that smooth muscle hyperplasia or hypertrophy was 
most likely not exhibited in the trachea of these mice. Furthermore, it can be inferred that 
inflammation In this model developed in the absence of prior airway smooth muscle 
pathology. However, it might be postulated that if the inflammation were allowed to 
continue in this model, prolonged exposure to inflammation may induce smooth muscle 
pathology, as exhibited in human asthma [84]. Prophylactic ES-62 treatment did not 
modulate the contractility of airway smooth muscle in this model either, indicating that the 
effects of ES-62 on pulmonary inflammation were exclusively immunological.
4.3.3 Differences in immunology between short-term and longer-term 
pulmonary Inflammation models
To better represent the immunology underlying prolonged pulmonary inflammation in 
asthma, the short-term airway inflammation model was extended, with the aim of inducing 
structural remodelling of the airways. Analysis of the immunology in this model revealed 
many similarities when compared and contrasted with the previous model of acute 
pulmonary inflammation. Thus, splenocytes from both models secreted IL-5, IL-4 and IL- 
10 in response to OVA re-stimulation in vitro, highlighting the TH2 nature of the 
inflammation in both models. Additionally, the ovalbumin administration protocol induced 
secretion of antigen-specific IgGI, lgG2a, IgE and total IgE in both models. Thus, it 
appeared that increasing the period of administration of the OVA Inflammation-induction 
protocol did not modulate the nature of the antigen-specific immune response that was 
generated. However, there were some differences observed when bone marrow-derived 
DC from both studies were compared. In contrast to the findings in the short-term model, 
bone marrow-derived DC from the chronic inflammation model exhibited reduced DC 
surface marker expression, yet increased spontaneous IL-12 production in response to 
the extended ovalbumin protocol in vivo. By contrast, DC from OVA-treated (fibrosis 
treatment group) mice in the chronic model exhibited reduced cell surface expression and 
THI-promoting cytokine response to LPS in vitro. Thus, modulation of bone marrow- 
derived DC phenotype was sensitive to chronicity of OVA application in vivo, it has 
previously been identified that DC phenotype is pivotal in communication of the immune 
response throughout the circulation and hence, the secondary lymphoid organs, where
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immune responses are generated. Moreover, DC generally secrete mainly TH1-promoting 
cytokines or anti-inflammatory cytokines such as IL-10, hence prolonged reduction of 
THI-promoting cytokine production by these cells in vivo may promote development of a 
TH2 immune response by T cells that activated DC communicate with. Indeed, ES-62- 
treated DC derived from naïve mice have been shown to promote development of a TH2 
immune response [189]. Furthermore, DC derived from naïve mice that were pre-treated 
with ES-62 in vivo or in vitro exhibit inhibited LPS-induced production of pro-inflammatory 
cytokines and reduced spontaneous expression levels of co-stimulatory molecules [189, 
191]. Thus, DC derived from OVA-treated mice in the chronic airway inflammation model 
also appear to exhibit this ‘DC2’ phenotype. However, in this model, ES-62 action appears 
to change the phenotype of the DC to become mature and hence, less TH2-promoting.
4.3.4 The modulatory action of ES-62 is altered in the chronic pulmonary 
inflammation model.
As discussed in section 4.2.12, loss of the mice in the long-term inflammation model led to 
a restricted capacity for comparison of the immunology between acute and chronic airway 
inflammation models. Nevertheless, it was an interesting observation that the majority of 
mice in the fibrosis group had to be removed from the study due to the severity of the 
inflammation protocol, whilst the mice treated with ES-62 all maintained a level of health 
consistent with continuation of the study to completion. This observation indicated that 
ES-62 treatment reduced the severity of the inflammation induced or delayed the onset of 
terminal pathology in this model. Given that the immune response and action of ES-62 on 
splenocytes from the short term model was similar to that observed upon analysis of DLN 
cells, It was concluded that (in the absence of sufficient DLN cell numbers) analysis of 
splenocytes from the longer-term model could provide appropriate information about the 
local OVA-specific immune response generated in this model.
As with the acute ‘Asthma’ model, ES-62 modulated the immune response observed in 
the longer-term model of airway inflammation. Unlike its inhibitory action in the short-term 
model, however, ES-62 treatment induced promotion of splenocyte antigen-specific TH2 
cytokine production in the longer-term model. This change in action suggested that the 
function of ES-62 in each model was different. Furthermore, it also suggested that ES-62 
action on splenocyte antigen-specific responses is dependent upon chronicity of 
inflammation.
At first sight, these results might appear counter-intuitive as it might be postulated that 
promotion of TH2 cytokine production in a model of TH2-mediated inflammation would 
enhance severity of the inflammation, however it has recently been demonstrated that 
parasite-mediated inhibition of TH2-type pathology was associated with increased
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production of certain TH2 cytokines [369]. More specifically, in a model of allergen- 
induced airway hyper-reactivity (AHR), infection with non-egg laying Schistosom a  
mansoni reduced development of AHR and It was demonstrated that the inhibitory effect 
was associated with elevated production of antigen-specific IL-4 and IL-10. In addition, the 
TH2-like cytokine, IL-10, can act as an anti-inflammatory cytokine, to counteract 
inflammation-promoting production of TH2 cytokines. Thus, recently it was demonstrated 
that CD4^CD25^ regulatory T cells function to reduce AHR in an IL-10-dependent 
mechanism [370]. Therefore, ES-62 mediated promotion of antigen-specific IL-4, IL-5 and 
IL-10 production in the long-term inflammation model does not necessarily reflect 
enhancement of severity, and may even indicate amelioration of disease. Indeed, the 
reduced mortality of ES-62 treated mice in this model would support the latter theory.
The inhibitory action of ES-62 treatment on the levels of antigen-specific serum IgE in the 
asthma model was maintained in the chronic model, indicating that ES-62 targets the 
antigen-specific IgE-mediated immune response In both models, independent of chronicity 
of inflammation. In the longer-term inflammation model, serum analysis uncovered 
additional inhibitory action of ES-62 on IgG antibody response development. More 
specifically, ES-62 treatment reduced OVA-specific (TH2-type) IgGI in the chronic, but 
not the acute model of airway inflammation. This difference indicated that longer 
application of ES-62 might be required to induce a change In antigen-specific IgG 
secretion/metabolism or that this action of ES-62 was only induced in response to the 
chronic inflammation. It is of notable interest that the inhibitory effect of ES-62 on antigen- 
specific IgG is on the IgGI isotype, indicating that ES-62 preferentially targets this IgG 
isotype despite elevating TH2 cytokines in this model. Thus, in the chronic inflammation 
model, ES-62 targeted production of IgE, an inflammatory TH2-isotype antibody and 
IgGI, the hallmark antibody isotype of TH2-mediated immune responses.
As mentioned previously, it was clear that the longer-term OVA administration protocol 
induced distinct effects on DC phenotype that had not been observed in the short-term 
acute model. These effects were partially reversed by prior ES-62 exposure in vivo. Thus, 
as mentioned above, DC derived from the chronic inflammation model spontaneously 
secreted elevated quantities of IL-12 and reduced IL-10 compared to control cells. This 
increased IL-12 production was not displayed by DC from ES-62 treated mice. Thus, in 
this model, ES-62 is acting in an inhibitory low level, manner on spontaneous TH I- 
promoting cytokine production. By contrast, although production of IL-12, TNFa and IL-10 
was increased when DC were stimulated with LPS in vitro, ihe level of production was 
inhibited in DC from OVA-treated mice relative to that observed with DC from control 
treatment group mice. Under these conditions, the inhibited TH1 cytokine response (IL-12 
and TNFa but not IL-10) to LPS was overcome by pre-exposure to ES-62 in vivo. Thus,
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exposure to ES-62 appears to act to normalise the modulated spontaneous cytokine 
production of the DC derived from OVA treated mice and it also normalises the cytokine 
response of these cells to inflammatory stimuli. The discussed effects of ES-62 in the 
longer-term model of airway inflammation are summarised in Figure 4.24.
4.3.5 The role of ST2 in the pathogenesis of ionger term pulmonary 
inflammation
As mentioned above (Section 4.1.3), ST2 is a gene encoding two proteins [371], which act 
to promote a TH2-mediated immune response [372], however, the precise nature of ST2 
action or function is yet to be fully elucidated. ST2 action in an acute model of asthma has 
been studied by Hoshino et al [343] and found to be non-essential for initiation of allergen- 
induced airway inflammation. Parallel development of the long-term pulmonary 
inflammation model in ST2 knock-out mice revealed clues about a potential 
immunological role of ST2 in initiation of this type of inflammation. Firstly, the increased 
mortality of wild-type mice following administration of the longer-term OVA protocol, was 
not exhibited in ST2-deficient mice subjected to the same protocol, indicating that the 
pulmonary inflammation induced may not have been as severe in the ST2-deficient mice. 
Moreover, and consistent with the findings of Hoshino et al, no reduction of antigen- 
induced TH2 cytokine production was observed in the ST2-deficient chronic airway 
inflammation model. In fact, splenocytes from ST2-deficient mice consistently secreted 
f7/gr/?er concentrations of OVA-specific IL-4, IL-5, IL10 and TNFa ex wVo than splenocytes 
from wild-type mice, indicating that the antigen-specific cytokine response in was more 
potent in the former than in the latter.
Interestingly, serum analysis revealed that ST2-deficient mice developed significantly 
higher levels of antigen-specific (TH1-isotype) lgG2a and lower levels of antigen-specific 
IgE in this inflammation model, when compared with the wild-type model mice. The effects 
of ST2 knock-out on serum Ig contradicted the findings of Townsend et al, [341] who 
demonstrated that serum antibody isotype profiles, in a model of TH2-mediated 
pulmonary granuloma, were similar in their comparison of ST2-deflcient and wild-type 
mice. In the current investigation, the observed difference in antibody response indicated 
that although there is evidence of both antigen specific IgGI and lgG2a antibody 
responses, ST2-deficient mice appear to be mounting a less TH2-polarised response (as 
exhibited in the wild type mice) in response to OVA administration, evidenced by a 
reduced IgE response. A compensatory enhanced TH1 immune response is consistent 
with the findings of another study, which observed that blockade of ST2 exacerbated TH I- 
mediated inflammation in a model of arthritis [337]. It has been suggested that whilst ST2 
is not necessary for TH2 cell differentiation, it is necessary for regulation of TH1 mediated 
immune responses [361], which would support the findings presented in this chapter; i.e.,
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development of a more TH1-polarised serum Ig response by ST2-deficient mice in a 
model of TH2-mediated inflammation. Indeed, TH2-mediated cytokine production was 
maintained in the absence of ST2, but TH1-mediated secretion of lgG2a was not reduced 
as it is in the wild-type chronic inflammation model. In conclusion, it appeared that 
despite continued ability to generate antigen-specific TH2 cytokines and antibody 
responses, ST2-deficient mice seemed less able to prevent development of a TH1-type 
antibody response.
Continuing analysis of the immunology underlying the long-term pulmonary inflammation 
model, bone marrow-derived DC were cultured in vitro from each treatment group in the 
ST2-deficient model. Comparison of bone marrow-derived DC analyses revealed few 
differences between models, in terms of the role of ST2. Apart from modestly elevated 
TNFa production by DC derived from ST2-deficient mice, DC from OVA-treated wild-type 
and ST2K0 mice exhibited similar cytokine production and surface expression profiles 
under control and LPS conditions in vitro. Nevertheless, although it was a small effect, the 
absence of ST2 expression in the fibrosis model mice appeared to prevent the 
development of DC with a slightly immature phenotype in response to the OVA- 
administration protocol. This suggests that the ‘immaturing’ effect of OVA immunisation on 
resultant DC phenotype in the chronic inflammation model may be ST2-dependent. 
Indeed, a DC2 phenotype (induced by ES-62 treatment of bone marrow DC in vitro), 
which normally induces priming of a TH2-type immune response, has been described as 
immature, evidenced by low-level expression of co-stimulatory and adhesion molecules 
[189]. Thus, if an 'immature' DC phenotype leads to induction of TH2-type immune 
responses, perhaps prevention of this immature phenotype would polarise the resultant 
immune response away from a TH2-phenotype, resulting in reduced TH2-type 
inflammation, which would support the survival-promoting effects of ST2 knock-out in this 
mode.
4.3.6 The relationship between ES-62 and ST2 in the long-term pulmonary 
inflammation model.
As mentioned in Section 4.1.5 it was proposed to determine whether ES-62-mediated 
action in the model of chronic airway inflammation was mediated by, or associated with, 
ST2 expression. Provided the ST2-dependent features of the chronic airway inflammation 
model (discussed above) are taken into account, comparison of the effects of ES-62 in the 
wild-type and ST2-deficient models will help to achieve this aim.
As mentioned previously, the survival rate of ST2-deficient fibrosis model mice was 
greater than that of wild-type fibrosis mice. In addition, treatment of wild-type fibrosis 
model mice with ES-62 also appeared to promote survival. Thus, it appears that treatment
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with ES-62 o r  knock-out of ST2 have anti-inflammatory action in this model of 
inflammation. Hence, it might be proposed that in wild-type mice, ES-62 could act to block 
the action of ST2. In addition, treatment of wild-type fibrosis model mice with ES-62 
resulted in promotion of antigen-specific IL-4, IL-5 and IL-10 production by splenocytes 
from these mice ex wVo, an effect also apparently induced by knock-out of ST2. 
Therefore, again, it appears that treatment of wild-type mice with ES-62 induced similar 
effects to knock-out of ST2. Furthermore, ES-62 treatment of fibrosis model mice in the 
wild-type model or removal of the ST2 gene both resulted in decrease of OVA-specific IgE 
production and differentiation of DC with enhanced surface marker expression
Nevertheless, ES-62-mediated promotion of antigen-specific cytokine production ex vivo 
was similar in splenocytes from wild-type and ST2-deficient mice, indicating that ES-62- 
mediated promotion of TH2 cytokine production in the longer-term inflammation model 
was ST2“independent. In contrast, ES-62-mediated inhibition of IgGI TH2-type antigen- 
specific antibody responses was not maintained in ST2-deficient mice. More specifically, 
inhibition of OVA-specific IgGI and IgE production by ES-62 treatment in the wild-type 
model was not exhibited in the ST2-deficient model, demonstrating the role of ST2 in 
mediating this inhibitory action of ES-62. However, it must be considered that the OVA- 
specific IgE response was not fully developed in the ST2-deficient model, therefore it 
could be postulated that, in this case, the loss of ES-62-mediated inhibition of IgE levels 
simply reflected the inability to further reduce the defective production of IgE in ST2KQ 
mice. Nevertheless, the lost ability of ES-62 to reduce antigen-specific IgGI in ST2- 
deficent mice was clear.
Down-regulation of surface marker expression by DC was observed in ES-62 treated ST2- 
deficient fibrosis model mice. This down-modulatory action of ES-62 was opposite to that 
exhibited in the wild-type model (and moreover, in the acute model), thus, it might be 
proposed that these actions of ES-62 were normalising and acted to ‘correct’ the effect of 
OVA-treatment on DC phenotype. However, it is also possible that the upregulatory effect 
of ES-62 in the wild-type model was ST2-dependent. Based on the treatment groups 
available, it is not clear which theory is true, Furthermore, it must be re-iterated that the 
exhibited effects on DC phenotype were modest.
ES-62 mediated rescue of the ameliorated TH1 cytokine response to LPS by DC from the 
wild type model was not exhibited in ST2K0 model DC, initially indicating that ST2 might 
be involved in this cytokine modulating action of ES-62. Indeed, recently it has been 
demonstrated that the cytokine production response to LPS by DC is dependent upon 
ST2 [373]. However in this investigation, the DC derived from the wild-type fibrosis model 
mice also exhibited a reduced cytokine production response to LPS, therefore the effect of
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ST2-knock out on the cytokine response to LPS in DC cannot be confirmed. 
Nevertheless, it has also been demonstrated that ES-62 mediated modulation of LPS- 
induced cytokine production by DC is not transduced by ST2 [374].
In summary, ES-62 action is different in ST2-expressing and ST2-deficient models of 
OVA-induced airway inflammation. As it has previously been determined that ES-62 does 
not act via ST2 [374] it is hypothesised that these distinct actions might be induced as a 
result of the different immune response to the inflammation induction protocol in wild-type 
and ST2K0 mice.
4.3.7 Conclusion
The findings presented in this chapter have highlighted novel actions of ES-62 in models 
of TH2-mediated inflammation. For the first time it has been demonstrated that ES-62 
inhibits eosinophilic airway inflammation when administered during development of the 
inflammatory immune response or when used to treat established inflammation. It has 
previously been demonstrated that infection with Strongyloides stercoralis or treatment 
with an extract of A. suum inhibits development of airway inflammation in mice [375, 376]. 
The anti-inflammatory action of ES-62 in the short-term model of airway inflammation was 
associated with inhibition of antigen-specific TH2-type cytokine and antibody responses 
and provides support for the previous studies citing anti-inflammatory action of parasites 
in this type of inflammation, despite their TH2-promoting activation per se. Furthermore, it 
was observed that ES-62 modulated the phenotype and function of bone marrow-derived 
cells by treatment of bone marrow progenitors in vivo. Consistent with the findings of 
Chapter 3, it appears that rather than preventing development of an immune response, 
ES-62 tailors the development of immunity to result in a less inflammatory response. It is 
possible that this action may be mediated by disruption of the normal function of bone 
marrow-derived innate immune cells, which leads to disruption of the ensuing adaptive 
immune response as a whole.
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Figure 4.1 Eosinophilia induced by ovalbumin, is suppressed by ES-62
BALB/c mice sensitised with OVA were challenged intranasally on days 14, 25, 26 and 
27. ES-62 (2 |jg) was administered on days -2 , 12, 25 and 27 and control mice received 
PBS. Mice were sacrificed on day 28 and broncho-alveolar lavage (BAL) performed as 
described in Chapter 2. A, Differential counts of cells present in the BAL fluid were 
conducted for each mouse. The numbers of macrophages, eosinophils, lymphocytes, 
neutrophils and epithelial cells were determined and displayed as a percentage of the 
total cell count. Data are expressed as mean ± SEM (n=6 mice/group). B, Eosinophil 
count data are expressed as mean ± SEM {n=6 mice/group). These results are 
representative of at least three independent experiments. ***p<0.001 vs. Control. **p<0.01 
vs Asthma (ANOVA).
C-F Intact lungs were carefully dissected from mice in each treatment group and fixed in 
formalin. Sections of lung tissue from Control (C), Asthma (D) and Asthma+ES-62 (E) 
mice were stained using H & E staining and viewed using a xIO objective. F, The peri­
bronchial infiltrate was scored 1=normal, 2=mild, 3=moderate and 4=severe, by scanning 
100 random bronchial walls in sufficient high power fields and data are expressed as 
mean ± SD (n=100). ***, p<0.001 vs Control; t .  p<0.001 vs Asthma using the Mann- 
Whitney U test.
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Figure 4.2 Ovalbumin-induced airway TH2 cytokine production inhibited by 
ES-62
BALB/c mice sensitised with OVA were challenged intranasally on days 14, 25, 26 and 
27. ES-62 (2 |jg) was administered on days -2 , 12, 25 and 27 and control mice received 
PBS. Mice were sacrificed on day 28 and broncho-alveolar lavage (BAL) performed as 
described in Chapter 2. The concentration of IL-4 (A), IL-5 (B) and IFN7 (0) in the BAL 
fluid was analysed for each mouse by ELISA. These results are representative of at least 
three independent experiments. BAL fluid cytokine concentrations are depicted as 
individual values for each mouse, and the bar represents the treatment group mean. ***, 
p<0.001(by ANOVA).
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Figure 4.3 ES-62 treatment in vivo inhibits draining lymph node cell antigen- 
specific TH2 cytokine production but not antigen-specific proliferation ex
vivo
Mice were treated and sacrificed as described in the legend to Figure 4.1 and thoracic 
and cervical lymph nodes from each mouse removed. Lung draining lymph node cells 
from mice in each group (n=6/group) were pooled and cultured in triplicate with medium 
alone (Control) or OVA (Ova; 500 pg/ml) for 72h. T cell proliferation was assayed by 
uptake of [^H] thymidine in the last 8 hours of culture (A). Proliferation data are expressed 
as mean ± SD of triplicate cultures and are representative of 3 experiments * p<0.05 by 
ANOVA, t  p<0.001 vs Control or ES-62. Culture supernatant concentrations of IL-4 (B), 
IL-5 (C), IFN7 (E) and TNFa (F) were measured by Luminex. Luminex data is expressed 
as the mean of duplicate samples from the supernatant of pooled cells and are 
representative of 3 experiments. Culture supernatant concentrations of IL-10 (D) were 
measured in triplicate by ELISA from supernatant of pooled cells and data are expressed 
as mean ± SD and are representative of 3 experiments. ***, p<0.001 vs Asthma treatment 
group.
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Figure 4.4 ES-62 treatment in vivo does not modulate mitogen-specific TH2 
cytokine production from draining lymph node cell ex vivo
Mice were treated and sacrificed as described in the legend to Figure 4.1 and lung 
draining lymph node cells from mice in each group (n=6/group) were pooled and cultured 
with medium alone (Control) or ConA (3 pg/ml) for 72h. T cell proliferation was assayed 
by uptake of [^H] thymidine in the last 8 hours of culture (A). Proliferation data are 
expressed as mean ± SD and are representative of 3 experiments. Culture supernatant 
concentrations of IL-4 (B), IL-5 (C), IFNy (E) and TNFa (F) were measured by Luminex. 
Luminex data is expressed as mean of duplicate samples from the supernatant of pooled 
cells and are representative of 3 experiments. Culture supernatant concentrations of IL-10 
(D) were measured in triplicate by ELISA from supernatant of pooled cells and data are 
expressed as mean ± SD and are representative of 3 experiments. No statistical 
difference in proliferation or cytokine production was observed between cultures from 
Asthma and Asthma+ES-62 treatment groups.
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Figure 4.5 ES-62 treatment in vivo modulates antigen-specific TH2 cytokine 
production by splenocytes ex vivo
Mice were treated and sacrificed as described in the legend to Figure 4.1 and spieen from 
each mouse was removed. Splenocytes from mice in each group (n=6/group) were pooled 
and cultured with medium alone (Control) or OVA (Ova; 500 pg/ml) for 72h. T cell 
proliferation was assayed by uptake of [^H] thymidine in the last 8 hours of culture (A). 
Proliferation data are expressed as mean ± SD of triplicate cultures and are 
representative of 2 experiments, ***, p< 0.001 vs control conditions. Culture supernatant 
concentrations of IL-4 (B), IL-5 (C), IL-10 (D), and IFNy(E) were measured by Luminex. 
Luminex data is expressed as mean of duplicate samples from supernatant of pooled 
cells and are representative of 2 experiments. Culture supernatant concentrations of 
TNFa (F) were measured in triplicate by ELISA from supernatant of pooled cells and data 
are expressed as mean ± SD and are representative of 3 experiments, **, p< 0.01 vs. 
Asthma treatment group.
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Figure 4.6 ES-62 treatment in vivo does not modulate mitogen-induced TH2 
cytokine production by splenocytes ex vivo
Mice were treated and sacrificed as described in the legend to Figure 4.1 and splenocytes 
from mice in each group (n=6/group) were pooled and cultured with medium alone 
(Control) or ConA (3 pg/ml) for 72h. T ceil proliferation was assayed by uptake of [^H] 
thymidine in the last 8 hours of culture (A). Proliferation data are expressed as mean ± SD 
of triplicate cultures and are representative of 3 experiments. Culture supernatant 
concentrations of IL-4 (B), IL-5 (C) and IFNy (E) were measured by Luminex. Luminex 
data is expressed as mean of duplicate samples from the supernatant of pooled cells and 
are representative of 3 experiments. Culture supernatant concentrations of IL-10 (D) and 
TNFa (F) were measured in triplicate by ELISA from supernatant of pooled cells and data 
are expressed as mean ± SD and are representative of 3 experiments. No statistical 
difference in proliferation or cytokine production was observed between cultures from 
Asthma and Asthma+ES-62 treatment groups.
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Figure 4.7 Exposure to ES-62 in vivo promotes peripheral lymph node cell 
proliferation and TH2 cytokine production ex vivo
BALB/c mice were treated and sacrificed as described in the legend to Figure 4.1 and 
non-draining lymph nodes from each mouse removed. Lymph node cells from mice in 
each group (n=6/group) were pooled and cultured with medium alone (Control) or OVA 
(Ova; 500 pg/ml) for 72h. T cell proliferation was assayed by uptake of [^H] thymidine in 
the last 8 hours of culture (A). Proliferation data are expressed as mean ± SD of triplicate 
cultures and are representative of 2 experiments. ***, p<0.001 vs Control treatment group;
p<0.001 vs Asthma treatment group. Culture supernatant concentrations of IL-4 (B), IL- 
5 (C) and IFNy (E) were measured by Luminex. Luminex data is expressed as mean of 
duplicate samples from the supernatant of pooled cells and are representative of 2 
experiments. IL-10 (D) and TNFa (F) were measured in triplicate by ELISA from 
supernatant of pooled cells and data are expressed as mean ± SD and are representative 
of 2 experiments. No statistical difference in cytokine production was observed between 
cultures from different treatment groups.
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Figure 4.8 Exposure to ES-62 in vivo does not modulate Ova-induced 
elevation of serum lgQ1 and lgG2a but inhibits serum IgE
A-D, BALB/c mice were treated and sacrificed as described in the legend to Figure 4.1. 
Serum samples from each mouse were obtained on day 28 and diluted with 10% PCS 
(1/200). Diluted samples were analysed by ELISA for OVA-specific IgE (A), total IgE (B), 
OVA-specific IgGI (C) and lgG2a (D). Data for each group are presented as mean ± SD 
(n=6 mice/group) and are representative of 3 experiments. **, p<0.01 vs Asthma group by 
Student’s t-test; no significant difference was observed in serum IgG levels between 
Asthma and Asthma+ES-62 treatment groups.
Panel E, IgE expression in lymph node follicles is induced by ovalbumin. Intact lymph 
nodes from each treatment group were snap frozen in liquid nitrogen and stored at -80®C. 
Frozen lymph nodes were cut into 6 |im sections and stained with anti-B220-FITC and 
anti-lgE-AF647. Sections were focused in the bright field and then viewed using red and 
green filters to pick up IgE and B220 signals respectively. B220 and IgE signal images 
were colourised according to their staining signal colour.
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Figure 4.9 ES-62 inhibits Ova-induced pulmonary eosinophilïa in a dose- 
dependent manner, when administered therapeutically
A, BALB/c mice were sensitised with OVA and challenged with OVA intranasally on days 
14, 26, 26 and 27. ES-62 (0.4 pg, 2 pg or 10 pg) was administered only on days 25, 26 
and 27 and control mice received PBS. Mice were sacrificed on day 28 and BAL 
performed as described in Chapter 2. Differential cell counts were conducted for each 
mouse and data for eosinophils are expressed as mean ± SD (n=6 mice/group). Data are 
from a single experiment representative of 2 experiments. *, p< 0.05 by ANOVA.
Panels B & C, Thoracic and cervical lymph nodes were removed from each mouse. Lung 
draining lymph node cells from mice in each group were pooled and cultured with medium 
alone (Control) or OVA (OVA; 100 pg/ml) for 72h. IL-4 (B) and IL-5 (C) released from DLN 
cells in response to stimulation with OVA ex vivo were analysed by ELISA from duplicate 
cultures. All data are from a single experiment representative of 2 experiments.
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Figure 4.10 Therapeutic administration of ES-62 does not significantly 
modulate serum ova-specific IgE, IgG or total IgE
Mice were treated and sacrificed as described In the legend to Figure 4.9. Serum samples 
from each mouse were obtained on day 28 and diluted with 10% FBS (in PBS; 1/200). 
Diluted samples were analysed by ELISA for OVA-speclfic IgE (A), total IgE (B), OVA- 
specific lgG1 (0) and lgG2a (D). Data for each group are presented as mean ± SD (n=6 
mice/group) and are representative of 2 experiments. No statistical differences between 
serum Ig levels were observed in Asthma and Asthma+ES-62 treatment group mice.
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Figure 4.11 Ovalbumin-induced pulmonary inflammation (or ES-62 treatment 
of such) does not modulate airway smooth muscle contractility
BALB/c mice were treated and sacrificed as described in the legend to Figure 4.1 and 
trachea from each mouse carefully micro-dissected. Using a large vessel myograph, 
tracheal rings from each treatment group were analysed for contractile response to 
cumulative concentrations of methacholine (10'^°M to 10'^M). Results are depicted as the 
mean ± SEM of percentage of the maximum response to KCI {n=2 at least). No statistical 
difference was observed between treatment groups.
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Figure 4.12 The cytokine production profile of splenocytes from the chronic 
airway inflammation model ex vivo: wild-type vs ST2-deficient mice
BALB/c (wild-type; A-E) and S T 2  knock-out (S T 2K 0 ; F-J) mice w ere  sensitised with O V A  
and challenged with O V A  Intranasally (O V A  i.n.) on day 14 (50[xg) and once every seven  
days until day 56 (2pig). E S -6 2  treatm ent (2[xg) w as adm inistered subcutaneously two  
days before and on the day of O V A  administration and control m ice received PBS. Mice  
w ere sacrificed on day 57 and the spleen w as rem oved from each m ouse. Splenocytes  
from mice In each group w ere  pooled and cultured with m edium  alone (Control), O V A  
(500  pg/ml) or Con A (5 pg/m l) for 72h. T he  concentrations of IL-4 (A, F), IL-5 (B, G), IL- 
10 (0 , H), TNFa (D, I) and IL-12 (E, J) In the culture supernatant w ere  m easured by 
ELISA. ELIS A  data are  expressed as m ean ±  S D  (n=3). ***, p<0.001 vs Fibrosis; ++, 
p<0.01 and +, p < 0 .05  vs w ild -type control (S tudent’s t-test). Production of all five  
cytokines In response to O V A  treatm ent in vitro w as significantly greater by splenocytes  
from S T2K O  Fibrosis model mice than their counterparts from the wild-type model (p<0.01  
at least).
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Figure 4.13 Ovalbumin-specific serum IgG and IgE levels in the wild-type 
chronic airway inflammation model are inhibited by ES-62 treatment and 
modulated in the absence of ST2
BALB/c and ST2-deficient mice were treated and sacrificed as described in the legend to 
Figure 4.12. Serum samples from each mouse were obtained on day 57 and titrated with 
10% FBS (in PBS; 1/200). Diluted samples were analysed by ELISA for OVA-speclfic 
IgGI (A), lgG2a (B), IgE (C) and total IgE (D). Data for each group are presented as mean 
± SD {n=2 mice for WT Fibrosis group, n=6 mice for other groups). Statistical differences 
are as follows: OVA-lgG1: p<0.001,wild-type fibrosis vs wild-type fibrosis +ES-62. OVA- 
lgG2a: p<0.01 wild-type fibrosis vs wild-type fibrosis+ES-62 and p<0.05 wild-type fibrosis 
vs ST2K0 Fibrosis. OVA-lgE: p<0.05 wild-type fibrosis vs wiid-type fibrosis +ES-62. No 
statistical differences were observed in serum ig levels between ST2KO Fibrosis and 
ST2KO Fibrosis +ES-62 mice.
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Figure 4.14 The ex vivo cytokine production profile of draining and 
peripheral lymph node cells from the chronic airway inflammation model In 
ST2-deficient mice
ST2-deficient mice were treated and sacrificed as described in the legend to Figure 4.12. 
Thoracic and cervical lung-draining lymph nodes (DLN; A-E) and non-draining (peripheral) 
lymph nodes (PLN, F-1) from each mouse were removed. DLN and PLN cells from mice 
in each group were pooled and cultured with medium alone (Control), OVA (Ova; 500 
pg/ml) or Con A (5 ^g/ml) for 72h. Culture supernatant concentrations of IL-4 (A), IL-5 (B, 
F), IL-10 (C, G), IL-12 (D, H) and TNFa(E, I) were measured by ELISA. ELISA data are 
expressed as mean ± SD (n=3). *, p<0.05; **, p<0.01 and ***, p<0.001 vs corresponding 
cells from fibrosis group mice.
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Figure 4.15 ES 62 treatment of the ovalbumin-induced asthma model in vivo 
modulates bone marrow-derived dendritic cell surface marker expression
BALB/c mice were treated and sacrificed as described in the legend to Figure 4.1 and 
femoral bone marrow from each mouse was removed. Bone marrow-derived DC were 
cultured in vitro for 7 days and stimulated with media (panel A) or LPS (l^ig/ml; panel B) 
for 24h. Expression of MHCII, CD40, CD54, CD80 and CD86 on CD11c+ DC was 
analysed by flow cytometry. Data were gated on the C D IIc^ population and expressed as 
histograms depicting the expression level of the surface marker versus the number of 
cells, as a percentage of the maximum C D IIc^ cell number. Data are representative of 2 
independent experiments.
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Figure 4.16 ES-62 treatment of the ovalbumin-induced asthma model in vivo 
modulates bone marrow-derived dendritic cell production of TH1-promoting 
cytokines
BALB/c mice were treated and sacrificed as described in the legend to Figure 4.1. 
Femoral bone marrow from each mouse was removed and pooled by treatment group. 
Bone marrow-derived DC were cultured in vitro for 7 days and stimulated with media 
(panel A) or LPS (1|a,g/ml: panel B) for 24h. Culture supernatants were analysed for IL-12 
and TNFaby ELISA. ELISA data are expressed as mean ± SD (n=3) and are 
representative of 2 independent experiments. ***, p<0.001 ES-62 vs Control and Asthma 
vs Asthma+ES-62: **, p<0.01 vs Control; *, p<0.05 vs Asthma.
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Figure 4.17 The effects of ES-62 treatment of the ovalbumin-induced chronic 
airway inflammation model in vivo on bone marrow-derived dendritic cell 
surface marker expression
BALB/c mice were treated and sacrificed as described in the legend to Figure 4.12 and 
femoral bone marrow from each mouse was removed. Bone marrow-derived DC were 
cultured in vitro for 7 days and stimulated with media or LPS (1|ig/ml, Panel B) for 24h. 
Expression of MHCII, CD40, CD54, CD80 and CD86 on CD11c+ DC was analysed by 
flow cytometry. Data were gated on the CD IIc '" population and expressed as histograms 
depicting the expression level of the surface marker versus the number of cells, as a 
percentage of the maximum CD11c^ cell number. A histogram of non-stained control DC 
is plotted for comparison.
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Figure 4.18 Dendritic cells derived from the chronic inflammation model 
display a modulated TH1-promoting cytokine production profile that is 
rescued by ES-62 exposure in vivo
BALB/c mice were treated and sacrificed as described in the legend to Figure 4.12 and 
femoral bone marrow from each mouse removed. Bone marrow-derived DC were cultured 
in vitro for 7 days and stimulated with media (panel A) or LPS (l^g /m l; panel B) for 24h. 
Culture supernatants were analysed for TNFa, IL-12 and IL-10 by ELISA in triplicate 
wells. ELISA data are expressed as mean ± SD (n=3). *, p<0.05 vs wild-type control; **, 
p<0.01 vs wild-type control; ***, p<0.001 vs wild-type control; $, p<0.01 vs wild-type 
fibrosis (by AN OVA).
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Figure 4.19 The effect of ES-62 exposure in vivo on the surface expression 
profile of dendritic cells from ST2-deficient chronic inflammation model mice
ST2-deficient mice were treated and sacrificed as described in the legend to Figure 4.12 
and femoral bone marrow from each mouse was removed. Bone marrow-derived DC were 
cultured in vitro for 7 days and stimulated with media (panel A) or LPS (1|uig/ml; panel B) 
for 24h. Expression of MHCII, CD40, CD54, CD80 and CD86 on CD11c+ DC was 
analysed by flow cytometry. Data were gated on the C D I I ^  population and expressed as 
histograms depicting the expression level of the surface marker versus the number of 
cells, as a percentage of the maximum CDIIc"" cell number. A histogram of non-stained 
ST2K0 DC is plotted for comparison.
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Figure 4.20 The cytokine production profile of dendritic cells derived from ,
ST2-deficient chronic inflammation model mice i
ST2-deficient mice were treated and sacrificed as described in the legend to Figure 4.12 ,
and femoral bone marrow from each mouse removed. Bone marrow-derived DC were 
cultured in vitro for 7 days and stimulated with media (panel A) or LPS (V g /m l; panel B) 
for 24h. Culture supernatants were analysed for TNFa, IL-12 and IL-10 by ELISA in 
triplicate wells. ELISA data are expressed as mean ± SD (/?=3). **, p<0.01 vs ST2K0 
fibrosis DC; +, p<0.05 vs wild-type fibrosis DC, +++, p<0.001 vs wild-type fibrosis DC (by 
ANOVA).
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Figure 4.21 Spontaneous cytokine production by bone marrow macrophages 
derived from ovalbumin-induced airway inflammation model mice.
BALB/c mice were treated and sacrificed as described in the legend for Figure 4.1 and 
femoral bone marrow from each mouse was removed. Bone marrow-derived 
macrophages from Control, Asthma and Asthma+ES-62 treatment groups were cultured 
in vitro for 7 days before culturing in fresh media for 72h. Triplicate culture supernatants 
were analysed for TNFa, IL-12 and IL-10 by ELISA. Data are expressed as mean ± SD 
(n=3) and are the results of one experiment. *, p<0.05 and **, p<0.01 vs Asthma treatment 
group.
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Figure 4.22 ES-62-mediated inhibition of inflammation in the short-term
ovalbumin-induced asthma model: modulation of initiation mechanisms
In the short-term airway inflammation model bone marrow-derived DC are released into 
the periphery expressing low/moderate levels of cell surface markers and producing low 
levels of TH1-promoting cytokines, IL-12 and TNFa. Upon recognition of ovalbumin 
(OVA), these DC present antigens of OVA to naïve T cells in the secondary lymphoid 
organs and induce generation of an antigen-specific TH2-mediated inflammatory immune 
response, evidenced by production of TH2 cytokines, IL-4 and IL-5, which, in turn, induce 
B cell production of antigen-specific IgE, the classical inflammatory TH2-type antibody 
isotype. In the ainA/ays, TH2 cytokines promote recruitment of eosinophils and mast cells. 
Antigen-specific IgE binds to high affinity FceRI receptors on the surface of mast cells and 
upon antigen-lgE complex fomation, mast cell degranulation ensues, resulting in release 
of pre-formed inflammatory mediators and further TH2 cytokines. Ail of these events 
contribute to development of TH2-mediated airway inflammation in this model.
Prophylactic ES-62 treatment of this model modulates the phenotype of DC that 
differentiate from bone marrow-progenitor cells, which results in development of DC with a 
more mature phenotype. This may result in development of a less potent TH2 immune 
response. ES-62 also acts to inhibit production of antigen-specific TH2 cytokines and IgE. 
Thus, recruitment of eosinophils to the airways and overall development of TH2 
inflammation in this model is inhibited as a result of prophylactic ES-62 treatment.
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Figure 4.23 ES-62 inhibits established TH2-mediated airway inflammation: 
modulation of effector mechanisms
Following establishment of a TH2-type inflammatory environment in the lungs (in the 
short-term model of airway inflammation) resident alveolar macrophages are activated 
and therefore, secrete enhanced quantities of pro-inflammatory cytokines, which act to 
continually recruit leukocytes to the inflammatory site. Antigen-specific TH2 ceiis secrete 
TH2-type cytokines in response to recognition of specific antigen. TH2 cytokines also help 
to recruit cells, especially eosinophils, to the airways. Antigen-specific IgE present in the 
airways binds to high-affinity FceRI receptors on the surface of mast cells and low-affinity 
receptors (e.g. CD23) on other cells present. Formation of antigen-lgE complexes on the 
surface of the mast cell results in degranulation, inducing release of pre-formed 
inflammatory mediators and further TH2 cytokines. Production of inflammatory mediators 
and TH2 cytokines helps to maintain the inflammatory environment, which is exacerbated 
following inhalation of antigen (OVA). Therapeutic ES-62 treatment result in development 
of bone marrow-derived alveolar macrophages with a reduced activation state, which, in 
turn, leads to reduced production of inflammatory cytokines by these cells. In addition ES- 
62 treatment reduces recruitment of eosinophils to the lungs, which may be a 
consequence of its inhibitory action on macrophage activation status or a result of 
inhibition of TH2 cell cytokine production in response to antigen challenge.
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Figure 4.24 ES-62 inhibits development of severe pulmonary inflammation in 
a model of chronic airway inflammation
In response to the extended protocol of OVA immunisation and challenge in vivo, bone 
marrow-derived DC exhibit a slightly immature phenotype, evidenced by reduced 
expression of cell surface markers. Nevertheless, these DC also exhibit enhanced IL-12 
production. Following activation of an antigen-specific TH2-type immune response, TH2 
cells secrete TH2 cytokines (IL-4 and IL-5), which help to induce switching of B celi 
antibody production to TH2-type isotypes, IgE and IgGI. Furthermore, anti-inflammatory 
cytokine IL-10 is also produced in response to antigen recognition. As previously 
described (Figure 4.22), ligation of antigen-specific IgE bound to FceRI receptors on the 
surface of mast cells in the inflammatory site, results in degranulation and release of TH2 
cytokines and inflammatory mediators, adding to the inflammatory environment of the 
airways. Chronic airway inflammation and repeated activation of the inflammatory 
response to antigen challenge over an extended period of time results in development of 
several features of airway remodelling, for example, laying down of collagen in the 
airways (i.e. fibrosis). It has been suggested that the features of airway remodelling that 
develop as a result of chronic airway inflammation act to reduce airway integrity and 
further promote inflammation, thus inducing a positive feedback loop. ES-62 treatment of 
this model results in differentiation of bone marrow DC with a ‘corrected’ phenotype, 
evidenced by slightly enhanced expression levels of co-stimulatory molecules and 
inhibited spontaneous IL-12 production. ES-62 also acts to inhibit development of the 
antigen-specific TH2-type antibody responses, IgE and IgGI, whilst promoting production 
of anti-inflammatory cytokine, IL-10. Therefore it is proposed that these combined actions 
of ES-62 (at least) help to reduce the inflammation induced in the airways and thus, 
ultimately reduce the severity of the irreversible changes to airway integrity as a result of 
airway remodelling.
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5 ES-62 inhibits inflammation exhibited in a model of systemic 
lupus erythematosus
6.1 Introduction
Systemic lupus erythematosus (SLE) is a chronic, remitting and relapsing, inflammatory 
disorder of unknown aetiology that is distinguished by its heterogeneous pathology in 
different patients. The average global prevalence of SLE Is approximately 1 in 1000 [377] 
and it is 10-foid more prevalent in women of childbearing age than in men [21]. It is also 
more common in Asian and Afro-Caribbean than in European populations [378]
5.1.1 The pathology of SLE
The hallm ark characteris tic  of SLE is the overproduction of antibodies 
(hypergammaglobulinemia) directed against auto-antigens (autoantibodies), including cell 
surface and nuclear proteins. It is understood that formation of gross autoantigen- 
autoantibody immune complexes (1C) initiates onset of the inflammatory pathologies 
exhibited in SLE [21]. These immune complexes usually form at the site of autoantigen 
expression, leading to organ- or cell-specific inflammation [22] and heterogeneous, SLE- 
associated inflammatory pathology can affect several different body systems 
simultaneously. In 1982 the American College of Rheumatology (ACR) proposed a set of 
criteria for identification and diagnosis of SLE [379, 380]. Patients exhibiting four or more 
of the eleven categorised manifestations of SLE (simultaneously or serially) can be 
confirmed as having the disorder. The eleven categories of pathology include different 
types of skin lesions, blood abnormalities, photosensitivity, haematological, 
immunological, neurological and renal disorders, arthritis and presence of antibodies 
specific for nuclear components (including double stranded DNA (dsDNA)). Most 
commonly in SLE patients, the kidneys, joints and skin are affected [381]. It is thought that 
SLE-associated nephritis (kidney inflammation) is initiated by ligation of pathogenic 
autoantibodies to antigen within the kidney glomeruii and immune complex formation, 
inducing proteinuria and haematuria [382, 383]. By measuring the levels of protein and 
blood excreted in the urine, the progression of kidney damage and therefore, disease 
severity, can be monitored. Non-erosive arthritis is also commonly exhibited [380]. This is 
most likely initiated by production of autoantibodies specific for joint proteins [21].
5.1.2 Animal models of SLE
Murine models of SLE have helped to define and clarify the underlying immunology of the
inflammation exhibited in heterogeneous human SLE pathology. Human and mouse
immune systems are generally similar, therefore, knowledge gained from studies using
murine models has been applicable to human disease. Spontaneous onset, genetically
determined murine models of SLE have been widely used, such as the NZB/W F I, BXSB
and MRL/lpr models. These mouse strains have single gene mutations and
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BXSB mice were proposed as a model for SLE a decade after discovery of the NZB/W 
model by a single cross between a female C57BL/6 mouse and a male SB/Le mouse
spontaneously develop autoimmune pathology similar to that exhibited in clinical SLE. 
Thus, pathologies deveioped by mice from all three strains include splenomegaly, 
lymphadenopathy, increased titre of IgG isotype autoantibodies and glomerulonephritis. 
[384, 385]. Surprisingly, whilst the genetics and pathology of each strain have been 
extensively characterised, the aetiology of disease in these models has not been 
elucidated.
NZB/W F1 mice are the hybrid progeny of a cross between New Zealand White (NZW) 
and New Zealand Black (NZB) mice, first proposed as a model for human SLE in 1963 
[386]. Disease onset is accelerated in female NZB/W FI mice, with symptoms arising at 
approximately 6 months and 50% mortality at 8.5 months old. Male NZB/W FI mice 
develop disease later, with 50% mortaiity at 15 months of age [384].
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homozygous for linked mutant genes, satin (sa) and beige (bg) [385]. The onset of clinical 
symptoms is also affected by sex in this model, however, in contrast to the NZB/W FI 
strain, male BXSB mice are first affected. It was identified that this was because BXSB 
mice carry a disease-enhancing Yaa gene on the Y chromosome [387], which was 
paternally transmitted. 50% mortality in male BXSB mice is reached at approximately 6 
months and in females at 15 months.
Most recently, the MRL/lpr model of SLE was developed. By far, the most severe and 
extensive pathology of the three spontaneous onset models described is exhibited by 
MRL/lpr mice [385]. In addition to the pathologies mentioned above, MRL/lpr mice exhibit 
RA-like footpad inflammation and systemic vasculitis [388], which are frequently 
diagnosed in human SLE [389]. Lymph node hyperplasia is up to 50 times greater in 
MRL/lpr mice than in NZB/W F Is  and, unlike the NZB/W F1 and BXSB strains, disease 
progression follows a similar time-course in males and females, with early onset of 
symptoms and 50% mortality at 5-6 months.
The genome of the MRL background strain is derived from LG (75%), AKR (12.6%), G3H 
(12.1%) and G57BL/6 (0.3%) murine strains [385]. A spontaneous, autosomal, recessive 
mutation (lymphoproliferation, /pr) triggered the development of MRL/lpr mice [390]. The 
homozygous Ipr mutation carried by MRL/lpr mice was found to be a mutation of the fas 
gene [391], preventing expression of a functional Fas protein in this mouse. Fas is a 
member of the TNF receptor family and is expressed at the cell surface. Following ligation 
by Fas ligand (FasL), Fas initiates caspase-mediated apoptosis [392] and inflammation 
signal transduction [393, 394]. Apoptosis mediated by Fas is essential for elimination of
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haematopoietic ceiis, which explains the increased levels of lymphocytes, monocytes and 
macrophages in MRL//pr mice [395]. The mechanism by which mutations in fas leads to 
accelerated autoimmunity is unknown [21], however the strongest hypothesis suggests 
that the pathology exhibited is the result of autoreactive T and B cells that are resistant to 
apoptosis. For example, it has been suggested that upregulation of Fas antigen, normally 
expressed by autoreactive precursor T cells in the thymus leads to thymic selection, 
preventing release to the periphery [391]. Thus, Fas deficiency permits migration of 
autoreactive T cells to the periphery, resulting in autoimmune pathology. Fas is also 
involved in T celi homeostasis in the periphery. Following activation, as part of an immune 
response, Fas functions to switch off T cell activation, therefore, Fas deficiency might also 
lead to defective T cell regulation, resulting in large numbers of circulating cross-reactive 
T cells with low-affinity for autoantigens [396]. Whilst it is important to note there is no 
counterpart to the MRL/lpr mouse in humans, fas mutations have been identified in a 
small number of children with autoimmune syndromes [21, 397].
It is understood that the MRL/lpr model mimics the immunopathology and serology of 
human SLE better than any other animal model [395] therefore; this model was employed 
to examine lupus-associated inflammation in this laboratory.
5.1.3 The immunology of SLE
As mentioned previously, the aetiology of SLE is currently unknown and the heterogeneity 
of the exhibited pathology suggests there may be several mechanisms of pathogenesis. 
Hereditary studies have indicated that a pre-disposition to SLE is inherited in a polygenic 
manner [381]. Despite evidence supporting a genetic component in SLE, 75% of 
monozygotic twins are discordant for the disease [21], indicating that environmental 
contributions also influence onset [37, 398]. It is stili not clear whether SLE is an 
autoimmune inflammatory disorder with many varied pathologies or whether the observed 
pathologies are a group of distinct inflammatory conditions. The common denominator in 
SLE is the production of anti-DNA autoantibodies. Irrespective of the inflammatory 
outcomes, almost all SLE patients exhibit high levels of autoantibodies [22]. Pathogenic 
autoantibodies are usually IgG isotype and their levels have been shown to correlate with 
disease severity [399]. Apoptotic cells are considered the source of DNA, histones and 
nucleoprotein complexes that drive production of pathological autoantibodies in SLE. 
Thus, it has been suggested that defective clearance of cell debris following apoptosis 
(programmed cell death) may be fundamental to lupus pathogenesis. ([400]; [401]). In 
addition to anti-dsDNA antibodies, there have been several suggested biomarkers of SLE 
[10, 402], including products of complement activation and various cytokines.
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5.1.3.1 B and T lymphocytes
Mature B cells mediate autoantibody production in SLE [403]; therefore dysregulated 
autoreactive B cells have been Implicated in SLE pathogenesis [404]. T cells do not 
appear to play a direct role in tissue damage exhibited in SLE however, they are 
necessary for the development of autoantibody production and the progression of SLE 
[21]. Consistent with this, it has been demonstrated that T cell deficient SLE-prone mice 
failed to develop lupus-associated pathology [405] and disruption of T cell signalling 
abrogates disease progression in a murine model of SLE [406, 407]. Thus, T and B cells 
(and the interactions between these two cell types, leading to autoantibody production) 
have been determined essential for progression of SLE. Moreover, whilst it has been 
demonstrated that T cells are integral to disease progression, It remains unclear whether 
the inflammation exhibited in SLE is of a particular TH-phenotype. It has been suggested 
that TH2 type immune responses may be important in SLE disease development [21], 
however in animal models of SLE (see below) the influence of Thi-mediated immunity 
has also been highlighted [408]. Therefore, T cell-derived cytokines of T H I- and TH2- 
promoting natures have been identified as important and facilitatory in the pathogenesis of 
SLE. Furthermore, contradictory evidence supporting a role for THI cytokine, IFNy, in SLE 
has been published [409-411] and THI-promoting cytokines, IL-6 and TNFa, have been 
implicated as important mediators of tissue injury in SLE [402]. The TH2 cytokine, IL-4, 
was detected in increased levels in SLE patient serum samples, however research 
investigating a role for this cytokine in disease pathogenesis has been conflicting [402]. In 
summary, SLE is an inflammatory disease of ambiguous immunological phenotype.
5.1.3.2 Dendritic cells
Dendritic cells (DC) have been dubbed the ‘sentinels’ of the immune system, providing the 
necessary communication conduit between innate and adaptive immune responses [412]. 
DC are necessary for priming and activating naïve T cells and for inducing anergy and 
deletion of autoreactive T cells [413-415]. With such an important facilitatory role, it is not 
surprising that DC have also been implicated in SLE pathogenesis. DC are capable of 
presenting auto-antigens as ‘immunogenic’, overproducing inflammatory cytokines or 
failing to adequately induce tolerance of autoreactive T cells. Under these conditions, DC 
could aberrantly initiate T cell priming resulting in many of the complex pathologies 
exhibited in clinical SLE. For example, SLE patient sera was found to induce maturation 
and differentiation of monocytes into DC [416], which was demonstrated to be a result of 
the characteristic elevated IFNa content of the serum [417]. Similarly, mice 
overexpressing CD40L (which ligates the DC co-stimulatory signal molecule, CD40) 
exhibited autoimmune pathology and autoantibodies specific for skin and nuclear 
antigens, including DMA [418]. Indeed, this study demonstrated that chronic DC activation 
leads to an autoimmune phenotype corresponding to the antigens that reside at the site of
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initial activation. Repeated transfer of DC (matured by exposure to apoptotic or necrotic 
cells) to immunologically normal C57/BL6 mice induced expression of anti-DNA antibodies 
[419], but did not induce autoimmune pathology, indicating that whilst DC might have a 
role to play in initiation of autoantibody production, this was not sufficient for triggering 
autoimmunity. In summary, maturation of DC appeared to be integral to promotion of 
autoimmunity in SLE. Thus, it was suggested that targeting DC maturation might be a 
viable method of treating SLE patients [420].
5.1.3.3 Macrophages
It has been identified that SLE patients exhibit accumulation of apoptotic cell debris in 
certain body tissues (e.g. germinal centres in lymph nodes) [421, 422] and it has been 
suggested that insufficient clearance of apoptotic cells and necrotic tissue (leading to 
autoantibody formation against nuclear antigens) is a result of defective macrophage 
function in SLE. Indeed, macrophages cultured in vitro from CD34^ stem cells obtained 
from SLE patients were demonstrated to be incapable of sufficiently clearing apoptotic 
cells, due to defects in phagocytosis [423]. It has been suggested that apoptotic cells, 
which are not cleared by phagocytes such as macrophages, become ‘secondary necrotic’, 
which leads to the release of danger signals from the dying cells and provides access for 
the immune system to target nuclear antigens [423]. Therefore, via activation of dendritic 
cells, an immune response specific for nuclear components can be initiated.
In particular, development of anti-double stranded DNA (dsDNA) autoantibodies has been 
implicated in the pathogenesis of SLE. Anti-dsDNA and anti-Sm (a nuclear 
ribonucleoprotein) antibodies are unique to patients with SLE [424]. Moreover, it has been 
suggested that anti-DNA antibodies contribute to lupus nephritis via cross-reactivity with 
renal antigen (a-actinin) expressed in mesangial cells of the kidney [425]. Furthermore, it 
has been demonstrated that polyclonal anti-DNA antibodies from patients with SLE 
(involving lupus nephritis) bound mesangial cells and this binding was positively 
correlated with severity of disease. Other kidney-derived cells (glomerular and proximal 
tubular epithelial cells) were also bound by the anti-DNA IgG, however, mesangial cells 
exhibited the greatest anti-DNA binding activity [426]. Thus, it would appear that 
development of anti-DNA autoantibodies leads to initiation of an inflammatory immune 
response particularly at the site of kidney mesangial cells. Ultimately this would lead to 
nephritis as exhibited in several SLE patients and in murine models of this disease.
In addition, autoantibody production in SLE appears to be dysregulated such that vast 
quantities of autoantibodies are generated. This leads to formation of gross immune 
complexes (1C), which induce tissue inflammation by immunological means (recognition of 
specific antigen), but also by mechanical means due to their macromolecular size. More
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specifically, formation of autoantibodies and autoantigens into large 1C results in trapping 
(or deposition) of the autoantibodies in certain tissues [424]. Indeed, it has been 
suggested that SLE-prone mice exhibit impaired ability to resolve immune complexes in 
the kidney [427], which contains some of the smallest blood vessels in the body. 
Therefore, it is perhaps not surprising that the kidney becomes a common end-point for 
autoimmune inflammation in SLE, considering that 1C of autoantibodies regularly become 
deposited in this organ.
5.1.4 Aims
It has previously been shown that ES-62 elicits anti-inflammatory action in a model of Th1- 
mediated autoimmune (CIA) inflammation (Chapter 3) and a model of TH2-mediated 
airway inflammation (Chapter 4). Thus, it was a core aim of this investigation to determine 
whether ES-62 would ameliorate inflammation, of ambiguous TH-phenotype, exhibited in 
a model of prototypic autoimmunity, SLE.
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It was planned to determine the effects of ES-62 in the MRL/lpr model of spontaneous 
autoimmunity, by treating with ES-62 in a prophylactic manner and monitoring the mice for 
signs of autoimmune pathology, such as lupus nephritis. Following identification of 
perceived ES-62 mediated modulation of inflammation In this model It was planned to 
determine the immunological mechanisms underlying such action. For example, it has 
been suggested that aberrant DC function might form an integral component of SLE 
pathogenesis [428]. Indeed, modulatory effects of ES-62 treatment on DC phenotype in 
vitro and in vivo, have previously been identified in other models of inflammatory disease 
(Chapter 3, Chapter 4, [192]). Hence, it was also planned to determine whether ES-62 
treatment would modulate the phenotype of DC isolated from SLE model mice, in 
summary, the individual aims of this investigation are:
1. To determine the effect of prophylactic ES-62 treatment of the inflammation 
exhibited in the MRL/lpr model of SLE.
2. To characterise the immunology of the MRL/lpr model of SLE and determine any 
effect of ES-62 treatment on this.
3. To dissect the mechanisms of any ES-62 action in the MRL/lpr model by 
investigating the phenotype of bone marrow-derived DC.
i'
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5.2 Results
The MRL//pr mouse model of systemic lupus erythematosus (SLE) exhibits several 
features of human SLE and has been widely established as a working system for 
investigation of SLE pathogenesis [429]. As mentioned above, the pathology of human 
lupus involves overproduction of self-specific antibody (autoantibodies) and subsequent 
formation of autoantigen-autoantibody immune complexes. Lymphadenopathy, 
splenomegaly and nephritis leading to kidney damage are common features of severe 
SLE and are exhibited in the MRL/lpr mouse model. MRL/lpr mice and patients with lupus 
persistently excrete protein via their urine (proteinuria). Consequently, proteinuria can be 
used as a measure of the progression of nephritis-induced kidney damage (and correlates 
with development of disease) in the SLE model. Thus, it was hypothesised that the anti­
inflammatory action of ES-62 evident in immune cells and other models of inflammatory 
disease ([192]; Chapter 3; Chapter 4), would inhibit the inflammation exhibited in this 
model of SLE.
5.2.1 MRL/lpr mice exhibited symptoms of progressive lupus-like disease
MRL//pr mice were observed from 5 weeks old. Micturation was induced twice weekly and 
urine was monitored for protein (proteinuria) and blood content (haematuria) as an 
indicator of nephritis-induced kidney damage and, hence, disease progress. PBS or ES- 
62 treatment was administered (subcutaneously) twice weekly throughout the 
investigation. Proteinuria was detected in PBS treatment group mice at approximately 11 
weeks of age (Figure 5.1a). In addition, haematuria was regularly detected in urine 
samples from these mice (Figure 5.1b). The progression of protein and blood loss 
detected in these mice indicated that kidney damage was occurring, similar to that 
observed in human lupus nephritis.
One day prior to sacrifice (at approximately 16 weeks of age), MRL/lpr mice were 
inspected for signs of arthritis, a common feature of lupus-associated inflammation. 
Arthritis-like footpad inflammation was observed in over 70% of the PBS-treated MRL/lpr 
mice, 1 day prior to sacrifice (Figure 5.1c). Therefore, in addition to nephritis, the SLE 
model mice exhibited symptoms of lupus-induced arthritis. At 16 weeks old, mice were 
euthanased and carefully dissected. Lymph nodes and spleen were removed and it was 
observed that these secondary lymphoid organs were markedly enlarged (Figure 5.2) 
compared with lymph nodes and spleens from naïve, non-MRL/lpr mice (approximately 
20-fold and 10-fold, respectively).
In summary, the MRL/lpr SLE model mice exhibited several pathological features 
commonly exhibited in SLE patients (proteinuria, haematuria, arthritis, splenomegaly and
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lymphadenopathy), therefore it was concluded that this was an appropriate model with 
which to determine the effect of ES-62 on SLE-associated inflammation.
5.2.2 ES-62 treatment of SLE model mice inhibits onset of lupus-
associated inflammation
Prophylactic ES-62 treatment of MRL/lpr mice significantly delayed the onset and reduced 
the concentration of proteinuria detected (Figure 5.1a), indicating inhibition of nephritis. In 
addition, there was a reduced incidence of haematuria in the ES-62 treatment group 
(Figure 5.1b). These results suggested that ES-62 treatment of SLE model mice inhibited 
Incidence and progression of kidney damage associated with SLE disease pathogenesis.
ES-62-treated MRL/lpr mice also exhibited significantly reduced severity and markedly 
reduced the incidence of arthritic Inflammation compared with PBS-treated mice (Figure 
5.1c, d). Indicating that ES-62 treatment inhibited lupus-associated arthritic inflammation, 
consistent with its anti-inflammatory action in the CIA model ([192]; Chapter 3).
Similar to the PBS treated mice, mice from the ES-62 treatment group exhibited 
widespread splenomegaly and lymphadenopathy. There was no difference in the size of
lymph nodes or spleen from mice in either treatment group (Figure 5.2a, b), To more 
clearly determine any difference in lymphadenopathy, CD3* T cells from each mouse 
were isolated and counted. Consistent with a lack of difference in lymph node size, 
hyperplasia of CD3* T cells and B220^ B cells were not significantly different between 
mice from PBS and ES-62 treatment groups (results not shown). These results indicated 
that ES-62-mediated inhibition of kidney damage or arthritic inflammation exhibited in this
model was not facilitated by modulation of splenocyte or lymph node cell hyperplasia.
E5.2.3 ES-62 treatment of SLE model mice does not significantly modulate
serological factors
5.2.3.1 Serum immunoglobulin
Following confirmation of the lupus-like pathology exhibited in the MRL/lpr SLE model 
mice, examination of the underlying immunology of this model began. SLE is 
characterised by hypersecretion of autoantibodies, particularly antibodies specific for 
nuclear antigens that are thought to derive from apoptotic and necrotic cells [400, 401]. 
Serum samples obtained from MRL/lpr mice at sacrifice were analysed for 
immunoglobulin (Ig) and cytokine content. Hypersecreted autoantibodies in MRL/lpr mice 
are primarily IgG (lgG2a, IgGI) and IgM isotypes [429] and it is known that pathological 
autoantibodies secreted in human SLE are generally IgG isotype [381], therefore, the 
serum samples were titrated and the serum content of total IgGI, lgG2a and lgG3 was
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determined. It was noted that serum from the SLE model mice contained strikingly 
elevated quantities of Ig overall, observed because the samples required markedly (up to 
50-fold) more dilution than was normally used for analysis of serum Ig in other models, to 
be measured in the normal range. Thus, high concentrations of IgGI, lgG2a and lgG3 
were detected in serum samples from PBS-treated mice (Figure 5.3a-c). In vivo treatment 
with ES-62 did not significantly modulate the average levels of the serum IgG in any of the 
subclasses analysed.
IgM is thought to play a role in opsonization and uptake of apoptotic and necrotic cells 
[21]. It has also been demonstrated that the presence of IgM anti-dsDNA antibodies 
correlated negatively with the development of nephritis (and the level of IgG) in SLE [430]. 
In light of this information, the level of total IgM in serum samples from the MRL/lpr mice 
was determined. Similar to the results of serum IgG analysis, IgM was readily detected in 
samples from PBS treated SLE model mice (Figure 5.3d) and ES-62 treatment did not 
significantly modulate these levels.
In summary, analysis of serum Ig indicated that there was a grossly elevated production of 
IgG in MRL/lpr mice, consistent with the observed hypersecretion of this pathogenic Ig 
isotype in human SLE. The increased serum IgG might have been responsible for the 
observed effector phase of this disease (nephritis) via formation of large immune 
complexes leading to tissue damage. ES-62 treatment did not modulate the serum 
content of IgG or IgM, indicating that modulation of the isotype or quantity of total serum 
antibody secreted was not a method employed by ES-62 for inhibition of inflammatory 
pathology. This finding was consistent with the fact that MRL/lpr mice from both treatment 
groups exhibited similar numbers of lymphocytes in lymph nodes and spleen ex vivo.
The presence of anti-double stranded (ds) DNA antibodies, in particular, has been 
demonstrated as integral to SLE pathogenesis. Indeed, the presence of anti-dsDNA 
antibodies fulfils one of the AGR classification criteria for diagnosis of SLE [381]. It has 
also been suggested that serum levels of anti-dsDNA correlate with severity of 
inflammatory pathology exhibited in SLE, especially nephritis [399]. Thus, the content of 
anti-DNA Ig in serum samples from SLE model mice was analysed. In addition the effect 
of ES-62 treatment of SLE model mice on the serum levels of these autoantibodies was 
determined. Serum samples were obtained at day 95, diluted and analysed for content of 
anti-single stranded (ss) DNA and anti-dsDNA. Anti-ssDNA !gG2a and anti-dsDNA lgG2a 
antibodies were detected in serum samples from PBS-treated and ES-62 treated MRL/lpr 
mice (Figure 5.3e, f). ES-62 treatment did not induce significant modulation of anti- (ss or 
ds) DNA lgG2a levels. This finding indicated that ES-62 did not mediate anti-inflammatory
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action in this SLE model by modulating production of anti-DNA autoantibodies of this 
isotype.
5.2.3.2 Serum cytokines
Serum samples from human SLE patients have been shown to contain elevated TH1 and 
TH2 cytokines [408]. Undiluted serum samples from MRL/lpr mice were analysed for 
cytokine content and found to contain TH1-promoting cytokines, TNFa, IL-12 and IL-2, 
TH2-type cytokine, IL-13 and B cell stimulating, T cell regulating cytokine, IL-10 (Figure 
5.4a-e). Serum samples were also analysed for IFNy, IL-1, IL-4, IL-5, IL-6 and IL-17, but 
these cytokines were not detected. This cytokine repertoire did not indicate a particular 
TH-phenotype of this disease. Such ambiguous immunological phenotype is consistent 
with the heterogeneous nature of the exhibited inflammation in human SLE. The TH- 
phenotype of SLE-associated inflammation is the subject of much controversy [409]. 
Treatment of the MRL/lpr mice with ES-62 did not significantly modulate the average 
serum cytokine content or repertoire of the group (Figure 5.4), indicating that modulation 
of serum cytokines or cytokine levels was not a method employed by ES-62 for its anti­
inflammatory action in this model.
5.2.4 ES-62 significantly inhibited mitogen-induced cytokine production by
LN cell from SLE model mice ex vivo
It has been widely accepted that T cells play an indispensable role in the pathogenesis of 
SLE [21], however, the TH-phenotype of these cells has been ill-defined. To determine 
the phenotype of lymphocytes in the MRL/lpr mice, lymph node (LN) cells from each 
mouse in both SLE model treatment groups were pooled and cultured ex vivo for 72h. It 
was not possible to stimulate an antigen-specific response by the LN cells ex vivo, 
because the antigen-specificity of the lymphocytes was not known. Therefore, LN cells 
from both treatment groups were stimulated ex vivo with media or the mitogen. Con A and 
analysed for cytokine, chemokine and growth factor production and DNA synthesis levels. 
Con A is a potent mitogen and when used to treat cells in vitro, it normally induces gross 
activation of cells, which demonstrated by high DNA synthesis and cytokine production 
levels.
Under control conditions, LN cells exhibited negligible levels of DNA synthesis ex vivo, 
indicating that they were not proliferating (Figure 5.5a) and ES-62 treatment in vivo did not 
significantly modulate this rate of DNA synthesis. However, when stimulated with Con A in 
vitro, SLE model LN cell proliferation was markedly elevated (Figure 5.5a). Again, ES-62 
treatment of the mice in vivo did not significantly modulate the level of Con A-induced 
DNA synthesis by the LN cells (Figure 5.5a). Thus, any modulation of LN cell cytokine
219
secretion induced by ES-62 could be viewed as a direct effect of ES-62 on the cytokine 
production machinery and not a result of changes to cell number.
LN cells isolated from PBS-treated MRL/lpr mice spontaneously secreted measurable 
quantities of TH1-promoting cytokines, IL-1 a and IL-12 (Figure 5.5). Interestingly, LN cells 
isolated from ES-62 treated SLE model mice exhibited significantly reduced IL-12 
production in vitro, indicating that ES-62 treatment in vivo selectively modulated 
lymphocyte production of inflammatory mediators.
Con A treatment of LN cells induced production of additional cytokines not detected under 
control culture conditions (Figure 5.5). In addition to the cytokines produced 
spontaneously (IL-1 a and IL-12,), Con A-treated LN cells produced significant quantities 
of THI-type cytokines, IL-2, TNFa, IFNy, and IL-17 and TH2-type cytokines, IL-10 and IL- 
13. LN cell culture supernatants were also analysed for the presence of cytokines, IL-4, 
IL-5 and IL-ip, but these were not detected. The range of cytokines secreted in response 
to mitogen indicated that the LN cells present were of different TH-phenotypes. ES-62 
treatment of SLE model mice in vivo induced modulation of the normal LN cell cytokine 
response to Con A ex wVo. Con A-induced LN cell production of inflammatory cytokines, 
IFNy, TNFa and IL-17 was significantly inhibited by ES-62 treatment of SLE model mice in 
vivo (Figure 5.5). Furthermore, LN cell production of inflammation-promoting IL-12 in 
response to Con A was abrogated by prior treatment with ES-62. Interestingly, LN cell 
production of the TH2 cytokine, IL-13, which was induced by Con A, was also inhibited by 
ES-62, indicating that ES-62 did not target solely THI-type cytokines. In summary, ES-62 
induced inhibition of the mitogen-induced cytokine response of lymphocytes present in the 
LN, independent of Th-phenotype.
5.2.6 ES-62 inhibits mitogen-induced chemokine production by LN cell
from SLE model mice ex vivo
Chemokines are chemotactic cytokines, which have a major function in recruitment of 
cells to the inflammatory site and direction of cells within the immune response, thus, 
supernatants of the LN cell cultures were also analysed for chemokine content. LN cells 
isolated from PBS-treated MRL//pr mice spontaneously secreted measurable quantities of 
IP-10 and MIG (Figure 5.6), chemokines induced by pro-inflammatory cytokine IFNy. 
Interestingly, ES-62 treatment of the MRL/lpr mice in vivo appeared to reduce the 
spontaneous production of MIG, but not IP-10 by the LN cells ex vivo.
In addition to the chemokines produced spontaneously (IP-10 and MIG), Con A-treated 
LN cells produced significant quantities of inflammatory chemokines, KG, MGP-1 and
2 2 0
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'M IP-1a. Con A-induced MIP-1a production was significantly inhibited, whilst KC 
production was abrogated by ES-62 treatment of SLE model mice in vivo (Figure 5.6c, e).
5.2.6 ES-62 inhibits spontaneous and mitogen-induced angiogenic growth
factor production by SLE model LN cells ex vivo
LN cells isolated from PBS-treated MRL/lpr mice spontaneously secreted measurable 
quantities of VEGF and FGF (Figure 5.7a, b), cellular growth factors with important roles 
in anglogenesis. Interestingly, ES-62 treatment of MRL/lpr mice induced inhibition of 
spontaneous VEGF, but not FGF production by LN cells ex wVo, suggesting that these 
factors may be differentially regulated.
Consistent with the enhanced proliferative response, Con A stimulation in vitro promoted 
the production levels of VEGF however a similar increase was not observed in FGF 
production by these cells. In addition to VEGF and FGF, Con A-treated LN cells produced 
significant quantities a distinct growth factor not detected under control conditions, GM- 
CSF (Figure 5.7c). The inhibitory action of ES-62 on VEGF production observed under 
control conditions was more potently observed following stimulation of LN cells with Con 
A. (Figure 5.7b). Furthermore, LN cell production of inflammation-promoting GM-CSF in 
response to Con A was abrogated by prior treatment with ES-62 (Figure 5.7c). Thus, ES- 
62 clearly targets LN cell production of growth factors in this model, suggesting that these 
factors may be important for development of the inflammatory pathology exhibited in 
these mice.
5.2.7 ES-62 treatment inhibits mitogen-induced proliferation of
spienocytes from SLE modei mice ex wVo
Previously it has been demonstrated that the immune response in the lymph nodes and 
spleen can be distinct (Chapter 4). To help determine the nature and mechanism of the 
immune response exhibited in the SLE model, it was important to follow up the LN cell 
analysis with examination of spienocytes isolated from the MRL/lpr mice. The DNA 
synthesis levels of SLE model spienocytes were negligible under control in vitro 
conditions (Figure 5.8a). Analogous to its action on LN cells, ES-62 treatment of SLE 
model mice in vivo did not modulate the minimal ex vivo proliferation rate of spienocytes.
As expected, treatment with mitogenic Con A in vitro induced markedly elevated levels of 
splenocyte proliferation (Figure 5.8a). Interestingly, and in contrast to the findings of LN 
cell analysis, spienocytes isolated from ES-62-treated SLE model mice exhibited a 
significantly reduced proliferative response to Con A (Figure 5.8a), when compared with 
spienocytes from PBS-treated mice. This indicated that ES-62 acted to reduce the normal 
proliferative response of spienocytes to a potent mitogenic stimulus, such as Con A, 
suggesting that this inhibitory effect may also be exhibited in vivo.
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5.2.8 ES-62 treatment inhibits mitogen-induced cytokine production by 
spienocytes from SLE model mice ex vivo
Despite exhibiting a low rate of DNA synthesis under control conditions, SLE model 
spienocytes spontaneously secreted detectable quantities of the TH1-promoting cytokine, 
IL-12 (Figure 5.8h). IL-12 had previously been detected spontaneously secreted by LN 
cells from these mice (Section 5.2.4), suggesting that this particular cytokine might be 
important for mediation of inflammation in this model. Interestingly, given that 
spontaneous cytokine production was minimal by spienocytes from PBS-treated MRL//pr 
mice, in vivo treatment of the SLE model mice with ES-62 stimulated spontaneous 
production of IL-2 by spienocytes (Figure 5.8d), but did not significantly modulate IL-12 
production levels. Therefore, these findings suggested that ES-62 acted to promote 
development of spienocytes that spontaneously produced IL-2 and to inhibit cells that 
spontaneously produced IL-12, in the absence of an external stimulus.
Interestingly, the low level of spontaneous IL-12 secretion by spienocytes under control 
conditions was not significantly modulated by Con A treatment in vitro (Figure 5.8h), 
suggesting that the IL-12-producing cell population had not been targeted by Con A. 
However, significant production of THI-type cytokines, IL-2, TNFa, IFNy, IL-1a, IL-6 and 
IL-17 and TH2-type cytokines, IL-13 and IL-10 by spienocytes was induced by Con A 
(Figure 5.8). Culture supernatants were also analysed for the presence of cytokines, IL-4, 
IL-5 and IL -lp , but these were not detected under either in vitro condition. ES-62 
treatment of SLE model mice in vivo appeared to inhibit Con A-induced production of IL- 
17 and IL-6 by spienocytes in vitro (Figure 5.8f, e). Thus, the pattern of IL-17 and IL-6 
production (under Con A stimulation) reflected the pattern of proliferation in spienocytes 
from the two in vivo treatment groups. Nevertheless, the levels of the other Con A induced 
cytokines secreted by spienocytes from PBS treated mice (IL-12, IL-2, TNFa, IFNy, IL-1 a, 
IL-13 and IL-10) were not significantly modulated by ES-62 treatment in vivo, indicating 
that the action of ES-62 was specific for IL-6 and IL-17 in these cells.
5.2.9 ES-62 treatment inhibits mitogen-induced chemokine production by 
spienocytes from SLE model mice ex vivo
In addition to THI-promoting cytokine, IL-12, SLE model spienocytes spontaneously 
produced detectable levels of inflammatory chemokines, MCP-1 and IP-10 (Figure 5.9a, 
d). As mentioned previously, IP-10 is induced by IFNy, whilst MCP-1 is induced by IL-1 
and TNFa and has been detected in increased levels in the serum of SLE patients [431]. 
Interestingly, although the spontaneous production of MCP-1 was low overall, spienocytes 
from ES-62 treated mice exhibited a trend of reduced production of MCP-1 (Figure 5.9d), 
however this difference was not statistically significant.
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The increase in proliferation of spienocytes induced by Con A treatment in vitro was 
reflected in the production levels of IP-10 and MCP-1 that had been secreted 
spontaneously by these cells under control conditions. In addition, inflammatory 
chemokines, KC, MIG and M!P-1a were induced by Con A treatment of spienocytes 
(Figure 5.9b, c, e). In a similar pattern to that of IL-17 production, the pattern of Con A- 
induced MCP-1 production reflected the pattern of proliferation in spienocytes from the 
two in vivo treatment groups (Figure 5.9d) That is, ES-62 treatment of SLE model mice in 
vivo significantly inhibited MCP-1 production by spienocytes in response to Con A 
treatment. However, the levels of other Con A induced chemokines secreted by 
spienocytes from PBS treated mice (IP-10, KC, MIG and M lP -la ) were not significantly 
modulated by ES-62 treatment in vivo. It was interesting to note that ES-62 targeted 
production of distinct chemokines by LN cells and spienocytes in this model respectively.
5.2.10 Analysis of growth factor production by SLE model spienocytes
Ex vivo, spienocytes from the SLE model mice spontaneously secreted low, but 
measurable quantities of angiogenic growth factors, FGF and VEGF (Figure 5.10a, b) and 
furthermore, production of both of these factors was also detected in spienocytes from 
ES-62 treated mice. FGF and VEGF are important factors with roles in angiogenesis, a 
process often initiated in chronic inflammation to provide enhanced blood (and hence, 
cell) supply to the site(s) of inflammation. Thus, it was interesting that ES-62 did not 
target secretion of either of these factors by spienocytes from this model, particularly 
considering it had inhibited spontaneous production of VEGF by LN cells.
In accordance with its action on proliferation. Con A treatment of spienocytes in vitro 
induced enhanced production of FGF and VEGF (Figure 5.10a, b). Furthermore, and 
similar to the results obtained during LN analysis, production of GM-CSF, a growth factor 
involved in differentiation of monocytes, was detected in splenocyte culture supernatants 
following Con A treatment (Figure 5.10c). However, unlike the action of ES-62 observed 
during LN cell analysis, the levels of Con A induced FGF, VEGF or GMCSF secreted by 
spienocytes from PBS treated mice were not significantly modulated by ES-62 treatment 
in vivo. Overall, ES-62 mediated inhibitory action on growth factor secretion observed in 
LN cells from this model was not exhibited in spienocytes, indicating that this effect of ES- 
62 treatment was targeted specifically at growth factor-secreting LN cells, but not 
spienocytes.
In summary, under control conditions, spienocytes from the SLE model mice 
spontaneously secreted a reduced range of inflammatory chemokines and cytokines 
when compared with LN cells from the same mice. In response to Con A stimulation the
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range of factors secreted was greatly increased to include both TH1-promoting and TH2- 
promoting cytokines, indicating that cells of distinct immune phenotypes were present in 
the spleen. Whilst ES-62 treatment in vivo resulted in an inhibited proliferative response of 
spienocytes to Con A, it appeared to have a more profound modulatory action on the in 
vitro cytokine response of LN cells, than on spienocytes in this model. This indicated that 
targeting the function of LN cells in preference to spienocytes might facilitate the anti­
inflammatory effects of ES-62. Nevertheless, it was of particular interest that Con A- 
induced IL-17 production by LN cells and spienocytes was consistently inhibited by ES-62 
and therefore, this finding may represent a major mechanism by which ES-62 induces 
inhibition of inflammation in this model.
5 .2.11 ES-62 treatment significantly modulates the phenotype of bone
marrow DC derived from SLE model mice
ES-62 has previously exhibited marked immunomodulatory action on bone marrow 
derived cells of the innate immune response, such as dendritic cells [189]. Dendritic cells 
(DC) facilitate communication between innate and adaptive immune responses and 
function as important antigen-presenting cells. In particular, it has been suggested that 
DC play an important role in pathogenesis of human lupus [420]. Having uncovered a 
potential anti-inflammatory effect of ES-62 on LN-localised lymphocytes and as previous 
work has suggested that ES-62 does not directly target T cell responses [186], it was 
hypothesised that ES-62 might target DC to mediate its observed anti-inflammatory 
effects in the MRL//pr model of SLE. Previously, it has been demonstrated that ES-62 
treatment of bone marrow in vivo results in differentiation of bone marrow-derived DC with 
a modulated phenotype, thus it was suggested that ES-62 mediated modulation of DC 
pre-cursors in the bone marrow was a mechanism by which the anti-inflammatory actions 
of ES-62 might be facilitated in vivo. To test this hypothesis, DC derived from pooled bone 
marrow samples isolated from the SLE model mice in the PBS and ES-62 treatment 
groups were cultured in vitro and then stimulated with LPS (or media) for 24h and their 
surface expression and cytokine production determined.
DC cultured from bone marrow of SLE model mice treated with ES-62 did not exhibit a 
markedly modulated phenotype to that of DC derived from PBS-treated mice (Figure 5.11, 
panel A). However, it was noted that DC derived from ES-62-treated SLE model mice 
exhibited marginal upregulation of MHCII, CD40, CD54, CD80 and CD86, compared to 
DC from PBS-treated SLE model mice. LPS treatment of DC in vitro induced uniform 
upregulation of all cell surface markers analysed on DC from both in vivo treatment 
groups. The modest upregulation of surface markers on DC derived from the ES-62 
treatment group mice (exhibited under control conditions) was maintained when DC were 
treated with LPS in vitro (Figure 5.11, panel B). Thus, prior ES-62 treatment of SLE model
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mice in vivo did not prevent activation of subsequently cultured bone marrow derived DC 
in response to a potent inflammatory stimulus, such as LPS. This action was in direct 
contradiction to the previously demonstrated inhibitory effects of ES-62 on this cell type, 
when DC were derived from naïve non-MRL/lpr model mice [191]. Moreover, it was 
unlikely that this understated effect would be responsible for the significant anti­
inflammatory effects of ES-62 on SLE model pathology.
To more comprehensively analyse the phenotype of the DC derived from the SLE model 
mice, culture supernatants of the bone marrow derived DC were also analysed for 
cytokine content. DC cultured from bone marrow of PBS-treated SLE model mice 
spontaneously secreted low (almost negligible) levels of THI-promoting inflammatory 
cytokines, IL-1 and TNFa (Figure 5.12). Consistent with co-stimulatory molecule 
upregulation, LPS stimulation induced marked increases in cytokine production by DC 
from both treatment groups. Thus, DC cultured from PBS-treated MRL/lpr mice secreted 
elevated levels of IL-1 and TNFa, whilst additionally secreting IL-12 and IL-6 in response 
to LPS (Figure 5.12). Furthermore, secretion of regulatory/TH2 cytokine, IL-10 was 
induced by LPS stimulation of DC from the SLE model mice
Interestingly, ES-62 treatment of mice in vivo, mediated an inhibitory effect on the bone 
marrow derived DC cytokine secretion response to LPS. When compared with PBS DC, 
DC cultured from ES-62 treated mice secreted significantly inhibited levels of all the 
cytokines detected (IL-1, TNFa, IL-12, IL-6 and IL-10) in response to LPS treatment. 
Thus, ES-62 treatment of SLE model mice resulted in differentiation of bone marrow- 
derived DC, which displayed an inhibited cytokine, but not cell surface expression 
response to LPS stimulation in vitro. This marked effect of ES-62 treatment in vivo on the 
cytokine production pattern of subsequently cultured DC in vitro is typical of the previously 
identified anti-inflammatory effects of ES-62 on bone marrow-derived cells [191] and 
highlighted an potential mechanism by which ES-62 might interfere with the normal 
progression of inflammatory pathways activated during pathogenesis of lupus-like 
disease.
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5.3 Discussion
SLE is an autoimmune disease of ambiguous immunological phenotype, with a 
prevalence of 0.1%. Its pathologies are diverse and heterogeneous, which adds to the 
complexity of diagnosis of this disease in humans. As described previously in this thesis, 
the anti-inflammatory effects of filarial nematode excretory-secretory product, ES-62 have 
been demonstrated in models of THI and TH2-mediated inflammation, collagen-induced 
arthritis and ovalbumin-induced asthma respectively. To incorporate examination of ES-62 
action in another inflammatory disease, MRL/lpr mice were monitored and it was 
confirmed that this was an appropriate model for the study of human lupus. Thus, by 
employing a genetically determined, spontaneous onset murine model of SLE, a novel 
anti-inflammatory action of ES-62 In a prototypic autoimmune disorder was uncovered.
5.3.1 ES-62 selectively inhibits progression of SLE-associated
inflammatory pathology
SLE model mice displayed evidence of progressive nephritis, a common inflammatory 
pathology incurred in human SLE, evidenced by proteinuria and haematuria that 
increased in severity with age. Indeed, it has previously been demonstrated that the levels 
of proteinuria and haematuria correlate with severity of nephritis in murine SLE models 
and in SLE patients [429]. ES-62 treatment of SLE model mice significantly inhibited 
proteinuria and non-significantly reduced the incidence of haematuria, indicating delayed 
onset and reduced progression of nephritis in the ES-62 treatment group.
Consistent with a lupus-like phenotype, symptoms of inflammatory arthritis were exhibited 
in the majority of the SLE model mice towards the end of the experiment. This is a 
common component of SLE-associated pathology in humans and has previously been 
observed regularly in this murine model [429]. ES-62 treatment of MRL/lpr mice abrogated 
onset of arthritis-like symptoms and where arthritis did occur, the severity was significantly 
reduced. Indeed, anti-arthritic action of ES-62 has previously been demonstrated in a 
murine model of rheumatoid arthritis [192], thus, in the current model this observation 
indicated that, supplementary to amelioration of nephritis, ES-62 mediated inhibition of 
additional inflammatory pathology exhibited in SLE.
In addition to nephritis and arthritis, splenomegaly and lymphadenopathy were evident in 
SLE model mice. Interestingly, these inflammatory pathologies were not targeted by ES- 
62. Treatment with ES-62 did not significantly modulate the hypertrophy of lymphoid 
organs or hyperplasia of cells exhibited in SLE model spleen and lymph nodes. These 
findings illustrated that ES-62 mediated anti-inflammatory action was focussed on the 
pathologies that caused the greatest morbidity (and ultimately, mortality) in this disease 
(that is, nephritis and arthritis).
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5.3.2 ES-62 mediated inhibition of SLE-associated inflammation is not
induced by modulation of serum antibodies or cytokines.
Accelerated lupus-like disease, such as that exhibited in the MRL/lpr model of SLE, has 
been associated with TH1-mediated immune responses [408]. Thus whilst MRL/lpr mice 
predominantly exhibit enhanced serum immunoglobulin of IgG and IgM isotypes, TH1- 
type lgG2a and IgGS subclasses are particularly nephritogenic in murine SLE [408, 432].
Consistent with hyperplasia of lymph node and spleen cells, hypersecretion of IgG 
antibodies (including DNA-specific) was also detected in the SLE model mice. The 
concentration of total monoclonal IgG circulating in the bloodstream has been shown to 
correlate with the degree of glomerulonephritis and necrotising vasculitis in MRL/lpr mice 
[429]. Furthermore, enhanced serum IgG is consistent with the antibody profile of SLE 
patients [21, 411, 429]. Thus, as an indicator of the onset of nephritis, an elevated titre of 
serum IgG and IgM antibodies was revealed in SLE model mice. ES-62 treatment of 
MRL/lpr mice did not significantly modulate the quantity or subclass balance of total serum 
IgG. In addition, ES-62 did not modulate total serum levels of IgM, suggesting that target 
of total serum IgM or IgG content was not necessary for modulation of synovial or renal 
inflammation. Furthermore, DNA-specific lgG2a was not significantly modulated by ES-62 
either, confirming that the anti-inflammatory action of ES-62 did not target antigen-specific 
or non-specific antibody production for mediation of its anti-inflammatory effects. These 
findings corresponded with the absence of modulatory action of ES-62 on splenocyte and 
lymph node cell hyperplasia in these mice and, thus, supported the finding that 
modulation of B cell number was not a method employed by ES-62 for mediation of anti­
inflammatory action in this model. Nevertheless, the lack of effect of ES-62 treatment on 
serum Ig in this model was surprising. It has been a commonly accepted theory that 
enhanced serum IgG induces production of 1C that initiate onset of inflammatory 
pathologies, such as nephritis. Therefore, ES-62-mediated inhibition of nephritis, without 
inhibition of serum Ig appeared contradictory. Furthermore, ES-62 must therefore have 
employed a mechanism distinct from modulation of hypergammaglobulinemia to mediate 
inhibition of onset of renal inflammation and arthritis. This mechanism may be down 
stream of 10 formation, for example, at the point of interaction of 10 and target antigens. 
However, it must also be considered that serum was sampled at a single time-point (at the 
time of sacrifice). Serum factors are most likely in continuous flux, therefore it is possible 
that repeated analysis over a series of time-points might have reveal alternate findings.
Examination of cytokines present in serum samples obtained from SLE model mice
revealed a combination of THI (TNFa, IL-2, IL-12), TH2 (IL-10, IL-13) promoting factors
and T-regulatory cytokine (IL-10), which were not significantly modulated by ES-62
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treatment. The mean concentration of IL-12 was modestly reduced in ES-62 treated mice, 
however this difference was not significant. Cytokines of different immune phenotypes 
have been identified as simultaneously elevated in SLE patients, suggesting that lupus is 
a complex disease that may be supported by different cytokine patterns at different time- 
points during the disease. Clearly, ES-62 did not elicit profound modulatory effects on the 
balance of serum cytokines in this model. In summary, analysis of SLE model serum 
revealed an elevated IgG titre and an ambiguous immunological profile, characteristics 
similar to serum samples of lupus patients [381]. ES-62 did not significantly alter serum 
levels of antibody or cytokine, indicating that, whilst these factors provided information 
about the immunological status of the model, they did not necessarily directly influence 
progression or inhibition of inflammatory pathologies, such as nephritis.
5.3.3 ES-62 mediated inhibition of SLE-associated inflammation correlated
with mitogen-induced cytokine production by SLE model LN cells.
The MRL/lpr model of SLE mimics an autoimmune disease of marked inflammation. 
Paradoxically, LN cells isolated from the SLE model mice exhibited relatively low 
spontaneous activation, demonstrated by minimal levels of spontaneous proliferation and 
cytokine production. Interestingly, impaired responsiveness to TCR ligation is 
characteristic of CD4+ T lymphocytes isolated from SLE patients [433]. Furthermore, 
whilst the phenotype of the immune response in SLE patients is often ambiguous, in the 
MRL/lpr model of autoimmunity the inflammation exhibited is often mediated 
predominantly by a TH1 immune response [408]. This perhaps reflects the spontaneous 
secretion of IL-12 by the SLE model LN cells ex vivo as IL-12 is necessary for initiation of 
a THI-mediated immune response [434]. Moreover, in the absence of stimulation ex vivo, 
SLE model LN cells spontaneously secreted a selection of inflammation promoting 
factors, highlighting the inflammatory nature of this disease. For example, IP-10, a THI 
chemoattractant [435] spontaneously secreted by SLE model LN cells in this investigation, 
has been associated with pulmonary inflammation in MRL mice [436]. In addition, IP-10 is 
detected in elevated concentrations in serum samples from SLE patients [431], 
suggesting that this inflammatory chemokine is involved In the pathogenesis of SLE.
ES-62 treatment abrogated spontaneous IL-12 production and reduced VEGF secretion 
by the LN cells, indicating that ES-62 had targeted its actions to reduce production of 
circulating factors necessary for initiation and maintenance of the exhibited THI-type 
inflammation and anglogenesis respectively. As previously mentioned, IL-12 promotes 
THI-type immunity and the MRL/lpr model of SLE is propagated by a THI-mediated 
immune response. Furthermore, it has been demonstrated previously that IL-12 deficient 
MRL/lpr mice exhibited delayed onset of nephritis and intra-renal IFNy expression [437]. 
Therefore, inhibitory action of ES-62 on LN cell IL-12 secretion might reflect a mechanism
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by which ES-62 inhibited progression of SLE. The angiogenic chemokine, VEGF is 
generally elevated in serum samples from SLE patients and has been identified as 
overexpressed in renal tissue in patients with lupus nephritis [438]. Moreover, serum 
levels of VEGF have been shown to correlate with the severity of inflammation exhibited 
in SLE [439]. Thus, inhibition of VEGF production by LN cells as a result of ES-62 
treatment also appears to be a potential mechanism of anti-inflammatory action in the 
SLE model.
Currently the auto-antigen or auto-antigens to which the immune response is targeted in 
MRL/lpr mice is unknown. Therefore, it was not possible to stimulate an antigen-specific 
response by the LN cells ex vivo. Instead, LN cells were stimulated ex vivo with the 
potent mitogen, Con A, which induces non-specific proliferation of cells. Thus, it was 
proposed that analysis of the cellular responses to Con A treatment would help to reveal 
the phenotype of the cell types present, because it would stimulate non-specific activation 
of cells.
As expected, DNA synthesis levels and the cytokine-producing repertoire of the SLE LN 
cells was markedly enhanced by treatment with Con A, compared with unstimulated cells, 
indicating that T cells of distinct phenotypes were present. In more detail. Con A treatment 
revealed the presence of TH2 cells in the LN cell culture, identified by secretion of IL-13. 
THI cells were also present, as indicated by detection of IFNy and IL-2 in the Con A- 
treated culture well. Detection of regulatory cytokine, IL-10 suggested that a population of 
regulatory cells might be present within the SLE model lymph nodes, for example IL-10- 
secreting regulatory T cells. Indeed, IL-10 is an important co-factor for survival of B cells 
(and hence, maintenance of autoantibody production), however no correlation between IL- 
10 levels and SLE severity has been identified [440]. In addition, inflammatory 
chemokines, IP-10, MIG, MlP-1a, MCP-1 and KC were detected in Con A-treated LN cell 
cultures from SLE model mice. These inflammatory factors would help to sustain an 
inflammatory milieu in vivo. All of these chemokines have been detected in elevated 
concentrations in serum samples from SLE patients, implicating roles in SLE 
pathogenesis [431].
In addition to inhibition of constitutive IL-12 production, ES-62 treatment of SLE model 
mice appeared to dampen the production of selected Con A-induced THI-promoting 
(IFNy, IL-12, IL-17, TNFa, KC, MIP-1a, VEGF) and TH2-promotlng (IL-13) factors, 
suggesting that although ES-62 had not significantly modulated the mitogen-induced 
proliferation of LN cells, the cytokine secretion function of these cells had been inhibited.
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IFNy is a definitive TH1 cytokine and as mentioned previously, the MRL/lpr model of SLE 
is predominantly associated with a TH1-mediated immune response. By contrast, the role 
of IFNy in human SLE has been the subject of much controversy, evidence has been 
published to demonstrate, both, enhancement and impairment of IFNy levels in SLE 
patients [410, 411]. Nevertheless, it has been demonstrated that IFNy is essential for 
development of glomerulonephritis in the MRL/lpr model [441] and exacerbations of SLE- 
induced nephritis are mediated by THI cytokines such as IFNy [442]. Therefore, ES-62- 
induced inhibition of IFNy would disrupt IFNy-mediated development of nephritis and, 
therefore, promotion of THI-mediated immune responses in the MRL/lpr mouse. This 
represents a potential mechanism for mediation of the inhibitory action of ES-62 in this 
model of SLE.
Likewise, IL-17 is an inflammatory cytokine that induces release of other pro-inflammatory 
cytokines, mobilises and recruits neutrophils and inflammatory cells and has been 
demonstrated to have important inflammatory effects on rheumatoid synoviocytes [443]. 
Consistent with such a role in inflammation, LN cells from the SLE model were induced to 
secrete IL-17 after mitogen treatment. Therefore, it is possible that IL-17 could induce 
maintenance of the arthritis-like inflammation exhibited in the SLE model. Moreover, IL-17 
induces production of TNFa [444] and GM-CSF [445], inflammatory cytokines also 
secreted by SLE LN cells in this investigation. Importantly TNFa has a proven integral role 
in pathogenesis and maintenance of inflammation in human and murine arthritis [207]. As 
mentioned in Chapter 3, blockade of TNFa is an established method for therapy of 
arthritis in humans and consistent with a link between these cytokines, inhibition of IL-17 
also attenuates inflammation in murine collagen-induced arthritis [446].
IL-17 is a powerful Inducer of neutrophilia and It has been identified that the neutrophilic 
action of IL-17 is mediated by KC [447], an inflammatory chemokine that potently recruits 
neutrophils and was also secreted by LN cells from the SLE model in response to Con A. 
Furthermore, IL-17 has been demonstrated to stimulate production of the angiogenic 
growth factor, such as VEGF and has been shown to co-operate with TNFa in mediation 
of this effect [448]. It has been identified that IL-17 induces production of TNFa also [449] 
and therefore, co-operation with TNFa to induce production of VEGF promotes a 
synergism between these two pro-inflammatory cytokines. Serum levels of VEGF, but not 
FGF have been shown to correlate with inflammation severity in SLE patients, suggesting 
that these angiogenic factors are differentially regulated [439]. Indeed, unlike VEGF, FGF 
Is not directly induced by IL-17 and in support of this, ES-62 treatment of the SLE model 
mediated inhibition of VEGF, but not FGF production by LN cells. Thus, neutrophilic 
inflammation and angiogenesis are clearly integral components of the pathology exhibited 
in the MRL./lpr mice. In summary, ES-62 treatment inhibited secretion of IL-17, KC, VEGF
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and TNFa by LN cells from the SLE model, consistent with a common link in their 
production (Figure 5.13). Therefore, the results presented in this chapter indicate that ES- 
62 may be targeting this group of related inflammatory mediators to facilitate its anti­
inflammatory action in this model of SLE.
It has been suggested that IL-17 production is induced by IL-23, a cytokine closely related 
to IL-12 [450]. Furthermore, it has been suggested that IL-23 represents a key therapeutic 
target in autoimmune inflammation [450]. Therefore, as an extension of the current 
investigation, it would be interesting and informative to additionally examine ex vivo IL-23 
production by LN and spleen cells from this model (Figure 5.13). This would determine 
whether ES-62 also targets the cytokine production upstream of IL-17 in the MRL/lpr 
mouse.
As previously mentioned, LN cell secretion of IL-17 and TNFa was inhibited by ES-62 
treatment in SLE model mice and hence, it is possible that this action of ES-62 could 
contribute to the observed inhibited arthritis in the SLE model mice. However, the role of 
TNFa in SLE is not as straightforward as its action in rheumatoid arthritis pathogenesis. 
For example, there have been several reports of anti-TNF therapy (in RA patients) 
inducing a lupus-like autoimmunity, after prolonged administration [451, 452] and 
furthermore, it has been suggested that TNFa might have a protective role against lupus 
onset [453]. Moreover, it has been identified that genetically determined TNFa production 
levels in humans are inversely associated with onset of lupus nephritis [453]. In contrast, 
TNFa has been cited as pathogenic in cutaneous lupus, because it is activated by ultra­
violet B light that exacerbates lupus-associated skin Inflammation [454]. Ultimately, TNFa 
is a pro-inflammatory cytokine therefore, ES-62 mediated inhibition of TNFa in this model 
of inflammation is likely to be anti-inflammatory in action.
However, as mentioned previously, LN cells from the SLE model mice secreted both TH1 
and TH2 cytokines. IL-13, a TH2 cytokine, which is recognised by the same receptor as 
the prototypic TH2 cytokine, IL-4, has been detected at increased levels in serum samples 
from SLE patients compared with normal individuals [455, 456], highlighting its role in 
rheumatic diseases including SLE. Based on these postulations, inhibition of IL-13 
secretion by ES-62 would therefore induce inhibition of SLE pathogenesis.
Elucidation of the cytokine inhibiting action of ES-62 in the SLE model implicated mitogen- 
induced LN cell cytokine production in the progression of inflammatory pathologies, such 
as nephritis and arthritis, exhibited in this disease. ES-62-mediated inhibition of cytokine 
production correlated with ES-62 mediated inhibition of nephritis and arthritis in this 
model. This suppressive effect of ES-62 was not TH-specific as it targeted THI and TH2
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LN cells. It must also be remembered that ES-62 was not present in the in vitro culture 
dish of these LN cells therefore, ES-62 treatment of the SLE model mice had (directly or 
indirectly) modulated the functionality of the LN cells in vivo and this had been maintained 
ex vivo. The sustained modulatory action of ES-62 that is maintained after ES-62 
exposure has stopped has been demonstrated previously in other models of inflammatory 
disease, such as collagen-induced arthritis model (Chapter 3) and the ovalbumin-induced 
asthma model (Chapter 4). Indeed, it appears that ES-62 treatment of cells in vivo results 
in permanent modulation of cell function, which is usually anti-inflammatory in effect. For 
example, in cells from a model of TH1-mediated inflammation (CIA), lymphocytes from 
ES-62 treated mice produce inhibited levels of TH1-promoting cytokines following re­
stimulation ex wVo. Conversely, in cells from a model of TH2-mediated inflammation 
(asthma), cells from ES-62 treated mice produce inhibited levels of TH2 cytokines when 
re-stimulated ex wVo. Therefore, it appears appropriate that in the current model of 
inflammation of TH I and TH2 phenotypes, cells from ES-62 treated mice produce 
inhibited levels of both, TH1- and TH2-promoting cytokines ex vivo.
5.3.4 ES-62 mediated inhibition of mitogen-induced splenocyte
proliferation ex vivo.
In a similar pattern to that observed In LN cells, spienocytes isolated from SLE model 
mice exhibited minimal DNA synthesis levels and secreted low levels of inflammation- 
promoting cytokines, including IL-12, inflammatory chemokines, IP-10 and MCP-1 and 
growth factors, FGF and VEGF. Interestingly, spontaneous production of MCP-1 had not 
been detected in untreated SLE LN cell cultures. ES-62 treatment Inhibited VEGF 
secretion by untreated SLE spienocytes (and mildly reduced the secretion of MCP-1), but, 
unlike the effect of ES-62 on LN cells, IL-12 secretion was not significantly modulated. In 
summary, it appeared that the inhibitory action of ES-62 observed in LN cells was not as 
potent in spienocytes from this model.
Surprisingly, ES-62 induced production of IL-2, predominantly described as a T cell 
growth factor [457], by SLE model spienocytes. However, interestingly, T cells from 
human SLE patients and SLE mouse models exhibit impaired IL-2 production [429, 458, 
459]. Furthermore, it is understood that IL-2 deficiency promotes breach of tolerance 
leading to production of autoantibodies in SLE [457]. It has been suggested that this is 
because IL-2 acts not only as a growth factor but also as a signal to promote tolerogenic 
responses in vivo, for example, development of CD4"^CD25^ regulatory T cells [460]. In 
addition, it has been demonstrated that induction of IL-2 by expression of the human IL-2 
gene ameliorates SLE disease activity in the MRL/lpr mouse [461]. Thus, ES-62-mediated 
promotion of IL-2 production by spienocytes In the SLE model mice, might help to prevent 
development of inflammation in this model.
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Con A treatment of spienocytes Induced elevated DNA synthesis levels accompanied by 
marked production of several more cytokines and chemokines. The profile of cytokines 
produced under these conditions was similar to that observed with Con A induced LN cell 
cytokine production, and included TH1- and TH2-promoting factors. Interestingly, the 
action of ES-62 on spienocytes from this model targeted the proliferative response of 
these cells to Con A, in addition to the cytokine secretion response. More specifically, ES- 
62 induced significant inhibition of mitogen-induced splenocyte proliferation. It has 
previously been demonstrated in this laboratory that ES-62 inhibits proliferation of T and B 
cells in vitro, however this anti-proliferative action was specific for proliferation triggered by 
ligation of the antigen receptor [185, 186]. In addition to inhibition of DNA synthesis by 
spienocytes from the SLE model, ES-62 inhibited production of IL-6, IL-17 and MCP-1 by 
spienocytes.
As discussed above (section 5.3.3), as an inducer of several inflammatory mediators, IL- 
17 has both direct and indirect roles in promoting development of inflammation exhibited 
in SLE. Therefore, ES-62-mediated inhibition of IL-17 production by LN cells and 
spienocytes most likely represents an efficient mechanism for anti-inflammatory action in 
the developing SLE model.
MCP-1 is a potent inflammatory chemoattractant for monocytes and T cells [12, 462], is 
upregulated in SLE and has been demonstrated to positively correlate with inflammation 
severity in SLE patients [463]. More specifically, it has been demonstrated that MCP-1 
functions to recruit and activate inflammatory cells in nephritis in MRL/lpr mice [464]. 
Furthermore, anti-MCP-1 gene therapy attenuated nephritis in MRL/lpr mice [464].
The THI-promoting pro-inflammatory cytokine, IL-6 has widespread roles in inflammation- 
induced tissue damage and regulation of inflammation [465]. Moreover, IL-6 is known to 
induce differentiation of B cells into antibody forming cells and activates T cells, therefore 
it is not surprising that IL-6 has been implicated in the pathogenesis of SLE. Furthermore, 
based on experiments conducted in murine models of SLE, it has been suggested that 
blockade of IL-6 may ameliorate inflammation exhibited in SLE patients [466].
Thus, ES-62-mediated inhibition of IL-17, MCP-1 and IL-6 production by spienocytes 
would be considered anti-inflammatory in SLE model mice. In summary, the anti­
inflammatory nature of ES-62, exhibited previously in the cytokine production profile of LN 
cells from this model, was also apparent, albeit in a reduced range of factors, in SLE 
model spienocytes.
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5.3.5 ES-62 modulation of DC function as a potential mechanism for
inhibition of inflammation exhibited in SLE model mice.
it has recently been suggested that, as professional antigen-presenting cells, DC have a 
role in activating self-reactive T cells, which brings about the autoimmune inflammation 
exhibited in SLE [428]. Examination of the phenotype of DC derived from bone marrow of 
the SLE model mice indicated that ES-62 treatment of SLE model mice Induced 
differentiation of a DC with a similar expression profile of cell surface markers to DC 
derived from control (PBS-treated) SLE model mice. Nevertheless previous work from this 
laboratory has demonstrated that whilst ES-62 treated DC appear relatively immature, 
they are capable of priming T cells to differentiate into an anti-inflammatory phenotype 
[189, 467].
Stimulation of bone marrow-derived DC from SLE model mice with potent inflammatory 
stimulus, LPS, induced markedly enhanced cytokine production and maturation of cells, 
demonstrated by uniform upregulation of cell surface marker expression. Interestingly, 
treatment with LPS revealed additional information about the nature of the DC derived 
from ES-62 treated mice. Unlike the PBS DC, the ES-62 DC exhibited a suppressed 
cytokine response to LPS treatment, indicating that whilst these DC appear matured (and 
hence, primed for direct T cell communication) by LPS treatment, they were programmed 
to elicit an inhibited response to an inflammatory stimulus. Dendritic cells are key 
organisers of the immune system therefore, modulation of DC activity as a result ES-62 
exposure might permit modulation of downstream immune signalling pathways and 
effector cells also. In the introduction to this chapter, it was mentioned that DC are integral 
to the pathogenesis of SLE. ES-62 treatment of SLE model has clearly resulted in 
differentiation of bone marrow-derived DC that exhibit a modulated phenotype. This 
modulated phenotype was represented by inhibition of the cytokine production response 
to inflammatory stimulus. This immunomodulatory action of ES-62 has previously been 
demonstrated in naïve, non-MRL/lpr mice by exposing bone marrow cells to ES-62 in vivo 
(administered via osmotic pumps) and subsequently culturing DC ex vivo [191]. Thus, in 
summary, the combined results suggest that ES-62 was able to manipulate bone marrow 
cell function ensuring that when they matured, they differentiated into re-programmed DC, 
promoting an ameliorated inflammatory immune response. ES-62 treatment of the SLE 
model mice delayed the onset of morbidly severe pathology and hence, would induce a 
prolonged life expectancy of the MRL/lpr mice. This action of ES-62 in a parasite-infected 
individual would be important for longevity of the host, and therefore, of the parasite also.
In conclusion, evidence has been provided which demonstrates a novel anti-inflammatory 
action of ES-62 in a distinct model of autoimmune disease, SLE. ES-62 mediated action 
inhibits onset and reduces severity of morbidity-inducing inflammatory nephritis and
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arthritis in a spontaneous onset murine model of SLE. This anti-inflammatory action 
appears to reflect modulation of LN cell and splenocyte cytokine production and alteration 
of DC function (illustrated in Figure 5.14). Nevertheless, it must be remembered, that the 
results presented in this chapter are preliminary (summarising the findings of two 
independent experiments), therefore, further investigations are required to more precisely 
Identify the mechanisms employed by ES-62.
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Figure 5.1 ES-62 inhibits proteinuria and arthritis exhibited in the MRL/lpr 
model of SLE
ES-62 (2^g) or PBS was administered subcutaneously to MRL/lpr (SLE model) mice twice 
weekly. Micturation was also induced twice weekly. Protein (A) and blood (B) content of 
the urine was measured using Multiistix (Bayer, UK). Incidence (C) and severity (D) of 
arthritic inflammation was measured in the footpad of SLE model mice 1 day before mice 
were euthanased. Score data are expressed as mean ± SEM (n=11 (PBS) and 12 (ES- 
62)) and are representative of two independent experiments. * p<0.05 and ** p<0.01 by 
Student’s t-test.
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Figure 5.2 ES-62 does not modulate lymphadenopathy or splenomegaly 
exhibited in the MRL/lpr model of SLE
ES-62 (2iig) or PBS was administered subcutaneously to MRL.Ipr (SLE model) mice twice 
weekly. Following sacrifice, mice were dissected and photographed, to illustrate 
lymphadenopathy (A) and splenomegaly (B). Pictures are representative of two 
independent experiments.
237
Bm i PBSES-62
Figure 5.3 ES-62 does not modulate total serum IgG or IgM or DNA-specifIc 
lgG2a in SLE model mice
MRL//pr mice were treated as described in the legend for figure 5.1.
A-D Serum samples from each SLE model mouse were diluted with 10% FBS (In PBS; 
1/1000). Diluted samples were titrated and analysed by ELISA for total IgGI (A), lgG2a 
(B), lgG3 (C) and IgM(D). Data for each group are presented as mean ± SD (n=11 (PBS) 
and 12 (ES-62) mice/group) and are representative of 2 independent experiments.
E, F Serum samples (obtained at sacrifice) from each SLE model mouse were diluted with 
10% FBS (in PBS; 1/50,000). Diluted serum samples were analysed by ELISA for lgG2a 
specific for single stranded DNA (ssDNA; E) and lgG2a specific for double stranded DNA 
(dsDNA; F). Data are presented as the mean of duplicate samples for each mouse (n=9 
(PBS) and 10 (ES-62)) and the bar represents the group mean. Data are representative of 
two independent experiments.
There were no statistical differences between serum levels of total IgGI, lgG2a, lgG3, 
IgM, ssDNA-specific IgG or dsDNA-specific IgG in mice from PBS or ES-62 treatment 
groups.
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Figure 5.4 ES-62 does not modulate SLE model serum cytokine content
SLE model mice were treated as described in the legend for figure 5.1. Serum samples 
from each SLE model mice were analysed in duplicate by Luminex for content of 
TNFa(A), IL-12 (B) IL-2 (C), IL-13 (D), and IL-10 (E). Data are expressed as the mean 
value of duplicate samples for each mouse (n=11 (PBS) and 12 (ES-62)) with the bar 
representing the treatment group mean. Data are representative of two independent 
experiments. There were no statistical differences observed between serum cytokine 
concentrations in PBS and ES-62 treatment groups.
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Figure 5.5 ES-62 inhibits mitogen-induced SLE model LN cell cytokine
production
SLE model mice were treated as described in the legend for figure 5.1. After sacrifice and 
dissection, lymph node cells from mice in each treatment group were pooled and cultured 
in triplicate with medium alone or stimulated with concanavalin A (Con A; 5 pg/ml) for 72h. 
T cell proliferation (DNA Synthesis) was assayed by uptake of [^H] thymidine in the last 8 
hours of culture (A). Data are expressed as mean ± SD (n=3) and are representative of 2 
experiments. Culture supernatant concentrations of IFNy (B), IL-1a (panel C), IL-2 (D), IL- 
17 (E), TNFa (F), IL-12 (G). IL-13 (H) and IL-10 (I) were measured by Luminex. The 
absence of bars indicates a zero value (or a value so small as not to be visible) for 
cytokine content. Data are expressed as the mean of triplicate cultures ± SD in each 
treatment group and are representative of 2 independent experiments. ** p<0.01, *** 
p<0.001 by Student’s t-test.
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Figure 5.6 ES 62 inhibits mitogen-induced SLE model LN cell chemokine
production
SLE model mice were treated as described in the legend for figure 5.1. After sacrifice and 
dissection, lymph node cells from mice in each treatment group were pooled and cultured 
in triplicate with medium alone or stimulated with concanavalin A (Con A; 5 pg/ml) for 72h. 
The concentrations of IP-10 (A), MIG (B), MIP-1a (C), MCP-1 (D) and KC (E) in the 
culture supernatants were measured by Luminex. The absence of bars or error bars 
indicates a zero value (or a value so small as not to be visible). Data are expressed as the 
mean of triplicate samples ± SD in each treatment group and are representative of two 
independent experiments. *, p<0.05 and ***, p<0.001 by Student’s t-test.
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Figure 5.7 ES-62 inhibits SLE model LN cell growth factor production
SLE model mice were treated as described in the legend for figure 5.1. After sacrifice and 
dissection, lymph node cells from mice In each treatment group were pooled and cultured 
in triplicate with medium alone or stimulated with concanavalin A (Con A; 5 pg/ml) for 72h. 
The concentrations of FGF (A), VEGF (B) and GM-CSF (C) in the culture supernatants 
were measured by Luminex. The absence of bars or error bars indicates a zero value (or 
a value so small as not to be visible). Data are expressed as the mean of triplicate 
samples ± SD in each treatment group and are representative of two independent 
experiments. *, p<0.05; **, p<0.01 by Student's t-test.
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Figure 5.8 ES-62 inhibits mitogen-induced SLE model splenocyte
proliferation and cytokine production
SLE model mice were treated as described in the legend for figure 5.1. After sacrifice and 
dissection, splenocytes from mice in each treatment group were pooled and cultured in 
triplicate with medium alone or concanavalin A (Con A; 5 pg/ml) for 72h. T cell 
proliferation was assayed by uptake of fH ] thymidine in the last 8 hours of culture (panel 
A). Data are expressed as mean ± SD (r?=3) and are representative of 2 experiments. ** 
p<0.01 by Student’s t.-test. Culture supernatant concentrations of IFNy (B), IL-1a (C), IL-2 
(D), IL-6 (E), IL-17 (F), TNFa (G), IL-12 (H), IL-13 (I) and IL-10 (J) were measured by 
Luminex. The absence of bars or error bars Indicates a zero value (or value so small as 
not to be visible). Data are expressed as the mean of triplicate cultures ± SD in each 
treatment group and are representative of 2 independent experiments. * p<0.05, ** p<0.01 
by Student’s t-test.
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Figure 5.9 ES-62 inhibits mitogen-induced SLE model splenocyte chemokine 
secretion
SLE model mice were treated as described in the legend for figure 5.1. After sacrifice and 
dissection, lymph node cells from mice in each treatment group were pooled and cultured 
in triplicate with medium alone or concanavalin A (Con A; 5 pg/ml) for 72h. Culture 
supernatant concentrations of IP-10 (A), MIG (B), MIP-1a (C), MCP-1 (D) and KC (E) 
were measured by Luminex. Data are expressed as mean of triplicate cultures ± SD in 
each treatment group and are representative of 2 independent experiments. *** p<0.001 
by Student’s t-test.
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Figure 6.10 SLE model splenocyte growth factor production ex wVo
SLE mode! mice were treated as described in the legend for figure 5.1. After sacrifice and 
dissection, lymph node cells from mice in each treatment group were pooled and cultured 
in triplicate with medium alone or concanavalin A (Con A; 5 pg/ml) for 72h. Culture 
supernatant concentrations of FGF (A), VEGF (B) and GM-CSF (C) were measured by 
Luminex. Data are expressed as the mean of triplicate cultures ± SD in each treatment 
group and are representative of 2 independent experiments. No statistical differences in 
growth factor secretion were observed between treatment groups.
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Figure 5.11 Surface expression profile of bone marrow-derived DC from SLE 
model mice
SLE model mice were treated as described in the legend for figure 5.1. Femoral bone 
marrow was obtained from each mouse and pooled by treatment group. Bone marrow- 
derived DC were cultured in vitro for 7 days and then stimulated with media (panel A) or 
LPS (Ijxg/ml; panel B) for 24h. Expression levels of MHCil, CD40, CD54, CD80 and CD86 
on CD11C+ DC from PBS (blue line) and ES-62 (pink line) treated mice were analysed by 
flow cytometry. This analysis was conducted using bone marrow derived DC from one 
SLE model experiment.
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Figure 5.12 ES-62 inhibits LPS-induced cytokine production by bone 
marrow-derived DC from SLE model mice
SLE mode! mice were treated as described in the legend for figure 5.1. Femoral bone 
marrow was obtained from each mouse and pooled by treatment group. Bone marrow- 
derived DC were cultured in vitro for 7 days and then stimulated with media (Control) or 
LPS (l^xg/ml) for 24h. Culture supernatants were analysed for IL-12 (A), TNFa (B), IL-6 
(C), IL-1 (D) and IL-10 (E) by Luminex. Cytokine data are expressed as the mean of 
duplicate samples from a single culture well and are representative of one experiment.
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Figure 5.13 The IL-17 effector pathway
IL-17 secreted by activated I  cells induces production of pro-inflammatory cytokine TNFa. 
In turn, TNFa induces production of VEGF, an angiogenic growth factor and KC, an 
inflam m atory chem okine which potently recruits neutrophils. N evertheless, IL -17  can  
induce production of VEGF and KC directly (In the absence of TNFa) however, w hen IL- 
17 co-operates with TNFa to induce secretion of e.g. VEGF, a synergistic effect results. 
Thus, IL-17 is an angiogenic and neutrophilic cytokine and therefore, has an important 
role in pathogenesis of SLE. It has been suggested that IL-23 induces IL-17. ES-62 
treatm ent of SLE inhibited T cell production of IL-17, TNFa, KC and VEGF, suggesting  
that ES-62 might be targeting a common link, which might be IL-23.
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Figure 5.14 Development of pathology in MRL/lpr mice
In the MRL/lpr mouse pathology appears to be brought about by activation of multiple 
inflammatory pathways running in series and in parallel. Activated auto-reactive B cells 
undergo hyperplasia and initiate hypersecretion of Autoantibodies, which leads to 
development of gross immune complexes and ultimately, organ damage, such as 
nephritis. In addition, secretion of inflammatory TH1 and TH2 cytokines, chemoattractant 
chemokines and angiogenic factors help to promote the developing inflammatory 
pathology. Furthermore, positive feedback is set up as target organs become inflamed 
and necrotic tissue is released, leading to generation of further auto-antibody 
deveiopment.
ES-62 treatment of MRL/lpr mice does not target T or B cell hyperplasia or production of 
autoantibodies. However, ES-62 does inhibit production of inflammatory chemokines and 
angiogenic growth factors required to help develop the pathology initiated by the effects of 
autoantibody production and immune complex formation. Thus, ES-62 inhibits 
development of inflammatory autoimmune pathoiogy, such as nephritis and arthritis, 
exhibited in this model, which is demonstrated by reduction of proteinuria and arthritic 
score
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6 Dissecting the immunomoduiatory components of parasite 
derived substances
6.1 Introduction
6.1.1 Phosphorylcholïne, an immunomodulatory component of ES-62
As described previously (Chapter 3), phosphorylchoiine (PC) is a common component of 
many pathogens in which it exhibits dual immunostimuiatory and Immunomoduiatory 
functions [177]. Published investigations from this laboratory, which indicate that PC 
(alone, or conjugated to albumin) mimics multiple immunomodulatory actions of ES-62 
[167, 183, 191], suggest that PC may be an active component of ES-62. Furthermore, the 
data presented in Chapter 3 demonstrated that the anti-inflammatory action of ES-62 in 
vivo could also be largely mimicked by OVA-PC. Nevertheless, PC-independent 
immunomoduiatory actions of ES-62 were also uncovered, indicating that PC is not the 
sole immunomoduiatory feature of ES-62. It was therefore prudent to examine, in more 
detail, the immunomodulatory properties of ES-62 substructures. Indeed, PC attached to 
a carbohydrate backbone, as exhibited within the structure of ES-62, Is a structural 
feature conserved amongst molecules derived from filarial nematodes [179].
6.1.2 A glycosphingolipid component of nematode, Ascaris suum, with 
immunomodulatory properties
A PC-containing glycosphingolipid (GSL) component of the porcine parasite. Ascaris  
suum  [468], has previously been investigated by this laboratory and found to exhibit 
several immunomodulatory properties similar to ES-62 (reviewed in [281]). To review, this 
GSL induced human peripheral blood mononuclear cells to produce low-levels of TH1 and 
pro-inflammatory cytokines [195] and inhibited murine B ceil proliferation, resulting from 
ligation of the antigen receptor [468]. Ascaris GSL also inhibited the normal response to 
the potent inflammatory agent, LPS in both murine B cells and macrophages [468]. A. 
s u u m  GSL comprises carbohydrate and ceramide moieties in addition to 
phosphorylchoiine (PC) (which is in phosphodiester linkage with N-acetyigiucosamine) 
[195]. Thus, with similar actions and analogous structural components to the PC- 
glycoprotein, ES-62, it was assumed that the PC component of GSL was responsible for 
its immunomodulatory properties.
6.1.3 Ascaris suum glycosphingolipid exhibits PC-dependent 
immunomodulatory action
To test whether PC was indeed the immunomodulatory moiety, the immunomodulatory 
properties of intact Ascaris glycosphingolipid were compared with glycosphingolipid from 
which PC was removed by treatment with hydrofluoric acid. As predicted, PC was found to 
be essential for production of cytokines by human peripheral blood mononuclear cells
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[195] and inhibition of both LPS-induced murine B cell proliferation and macrophage Thi 
cytokine production [468]. However unexpectedly, glycosphingolipid-lnduced inhibition of 
antigen receptor dependent B ceil proliferation was found not to be dependent on PC 
[468]. This latter finding suggested that PC is not the only immunomodulatory 
substructure present in A. suum glycosphingolipid.
6.1.4 Aims
In Chapters 3, 4 and 5, it was demonstrated that ES-62 treatment in vivo consistently 
reduced disease-associated inflammation, at least in part via the induction of 
immunomodulatory effects on bone marrow-derived cells of the innate immune system 
(e.g. dendritic celis and macrophages). Furthermore, previous investigations conducted in 
this laboratory have demonstrated that ES-62 targets these cell types primarily, for direct 
or indirect modulation of the immune response [189-191]. As mentioned previously, the 
nematode product, GSL contains similar PC-glycan structure to those of ES-62 and 
displays analogous immunomodulatory effects on macrophages. Therefore, the core aim 
of this investigation was to determine the actions of parasite-derived PC-containing 
substructures on dendritic cells and macrophages. It was intended that this would aid 
dissection of the mechanism of action of ES-62 in models of inflammatory disease.
With the aid of collaborators (R Geyer et al, Giessen, Germany), the role of PC, glycans or 
their combination in the immunomodulatory actions of ES-62 and other PC-containing 
parasite products were dissected. In particular, three synthetic mimetics of A. suum GSL 
with specific components of the native structure removed or replaced (as detailed In 
Figure 6.1) were synthesised. In addition, complete and PC-free versions of native GSL 
were prepared. The specific aims of this investigation were as follows:
1. To establish the, as yet undetermined, immunomodulatory effect of native Ascaris 
GSL on DC phenotype and cytokine production.
2. To extend the previous investigations conducted with Ascaris GSL by determining 
the respective actions of the ceramide, carbohydrate and PC components of the 
GSL structure on macrophage function.
3. To determine the respective actions of ceramide, carbohydrate and PC 
components of the GSL structure on normal DC phenotype and function.
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6.2 Results
6.2.1 Native A. suum glycosphingolipid does not modulate DC cytokine 
production or cell surface expression
As mentioned in Section 6.1, the effects of native A. suum  GSL treatment on 
macrophages, but not DC, have previously been determined [468]. Thus, DC were 
cultured with native Ascaris glycosphingolipid and their phenotype determined in terms of 
cytokines secreted and cell surface molecule expression. However, treatment of DC with 
native glycosphingolipid alone did not significantly modulate DC IL-12 or TNFa production 
or surface molecule expression (Figure 6.2). The observed lack of immunostimuiatory 
action of native Ascaris glycosphingolipid on DC was therefore similar to the results of this 
analysis in macrophages.
6.2.2 Native A. suum glycosphingolipid inhibits LPS-induced cytokine 
production and up-reguiation of cell surface expression by DCs
Stimulation with LPS Induced marked maturation of DC. This was demonstrated by 
elevated secretion of IL-12 and TNFa (Figure 6.3b, c) and up-regulation of cell surface 
markers: MHCII, CD40, CD86, CD80 and CD54 (Figure 6.3a). Pre-treatment of DC with 
Ascaris  glycosphingolipid significantly Inhibited LPS-induced IL-12, but not TNFa, 
production. This effect was found to be PC-independent as demonstrated by maintenance 
of the inhibitory effect when DC were pre-treated with PC-free glycosphingolipid. 
Interestingly, this inhibitory action had been demonstrated to be PC-dependent in 
macrophages [468], indicating that the action of Ascaris  glycosphingolipid was not 
identical in DC and macrophages. Consistent with the PC-independent inhibitory effect on 
cytokine production, native and PC-free glycosphingolipid also slightly inhibited LPS- 
induced up-reguiation of CD86 (Figure 6.3), but had negligible effects on MHC II, CD40, 
CD80 and CD54.
6.2.3 Effect of synthetic glycosphingolipids on cytokine production in 
macrophages
To extend the analysis of glycosphingolipid action on macrophages and DC and 
determine more comprehensively the structural components necessary for the PC- 
dependent and independent immunomoduiatory action of Ascaris glycosphingolipid, the 
immunomodulatory potential of three synthetic glycosphingolipids (Figure 6.1) was 
explored.
Previously, it was determined that native Ascaris glycosphingolipid did not have any
cytokine-inducing action on bone marrow-derived macrophages [468]. To determine
whether the same was true of the synthetic glycosphingolipids, bone marrow-derived
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macrophages were cultured with them and the resulting supernatants analysed for 
cytokines. Treatment with Compound 1 or Compound 2 did not induce production of IL- 
12p40 or TNFa (Figure 6.4). Interestingly however, Compound 3 markedly Induced 
production of IL-12p40 and TNFa by macrophages l^igure 6.4), indicating that it 
possessed modest immunostimuiatory properties, similar to ES-62 in this cell type [190].
6.2.4 Effect of synthetic giycosphingoiipicfs on LPS/IFNy-induced IL-12 
production in macrophages
The immunomodulatory potential of the synthetic glycosphingolipids on the macrophage 
response to potent inflammatory stimuli was also determined. Thus, macrophages were 
pre-treated with synthetic glycosphingolipid, before stimulation with LPS plus IFNy and 
culture supernatants were analysed for cytokines. As expected, treatment of 
macrophages with LPS/IFNy alone induced markedly elevated production of the TH1- 
promoting cytokine, IL-12 and the pro-inflammatory cytokine TNFa (Figure 6.4). Pre­
treatment with Compound 1 or Compound 2 did not significantly modulate LPS/IFNy- 
induced Th i cytokine production. These findings were somewhat unexpected, as the 
structure of PC-containing Compound 1 exhibited the greatest similarity of the three 
synthetic compounds to native Ascaris GSL (Figure 6.1), which had previously been 
demonstrated to inhibit the response to LPS in this cell type. However, pre-treatment with 
Compound 3, significantly reduced LPS/lFNy-induced macrophage IL-12p40 production 
(Figure 6.4). Macrophage TNFa production induced by LPS/IFNy was also routinely found 
to be slightly reduced by prior treatment with Compound 3, but this was not found to be 
statistically significant. These results indicated that exposure to Compound 3, but not 
Compounds 1 or 2, inhibited the subsequent pro-inflammatory cytokine response of 
macrophages to LPS. Again, this was similar to the action of ES-62 on this cell type.
6.2.6 Synthetic glycosphingolipids induce THI-promoting cytokine 
production by, and maturation of, dendritic celis
Following observation of the somewhat unexpected effects of the three synthetic mimetics 
of Ascaris GSL on macrophage cytokine production reponses, it was of particular interest 
to also determine the action of these three compounds on DC phenotype and function. 
Thus, DC were cultured with synthetic glycosphingolipid and their phenotype assessed as 
described above. Treatment with Compound 1 or 2 did not significantly modulate DC TH I- 
promoting cytokine production (Figure 6.6). However, similar to the results for synthetic 
glycosphingolipid treatment of macrophages, Compound 3 stimulated DC to produce 
elevated IL-12 and to a lesser extent TNFa, This maturation effect of Compound 3 was 
reflected by up-regulation of MHC II and CD54 expression (Figure 6.5) although, 
interestingly. Compound 1 also showed a little activity in terms of up-regulation of MHCII 
and CD54 expression on these CD11 DC.
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6.2.6 Synthetic glycosphingolipids inhibit LPS-induced IL-12 production in 
dendritic ceils
To determine the action of various structural components of glycosphingolipid on the 
dendritic ceil response to LPS, DC were treated with synthetic glycosphingolipid before 
stimulation with LPS and the cytokines produced were analysed. As demonstrated 
previously, LPS induced markedly increased IL-12 cytokine production by DC (Figure 6.6). 
In accordance with their effects on cell surface expression, LPS-induced IL-12 production 
was not significantly modulated by pre-treatment with Compounds 1 or 2. Confirming that 
although Compounds 1 and 2 exhibited the greatest similarity to intact and PC-free native 
Ascaris glycosphingolipid respectively, their actions did not reflect the immunomodulatory 
effects of their native counterparts on DC phenotype and function (Section 6.2.2). 
However, inhibition of LPS-induced DC IL-12 production was observed when DC were 
pre-treated with Compound 3. In combination with the results presented in section 6.2.5, 
this observation confirmed that PC-containing Compound 3 exhibited similar inhibitory 
actions to those of native Ascaris  GSL and furthermore, similar immunomodulatory 
(stimulatory and inhibitory) effects to those of PC-containing glycoprotein, ES-62 [190], on 
DC.
254
6.3 Discussion
In summary, it has been demonstrated that synthesis of viable small molecule derivatives 
of parasite products (with immunomodulatory capacity) is possible in the laboratory. The 
results described in this chapter demonstrate how, by utilising an in vitro system, it has 
also been made possible to determine the immunomodulatory potential of distinct 
structural components common to many PC-containing parasite products. Furthermore, 
new information about the action of nematode-derived GSL on DC has been uncovered.
6.3.1 PC is not sufficient for immunomodulatory action of parasite-derived 
substances
It has previously been shown that native Ascaris glycosphingolipid has similar properties 
to ES-62, such as inhibition of macrophage responses to LPS and IFNy, in particular, IL- 
12 production [468]. Furthermore this effect appeared to be dependent on the PC moiety 
of the glycosphingolipids. It is perhaps not surprising therefore that PC-free Compound 2 
(Figure 6.1), was unable to inhibit the LPS/IFNy-induced IL-12 production (Figure 6.6). 
Curiously however, of the two PC-containing compounds (Compound 1 and Compound 
3), only compound 3 was able to inhibit IL-12 production. This is perhaps all the more 
surprising as Compound 1 might be considered to resemble the native material more than 
Compound 3. Perhaps the structure of Compound 1 may have unforeseen effects on the 
availability of the PC group for interaction with macrophages. However it should be noted 
that it has not formally been demonstrated that PC is the inhibitory component of 
Compound 3. Whatever the case it can be concluded that simply containing PC is 
insufficient for parasite-derived substances to modulate cytokine responses.
6.3.2 Compound 3: a PC-containing synthetic giycolipid that exhibits 
immunostimuiatory actions similar to ES-62.
Compound 3 demonstrated a property that was distinct from the native glycosphingolipids 
in that it was able to induce the secretion of TNFa and IL-12 by murine macrophages and 
DC in vitro. This result was, however, reminiscent of the effect of the native material on 
human peripheral blood mononuclear cells [195]. However, the dual stimulatory and 
inhibitory actions of Compound 3 appear to most closely resemble the actions of PC- 
containing glycoprotein, ES-62 [190, 191]. As mentioned previously, the effects of ES-62 
are largely PC-dependent suggesting that PC may indeed be the important moiety with 
respect to Compound 3. Curiously however, PC is attached to ES-62 via an N-type giycan 
and more specifically, as with Compound 1, to an N-acetylgiucosamine residue (reviewed 
in [469]). Thus once again the lack of any immunomodulatory activity in Compound 1 can 
perhaps be considered surprising.
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6.3.3 Ascaris suum GSL exhibits inhibitory action with distinct PC- 
dependencies in DC and macrophages.
The results of the current study indicate that intact native glycosphingolipid also 
significantly inhibits the DC response to LPS, demonstrated by reduced cytokine 
production and suppression of LPS-mediated up-regulation of DC surface marker 
expression. This result suggested that glycosphingolipid of A. suum has similar 
immunomodulatory action on both, macrophages and DC. ES-62 generally also has 
similar immunomoduiatory action on macrophages and DC with again PC playing a 
prominent role [193]. It is surprising therefore that the inhibitory effect of A sca ris  
glycosphingolipid on LPS-induced DC IL-12 production, is apparently PC-independent. 
This suggests that the PC-free portion of the Asca r i s  molecule contains the 
immunomodulatory entity responsible for inhibition of LPS-induced cytokine production by 
DC, but not by macrophages. Previously, it has been shown that this portion of the 
glycosphingolipid has immunomodulatory capacity in B ceils [468]. More specifically, it 
was responsible for inhibition of surface antigen receptor-induced B ceil proliferation.
6.3.4 A non-PC immunomodulatory component of glycosphingolipid
The discovery of more than one immunomodulatory moiety within the glycosphingolipid 
structure, triggered speculation as to what the undefined, PC-independent 
immunomodulatory substructure might be. Ceramide, present in Compound 2 and native 
Ascaris GSL, has previousiy been identified as an immunomodulator [470] and has been 
shown to be apoptotic in many celi types [471, 472]. Furthermore, it was postulated that 
this apoptotic action of ceramide was responsible for GSL-mediated PC-independent 
inhibition of B celi proliferation [468]. However as Compound 2 has been shown to have 
no effect on DC responses clearly the ceramide moiety (consisting of C18-sphingosine 
and an amide-iinked palmitic acid) is unable or insufficient to promote inhibition of 
cytokine production. The question remains open as to whether native ceramide moieties 
of Ascaris glycosphingoiipids consisting of a iong-chained 2-hydroxy fatty acid and iso­
branched C17-sphingosine or C17-sphinganine derivatives may promote inhibition of 
cytokine production.
Carbohydrate, the remaining PC-independent component of giycosphingoiipid has iong 
been known to possess immunosuppressive activity [473, 474]. If it is, as seems likely, 
responsible for the PC-independent inhibitory effect observed then resuits obtained with 
synthetic Compounds 1 and 2 dictate that the intact carbohydrate chain and/or one or 
both of the two terminal sugars (galactose and N-acety! galactoamine; Figure 2.1) are 
necessary for activity.
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:6.3.5 A receptor for the carbohydrate moiety of glycosphingolipid?
If a carbohydrate component is responsible for the immunosuppressive action of the 
glycosphingolipids, consideration of the mechanism of action at the surface of DC and 
macrophages is permitted. CD83 is an Ig-iike lectin adhesion receptor that appears to be 
present on DC, but not on macrophages and hence, has an expression distribution 
consistent with the differential effects of PC-free Ascaris giycosphingoiipid. However,
CD83 appears to bind siaiic acid [475], which is absent from the glycosphingolipids. The 
data obtained with the three synthetic glycosphingolipids might argue a case for N-
■acetyigalactosamine and/or galactose being important in recognition, as virtuaily no 
activity was observed in their absence (Compound 1). Furthermore, the oniy carbohydrate 'v’-component of Compound 3 is galactose, although, as mentioned earlier, the PC 
dependence  of th is  g lyco iip id  is unknow n. W ith  respect to N- :îÏ'
acetylgalactosamine/gaiactose binding, a C-type lectin (macrophage lectin specific for
gaiactose/N-acetylgalactosamine; MGL) has been described with specificity for these two 
sugars. Studies on cells derived from humans indicated that MGL was expressed on | |
immature DC but not mature DC, monocytes or macrophages [476]. Nevertheless, 
recently published studies contradict these findings by indicating that MGL is expressed 
on macrophages in mice and, in addition suggesting that it may not recognise gaiactose, 
but only N-acetylgalactosamine [477]. Thus, clearly at this stage further information is 
required before speculation can be made as to the receptor for the carbohydrate 
component of Compound 3.
6.3,6 What do these findings mean in terms of ES-62 action in vivo?
In summary, both carbohydrate and PC components of the Ascaris giycosphingoiipid 
structure exhibit immunomodulatory action. In Chapter 3 it became dear that non-PC 
components of ES-62 also exhibited immunological action because PC-deficient rES-62 
did not lack all of the immunomodulatory actions of its parasite-derived intact homologue. 
Similarly, PC conjugated to OVA did not mimic the actions of ES-62 entireiy. Thus, it was 
concluded that non-PC (i.e. giycan) components of ES-62 were also important for the anti­
inflammatory and immunomodulatory actions of ES-62 in CIA. Given the results presented 
in this chapter it is dear that the carbohydrate component of ES-62 represents a viable 
candidate for mediation of PC-independent ES-62 action in CIA.
Figure 6.1 Structures of parasite-derived and synthetic mimetics of A. suum 
glycosphingolipid
Compound 1 (B) is resembles native GSL (A) without the ceramide (Car) moiety (which 
has been replaced with an octyl group (Oct)) and the two N-terminal sugars (Galactose 
and N-acetylgalactosamine). Compound 2 (C) contains ceramide, but lacks PC and the 
two N-terminal sugars. Compound 3 (D) resembles a related PC-glycolipid and consists of 
PC and two galactose sugars, with PC attached to one and an octyl group to the other.
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Figure 6.2 Native Ascaris glycosphingolipid does not modulate DC surface 
expression profile or stimulate DC cytokine production.
Bone m arrow-derived dendritic cells w ere  treated with m edia (Control), native Ascaris 
glycosphingolipid (G SL, 5 pig/ml) or PC -free Ascaris glycosphingolipid (G S L-P C , 5 pg/ml) 
and cuitured for 24h. Control cells (Control) received m edia instead of glycosphingolipid 
treatment.
P an el A Cells w ere  stained for flow cytometry and analysed as described in C hapter 2. 
D ata  from only C D 11c'' cell populations are  expressed and are  representative  of 4  
independent experim ents. Cell surface expression levels are depicted as % of m axim um  
com paring control (b lack line) vs intact g lycosphingolipid (b lue line) or P C -free  
giycosphingoiipid (green line) for the cell surface m arkers M H C  class II, C D 40 , C D 54, 
C D 80 and C D 86 and w ere gated positive related to the relevant isotype control.
B, C Culture supernatants w ere  harvested and analysed for IL -12p40  (B) and TNFa (C) 
cytokine content by E L IS A . D ata  are  expressed  as m ean ± S D  (n = 3 )  and are  
representative of 3 independent experim ents. No statistically significant differences w ere  
observed between cytokine production levels (student’s T-test).
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Figure 6.3 Native Ascaris glycosphingolipid inhibits dendritic cell responses 
to LPS in a PC-independent manner.
B one m a rro w -d e riv e d  d e n d ritic  ce lls  w e re  p re -tre a te d  w ith  n a tiv e  Ascaris 
glycosphingolipid (5^ig/ml) or PC -free  Ascaris glycosphingolipid (panel B, 5 [xg/ml) for 18h 
prior to treatm ent with LPS (1 pig/ml) for a further 24h. Control cells ((-)) received media  
instead of glycosphingolipid pre-treatm ent or LPS treatment.
P anel A  Cells w ere  stained for flow cytometry and analysed as described in C hapter 2. 
D ata from only CD11c^ cell populations are expressed and are  representative  of 4  
independent experim ents. Cell surface expression levels are depicted as % of m axim um  
com paring control vs native glycosphingolipid or P C -free  giycosphingoiipid for the  cell 
surface m arkers M H C  class II, C D 40 , C D 54 , C D 80  and C D 86  and w ere  gated positive 
related to the relevant isotype control.
B, 0  Culture supernatants w ere  harvested and analysed for IL -12p 40  (B) and T N F a  (C) 
cytokine content. Data are expressed as m ean ± S D  (n= 3) and are representative of 3 
independent experim ents. Significance is calculated by student’s t-test and illustrated by 
*p<0 .05 , ***p<0.001 com pared with LPS alone levels (unless otherwise indicated). +LP S  
indicates LPS treatment.
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Figure 6.4 Compound 3 induces immunomodulatory action on bone marrow- 
derived macrophage cytokine production
A , B Bone m arrow -derived m acrophages w ere  cultured for 42h  in m edia (Control), 
Compound 1 (GSL1, 10 pg/ml), Com pound 2 (G SL2, 10 txg/ml) or Com pound 3 (G SL3, 10 
p.g/ml). Supernatants w ere  harvested and analysed for IL -12p 40  (A) and T N F a  (B) 
cytokine content. Data are expressed as m ean ± SD  {n=3) and are representative of 3 
independent experim ents. Significance calculated by student’s t-test and illustrated by 
**p<0.01, *p<0.05 com pared with control levels.
C, D Bone m arrow -derived  m acrophages w ere  p re -trea ted  w ith m edia  (C ontro l), 
Compound 1 (G SL1, 10 ng/m l), Com pound 2 (G SL2, 10 p.g/ml) or Com pound 3 (G SL3, 10 
p,g/ml) for 18h prior to treatm ent with LPS (100  ng/ml) and IFNy (100  U /m l) for a further 
24h . Control cells w ere  cultured in m edia only for the entire  42h  culture period. 
Supernatants w ere  harvested and analysed for IL -12p 40  (C ) and T N F a  (D ) cytokine  
content. Data are expressed as m ean ±  S D  (n=3) and are representative of 3 independent 
experim ents. Significance is calculated by student’s t-test and illustrated by **p < 0 .0 1 , 
*p < 0 .0 5  com pared with LPS a lone  levels (unless otherw ise ind icated). +L P S /IF N y  
indicates LPS and IFN-y treatm ent.
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Figure 6.5 Compound 3 induces upregulation of dendritic cell surface 
expression.
Bone marrow-derived dendritic cells were cultured for 42h in media (Control), Compound 
1 (panel A, 10 p-g/ml), Compound 2 (panel B, 10 p,g/ml) or Compound 3 (panel C, 10 
fxg/ml). Cells were stained for flow cytometry and analysed as described in Chapter 2. 
Data for the CD11c+ cell populations are expressed and cell surface expression levels are 
depicted as % of maximum comparing control (solid line) and glycosphingolipid-treated 
(dotted line) celis for the cell surface markers MHC class II, CD40, CD54 and CD86 and 
were gated positive related to the relevant isotype control.
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Figure 6.6 Compound 3 exhibits immunomodulatory action on bone marrow- 
derived dendritic cell cytokine production.
A, B Bone marrow-derived dendritic cells were cultured for 42h in media (Control, open 
bars), Compound 1 (GSL1, 10 pg/mi), Compound 2 (GSL2, 10 p,g/ml) or Compound 3 
(GSL3, 10 pig/mi). Supernatants were harvested and analysed for IL-12p40 (A) and TNFa 
(B) cytokine content. Data are expressed as mean ± SD {n~3) and are representative of 3 
independent experiments. Significance is calculated using student’s t-test and illustrated 
by *p<0.05, **p<0.01 compared with control levels (unless otherwise indicated).
C Bone marrow-derived dendritic cells were pre-treated with media (Control), Compound 
1 (GSL1, 10 fxg/ml). Compound 2 (GSL2, 10 pig/ml) or Compound 3 (GSL3, 10 pg/ml) for 
18h prior to treatment with LPS (1 pg/ml) for a further 24h. Negative control cells ((-)) 
were cultured in media only for the entire 42h culture period. Supernatants were 
harvested and analysed for IL-12p40 content. Data are expressed as mean ± SD (n=3) 
and are representative of 3 independent experiments. Significance is calculated using 
student’s t-test and illustrated by *p<0.05 compared with LPS alone levels (unless 
otherwise indicated). +LPS indicates LPS treatment.
263
3500
* *
3000
— 1500
1000
500
Control GSL1 GSL2 GSL3
B
350
300
E 250 
™  200ÜLUZ
I - 150
100
50
Control GSL1 GSL2 GSL3
E 60-
(-) Control GSL1 GSL2 GSL3
+LPS
"1
7 Promotion of differential T cell-mediated immune responses 
by plant 2S seed albumins, via modulation of dendritic cell 
phenotype.
7.1 Introduction A;
Dendritic ceils form an essential part of the immune system responsible for distinguishing 
pathogenic from non-pathogenic stimuli. Indeed, the previous chapters of this thesis have 
provided evidence to demonstrate modulatory effects of parasite-derived glycoprotein 
(Chapter 4) and glycolipids (Chapter 6) on DC phenotype. Thus, it has been suggested 
that via the modulatory actions of these parasite-derived substances on DC phenotype, 
inflammatory immune responses to parasite infections can be subverted. In allergic 
individuals, aberrant TH2-mediated inflammatory immune responses are normally 
triggered in response to recognition of non-self, non-pathogenic proteins. However it is not 
yet clear how an allergen is distinguished from a non-allergenic protein and furthermore, 
how a TH2-mediated immune response is initiated in response to allergen recognition by ■'i-!cells such as DC [478]. Therefore, it was of particular interest to determine whether 
allergenic proteins induce modulation of DC, hence distinguishing allergen from non­
allergen at this stage in immune response initiation.
7.1.1 Allergy to consumed antigen
Many research studies have investigated the allergic response to otherwise harmless 
antigens that are inhaled, eaten or absorbed. In certain susceptible individuals there is a 
breakdown of tolerance to specific components (allergens) of food products. In allergic 
reaction to food proteins, TH2-type, IgE-mediated immune responses are most prevalent 
[479]. IgE antibodies specific for allergenic antigen are bound to the high-affinity FceRI 
receptors on the surface of mast cells present in the mucosa of many body systems (for 
example: the oral, pulmonary or gut mucosae). When the bound IgE is ligated by its 
specific antigen (or allergen); mast cell degranulation is initiated and a cascade of 
inflammation (direct hypersensitivity reaction) ensues. This acute inflammatory immune 
response can range from mild and temporary to severe (or fatal) anaphylactic pathology.
As mentioned in Chapter 1, allergy to foodstuffs, such as fish or nut proteins, manifest the 
most severe allergic responses, when compared with other inhaled or injested allergens 
[65]. In particular, several plant proteins (e.g. 2S seed albumins) present in nuts and
seeds have been reported to trigger an allergic response.
7.1.2 2S seed albumins as allergenic proteins
Historically, 2S albumins from seeds have been associated with allergy in the oil milling 
(castor and rapeseed) and baking industries and several proteins from this group have 
been characterised as clinically important allergens [480-464]. As a class, the 28 r
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albumins are water-soluble proteins, products of multi-gene families and are present in 
seeds of a wide range of flowering plant species [485] with an as yet unknown specific 
biological function. Structurally the 28 albumins belong to the bifunctional inhibitor/lipid 
transfer protein/ storage 28 albumin or plant prolamin superfamily [486] of proteins, 
characterised by their conserved anti-parallel bundle of four a-helices held together by 
four disulphide bonds in a distinctive right-handed fold. A large number of known food 
allergens such as plant a-amylase/trypsin inhibitors, 28 storage proteins and lipid transfer 
proteins (LTPs) belong to the prolamin superfamily and seem to have evolved from the 
same ancient gene [486].
7.1.3 Comparison of two 2S seed albumins of differing aiiergenicity
To examine initiation of the direct hypersensitivity allergic response and the components 
of plant proteins involved, recombinant 28 seed albumins from Brazil nut seeds (Ber e 1) 
and sunflower seeds (SFA 8) have been compared. Ber e 1 has been identified as a 
major allergen [487], whilst the aiiergenicity of SFA 8 is yet to be conclusively established. 
The aiiergenicity of Ber e 1 was established when it was genetically engineered into 
soybean to improve its nutritional value and found to induce allergic reactivity when tested 
in allergic individuals [484]. By contrast, whilst there are reports of SFA8-binding IgE in 
the sera of some patients who are allergic to sunflower seeds [488-490], the overall 
incidence of sunflower seed allergy is very low, even in areas of high consumption such 
as Spain, Germany and Greece. The majority of cases of allergy to sunflower seed 
proteins are reported to be via inhalation instead of ingestion by, for example, caged bird 
owners [491, 492].
It has been suggested that stability in the gastrointestinal tract is a pre-requisite for 
aiiergenicity [479] and many allergens, especially those derived from plant foods, are 
consistently more resistant to degradation by pepsin than other proteins [493]. The native 
and the recombinant forms of both Ber e 1 and SFA8 have previously been shown to 
possess similar stability to pepsin-containing simulated gastric fluid (SGF) [200, 494] and 
also resistance to high temperatures, guanidinium chloride and acidic pH conditions [494, 
495]. Moreover, SFA8 and Ber e 1 proteins also have similar structures. The tertiary 
structure of SFA8 in solution has recently been determined [496] and agrees with the 
tertiary structures of other 28 albumins and the model structure proposed for Ber e 1 
[200]. This conservation of the 3D structure was exploited in the design of chimeric 
proteins for the mapping of the human structural IgE epitope of Ber e 1 whereby proteins 
containing exchanged domains were produced [497]. Therefore, the stability or structure 
of these proteins does not appear to account for their different allergenicities. In summary, 
the precise mechanisms underlying initiation of allergy to antigens such as seed albumins 
remains unclear.
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As mentioned above, it is well known that DC can form the first point of contact for foreign 
antigens and play an essential and important role in initiation and direction of immune 
responses. It has previously been demonstrated that DC phenotype can direct immune 
response phenotype via interaction with naïve CD4"  ^ T cells [189]. Furthermore, it has 
been identified that substances present in the local environment at the time of DC 
activation can influence the phenotype of the subsequent immune response activated 
[189]. Using this system, the action of recombinant seed albumins Ber e 1 and SFA 8 on 
DC phenotype could be identified and hence, the subsequent immune phenotype these 
DC would confer on naïve CD4'' T cells could potentially be deduced. Therefore, the core 
aim of this investigation was to determine whether the distinct allergenic properties of Ber 
e 1 and SFA8 were reflected in their effects, if any, on DC phenotype.
7.1.4 Aims
It was hypothesised that allergenic Ber e 1 would promote activation of DC that would 
drive a type II immune response; therefore the aims of this investigation were as follows:
1. To determine the effects of recombinant Ber e 1 and SFA 8 on the activation of 
bone marrow derived dendritic cells (DC)
2. To determine whether the TH-phenotype of the mouse strain from which the DC 
were derived influenced the effects of Ber e 1 and SFA 8 on bone marrow derived 
DC
3. To determine whether, via differential modulation of DC phenotype, Ber e l and 
SFA 8 would promote development of T cell-mediated immune responses with 
distinct phenotypes, in terms of cytokine production and transcription factor 
expression.
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i7.2 Results
7.2.1 The effects of 2S seed albumins on cytokine production by BMDC 
from C57 BL/6 mice.
It has been well established that the immunological nature of different substances present 
at the time and place of DC activation can influence the phenotype of the resultant 
immune response, by modulation of DC phenotype. To determine the action of 
recombinant seed albumins on dendritic cell (DC) phenotype and function, bone marrow- 
derived DC were cultured with media containing increasing concentrations of SFA 8 or 
Ber e 1 for 24h. DC cultured from bone marrow of C57 BL/6 mice secreted the TH I- 
promoting cytokine IL-12 and the pro-inflammatory cytokine TNFa in response to 
treatment with SFA 8, but not Ber e 1 recombinant seed albumins (Figure 7.1a, b). 
Moreover, this response to SFA 8 treatment was dose-dependent, indicating that whilst 
non-allergenic SFA 8 potently induced secretion of pro-inflammatory cytokines by DC (that 
was proportional to the concentration of protein), allergenic Ber e 1 did not. Based on the 
results of this assay, a concentration of 50 p.g/ml 2S seed albumin was considered 
optimum for further in vitro experiments.
LPS is a well-known inducer of THI-promoting cytokine production by DC. Pre-exposure 
with seed albumins (SFA 8 or Ber e 1) did not significantly modulate the IL-12 or TNFa 
response to LPS treatment in these bone marrow-derived DC (Figure 7.1c, d). Therefore, 
although SFA 8 and Ber e 1 treatment alone stimulated different DC cytokine production 
profiles they were not immune response - dampening substances (such as ES-62), in 
terms of the normal cytokine response to LPS. The LPS cytokine response is initiated by 
ligation of pattern-recognition Toll-like receptor 4 (TLR4) on the surface of DC and 
facilitated by down-stream adapter molecule MyD88 [498]. To determine whether SFA 8- ^
induced DC production of IL-12 and TNFa employed this mechanism, DC were cultured i
, 'from MyD88-deficient mice, treated with SFA 8 and cytokine production was analysed. It 
was found that the observed cytokine response to SFA 8 was not mediated via activation
:
of this signalling pathway, because SFA 8-induced IL-12 and TNFa production was ".;a:
maintained in DC from MyD88-deficient mice (Figure 7.1e, f).
7.2.2 SFA 8 seed albumin action is maintained in BMDC from BALB/c 
mice.
It has been well documented that C57 BL/6 mice are more likely to develop TH1-mediated
immune responses. Thus, to determine any influence of strain TH-bias, DC were cultured
from bone marrow of BALB/c mice, which are pre-disposed to generate TH2-polarised
immune responses. Similarly to C57 BL/6 DC, SFA 8, but not Ber e 1, induced IL-12 and
TNFa secretion by BALB/c DC (Figure 7.1 g, h). This result indicated that the cytokine
response to the 2S seed albumins was not dependent on the TH-bias of the mouse strain.
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In addition to secretion of TH1-promoting cytokines, DC can also produce the TH2 / anti­
inflammatory cytokine, IL-10. Thus, IL-10 is an important mediator of anti-inflammatory 
signals and TH2-mediated immunity; both of which can down-regulate TH1-mediated 
immune responses. Given that Ber e 1 did not induce TH1-promoting pro-inflammatory 
cytokine production by DC, it was therefore postulated that Ber e 1 might induce IL-10. 
Furthermore, as an anti-inflammatory cytokine, IL-10 can act to induce suppression of 
TH2-mediated immune responses also. Therefore, as SPA 8 had been demonstrated to 
induce production of TH1-promoting cytokines and hence, promotion of TH1-mediated 
immune responses, it was additionally proposed that SPA 8 might also induce iL-10 to 
reduce TH2-mediated immunity and further polarise the immune response towards a TH1- 
phenotype. However, following analysis of DC culture supernatants, it was concluded that 
SPA 8 or Ber e 1 did not induce IL-10 production by BMDC from either mouse strain 
(results not shown).
7.2.3 SPA 8 induces moderate upregulation of cell surface molecules on 
DC
Following recognition of antigen and activation, DC upreguiate cell surface expression of 
co-stimulatory, adhesion and antigen-presentation molecules necessary for priming naïve 
T cells and initiation of an antigen-specific immune response [3]. Thus, using flow 
cytometry, cell surface expression on DC cultured from bone marrow of C57 BL/6 mice 
was analysed. SPA 8 treatment induced a small upregulation of MHC II, CD40, CD80 and 
CD86 expression on CDIIc"^ DC (Figure 7.2). The expression of adhesion molecule, 
CD54, was also measured, but this was not modulated by SPA 8 treatment. The 
upregulation of surface expression induced by SPA 8 was much more subtle than that 
induced by the potent inflammatory agent, LPS. Consistent with the cytokine production 
analysis, Ber e 1 treatment of DC did not modulate expression levels of the five cell 
surface molecules examined.
These studies were repeated using DC cultured from bone marrow of BALB/c mice. 
Surprisingly, in BALB/c DC, SPA 8 induced greater upregulation of MHC II, CD40, CD80 
and CD86 (Figure 7.3a), compared to its action on DC from C57 BL/6 mice. Furthermore, 
unlike the effect of SPA 8 on C57 BL/6 DC, CD54 expression was upregulated by SPA 8 
in BALB/c DC. The reasons for the difference in SPA 8-induced upregulation of cell 
surface molecule expression on BALB/c and C57 BL/6 DC were not dear. However, 
because DC from both mouse strains were cultured and treated in an identical manner, it 
was postulated that these differences might be due to the distinct TH-bias of BALB/c and 
C57 BL/6 mice. Pretreatment with Ber e 1 or SPA8 did not alter LPS-induced BALB/c DC 
maturation (Figure 7.3b).
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The results of cell surface expression analysis in both DC types indicated that DC treated 
with SFA 8 exhibited a more mature phenotype than those treated with Ber e 1 and these 
phenotypes were consistent with the cytokine production patterns discussed above.
7.2.4 The effect of 2S seed albumins on priming and polarisation of naïve 
T cell responses.
As mentioned previously, DC activation precedes priming of CD4* T cells, to enable 
initiation of an adaptive antigen-specific immune response. In vivo, activated DC, 
presenting portions of antigen at the cell surface (in complex with MHCII) activate naïve T 
cells specific for the antigen presented. Depending on the signals received from the
antigen-presenting DC, at the time of priming, a TH1 or TH2-mediated immune response 
results. To determine, in vitro, the phenotype of the adaptive immune response that would 
be mounted, following T cell priming with seed albumin-treated DC, the DO.11.10 
transgenic OVA-specific TCR system was employed. BMDC derived from BALB/c bone 
marrow were pre-treated with 2S seed albumin or LPS (as a positive control fro driving 
TH1-mediated immune responses) before pulsing with OVA and then co-culturing with 
naïve DO.11.10 CD4^ T cells (specific for OVA) in fresh media. DC treatment with SFA 8, 
Ber e 1 or LPS did not significantly modulate T cell proliferation in response to OVA 
presentation, however, LPS-stimulated DC induced slightly elevated proliferation of T cells 
at reduced OVA concentrations (Figure 7.4a). Interestingly, all co-cultures produced 
significant levels of IFNy. Surprisingly, given their apparent immature phenotype, DC pre­
exposed to Ber e l induced significantly more IFN7 than those matured with LPS (Figure 
7.4b). DC treated with SFA8 also appeared to induce higher levels of IFNy than those 
exposed to LPS but this effect was not statisticaliy significant. Pre-treatment of DC with 
Ber e 1 induced markedly elevated IL-5 and IL-4 production by co-cultured T cells 
compared to those co-cultured with LPS- or SFA 8-treated DC (Figure 7.4c and d). IL-10 
production was also significantly higher in T cells co-cultured with Ber e 1-treated DC 
compared to cultures containing LPS or SFA 8 treated DC (Figure 7.4e).
7.2.5 The profile of T cell transcription factors induced by 2S seed 
albumins
Initiation, development and maintenance of antigen-specific immune responses by T cells 
is under the direction of key T cell transcription factors. Development of TH1 and TH2- 
mediated immune responses is induced by expression of T-bet and GATA-3, respectively 
[499]. Anti-infiammatory antigen-specific T cell-driven immune responses can also be 
generated and function to regulate the action of TH1 or TH2-type immune responses. 
These regulatory T cells can be distinguished by their expression of transcription factor, 
Foxp3 [500]. To determine the phenotype of T cell present in the seed albumin-treated
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DC-T cell co-cultures, T cell transcription factor profiles were analysed by RT-PCR. 
Cultures were analysed for TH1 (T-bet), TH2 (GATA-3) and T regulatory (Foxp3) 
transcription factors. Consistent with the IFNy production by all cultures, T cells from 
cultures containing Ber e 1-, LPS- or SFA 8-treated DC expressed elevated levels of T-bet 
mRNA, with Ber e 1-treated cultures showing the highest levels (Figure 7.4f). Similarly, 
and consistent with the elevated IL-4 and IL-5 observed, GATA-3 levels were highest in T 
cells cultured with Ber e1-treated DCs (Figure 7.4g). By contrast, there was no apparent 
induction of T-regulatory transcription factor, Foxp3 in any of the cultures (Figure 7.4h), 
indicating that Ber e 1-induced iL-10 detected in these co-cultures was not produced by 
anti-inflammatory T-regulatory cells.
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7.3 Discussion
It has previously been determined that recombinant seed albumins, Ber e 1 and SFA 8 
show similar degradation resistance properties to their native counterparts [501]; an 
important characteristic of albumins. Based on the results presented above, it was 
possible to extend this analysis of recombinant seed allergens to include proposals for 
initiation of the allergic response, involving direct action of seed albumins on dendritic Iï'îcells and subsequent direction of an adaptive immune response.
SFA 8, a sunflower seed component of, as yet, undefined aliergenicity induced maturation 
and TH1-promoting cytokine production by BMDC derived from two mouse strains of 
different Th-bias. Conversely, Ber e l ,  a Brazil nut albumin renowned for its allergenic 
properties, did not appear to activate DC in this way. Further, Ber e 1-treated DC Induced 
priming and activation of naïve T cells into TH2-type T helper (Th) cells. These Th cells 
were defined as such because they produced elevated levels of IL-4, IL-5 and IL-10 and 
expressed increased levels of GATA-3 (a TH2-type transcription factor), compared to T 
cells primed by SFA 8- or LPS-treated DC.
7.3.1 Recombinant Brazil nut allergen fails to induce a TH1-mediated 
immune response in DC
These results provide novel information concerning how these two albumins of potentially 
different aliergenicity, have corresponding different actions on cells of the innate and 
(indirectly) adaptive immune responses. As mentioned in Chapter 1, when B cells receive 
help from TH2 cells, secretion of IgE is induced. IgE is a key immune mediator in allergy, 
therefore, allergic immune responses are facilitated by the TH2 arm of the immune 
system. It is clear from the results of this study that Ber e 1 is capable of inducing a TH2- 
mediated immune response. Conversely, SFA 8 appears to promote a TH1-mediated
.immune response. Given that Ber e 1 is certainly more allergenic than SFA 8, it would 
appear that allergy to Brazil nut may be the result of an inability to induce a TH1 immune 
response. DC action is key in the development and direction of an adaptive immune 
response. In this study it appears that DC are induced to produce IL-12 and TNFa by 
stimulation with SFA 8 which (combined with changes in cell surface expression), leads to
a THI-type adaptive immune response. Conversely, Ber e 1 does not induce DC IL-12 or 
TNFa production or cell surface expression changes and these DC promote induction of a 
TH2 adaptive immune response. Consistent with this theory, Reider and colleagues 
demonstrated that DC isolated from atopic patients exhibited a reduced IL-12 response to 
CD40 ligation (simulating T cell activation) when compared to DC from non-atopic donors. 
[502]. Overall, this would suggest that induction of allergy (in terms of DC response) is the 
consequence of not inducing a TH1-promoting response in DC. The reverse scenario 
would therefore be that induction of a TH1-promoting response in DC ensures failure to
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promote an allergic response, in other words, SFA 8, a protein that does not appear to 
induce allergy, induces a TH1-promoting immune response in DC. Consistent with this 
proposal, a study by Smart and colleagues revealed that oral consumption of sunflower 
seed albumin (after prior sensitisation) promoted induction of an lgG2a (TH1) antibody 
response in a model of experimental asthma. It also attenuated the induction of a 
deiayed-type hypersensitivity response in this modei [503].
7.3.2 Brazil nut allergen-treated DC induce TH2 cell differentiation.
The results of the DC-T cell co-culture revealed that not only does Ber e 1 fail to induce a 
TH1 immune response in DC, it also promotes development of a TH2-type immune 
response. This was demonstrated by secretion of TH2 cytokines and expression of GATA- 
3 (a TH2 transcription factor). Consistent with the opposing action of SFA 8 to Ber e 1 in 
DC, SFA 8 maintains its TH1-promoting action in this co-culture system. It has previously 
been demonstrated that different DC phenotypes (induced by different in vitro treatments) 
can direct T cell phenotype in the ensuing adaptive immune response [189]. LPS-treated 
DC induced differentiation of THI-type T cells producing high levels of IFNy and low levels 
of IL-4. Contrastingly, ES-62-treated DC induced differentiation of T cells of a different 
phenotype, producing high levels of IL-4 and low levels of IFNy. The data presented here 
demonstrate that seed albumins can also induce distinct DC phenotypes that direct 
resulting T cell phenotypes. It is noteworthy that all groups of T cells in this study 
produced high levels of IFNy and expressed T-bet, suggesting IF f'lor T-bet do not 
absolutely determine T cell phenotype in this system. It may be production of TH2 
cytokine, e.g. iL-4 or IL-5 or more likely, the ratio of IL-4 to IFNy production that dictates 
the observed immune response phenotype. Further investigation is required to dissect this 
theory. However, support for these findings was provided by a recent study that 
demonstrated differences between allergen-treated DC from atopic and non-atopic donors 
and their effect on autologous naïve and memory T cells. Here, T cells from atopic donors 
produced increased TH2 cytokines (IL-4, IL-5 and IL-10) in response to co-culture with 
allergen-pulsed DC than T cells from non-atopic donors. In accordance with the findings 
presented in this chapter, T ceil IFNy production and proliferation rates were not 
significantly different between groups, however it was suggested that differences were not 
due to DC IL-12 production [504].
7.3.3 Strain-specific differences in DC surface expression response
SFA 8 induced upregulation of cell surface co-stimulatory molecule expression on DC 
from BALB/c mice more than on DC from C57BL/6 mice. SFA 8 also conferred a TH1- 
promoting phenotype on such DC, demonstrated by TH1-promoting cytokine production. 
As this TH1-inducing action of SFA 8 was observed to a lesser degree in TH-1 prone C57 
BL/6 DC, this may indicate that less action was required by SFA 8 to obtain a TH1
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outcome in this strain. Using this postulation, the reverse is true for BALB/c DC. BALB/c 
mice are TH2-prone, therefore SFA 8 ‘needed’ to induce a more marked response in DC 
from BALB/c mice to ensure a TH1 phenotype. Consistent with this proposal, in a recent 
study, using a murine model of TH2-mediated allergic airway inflammation, BALB/c mice 
demonstrated significantly more perivascular pulmonary inflammation than C57 BL/6 
mice, indicating that the former were more prone to development of TH2 mediated 
Inflammation than the latter [505].
7.3.4 Activation of DC TH1-promoting cytokine production by SFA 8 was 
independent of MyD88
DC production of IL-12 and TNFa in response to SFA 8 occurred independently of the 
important Toil signalling adapter protein, MyD88. The majority, but not all, Toll-like 
receptors (TLRs) signal via MyD88 [498]. Therefore, this result suggests SFA 8 was either 
recognised by a TLR that does not use MyD88 for downstream signalling or it was 
detected by an entirely different pattern-recognition signalling system within the DC.
it is well understood that, in vivo, allergens are recognised by their specific IgE antibody, 
bound to FceRI on the surface of mast cells in allergic individuals. The results of this 
study provide interesting data on the interaction between allergens and DC, another cell 
type of the ‘first line of defence’ that would be encountered by allergen upon entering the 
body. It has been recently demonstrated that DC from the peripheral blood of atopic 
patients express FceRI on their surface [506]. This observation is consistent with a role for 
DC in mediation of the allergic immune response, following allergic sensitisation. 
Therefore the interaction between allergens and DC demonstrated in this study may be a 
viable allergy-initiating process in susceptible individuals in vivo.
7.3.5 Production of IFNy and expression of T-bet does not necessarily 
determine TH cell phenotype.
As described above, pre-treatment of DC with SFA 8, LPS or Ber e 1 resulted in similar 
production of IFNy and expression of T-bet by DC-primed T cells. Therefore, induction of 
distinct immune response phenotypes by SFA 8 and Ber e 1 appears independent of 
IFNy and T-bet. However, in addition to IFNy production, Ber e 1 treatment of DC induced 
production of IL-4 and IL-5 and expression of GATA-3 in cognate T cells. This was not 
observed in T cells primed by SFA 8- or LPS-treated DC and it therefore appears that in 
this system a TH1-type immune response is the default and TH2 signals need to be 
induced additionally, to promote a TH2 immune response. Nevertheless, instead of an 
‘either/or’ TH-phenotype, there appears to be a sliding scale of TH1 to TH2-like responses 
depending on conditions. Thus, the ratio of TH2:TH1 signals, such as transcription factor 
expression and cytokine secretion etc, (instead of absolute production) may underlie the
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nature of the allergic immune response in this system. Consistent with this, in a recent 
study, atopic patients diagnosed with allergic rhinitis were treated with a TH1-promoting 
anti-tumour agent. This treatment reduced nasal Inflammation by reducing allergy- 
promoting TH2 cytokines, iL-4 and IL-5, and by increasing production of IL-12, but not 
IFNy[507]. This study therefore provides support for development of a TH2-mediated 
immune response regardless of IFNy levels. Furthermore, it has been demonstrated that 
amelioration of TH2-mediated allergic airway inflammation can be induced by treatment 
with bacterial lipopeptide, due to promotion of a TH1-mediated immune response that was 
dependent upon IL-12 production [508]. Therefore, it is likely that IL-12 secreted by DC in 
response to culture with SFA 8 (and more potently, in response to LPS) promoted 
development of the T cell-mediated immune response that was biased toward a TH1 
phenotype. On the other hand, Ber e 1 did not induce IL-12 and, therefore, the result was 
development of a more TH2-like immune response.
In this investigation, development of TH1 cells, secreting IFNy and expressing T-bet, 
appeared to be default and independent of the nature of the DC-stimulating factor. The 
action of Ber e l on DC was unusual because it additionally induced development of TH2 
cells, secreting IL-4 and iL-5 and expressing GATA-3. Based on the findings of this 
Investigation it might be postulated that, due to its structural homology to SFA 8, rather 
than passively failing to induce DC cytokine production and upregulation of cell surface 
expression, Ber e 1 may have actively prevented these events that occur as part of the 
default maturation process of TH1-promoting DC. This alternate action of Ber e 1 resulted 
in development of TH2-promoting DC that would induce development of a TH2-mediated 
immune response in vivo.
7.3.6 Lack of allergenic action of SFA 8 contradicts reported incidence of 
sunflower seed allergy
Based on the data presented in this investigation, recombinant SFA 8 does not appear to 
induce allergy-promoting TH2-mediated immune responses. However, as mentioned 
previously, sunflower seed albumins have been demonstrated as IgE binding proteins in a 
small set of susceptible individuals, which would support an allergenic role for this seed 
protein. Thorough explanation of the difference between these apparently contradictory 
findings is not possible based on the results of this study. Epidemiologically, reported 
cases of sunflower seed allergy are relatively rare compared with e.g. peanut allergy 
cases, suggesting that these individuals exhibit an atypical response to sunflower seed 
albumin. Furthermore, the majority of cases of allergy to sunflower seed proteins are 
reported to be via inhalation instead of ingestion by, for example, caged bird owners, who 
experience abnormally high exposure to this protein [491, 492]. it is possible, however, 
that this allergy may be the result of a inappropriate immune response to sunflower seed
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The actions of these recombinant albumins, observed in this study, provide interesting
in patients with a dysfunctional TH1 immune system. However, this hypothesis cannot be 
tested based on the results of this small study. In addition, the protein investigated here 
may be different to the proteins investigated in previous studies inferring allergenic 
properties of sunflower seed albumins. Further study is required to expiain the apparent 
discrepancy.
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7.3.7 Conclusion
As mentioned above, the findings presented here represent the overall results of a 
relatively small study. Due to time restraints this study could not be continued further. 
However, if made possible, future studies should concentrate on investigation of the 
molecular mechanisms of DC interaction with SFA 8 or Ber e 1, including the 
mechanism(s) by which DC recognise these proteins; and identification of T cell subsets 
(by analysis of T cell surface expression) induced by allergen-treated DC.
theories about how the native seed albumins could interact with the immune system to 
initiate (or not) allergy (illustrated in Figure 7.5). Further investigation of their properties 
and actions will help to reveal an understanding of the processes leading to allergic 
sensitisation and hopefully, methods by which it can be prevented.
î :
I
275
Figure 7.1 Recombinant sunflower seed 2S albumin, SFA 8, induces 
production of TH1 cytokines by bone marrow-derived dendritic cells
Dendritic cells cultured from bone marrow of C57BL/6 (a-d), MyD88 knock-out (e, f), 
BALB/c (g, h) mice were treated with recombinant Ber e 1 or SFA 8 for 24h. SFA 8 and 
Ber e 1 were added to culture wells at 50 pg/ml unless otherwise stated. In c and d, cells 
were further stimulated for 24h with 1 pig/ml LPS (E. coli) after seed albumin treatment. 
Supernatants were harvested and cytokines measured by ELISA. Results are expressed 
as meaniSD n=3 and are representative of at least 4 independent experiments. **p<0.01, 
***p<0.001 vs untreated DC.
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Figure 7.2 Recombinant sunflower seed 2S albumin, SFA 8, induces 
moderate upregulation of cell surface expression on C57BL/6 bone marrow- 
derived dendritic cells
Dendritic cells cultured from bone marrow of C57BL/6 mice were treated with Ber e 1(50 
p,g/ml), SFA 8 (50 jxg/ml) or LPS (1 E. coif) for 24h. After the culture period, DC
were stained for CD11c and MHO class II, CD40, CD54, CD80 or CD86 and analysed by 
flow cytometry. Histograms represent expression levels of GD11c'" cells. Results are 
representative of at least 2 independent experiments.
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Figure 7.3 Recombinant sunflower seed 2S albumin, SFA 8, induces 
upregulation of cell surface expression on BALB/c bone marrow-derived 
dendritic cells
Dendritic cells cultured from bone marrow of BALB/c mice were pre-treated with Ber e 
1(50 pg/ml) or SFA 8 (50 p,g/ml) for 24h, followed by stimulation with media (A) or LPS (1 
ng/ml; E. coli) (B) for 24h. After the culture period, DC were stained for CD11c and MHC 
class II, CD40, CD54, CD80 or CD86 and analysed by flow cytometry. Histograms 
represent expression levels of C D IIc^  cells. Results are representative of at least 2 
independent experiments.
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Figure 7.4 Co-culture of recombinant 2S seed albumin-treated bone marrow- 
derived dendritic ceils and naïve OVA-specific CD4* T cells
Dendritic cells cultured from bone marrow of BALB/c mice were pre-treated with Ber e 
1(50 M-g/ml), SFA 8 (50 p.g/ml) or LPS (1 ng/ml; E. coli) for 24h before co-culturing with 
naïve DO.11.10 CD4* T cells. (1 DC:10 T cells) and OVA (0.3 or 3 nM) for 72h. 
Proliferation (a) was determined by measuring [^H]-thymidine incorporation during the last 
8 hours of culture. Culture supernatants were analysed for IFNy (b), IL-4 (c), IL-5 (d) and 
IL-10 (e) by ELISA. Cells were analysed for T-bet (f), GATA-3 (g) and Foxp3 (h) 
transcription factor mRNA levels by RT-PCR (levels expressed relative to HPRT leveis). In 
b, LPS p<0.02 vs Ber e 1. In c, LPS p<0.001 vs Ber e 1, SFA 8 p<0.002 vs Ber e l .  In d, 
Ber e 1 p<0.02 vs SFA 8 and LPS. In e, LPS p<0.01 vs Ber e 1. Data are representative 
of 3 independent experiments and expressed as mean ± SD n=3.
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Figure 7.5 Model of response of atopic and non-atopic individuals to 2S seed 
albumin exposure
Data presented in this chapter has demonstrated that SFA8, but not Ber e 1, induces IL- 
12 production from bone marrow-derived DC. Moreover, a recent report demonstrates that 
PBMC-derived DC from atopic patients produce less IL-12 in response to CD40 ligation 
than those from non-atopic donors [502]. This recent finding is therefore likely to further 
impact on the potential functional outcome of T cells primed with DC exposed to either 
SFA8 or Ber e 1. Thus, the IL-12 shown to be associated with Ber e1 in the non-atopic 
panel (A) refers to that potentially produced by Ber e l in conjunction with T cell-mediated 
CD40-signalling in non-atopic patients. Such IL-12 production is not likely to be observed 
in atopic patients (B), a prediction consistent with the data presented here, showing that 
Ber e 1 does not upreguiate CD40 on DC. By contrast, SFA8, which has been shown to 
be capable of inducing IL-12, in the absence of CD40 signalling, could therefore induce 
IL-12 even in atopic patients whilst in non-atopic patients, could induce enhanced levels of 
IL-12 in conjunction with CD40 signalling. Thus, in conclusion, as SFA8 can induce IL-12 
by DC, it biases the immune response of both non-atopic and atopic individuals away 
from a TH2 allergic phenotype. By contrast, as atopic individuals produce little CD40- 
induced IL-12 relative to that generated by non-atopics, they would be rendered more 
likely to develop a TH2-biased allergic response to Ber e 1.
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8 General Discussion
It has been observed that the prevalence of asthma, allergic diseases and autoimmunity 
is reduced in parasite-infected individuals [110, 509]. Indeed, parasite infection has been 
proposed as protective against development of allergy and autoimmunity [118, 140]. It is 
clear that parasites have evolved to mount self-protective mechanisms to ensure longevity 
of infection in the host, which can involve secretion of immunomodulatory substances. 
This action, whilst beneficial to the parasite, can also benefit the host by protecting them 
not only from development of pathology, but also from development of allergy or 
autoimmune disease
ES-62 is an ES product generated by rodent filarial nematode, A. viteae, and has 
previously been demonstrated to exhibit immunomodulatory properties when examined in 
vivo and in vitro on specific cells of the immune system [190, 191, 193, 281]. The results 
described in this thesis have extended the current understanding of ES-62 action to 
include anti-inflammatory actions in models of inflammatory disease. Moreover, evidence 
has been provided to establish that ES-62 treatment of two distinct models of 
autoimmunity and a model of allergic airway inflammation induces amelioration of 
inflammatory symptoms. In more detail, ES-62 inhibited TH1-mediated inflammation in 
collagen-induced arthritis, TH2-mediated inflammation in ovalbumin-induced asthma and 
development of heterogeneous lupus-like inflammation in MRL/lpr mice. These combined 
findings highlight novel anti-inflammatory properties of ES-62 that are mediated 
unreservedly, independent of inflammation source, phenotype or manifestation.
8.1 How does ES-62 manipulate the immune system in inflammatory 
disease?
Clearly, ES-62 modulates the normal action of several different mechanisms necessary 
for mediation of the inflammatory immune response in the three models described above. 
For example, an interesting pattern was observed in ES-62-mediated modulation of serum 
antigen-specific antibody responses during analysis of the CIA and asthma models. 
Moreover, it appeared that ES-62 mediated modulation of the serum antibody response to 
antigen sensitisation in both models was most likely not necessarily directly related to ES- 
62-mediated reduction of inflammation. This was evidenced by inhibition of antigen- 
specific lgG2a in the CIA model and antigen-specific IgE in the asthma model, induced 
when ES-62 was administered prophyiactically, but not when it was administered 
therapeutically, despite maintenance of the anti-inflammatory effect of ES-62 in both 
treatment protocols. Furthermore, ES-62 mediated inhibition of collagen-specific lgG2a in 
the prophylactic treatment CIA model appeared to be PC-independent and therefore, did 
not correlate with the anti-inflammatory effect of ES-62 in this model. This was confirmed 
by maintenance of the inhibitory effect on collagen-specific lgG2a when mice were treated
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with PC-deficient rES-62, despite loss of anti-inflammatory action, leading to the 
suggestion that ES-62-medlated inhibition of collagen-specific lgG2a was mediated by a 
non-PC component of ES-62. Therefore, considering that modulation of the serum 
antibody response does not appear to correlate directly with modulation of inflammation, it 
might be predicted that if an antigen-specific antibody response could be measured in the 
MRL/lpr SLE model, it would not be directly related to the anti-inflammatory effects of ES- 
62 in this model either.
Nevertheless the difference in the effects of prophylactic and therapeutic ES-62 treatment 
on the serum antibody responses in the CIA and asthma models did reveal differences in 
the action of ES-62 in each treatment protocol. For example, when administered 
prophyiactically, ES-62 most likely inhibits immune response initiation mechanisms 
(reflected by antibody production) and when administered therapeutically, ES-62 disrupts 
inflammatory effector mechanisms (which do not influence the antibody response). 
Therefore, the serum antibody profile reflects the nature of the immune response 
generated but not necessarily the inflammatory status of the model. In summary, it 
appears that ES-62 has probably two major modes of action on the models of 
inflammation investigated in this thesis, namely modulation of immune response initiation 
mechanisms and inhibition of inflammation effector mechanisms
8.1.1 ES-62 mediated disruption of immune response initiation
It has been clearly established that DC are Integral In development of an antigen-specific 
immune response. As it is currently understood, initiation of an immune response normally 
involves recognition of antigen (in the presence of a ‘danger signal’) to induce DC 
activation, migration of activated antigen-presenting DC to the secondary lymphoid organs 
and priming of naïve T cells to initiate an antigen-specific adaptive immune response [3]. 
It has previously been suggested that DC comprise a primary target for ES-62-mediated 
modulation of the immune response [467] and as demonstrated by this laboratory, ES-62 
can modulate DC phenotype and function at several stages of this immune response 
initiation process. Indeed, ES-62 treatment in vivo (delivered via implanted osmotic 
pumps) modulates the phenotype and function of DC that are subsequently differentiated 
from bone marrow progenitor cells [191]. Furthermore, ES-62 treatment of pre­
differentiated bone marrow-derived DC in vitro results in modulation of the normal 
cytokine production and cell surface expression response of these cells to stimulation with 
‘danger signals’ such as bacterial LPS [191], indicating that ES-62 treatment of immature 
DC in peripheral tissues in vivo would disrupt their activation and hence, their ability to 
activate naïve T cells.
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Therefore, the results presented in this thesis have consolidated these previous findings | 
by providing evidence to suggest that such modulatory effects of ES-62 on immune 
response initiation mechanisms are also mediated in models of inflammatory disease. For 
example, in the CIA model (Chapter 3), the action of ES-62 on bone marrow-derived DC 
phenotype, whilst modest, was apparent, the effects being enhanced by increasing the 
number of doses of ES-62 in vivo and reducing the time between ES-62 application and 
the beginning of bone marrow cell culture ex vivo. This was exemplified by the more 
potent effects being observed on DC derived from the therapeutic relative to the 
prophylactic model. Therefore it appears that the modulatory effect of ES-62 is positively 
associated with the quantity of treatment and negatively associated with the time period 
between the application of ES-62 in vivo and the beginning of DC culture period. 
Interestingly, DC have been implicated in treatment of autoimmunity, therefore modulation 
of DC phenotype or function represents an effective mechanism for disruption of immune 
response initiation.
Nevertheless, DC activation is only the first stage of antigen-specific immune response 
development. Following activation, DC migrate to lymph nodes in order to trigger 
activation of antigen-specific T cells, which normally leads to clonal expansion of antigen- 
specific T cells, heralding the beginning of the adaptive immune response. As a result of 
communication between activated antigen-specific T cells and B cells in the lymph node 
follicles, B cell antigen-specific antibody production is switched to an appropriate isotype 
and initiation of the adaptive immune response is complete. Indeed, as mentioned above, 
prophylactic ES-62 treatment of the CIA and asthma models inhibited development of the 
appropriate antigen-specific antibody response, indicating that ES-62 action must disrupt 
the mechanisms resulting in antigen-specific antibody production by B cells. Indeed, it has 
recently been identified (using an adoptive transfer system) that T cells from ES-62- 
treated mice exhibit reduced clonal expansion and antigen-specific pro-inflammatory 
cytokine production [467]. Furthermore, it has been demonstrated that such T cells exhibit 
reduced migration into B cell follicles, a process necessary for induction of the antigen- 
specific antibody response. Consistent with this, antigen-specific lgG2a responses were 
inhibited in this TH1-biased model, therefore, it might be postulated that this mechanism is 
employed by ES-62 in the CIA and asthma models for inhibiting production of antigen- 
specific lgG2a and IgE respectively. In summary, by combining the published results from 
this laboratory and the findings presented in this thesis it has been demonstrated that the 
action of ES-62 influences the function of different cell types, at several stages during 
initiation of an immune response, which contributes to development of an inhibited 
inflammatory immune response in models of inflammatory disease (Figure 8.1).
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8.1.2 ES-62 mediated disruption of immune response effector mechanisms
At the inflammatory site, a number of different cell types work in unison, secreting 
inflammatory factors (cytokines and chemokines) to recruit and stimulate survival of other 
cells and enhance or amplify the inflammatory environment. Usually the cellular infiltrate is 
representative of the phenotype of the inflammatory response. Moreover, TH1-type 
responses are largely mediated by phagocytes (macrophages and neutrophils) and 
cytotoxic T cells, whereas mast cells and eosinophils are most commonly associated with 
TH2-type/a!lergic immune responses.
Cytokine production by antigen-specific T cells in response to antigen challenge can be 
considered an primary step in the effector stage of an immune response. In response to 
antigen-specific TH1 or TH2 cytokine production by activated TH cells, inflammation is 
triggered in TH1- and TH2~mediated immune responses respectively. Thus, ES-62 
mediated inhibition of antigen-specific cytokine production by TH cells from the CIA and 
asthma models can be considered contributory to its anti-inflammatory action in both 
these models. However, it is important to note that this is unlikely to be a direct effect of 
ES-62 treatment on T cells, as the direct immunomodulatory effects of ES-62 on T cells 
are minimal [167]. It is more likely that ES-62 modulates DC phenotype, which becomes 
translated, in vivo, into augmented lymphocyte and effector cell responses. This DC- 
facilitated anti-inflammatory action has previously been identified in a model of arthritis, 
where IL-10-treated DC administered peh-articularly ameliorated inflammation [510].
In both, TH1-mediated RA and TH2-mediated asthma, macrophages located in the 
inflammatory site act to maintain and promote inflammation. In particular, it has been 
proposed that contact-dependent communication between activated T cells and adjacent 
macrophages in the joint is necessary for progression of synovial inflammation in RA 
[245]. Indeed, by employing an in vitro system it was demonstrated that ES-62 treatment 
in vitro or in vivo can disrupt contact-dependent communication between T cells and 
macrophages, thus it was proposed that this might be an important method employed by 
ES-62 for inhibition of the effector mechanisms of inflammation in the CIA model. 
Similarly, macrophages are the major cell type present in the inflammatory infiltrate of the 
asthmatic lungs [363] and hence, represent an important effector cell for mediation of 
TH2-type inflammation in asthma. ES-62 induced differentiation of macrophages from 
asthma model mice with reduced activation, evidenced by reduced overall cytokine 
production rates. Therefore, in TH1-mediated and TH2-mediated inflammation, it is likely 
that macrophages are targeted by ES-62 for inhibition of existing inflammation.
Associated with TH2-mediated inflammatory immune responses, eosinophils are a major 
component of the inflammatory cell infiltrate and therapeutic ES-62 treatment was
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demonstrated to inhibit recruitment of this cell type In the asthma model. As recruitment of 
eosinophils can be induced by production of TH 2-type cytokine, IL-5, it is likely that ES- 
62-mediated inhibition of antigen-specific TH2 cell cytokine production may have been 
responsible for this effect on the pulmonary cellular infiltrate. In addition, another 
important effector cell of the inflammatory response in TH2-mediated immunity is the mast 
cell. Recently it has been demonstrated in vitro that mast cell degranulation in response to 
cross-linking of FceRI, an important effector step in mediation of the inflammatory 
response in TH2-mediated inflammation, was inhibited by direct ES-62 treatment (A 
Melendez, M Harnett and W Harnett, unpublished observations). Thus, similar to its action 
in TH1-mediated inflammation, ES-62 appears to target distinct, appropriate cell types for 
mediation of anti-inflammatory action in the effector stage of TH2-medlated inflammation. 
Figure 8.2 depicts the proposed pattern of ES-62 mediated action in effector mechanisms 
of inflammation.
In summary, it appears that ES-62 acts to inhibit development or progression of 
inflammation, independent of source, cell type or phenotype. In particular it is interesting 
that the modulatory effect of ES-62 on DC appears to be dependent on the extent of 
application as observed in the CIA model. Furthermore, the anti-inflammatory action of 
therapeutic ES-62 treatment on asthma model mice was dose-dependent. These findings 
suggest that infection with A. viteae (resulting in consistent exposure to ES-62) would 
mediate more potent effects on the cells responsible for mediation of the inflammatory 
immune response. Indeed, there are several homologues of ES-62 secreted by human 
filarial nematodes [161], thus it might be suggested that infection with filarial nematodes 
may protect these infected individuals from development of aberrant inflammatory immune 
responses (i.e. autoimmunity or allergy), which might be viewed as a beneficial side-effect 
of nematode infection, certainly by sufferers of autoimmunity or allergic asthma in the 
Western world.
8.2 How are the immunomodulatory effects of ES-62 mediated?
The molecular mechanism(s) of the interaction between immune cells and ES-62 
(resulting in modulation of their normal cellular responses) is currently under investigation 
in this laboratory. As part of their innate immune functions, DC and macrophages express 
Toll-like receptors (TLRs) on their extracellular surface. As mentioned previously, TLRs 
are a family of pattern recognition receptors that recognise specific pathogen-associated 
molecular patterns (PAMPs) and ligation of TLRs results in activation of innate immune 
cells [511]. For example, TLR2 and TLR4 recognise Gram-positive and Gram-negative 
bacteria, respectively [511], In response to ligation of TLRs, downstream Intracellular 
signalling pathways are activated which induce secretion of pro-inflammatory cytokines, to 
recruit other innate immune cells and upregulation of cell surface molecules, required by
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DC for activation of T cells. Recently, it has been identified that ES-62 requires TLR4 and 
a downstream adaptor protein/signal transducer of several TLR signalling cascades, 
MyD88, for mediation of its immunomodulatory effects on DC and macrophage cytokine 
production [374]. However interestingly, ES-62 appears to interact with TLR4 on DC and 
macrophages utilising a novel mechanism, evidenced by maintenance of its 
immunomodulatory action in C3H/HeJ mice, which do not express a functional TLR4. It 
has been suggested that ES-62 preferentially targets cells of the innate immune response 
for mediation of its anti-inflammatory action and, indeed, this suggestion has not been 
disputed by the results presented in this thesis. Therefore, via TLR4 (and MyD88), ES-62 
may modulate the function of innate immune cells thereby indirectly augmenting the 
ensuing adaptive immune response in inflammatory diseases. For example, the anti­
inflammatory effects of ES-62 observed in Chapter 3 may be initiated by interaction of ES- 
62 and TLR4 expressed by macrophages and DC, a theory that remains to be 
investigated.
TLR4 is also expressed on innate immune cells associated with TH2-type inflammation, 
such as mast cells [512]. As mentioned above, it has been demonstrated that ES-62 
treatment of mast cells inhibits their de-granulation in response to cross-linking of the IgE 
receptor (FceRI). Thus, it might be proposed that TLR4 also acts as a receptor for ES-62- 
mediated anti-inflammatory action in this cell type. In particular, the anti-eosinophilic 
action of ES-62 in the OVA-induced airway inflammation model, described in Chapter 4, 
was the predominant anti-inflammatory action of ES-62 in this model. However, the 
expression of TLR4 on eosinophils is currently a topic of debate [513-515]. Nevertheless, 
it has recently been identified that LPS-induced enhancement of eosinophilia in the OVA- 
induced airway inflammation model is dependent on TLR4 expression by mast cells [516]. 
Thus in response to ligation of TLR4 (by LPS), mast cells release TH2-promoting soluble 
mediators, including TH2 cytokines and eotaxin 2, which act to recruit eosinophils. 
Therefore, it could be hypothesised that, via TLR4 expressed on mast cells, ES-62 acts 
(in an alternative method to LPS) to stimulate negative signalling, resulting in reduced 
mast cell de-granulation (in response to cross-linking of FceRI) and hence, inhibited 
release of eosinophil-recruiting factors, ultimately reducing eosinophilia in this model. This 
hypothesis represents an entirely new investigation that could be conducted as part of the 
future directions of this project.
8.3 Future Work
The therapeutic actions of ES-62 (after the onset of established inflammation) in the TH1- 
mediated CIA model and TH2-mediated asthma model have been demonstrated in 
Chapters 3 and 4. Thus, by direct action of ES-62 on inflammatory effector mechanisms, 
inhibition of established inflammation could be enabled. Thus, it would be interesting to
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examine the effect of ES-62 treatment of MRL/lpr mice after establishment of lupus-like 
immunopathology. It might be proposed that T and B cell responses, triggered during 
initiation of the inflammatory immune response in MRL/lpr mice, would be minimally 
modulated by therapeutic ES-62 treatment. Moreover, ES-62 cannot ‘reverse’ established 
immune pathways when administered after the onset of inflammation, but prevents 
amplification of inflammatory signals and maintenance of inflammation by direct action on 
effector cells.
Ultimately, based on the results presented in this thesis, it may be prudent to suggest that 
a therapy for inflammatory conditions might be designed, using ES products, such as ES- 
62, as a template. Indeed, the PC component of ES-62 has been demonstrated to mimic 
several of the anti-inflammatory effects of ES-62, in the CIA model, therefore an 
interesting first step in this process would be to additionally determine the PC-dependency 
of the anti-inflammatory effects of ES-62 in the asthma and SLE models. As discussed in 
Chapter 6, PC was deemed responsible for immunomodulatory action, similar to ES-62, 
induced by mimetics of another helminth product, GSL. However, designing a anti­
inflammatory drug based on the structure of PC alone would be ill-advised as PC has also 
been shown to have immunogenic properties [177], depending on how it is presented to 
cells of the immune system. Furthermore, immunomodulatory effects of native ES-62 and 
GSL that were PC-independent were uncovered, indicating that a d istinct 
combination/structure of carbohydrate, protein and PC are required to mimic the anti­
inflammatory and non-immunogenic effects of native parasite products. As yet, it has not 
been possible to precisely mimic the biosynthesis of parasite-derived products 
synthetically [199], however small molecule derivatives of ES products, such as ES-62 
and GSL, are currently under investigation in this laboratory with a view to designing anti­
inflammatory therapy for inflammatory disease.
8.4 Conclusion
ES-62-mediated anti-inflammatory action, in the OVA-induced airway inflammation model 
(Chapter 4), has been mirrored by treating a model of allergic airway inflammation with 
extracts of filarial nematode parasite, Ascaris suum [375], or by infection of such model 
mice with gastrointestinal nematode, Heligmosomoides polygyrus [139]. In addition, it has 
previously been demonstrated that infection with malarial parasite, Plasmodium chabaudi, 
ameliorates inflammation in the NZB/W murine model of SLE [517], an effect induced by 
prophylactic treatment with ES-62 (Chapter 5). Similar to the action of ES-62 observed in 
the murine CIA model (Chapter 3), infection with protozoan parasite. Trypanosoma brucei 
brucei, inhibits development of inflammation in a rat model of CIA [282]. Therefore, 
parasite-mediated inhibition of inflammation in the host is not a novel theory. However, 
ES-62 represents the first example of a defined secreted parasite product that exhibits
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anti-inflammatory action across a panel of inflammatory diseases of different 
immunological phenotype. Indeed, as mentioned previously, ES-62 has several 
homologues secreted by filarial nematodes that infect humans [161, 518]. Thus, the 
combined findings presented in this thesis may be extrapolated to provide an explanation 
for the observed immunosuppression and reduced prevalence of inflammatory disease in 
countries endemic for filarial nematode infection. The evidence put forward here does not 
directly support the hygiene hypothesis as it was originally stated (lack of exposure to 
TH1-inducing bacterial infection predisposes TH2-skewed atopy; [102]). However, in 
terms of infection modifying disposition to inflammatory disease (and taking into 
consideration the role of genetic and environmental factors) an alternative hypothesis can 
be supported. That is, the reduced prevalence of inflammatory autoimmune and allergic 
disease in many developing countries is a direct result of anti-inflammatory action 
mediated by parasite-derived immunomodulatory products.
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Figure 8.1 ES 62 disrupts inflammatory Immune response initiation
mechanisms
Following differentiation of immature (dendritic cells) DC from bone marrow progenitor 
cells they are released into the peripheral tissues, where they perform a surveillance 
function as part of the innate immune system. In this state, immature DC continually take 
up and process antigen until they are activated by antigen in the presence of a danger 
signal (e.g. an adjuvant). In response to activation, DC antigen uptake ceases and 
antigen-presentation becomes a major function. Furthermore, the activated DC are 
deemed ‘mature’ in phenotype, evidenced by a morphological change (which increases 
their surface area), enhanced secretion of cytokines and upregulation of cell surface co­
stimulatory, antigen-presentation and adhesion molecules necessary for activation of T 
cells. Following migration to a secondary lymphoid organ the activated DC prime antigen- 
specific T cells. Such T cell activation heralds the start of an antigen-specific adaptive 
immune response and begins with clonal expansion of antigen-specific T cells, ES-62 
treatment in vivo and in vitro has been demonstrated to disrupt this immune response 
initiation pathway at multiple stages. For example, it has been demonstrated that 
exposure of bone marrow progenitors to ES-62 in vivo results in differentiation of DC that 
preferentially stimulate production of a less inflammatory immune response [191]. 
Furthermore, pre-treatment of differentiated bone marrow-derived "immature" DC with ES- 
62 inhibits their activation, and disrupts subsequent DC-mediated T cell activation [189, 
191]. Thus, in vivo, in a model of inflammatory disease, exposure to ES-62 acts to inhibits 
the initiation mechanisms leading to development of antigen-specific inflammation.
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Figure 8.2 ES-62 treatment inhibits effector mechanisms of inflammatory 
disease
In general terms, following initiation of an inflammatory immune response (Figure 8.1), 
antigen-specific T helper (TH) cells secrete cytokines specific for the phenotype of the 
immune response, which help to induce switching of B cell antibody production to a 
corresponding phenotype, in response to antigen stimulation, antigen-specific T cells 
produce further TH-phenotype specific cytokines, which help to recruit and activate 
appropriate effector cells at the inflammatory site. In response to activation, such effector 
cells secrete inflammation-promoting chemokines and cytokines, which circulate in the 
bloodstream and help to recruit further inflammatory cells, inducing an positive feedback 
cycle of inflammation and potential tissue destruction. ES-62 treatment of established 
inflammation in models of autoimmune or allergic disease appears to induce inhibition of 
antigen-specific cytokine production by activated T cells and, via inhibitory action on 
effector cells in the inflammatory site, reduces recruitment of cells and ultimately inhibits 
inflammation and tissue destruction.
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